_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,b1,b2,confirmids1,confirmids2,e1,e2,factor1,factor2,firstfactor,saveselectionids1,saveselectionids2,secondfactor,sentence,wordid1,wordid2,orig_b1,orig_b2,orig_e1,orig_e2,expertdecision,relation,sent_id,orig_sentence,term1,term2
503461323,7/16/2014 13:48:48,,1324260718,7/16/2014 13:48:29,prodege,1,13300986,CAN,AB,Edmonton,68.150.33.230,31,50,,,34,55,SLE,LUPUS,Systemic lupus erythematosus: SLE,0-9-15-31,31-41-50-56,SLE Systemic LUPUS Erythematosus,"Systemic lupus erythematosus:  SLE (see  Systemic Lupus Erythematosus (SLE) ) may first appear during pregnancy; women who have had an unexplained 2nd-trimester stillbirth, a fetus with growth restriction, preterm delivery, or recurrent spontaneous abortions are often later diagnosed with SLE.",31,50,31,50,34,55,-1,RO-has_manifestation,906170,"Systemic lupus erythematosus:  SLE (see  Systemic Lupus Erythematosus (SLE) ) may first appear during pregnancy; women who have had an unexplained 2nd-trimester stillbirth, a fetus with growth restriction, preterm delivery, or recurrent spontaneous abortions are often later diagnosed with SLE",SLE,Lupus
503461323,7/16/2014 13:49:29,,1324260903,7/16/2014 13:49:06,tremorgames,1,24449707,CAN,QC,Laval,96.21.249.72,31,50,,,34,55,SLE,LUPUS,SLE,31,41-50-56,Systemic LUPUS Erythematosus,"Systemic lupus erythematosus:  SLE (see  Systemic Lupus Erythematosus (SLE) ) may first appear during pregnancy; women who have had an unexplained 2nd-trimester stillbirth, a fetus with growth restriction, preterm delivery, or recurrent spontaneous abortions are often later diagnosed with SLE.",31,50,31,50,34,55,-1,RO-has_manifestation,906170,"Systemic lupus erythematosus:  SLE (see  Systemic Lupus Erythematosus (SLE) ) may first appear during pregnancy; women who have had an unexplained 2nd-trimester stillbirth, a fetus with growth restriction, preterm delivery, or recurrent spontaneous abortions are often later diagnosed with SLE",SLE,Lupus
503461323,7/16/2014 13:50:38,,1324261330,7/16/2014 13:50:24,clixsense,1,20709884,CAN,NS,Berwick,24.142.36.5,31,50,,,34,55,SLE,LUPUS,Systemic lupus erythematosus: SLE,0-9-15-31,31-35-41-50-56,SLE (see Systemic LUPUS Erythematosus,"Systemic lupus erythematosus:  SLE (see  Systemic Lupus Erythematosus (SLE) ) may first appear during pregnancy; women who have had an unexplained 2nd-trimester stillbirth, a fetus with growth restriction, preterm delivery, or recurrent spontaneous abortions are often later diagnosed with SLE.",31,50,31,50,34,55,-1,RO-has_manifestation,906170,"Systemic lupus erythematosus:  SLE (see  Systemic Lupus Erythematosus (SLE) ) may first appear during pregnancy; women who have had an unexplained 2nd-trimester stillbirth, a fetus with growth restriction, preterm delivery, or recurrent spontaneous abortions are often later diagnosed with SLE",SLE,Lupus
503461323,7/16/2014 13:51:57,,1324261789,7/16/2014 13:51:27,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,31,50,,,34,55,SLE,LUPUS,SLE Systemic Lupus Erythematosus,31-41-50-56,41-50-56-70,Systemic LUPUS Erythematosus (SLE),"Systemic lupus erythematosus:  SLE (see  Systemic Lupus Erythematosus (SLE) ) may first appear during pregnancy; women who have had an unexplained 2nd-trimester stillbirth, a fetus with growth restriction, preterm delivery, or recurrent spontaneous abortions are often later diagnosed with SLE.",31,50,31,50,34,55,-1,RO-has_manifestation,906170,"Systemic lupus erythematosus:  SLE (see  Systemic Lupus Erythematosus (SLE) ) may first appear during pregnancy; women who have had an unexplained 2nd-trimester stillbirth, a fetus with growth restriction, preterm delivery, or recurrent spontaneous abortions are often later diagnosed with SLE",SLE,Lupus
503461323,7/16/2014 13:56:11,,1324263478,7/16/2014 13:55:52,clixsense,1,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,31,50,,,34,55,SLE,LUPUS,SLE,31,50,LUPUS,"Systemic lupus erythematosus:  SLE (see  Systemic Lupus Erythematosus (SLE) ) may first appear during pregnancy; women who have had an unexplained 2nd-trimester stillbirth, a fetus with growth restriction, preterm delivery, or recurrent spontaneous abortions are often later diagnosed with SLE.",31,50,31,50,34,55,-1,RO-has_manifestation,906170,"Systemic lupus erythematosus:  SLE (see  Systemic Lupus Erythematosus (SLE) ) may first appear during pregnancy; women who have had an unexplained 2nd-trimester stillbirth, a fetus with growth restriction, preterm delivery, or recurrent spontaneous abortions are often later diagnosed with SLE",SLE,Lupus
503461323,7/16/2014 13:57:08,,1324263898,7/16/2014 13:56:49,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,31,50,,,34,55,SLE,LUPUS,Systemic lupus erythematosus: SLE,0-9-15-31,41-50-56-70,Systemic LUPUS Erythematosus (SLE),"Systemic lupus erythematosus:  SLE (see  Systemic Lupus Erythematosus (SLE) ) may first appear during pregnancy; women who have had an unexplained 2nd-trimester stillbirth, a fetus with growth restriction, preterm delivery, or recurrent spontaneous abortions are often later diagnosed with SLE.",31,50,31,50,34,55,-1,RO-has_manifestation,906170,"Systemic lupus erythematosus:  SLE (see  Systemic Lupus Erythematosus (SLE) ) may first appear during pregnancy; women who have had an unexplained 2nd-trimester stillbirth, a fetus with growth restriction, preterm delivery, or recurrent spontaneous abortions are often later diagnosed with SLE",SLE,Lupus
503461323,7/16/2014 14:16:46,,1324272165,7/16/2014 14:16:25,instagc,1,13763729,USA,"","",75.182.89.225,31,50,,,34,55,SLE,LUPUS,Systemic lupus erythematosus: SLE,0-9-15-31,41-50-56,Systemic LUPUS Erythematosus,"Systemic lupus erythematosus:  SLE (see  Systemic Lupus Erythematosus (SLE) ) may first appear during pregnancy; women who have had an unexplained 2nd-trimester stillbirth, a fetus with growth restriction, preterm delivery, or recurrent spontaneous abortions are often later diagnosed with SLE.",31,50,31,50,34,55,-1,RO-has_manifestation,906170,"Systemic lupus erythematosus:  SLE (see  Systemic Lupus Erythematosus (SLE) ) may first appear during pregnancy; women who have had an unexplained 2nd-trimester stillbirth, a fetus with growth restriction, preterm delivery, or recurrent spontaneous abortions are often later diagnosed with SLE",SLE,Lupus
503461323,7/16/2014 14:24:56,,1324275541,7/16/2014 14:24:23,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,31,50,,,34,55,SLE,LUPUS,SLE,31,41-50-56,Systemic LUPUS Erythematosus,"Systemic lupus erythematosus:  SLE (see  Systemic Lupus Erythematosus (SLE) ) may first appear during pregnancy; women who have had an unexplained 2nd-trimester stillbirth, a fetus with growth restriction, preterm delivery, or recurrent spontaneous abortions are often later diagnosed with SLE.",31,50,31,50,34,55,-1,RO-has_manifestation,906170,"Systemic lupus erythematosus:  SLE (see  Systemic Lupus Erythematosus (SLE) ) may first appear during pregnancy; women who have had an unexplained 2nd-trimester stillbirth, a fetus with growth restriction, preterm delivery, or recurrent spontaneous abortions are often later diagnosed with SLE",SLE,Lupus
503461323,7/16/2014 14:27:09,,1324276317,7/16/2014 14:26:48,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,31,50,,,34,55,SLE,LUPUS,SLE Lupus,31-50,31-50,SLE LUPUS,"Systemic lupus erythematosus:  SLE (see  Systemic Lupus Erythematosus (SLE) ) may first appear during pregnancy; women who have had an unexplained 2nd-trimester stillbirth, a fetus with growth restriction, preterm delivery, or recurrent spontaneous abortions are often later diagnosed with SLE.",31,50,31,50,34,55,-1,RO-has_manifestation,906170,"Systemic lupus erythematosus:  SLE (see  Systemic Lupus Erythematosus (SLE) ) may first appear during pregnancy; women who have had an unexplained 2nd-trimester stillbirth, a fetus with growth restriction, preterm delivery, or recurrent spontaneous abortions are often later diagnosed with SLE",SLE,Lupus
503461323,7/16/2014 14:30:15,,1324277721,7/16/2014 14:29:47,prodege,1,6316959,GBR,"","",46.208.145.114,31,50,,,34,55,SLE,LUPUS,Systemic lupus erythematosus: SLE,0-9-15-31,41-50-56-70,Systemic LUPUS Erythematosus (SLE),"Systemic lupus erythematosus:  SLE (see  Systemic Lupus Erythematosus (SLE) ) may first appear during pregnancy; women who have had an unexplained 2nd-trimester stillbirth, a fetus with growth restriction, preterm delivery, or recurrent spontaneous abortions are often later diagnosed with SLE.",31,50,31,50,34,55,-1,RO-has_manifestation,906170,"Systemic lupus erythematosus:  SLE (see  Systemic Lupus Erythematosus (SLE) ) may first appear during pregnancy; women who have had an unexplained 2nd-trimester stillbirth, a fetus with growth restriction, preterm delivery, or recurrent spontaneous abortions are often later diagnosed with SLE",SLE,Lupus
503461324,7/16/2014 13:53:10,,1324262254,7/16/2014 13:52:59,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,78,0,,,82,15,BONE,PAGET'S DISEASE,"BONE turnover,",78-83,0-8,PAGET'S DISEASE,"Paget's disease is a metabolic bone disease characterized by abnormalities of bone turnover, structure and architecture.",78,0 8,78,0,82,15,1,RO-has_finding_site,905143,"Paget's disease is a metabolic bone disease characterized by abnormalities of bone turnover, structure and architecture",bone,Paget's disease
503461324,7/16/2014 13:57:58,,1324264323,7/16/2014 13:57:26,prodege,1,9525153,CAN,ON,Toronto,65.95.94.44,78,0,,,82,15,BONE,PAGET'S DISEASE,"Paget's disease metabolic bone disease BONE turnover, structure architecture.",0-8-21-31-36-78-83-93-107,0-8-21-31-36-78-83-93-107,"PAGET'S DISEASE metabolic bone disease bone turnover, structure architecture.","Paget's disease is a metabolic bone disease characterized by abnormalities of bone turnover, structure and architecture.",78,0 8,78,0,82,15,1,RO-has_finding_site,905143,"Paget's disease is a metabolic bone disease characterized by abnormalities of bone turnover, structure and architecture",bone,Paget's disease
503461324,7/16/2014 14:20:50,,1324273871,7/16/2014 14:20:25,vivatic,1,25451531,GBR,"","",83.67.28.193,78,0,,,82,15,BONE,PAGET'S DISEASE,"abnormalities of BONE turnover,",61-75-78-83,0-8,PAGET'S DISEASE,"Paget's disease is a metabolic bone disease characterized by abnormalities of bone turnover, structure and architecture.",78,0 8,78,0,82,15,1,RO-has_finding_site,905143,"Paget's disease is a metabolic bone disease characterized by abnormalities of bone turnover, structure and architecture",bone,Paget's disease
503461324,7/16/2014 14:30:42,,1324277968,7/16/2014 14:30:28,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,78,0,,,82,15,BONE,PAGET'S DISEASE,BONE,78,0-8,PAGET'S DISEASE,"Paget's disease is a metabolic bone disease characterized by abnormalities of bone turnover, structure and architecture.",78,0 8,78,0,82,15,1,RO-has_finding_site,905143,"Paget's disease is a metabolic bone disease characterized by abnormalities of bone turnover, structure and architecture",bone,Paget's disease
503461324,7/16/2014 14:37:45,,1324280887,7/16/2014 14:37:30,prodege,1.0,6316959,GBR,"","",46.208.145.114,78,0,,,82,15,BONE,PAGET'S DISEASE,BONE,78,0-8,PAGET'S DISEASE,"Paget's disease is a metabolic bone disease characterized by abnormalities of bone turnover, structure and architecture.",78,0 8,78,0,82,15,1,RO-has_finding_site,905143,"Paget's disease is a metabolic bone disease characterized by abnormalities of bone turnover, structure and architecture",bone,Paget's disease
503461324,7/16/2014 14:46:13,,1324283276,7/16/2014 14:45:58,clixsense,1,28059098,USA,TN,Nashville,165.214.11.74,78,0,,,82,15,BONE,PAGET'S DISEASE,"abnormalities of BONE turnover, structure and architecture.",61-75-78-83-93-103-107,0-8,PAGET'S DISEASE,"Paget's disease is a metabolic bone disease characterized by abnormalities of bone turnover, structure and architecture.",78,0 8,78,0,82,15,1,RO-has_finding_site,905143,"Paget's disease is a metabolic bone disease characterized by abnormalities of bone turnover, structure and architecture",bone,Paget's disease
503461324,7/16/2014 14:51:32,,1324284917,7/16/2014 14:51:20,clixsense,1,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,78,0,,,82,15,BONE,PAGET'S DISEASE,BONE,78,0-8,PAGET'S DISEASE,"Paget's disease is a metabolic bone disease characterized by abnormalities of bone turnover, structure and architecture.",78,0 8,78,0,82,15,1,RO-has_finding_site,905143,"Paget's disease is a metabolic bone disease characterized by abnormalities of bone turnover, structure and architecture",bone,Paget's disease
503461324,7/16/2014 14:56:05,,1324286442,7/16/2014 14:55:33,irazoo,1,7022810,USA,IA,Ankeny,216.161.121.1,78,0,,,82,15,BONE,PAGET'S DISEASE,"BONE turnover, structure and architecture.",78-83-93-103-107,0-8,PAGET'S DISEASE,"Paget's disease is a metabolic bone disease characterized by abnormalities of bone turnover, structure and architecture.",78,0 8,78,0,82,15,1,RO-has_finding_site,905143,"Paget's disease is a metabolic bone disease characterized by abnormalities of bone turnover, structure and architecture",bone,Paget's disease
503461324,7/16/2014 14:57:18,,1324286959,7/16/2014 14:57:00,prodege,1,27934334,GBR,Q2,Wokingham,86.166.73.7,78,0,,,82,15,BONE,PAGET'S DISEASE,BONE,78,0-8,PAGET'S DISEASE,"Paget's disease is a metabolic bone disease characterized by abnormalities of bone turnover, structure and architecture.",78,0 8,78,0,82,15,1,RO-has_finding_site,905143,"Paget's disease is a metabolic bone disease characterized by abnormalities of bone turnover, structure and architecture",bone,Paget's disease
503461324,7/16/2014 14:57:52,,1324287189,7/16/2014 14:57:25,clixsense,1,24896327,GBR,V2,Glasgow,94.2.231.4,78,0,,,82,15,BONE,PAGET'S DISEASE,BONE,78,0-8,PAGET'S DISEASE,"Paget's disease is a metabolic bone disease characterized by abnormalities of bone turnover, structure and architecture.",78,0 8,78,0,82,15,1,RO-has_finding_site,905143,"Paget's disease is a metabolic bone disease characterized by abnormalities of bone turnover, structure and architecture",bone,Paget's disease
503461325,7/16/2014 13:55:10,,1324263043,7/16/2014 13:54:56,clixsense,1,19803139,NLD,06,Veldhoven,212.61.84.196,102,187,,,113,200,GALLBLADDER,CHOLECYSTITIS,GALLBLADDER metastasis,102-114,187,CHOLECYSTITIS.,The two reported cases and the 18 cases from the literature indicate that the physician must consider gallbladder metastasis in melanoma patients presenting with symptoms compatible with cholecystitis.,102,187,102,187,113,200,1,RO-has_finding_site,905346,The two reported cases and the 18 cases from the literature indicate that the physician must consider gallbladder metastasis in melanoma patients presenting with symptoms compatible with cholecystitis,gallbladder,cholecystitis
503461325,7/16/2014 14:14:18,,1324271329,7/16/2014 14:14:07,clixsense,1,20614047,USA,MO,Maryville,174.32.162.147,102,187,,,113,200,GALLBLADDER,CHOLECYSTITIS,physician must consider GALLBLADDER metastasis in melanoma,78-88-93-102-114-125-128,162-171-182-187,symptoms compatible with CHOLECYSTITIS.,The two reported cases and the 18 cases from the literature indicate that the physician must consider gallbladder metastasis in melanoma patients presenting with symptoms compatible with cholecystitis.,102,187,102,187,113,200,1,RO-has_finding_site,905346,The two reported cases and the 18 cases from the literature indicate that the physician must consider gallbladder metastasis in melanoma patients presenting with symptoms compatible with cholecystitis,gallbladder,cholecystitis
503461325,7/16/2014 14:27:17,,1324276360,7/16/2014 14:27:02,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,102,187,,,113,200,GALLBLADDER,CHOLECYSTITIS,GALLBLADDER,102,187,CHOLECYSTITIS.,The two reported cases and the 18 cases from the literature indicate that the physician must consider gallbladder metastasis in melanoma patients presenting with symptoms compatible with cholecystitis.,102,187,102,187,113,200,1,RO-has_finding_site,905346,The two reported cases and the 18 cases from the literature indicate that the physician must consider gallbladder metastasis in melanoma patients presenting with symptoms compatible with cholecystitis,gallbladder,cholecystitis
503461325,7/16/2014 14:28:42,,1324276952,7/16/2014 14:28:29,gifthulk,1,22552178,AUS,05,Adelaide,14.2.42.59,102,187,,,113,200,GALLBLADDER,CHOLECYSTITIS,GALLBLADDER,102,187,CHOLECYSTITIS.,The two reported cases and the 18 cases from the literature indicate that the physician must consider gallbladder metastasis in melanoma patients presenting with symptoms compatible with cholecystitis.,102,187,102,187,113,200,1,RO-has_finding_site,905346,The two reported cases and the 18 cases from the literature indicate that the physician must consider gallbladder metastasis in melanoma patients presenting with symptoms compatible with cholecystitis,gallbladder,cholecystitis
503461325,7/16/2014 14:31:54,,1324278383,7/16/2014 14:31:33,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,102,187,,,113,200,GALLBLADDER,CHOLECYSTITIS,GALLBLADDER cholecystitis.,102-187,102-187,gallbladder CHOLECYSTITIS.,The two reported cases and the 18 cases from the literature indicate that the physician must consider gallbladder metastasis in melanoma patients presenting with symptoms compatible with cholecystitis.,102,187,102,187,113,200,1,RO-has_finding_site,905346,The two reported cases and the 18 cases from the literature indicate that the physician must consider gallbladder metastasis in melanoma patients presenting with symptoms compatible with cholecystitis,gallbladder,cholecystitis
503461325,7/16/2014 14:33:10,,1324278859,7/16/2014 14:32:53,prodege,1.0,6316959,GBR,"","",46.208.145.114,102,187,,,113,200,GALLBLADDER,CHOLECYSTITIS,GALLBLADDER metastasis,102-114,187,CHOLECYSTITIS.,The two reported cases and the 18 cases from the literature indicate that the physician must consider gallbladder metastasis in melanoma patients presenting with symptoms compatible with cholecystitis.,102,187,102,187,113,200,1,RO-has_finding_site,905346,The two reported cases and the 18 cases from the literature indicate that the physician must consider gallbladder metastasis in melanoma patients presenting with symptoms compatible with cholecystitis,gallbladder,cholecystitis
503461325,7/16/2014 14:41:04,,1324281944,7/16/2014 14:40:52,prodege,1,1889141,USA,NC,Goldsboro,198.86.16.151,102,187,,,113,200,GALLBLADDER,CHOLECYSTITIS,GALLBLADDER metastasis melanoma,102-114-128,187,CHOLECYSTITIS.,The two reported cases and the 18 cases from the literature indicate that the physician must consider gallbladder metastasis in melanoma patients presenting with symptoms compatible with cholecystitis.,102,187,102,187,113,200,1,RO-has_finding_site,905346,The two reported cases and the 18 cases from the literature indicate that the physician must consider gallbladder metastasis in melanoma patients presenting with symptoms compatible with cholecystitis,gallbladder,cholecystitis
503461325,7/16/2014 14:52:51,,1324285275,7/16/2014 14:52:28,clixsense,1,21478140,CAN,ON,Toronto,69.165.146.96,102,187,,,113,200,GALLBLADDER,CHOLECYSTITIS,GALLBLADDER metastasis melanoma cholecystitis.,102-128-187-114,102-114-187-128,gallbladder metastasis melanoma CHOLECYSTITIS.,The two reported cases and the 18 cases from the literature indicate that the physician must consider gallbladder metastasis in melanoma patients presenting with symptoms compatible with cholecystitis.,102,187,102,187,113,200,1,RO-has_finding_site,905346,The two reported cases and the 18 cases from the literature indicate that the physician must consider gallbladder metastasis in melanoma patients presenting with symptoms compatible with cholecystitis,gallbladder,cholecystitis
503461325,7/16/2014 14:54:28,,1324285853,7/16/2014 14:54:18,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,102,187,,,113,200,GALLBLADDER,CHOLECYSTITIS,GALLBLADDER metastasis,102-114,187,CHOLECYSTITIS.,The two reported cases and the 18 cases from the literature indicate that the physician must consider gallbladder metastasis in melanoma patients presenting with symptoms compatible with cholecystitis.,102,187,102,187,113,200,1,RO-has_finding_site,905346,The two reported cases and the 18 cases from the literature indicate that the physician must consider gallbladder metastasis in melanoma patients presenting with symptoms compatible with cholecystitis,gallbladder,cholecystitis
503461325,7/16/2014 14:57:25,,1324287019,7/16/2014 14:57:16,neodev,1,14861092,GBR,H9,London,90.194.156.173,102,187,,,113,200,GALLBLADDER,CHOLECYSTITIS,GALLBLADDER metastasis,102-114,187,CHOLECYSTITIS.,The two reported cases and the 18 cases from the literature indicate that the physician must consider gallbladder metastasis in melanoma patients presenting with symptoms compatible with cholecystitis.,102,187,102,187,113,200,1,RO-has_finding_site,905346,The two reported cases and the 18 cases from the literature indicate that the physician must consider gallbladder metastasis in melanoma patients presenting with symptoms compatible with cholecystitis,gallbladder,cholecystitis
503461326,7/16/2014 13:50:04,,1324261110,7/16/2014 13:49:50,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,257,194,,,263,205,EYELID,BLEPHARITIS,EYELID,257,194,BLEPHARITIS,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic blepharitis that persists despite usual medical management and eyelid hygiene.",257,194,257,194,263,205,1,RO-has_finding_site,905409,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic blepharitis that persists despite usual medical management and eyelid hygiene",eyelid,blepharitis
503461326,7/16/2014 13:50:29,,1324261284,7/16/2014 13:50:14,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,257,194,,,263,205,EYELID,BLEPHARITIS,EYELID hygiene.,257-264,194,BLEPHARITIS,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic blepharitis that persists despite usual medical management and eyelid hygiene.",257,194,257,194,263,205,1,RO-has_finding_site,905409,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic blepharitis that persists despite usual medical management and eyelid hygiene",eyelid,blepharitis
503461326,7/16/2014 14:02:43,,1324266228,7/16/2014 14:02:28,instagc,1,28301350,GBR,K4,Plymouth,92.28.208.109,257,194,,,263,205,EYELID,BLEPHARITIS,chronic blepharitis EYELID,186-194-257,194,BLEPHARITIS,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic blepharitis that persists despite usual medical management and eyelid hygiene.",257,194,257,194,263,205,1,RO-has_finding_site,905409,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic blepharitis that persists despite usual medical management and eyelid hygiene",eyelid,blepharitis
503461326,7/16/2014 14:07:50,,1324268470,7/16/2014 14:07:13,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,257,194,,,263,205,EYELID,BLEPHARITIS,madarosis DLE erythema scarring differential diagnosis chronic blepharitis medical management EYELID hygiene.,9-49-96-109-160-173-186-194-234-242-257-264,9-49-96-109-160-173-186-194-234-242-257-264,madarosis DLE erythema scarring differential diagnosis chronic BLEPHARITIS medical management eyelid hygiene.,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic blepharitis that persists despite usual medical management and eyelid hygiene.",257,194,257,194,263,205,1,RO-has_finding_site,905409,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic blepharitis that persists despite usual medical management and eyelid hygiene",eyelid,blepharitis
503461326,7/16/2014 14:13:27,,1324270919,7/16/2014 14:13:07,instagc,1.0,13763729,USA,"","",75.182.89.225,257,194,,,263,205,EYELID,BLEPHARITIS,EYELID hygiene.,257-264,186-194,chronic BLEPHARITIS,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic blepharitis that persists despite usual medical management and eyelid hygiene.",257,194,257,194,263,205,1,RO-has_finding_site,905409,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic blepharitis that persists despite usual medical management and eyelid hygiene",eyelid,blepharitis
503461326,7/16/2014 14:29:54,,1324277584,7/16/2014 14:29:39,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,257,194,,,263,205,EYELID,BLEPHARITIS,EYELID,257,194,BLEPHARITIS,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic blepharitis that persists despite usual medical management and eyelid hygiene.",257,194,257,194,263,205,1,RO-has_finding_site,905409,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic blepharitis that persists despite usual medical management and eyelid hygiene",eyelid,blepharitis
503461326,7/16/2014 14:31:34,,1324278314,7/16/2014 14:31:04,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,257,194,,,263,205,EYELID,BLEPHARITIS,EYELID hygiene.,257-264,186-194,chronic BLEPHARITIS,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic blepharitis that persists despite usual medical management and eyelid hygiene.",257,194,257,194,263,205,1,RO-has_finding_site,905409,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic blepharitis that persists despite usual medical management and eyelid hygiene",eyelid,blepharitis
503461326,7/16/2014 14:32:59,,1324278786,7/16/2014 14:32:25,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,257,194,,,263,205,EYELID,BLEPHARITIS,blepharitis EYELID,194-257,194-257,BLEPHARITIS eyelid,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic blepharitis that persists despite usual medical management and eyelid hygiene.",257,194,257,194,263,205,1,RO-has_finding_site,905409,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic blepharitis that persists despite usual medical management and eyelid hygiene",eyelid,blepharitis
503461326,7/16/2014 14:38:35,,1324281126,7/16/2014 14:38:23,prodege,1.0,6316959,GBR,"","",46.208.145.114,257,194,,,263,205,EYELID,BLEPHARITIS,EYELID,257,186-194,chronic BLEPHARITIS,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic blepharitis that persists despite usual medical management and eyelid hygiene.",257,194,257,194,263,205,1,RO-has_finding_site,905409,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic blepharitis that persists despite usual medical management and eyelid hygiene",eyelid,blepharitis
503461326,7/16/2014 14:51:36,,1324284931,7/16/2014 14:51:13,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,257,194,,,263,205,EYELID,BLEPHARITIS,EYELID,257,194,BLEPHARITIS,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic blepharitis that persists despite usual medical management and eyelid hygiene.",257,194,257,194,263,205,1,RO-has_finding_site,905409,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic blepharitis that persists despite usual medical management and eyelid hygiene",eyelid,blepharitis
503461327,7/16/2014 13:39:51,,1324257579,7/16/2014 13:39:17,prodege,1,17780691,CAN,ON,Toronto,24.114.226.82,66,93,,,70,110,SKIN,ACTINIC KERATOSIS,SKIN,66,93-101,ACTINIC KERATOSIS.,"The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis.",66,93 101,66,93,70,110,1,RO-disease_has_primary_anatomic_site,902260,"The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis",skin,actinic keratosis
503461327,7/16/2014 13:47:25,,1324260233,7/16/2014 13:47:18,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,66,93,,,70,110,SKIN,ACTINIC KERATOSIS,"SKIN conditions,",66-71,93-101,ACTINIC KERATOSIS.,"The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis.",66,93 101,66,93,70,110,1,RO-disease_has_primary_anatomic_site,902260,"The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis",skin,actinic keratosis
503461327,7/16/2014 13:50:32,,1324261298,7/16/2014 13:50:22,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,66,93,,,70,110,SKIN,ACTINIC KERATOSIS,SKIN,66,83-93-101,including ACTINIC KERATOSIS.,"The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis.",66,93 101,66,93,70,110,1,RO-disease_has_primary_anatomic_site,902260,"The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis",skin,actinic keratosis
503461327,7/16/2014 13:55:00,,1324263005,7/16/2014 13:54:36,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,66,93,,,70,110,SKIN,ACTINIC KERATOSIS,"SKIN conditions,",66-71,93-101,ACTINIC KERATOSIS.,"The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis.",66,93 101,66,93,70,110,1,RO-disease_has_primary_anatomic_site,902260,"The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis",skin,actinic keratosis
503461327,7/16/2014 13:58:32,,1324264543,7/16/2014 13:58:19,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,66,93,,,70,110,SKIN,ACTINIC KERATOSIS,SKIN actinic keratosis.,66-93-101,93-101,ACTINIC KERATOSIS.,"The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis.",66,93 101,66,93,70,110,1,RO-disease_has_primary_anatomic_site,902260,"The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis",skin,actinic keratosis
503461327,7/16/2014 13:58:44,,1324264637,7/16/2014 13:58:32,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,66,93,,,70,110,SKIN,ACTINIC KERATOSIS,"SKIN conditions,",66-71,93-101,ACTINIC KERATOSIS.,"The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis.",66,93 101,66,93,70,110,1,RO-disease_has_primary_anatomic_site,902260,"The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis",skin,actinic keratosis
503461327,7/16/2014 14:17:06,,1324272355,7/16/2014 14:16:42,vivatic,1.0,25451531,GBR,"","",83.67.28.193,66,93,,,70,110,SKIN,ACTINIC KERATOSIS,"SKIN conditions,",66-71,93-101,ACTINIC KERATOSIS.,"The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis.",66,93 101,66,93,70,110,1,RO-disease_has_primary_anatomic_site,902260,"The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis",skin,actinic keratosis
503461327,7/16/2014 14:20:05,,1324273587,7/16/2014 14:19:31,cotter,1,7461147,USA,VA,Saluda,71.253.203.209,66,93,,,70,110,SKIN,ACTINIC KERATOSIS,"SKIN conditions,",66-71,93-101,ACTINIC KERATOSIS.,"The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis.",66,93 101,66,93,70,110,1,RO-disease_has_primary_anatomic_site,902260,"The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis",skin,actinic keratosis
503461327,7/16/2014 14:27:51,,1324276647,7/16/2014 14:27:36,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,66,93,,,70,110,SKIN,ACTINIC KERATOSIS,SKIN actinic keratosis.,66-93-101,66-93-101,skin ACTINIC KERATOSIS.,"The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis.",66,93 101,66,93,70,110,1,RO-disease_has_primary_anatomic_site,902260,"The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis",skin,actinic keratosis
503461327,7/16/2014 14:43:04,,1324282516,7/16/2014 14:42:55,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,66,93,,,70,110,SKIN,ACTINIC KERATOSIS,SKIN,66,93-101,ACTINIC KERATOSIS.,"The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis.",66,93 101,66,93,70,110,1,RO-disease_has_primary_anatomic_site,902260,"The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis",skin,actinic keratosis
503461328,7/16/2014 13:40:46,,1324257919,7/16/2014 13:40:35,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,29,51,,,41,61,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,29,51-72,"TUBERCULIN specificity,","Current diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",29,51,29,51,41,61,1,RO-may_diagnose,906619,"Current diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis",tuberculosis,tuberculin
503461328,7/16/2014 13:41:31,,1324258187,7/16/2014 13:41:20,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,29,51,,,41,61,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,29,51,TUBERCULIN,"Current diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",29,51,29,51,41,61,1,RO-may_diagnose,906619,"Current diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis",tuberculosis,tuberculin
503461328,7/16/2014 13:50:07,,1324261133,7/16/2014 13:49:54,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,29,51,,,41,61,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,29,51,TUBERCULIN,"Current diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",29,51,29,51,41,61,1,RO-may_diagnose,906619,"Current diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis",tuberculosis,tuberculin
503461328,7/16/2014 13:51:58,,1324261788,7/16/2014 13:51:34,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,29,51,,,41,61,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,29,51,TUBERCULIN,"Current diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",29,51,29,51,41,61,1,RO-may_diagnose,906619,"Current diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis",tuberculosis,tuberculin
503461328,7/16/2014 13:55:10,,1324263048,7/16/2014 13:54:49,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,29,51,,,41,61,TUBERCULOSIS,TUBERCULIN,diagnostic tests for TUBERCULOSIS,8-19-25-29,29-42-48-51,tuberculosis based on TUBERCULIN,"Current diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",29,51,29,51,41,61,1,RO-may_diagnose,906619,"Current diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis",tuberculosis,tuberculin
503461328,7/16/2014 14:07:10,,1324268155,7/16/2014 14:06:55,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,29,51,,,41,61,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,29,51,TUBERCULIN,"Current diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",29,51,29,51,41,61,1,RO-may_diagnose,906619,"Current diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis",tuberculosis,tuberculin
503461328,7/16/2014 14:09:42,,1324269274,7/16/2014 14:09:24,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,29,51,,,41,61,TUBERCULOSIS,TUBERCULIN,diagnostic tests for TUBERCULOSIS,8-19-25-29,29-42-48-51,tuberculosis based on TUBERCULIN,"Current diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",29,51,29,51,41,61,1,RO-may_diagnose,906619,"Current diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis",tuberculosis,tuberculin
503461328,7/16/2014 14:12:45,,1324270689,7/16/2014 14:12:32,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,29,51,,,41,61,TUBERCULOSIS,TUBERCULIN,diagnostic tests for TUBERCULOSIS based on tuberculin,8-19-25-29-42-48-51,29-42-48-51-62-67-72,"tuberculosis based on TUBERCULIN have poor specificity,","Current diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",29,51,29,51,41,61,1,RO-may_diagnose,906619,"Current diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis",tuberculosis,tuberculin
503461328,7/16/2014 14:14:11,,1324271288,7/16/2014 14:13:57,instagc,1.0,13763729,USA,"","",75.182.89.225,29,51,,,41,61,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,29,51,TUBERCULIN,"Current diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",29,51,29,51,41,61,1,RO-may_diagnose,906619,"Current diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis",tuberculosis,tuberculin
503461328,7/16/2014 14:21:55,,1324274331,7/16/2014 14:20:58,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,29,51,,,41,61,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,29,51,TUBERCULIN,"Current diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",29,51,29,51,41,61,1,RO-may_diagnose,906619,"Current diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis",tuberculosis,tuberculin
503461329,7/16/2014 13:40:27,,1324257838,7/16/2014 13:40:13,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,53,0,,,69,7,BIPOLAR DISORDER,LITHIUM,"BIPOLAR DISORDER,",53-61,0,LITHIUM,"Lithium treatment, initially considered specific for bipolar disorder, has since been shown to provide additional benefits in affective and other disorders.",53 61,0,53,0,69,7,1,RO-may_treat,908289,"Lithium treatment, initially considered specific for bipolar disorder, has since been shown to provide additional benefits in affective and other disorders",bipolar disorder,Lithium
503461329,7/16/2014 13:47:17,,1324260193,7/16/2014 13:47:07,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,53,0,,,69,7,BIPOLAR DISORDER,LITHIUM,"BIPOLAR DISORDER,",53-61,0,LITHIUM,"Lithium treatment, initially considered specific for bipolar disorder, has since been shown to provide additional benefits in affective and other disorders.",53 61,0,53,0,69,7,1,RO-may_treat,908289,"Lithium treatment, initially considered specific for bipolar disorder, has since been shown to provide additional benefits in affective and other disorders",bipolar disorder,Lithium
503461329,7/16/2014 13:49:36,,1324260939,7/16/2014 13:49:25,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,53,0,,,69,7,BIPOLAR DISORDER,LITHIUM,"BIPOLAR DISORDER,",53-61,0,LITHIUM,"Lithium treatment, initially considered specific for bipolar disorder, has since been shown to provide additional benefits in affective and other disorders.",53 61,0,53,0,69,7,1,RO-may_treat,908289,"Lithium treatment, initially considered specific for bipolar disorder, has since been shown to provide additional benefits in affective and other disorders",bipolar disorder,Lithium
503461329,7/16/2014 13:55:52,,1324263336,7/16/2014 13:55:26,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,53,0,,,69,7,BIPOLAR DISORDER,LITHIUM,"BIPOLAR DISORDER,",53-61,0-8,"LITHIUM treatment,","Lithium treatment, initially considered specific for bipolar disorder, has since been shown to provide additional benefits in affective and other disorders.",53 61,0,53,0,69,7,1,RO-may_treat,908289,"Lithium treatment, initially considered specific for bipolar disorder, has since been shown to provide additional benefits in affective and other disorders",bipolar disorder,Lithium
503461329,7/16/2014 13:57:00,,1324263821,7/16/2014 13:56:46,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,53,0,,,69,7,BIPOLAR DISORDER,LITHIUM,"BIPOLAR DISORDER,",53-61,0-8,"LITHIUM treatment,","Lithium treatment, initially considered specific for bipolar disorder, has since been shown to provide additional benefits in affective and other disorders.",53 61,0,53,0,69,7,1,RO-may_treat,908289,"Lithium treatment, initially considered specific for bipolar disorder, has since been shown to provide additional benefits in affective and other disorders",bipolar disorder,Lithium
503461329,7/16/2014 13:58:39,,1324264595,7/16/2014 13:58:22,instagc,1.0,18960682,GBR,"","",86.29.147.112,53,0,,,69,7,BIPOLAR DISORDER,LITHIUM,"BIPOLAR DISORDER,",53-61,0,LITHIUM,"Lithium treatment, initially considered specific for bipolar disorder, has since been shown to provide additional benefits in affective and other disorders.",53 61,0,53,0,69,7,1,RO-may_treat,908289,"Lithium treatment, initially considered specific for bipolar disorder, has since been shown to provide additional benefits in affective and other disorders",bipolar disorder,Lithium
503461329,7/16/2014 14:09:14,,1324269108,7/16/2014 14:09:05,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,53,0,,,69,7,BIPOLAR DISORDER,LITHIUM,"BIPOLAR DISORDER,",53-61,0-8,"LITHIUM treatment,","Lithium treatment, initially considered specific for bipolar disorder, has since been shown to provide additional benefits in affective and other disorders.",53 61,0,53,0,69,7,1,RO-may_treat,908289,"Lithium treatment, initially considered specific for bipolar disorder, has since been shown to provide additional benefits in affective and other disorders",bipolar disorder,Lithium
503461329,7/16/2014 14:13:10,,1324270806,7/16/2014 14:12:48,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,53,0,,,69,7,BIPOLAR DISORDER,LITHIUM,"considered specific for BIPOLAR DISORDER, has since been",29-40-49-53-61-71-75-81,0-8-19-29,"LITHIUM treatment, initially considered","Lithium treatment, initially considered specific for bipolar disorder, has since been shown to provide additional benefits in affective and other disorders.",53 61,0,53,0,69,7,1,RO-may_treat,908289,"Lithium treatment, initially considered specific for bipolar disorder, has since been shown to provide additional benefits in affective and other disorders",bipolar disorder,Lithium
503461329,7/16/2014 14:15:40,,1324271759,7/16/2014 14:15:31,prodege,1.0,17932518,GBR,"","",81.133.61.60,53,0,,,69,7,BIPOLAR DISORDER,LITHIUM,"BIPOLAR DISORDER,",53-61,0,LITHIUM,"Lithium treatment, initially considered specific for bipolar disorder, has since been shown to provide additional benefits in affective and other disorders.",53 61,0,53,0,69,7,1,RO-may_treat,908289,"Lithium treatment, initially considered specific for bipolar disorder, has since been shown to provide additional benefits in affective and other disorders",bipolar disorder,Lithium
503461329,7/16/2014 14:38:53,,1324281257,7/16/2014 14:38:36,prodege,1.0,6316959,GBR,"","",46.208.145.114,53,0,,,69,7,BIPOLAR DISORDER,LITHIUM,"BIPOLAR DISORDER,",53-61,0,LITHIUM,"Lithium treatment, initially considered specific for bipolar disorder, has since been shown to provide additional benefits in affective and other disorders.",53 61,0,53,0,69,7,1,RO-may_treat,908289,"Lithium treatment, initially considered specific for bipolar disorder, has since been shown to provide additional benefits in affective and other disorders",bipolar disorder,Lithium
503461330,7/16/2014 13:43:25,,1324258908,7/16/2014 13:43:12,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,344,287,,,350,298,EMESIS,GRANISETRON,EMESIS.,344,287,GRANISETRON,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis.,344,287,344,287,350,298,1,RO-may_prevent,907359,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis,emesis,granisetron
503461330,7/16/2014 13:55:08,,1324263026,7/16/2014 13:54:51,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,344,287,,,350,298,EMESIS,GRANISETRON,EMESIS.,344,287,GRANISETRON,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis.,344,287,344,287,350,298,1,RO-may_prevent,907359,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis,emesis,granisetron
503461330,7/16/2014 14:01:33,,1324265737,7/16/2014 14:01:18,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,344,287,,,350,298,EMESIS,GRANISETRON,EMESIS.,344,287-344,GRANISETRON emesis.,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis.,344,287,344,287,350,298,1,RO-may_prevent,907359,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis,emesis,granisetron
503461330,7/16/2014 14:03:57,,1324266800,7/16/2014 14:03:01,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,344,287,,,350,298,EMESIS,GRANISETRON,dexamethasone serotonin receptor (5 HT3) antagonist granisetron acute emesis cancer patients high dose cisplatin chemotherapy granisetron delayed EMESIS.,49-92-102-111-114-119-130-157-177-187-194-213-218-223-233-287-344-336,49-92-102-111-114-119-130-157-177-187-194-223-233-287-336-344,dexamethasone serotonin receptor (5 HT3) antagonist granisetron acute emesis cancer patients cisplatin chemotherapy GRANISETRON delayed emesis.,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis.,344,287,344,287,350,298,1,RO-may_prevent,907359,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis,emesis,granisetron
503461330,7/16/2014 14:09:10,,1324269061,7/16/2014 14:08:52,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,344,287,,,350,298,EMESIS,GRANISETRON,occurrence of delayed EMESIS.,322-333-336-344,263-271-284-287-299-305-308,whether continuation of GRANISETRON after 24 h,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis.,344,287,344,287,350,298,1,RO-may_prevent,907359,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis,emesis,granisetron
503461330,7/16/2014 14:26:55,,1324276220,7/16/2014 14:26:38,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,344,287,,,350,298,EMESIS,GRANISETRON,EMESIS.,344,287,GRANISETRON,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis.,344,287,344,287,350,298,1,RO-may_prevent,907359,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis,emesis,granisetron
503461330,7/16/2014 14:39:00,,1324281308,7/16/2014 14:37:56,prodege,1.0,26790109,USA,"","",23.125.64.233,344,287,,,350,298,EMESIS,GRANISETRON,in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed EMESIS.,142-145-157-163-171-174-177-184-187-194-203-213-218-223-233-246-250-253-263-271-284-287-299-305-308-310-322-333-336-344-318,177-184-187-194-203-213-218-223-233-246-250-263-271-284-287-299-305-308-310-318-322-333-336-344-253,emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed emesis.,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis.,344,287,344,287,350,298,1,RO-may_prevent,907359,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis,emesis,granisetron
503461330,7/16/2014 14:50:28,,1324284632,7/16/2014 14:49:59,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,344,287,,,350,298,EMESIS,GRANISETRON,delayed EMESIS.,336-344,287,GRANISETRON,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis.,344,287,344,287,350,298,1,RO-may_prevent,907359,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis,emesis,granisetron
503461330,7/16/2014 14:50:48,,1324284720,7/16/2014 14:50:24,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,344,287,,,350,298,EMESIS,GRANISETRON,occurrence of delayed EMESIS.,322-333-336-344,287,GRANISETRON,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis.,344,287,344,287,350,298,1,RO-may_prevent,907359,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis,emesis,granisetron
503461330,7/16/2014 14:52:45,,1324285257,7/16/2014 14:52:33,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,344,287,,,350,298,EMESIS,GRANISETRON,EMESIS.,344,287,GRANISETRON,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis.,344,287,344,287,350,298,1,RO-may_prevent,907359,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis,emesis,granisetron
503461331,7/16/2014 13:54:11,,1324262700,7/16/2014 13:53:53,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,127,160,,,139,170,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,127,160,TUBERCULIN,"In 1954, 70 of the 210 survey areas of the previous year were re-surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to tuberculin-testing during the year and to determine the tuberculosis incidence.",127,160,127,160,139,170,1,RO-may_diagnose,906799,"In 1954, 70 of the 210 survey areas of the previous year were re-surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to tuberculin-testing during the year and to determine the tuberculosis incidence",tuberculosis,tuberculin
503461331,7/16/2014 13:56:57,,1324263804,7/16/2014 13:56:27,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,127,160,,,139,170,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS tuberculin,127-160,127-160,tuberculosis TUBERCULIN,"In 1954, 70 of the 210 survey areas of the previous year were re-surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to tuberculin-testing during the year and to determine the tuberculosis incidence.",127,160,127,160,139,170,1,RO-may_diagnose,906799,"In 1954, 70 of the 210 survey areas of the previous year were re-surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to tuberculin-testing during the year and to determine the tuberculosis incidence",tuberculosis,tuberculin
503461331,7/16/2014 13:58:32,,1324264542,7/16/2014 13:57:59,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,127,160,,,139,170,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,127,160-171,TUBERCULIN testing,"In 1954, 70 of the 210 survey areas of the previous year were re-surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to tuberculin-testing during the year and to determine the tuberculosis incidence.",127,160,127,160,139,170,1,RO-may_diagnose,906799,"In 1954, 70 of the 210 survey areas of the previous year were re-surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to tuberculin-testing during the year and to determine the tuberculosis incidence",tuberculosis,tuberculin
503461331,7/16/2014 13:59:59,,1324265219,7/16/2014 13:59:37,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,127,160,,,139,170,TUBERCULOSIS,TUBERCULIN,extent of TUBERCULOSIS,117-124-127,160-171,TUBERCULIN testing,"In 1954, 70 of the 210 survey areas of the previous year were re-surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to tuberculin-testing during the year and to determine the tuberculosis incidence.",127,160,127,160,139,170,1,RO-may_diagnose,906799,"In 1954, 70 of the 210 survey areas of the previous year were re-surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to tuberculin-testing during the year and to determine the tuberculosis incidence",tuberculosis,tuberculin
503461331,7/16/2014 14:03:42,,1324266672,7/16/2014 14:03:27,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,127,160,,,139,170,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,127,160-171,TUBERCULIN testing,"In 1954, 70 of the 210 survey areas of the previous year were re-surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to tuberculin-testing during the year and to determine the tuberculosis incidence.",127,160,127,160,139,170,1,RO-may_diagnose,906799,"In 1954, 70 of the 210 survey areas of the previous year were re-surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to tuberculin-testing during the year and to determine the tuberculosis incidence",tuberculosis,tuberculin
503461331,7/16/2014 14:16:07,,1324271927,7/16/2014 14:15:56,prodege,1.0,17932518,GBR,"","",81.133.61.60,127,160,,,139,170,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,127,160,TUBERCULIN,"In 1954, 70 of the 210 survey areas of the previous year were re-surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to tuberculin-testing during the year and to determine the tuberculosis incidence.",127,160,127,160,139,170,1,RO-may_diagnose,906799,"In 1954, 70 of the 210 survey areas of the previous year were re-surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to tuberculin-testing during the year and to determine the tuberculosis incidence",tuberculosis,tuberculin
503461331,7/16/2014 14:24:24,,1324275296,7/16/2014 14:24:05,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,127,160,,,139,170,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,127,160,TUBERCULIN,"In 1954, 70 of the 210 survey areas of the previous year were re-surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to tuberculin-testing during the year and to determine the tuberculosis incidence.",127,160,127,160,139,170,1,RO-may_diagnose,906799,"In 1954, 70 of the 210 survey areas of the previous year were re-surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to tuberculin-testing during the year and to determine the tuberculosis incidence",tuberculosis,tuberculin
503461331,7/16/2014 14:33:29,,1324279004,7/16/2014 14:32:59,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,127,160,,,139,170,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,127,160-171,TUBERCULIN testing,"In 1954, 70 of the 210 survey areas of the previous year were re-surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to tuberculin-testing during the year and to determine the tuberculosis incidence.",127,160,127,160,139,170,1,RO-may_diagnose,906799,"In 1954, 70 of the 210 survey areas of the previous year were re-surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to tuberculin-testing during the year and to determine the tuberculosis incidence",tuberculosis,tuberculin
503461331,7/16/2014 14:48:31,,1324283995,7/16/2014 14:48:08,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,127,160,,,139,170,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,127,127-160,tuberculosis TUBERCULIN,"In 1954, 70 of the 210 survey areas of the previous year were re-surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to tuberculin-testing during the year and to determine the tuberculosis incidence.",127,160,127,160,139,170,1,RO-may_diagnose,906799,"In 1954, 70 of the 210 survey areas of the previous year were re-surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to tuberculin-testing during the year and to determine the tuberculosis incidence",tuberculosis,tuberculin
503461331,7/16/2014 14:56:14,,1324286472,7/16/2014 14:55:59,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,127,160,,,139,170,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,127,160-171,TUBERCULIN testing,"In 1954, 70 of the 210 survey areas of the previous year were re-surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to tuberculin-testing during the year and to determine the tuberculosis incidence.",127,160,127,160,139,170,1,RO-may_diagnose,906799,"In 1954, 70 of the 210 survey areas of the previous year were re-surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to tuberculin-testing during the year and to determine the tuberculosis incidence",tuberculosis,tuberculin
503461332,7/16/2014 13:48:26,,1324260560,7/16/2014 13:48:08,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,224,143,,,252,148,SYSTEMIC LUPUS ERYTHEMATOSUS,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,224-233-239,143,LUPUS,"Development of autoantibodies before the clinical onset of systemic lupus erythematosus  Premature coronary-artery atherosclerosis in systemic lupus erythematosus  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus  Lineage-specific hematopoietic growth factors  Combined oral contraceptives in women with systemic lupus erythematosus  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX  Rheumatology (Oxford)  Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort  Mycophenolate mofetil is as efficacious as.",224 233 239,143,224,143,252,148,-1,RO-has_manifestation,906287,"Development of autoantibodies before the clinical onset of systemic lupus erythematosus  Premature coronary-artery atherosclerosis in systemic lupus erythematosus  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus  Lineage-specific hematopoietic growth factors  Combined oral contraceptives in women with systemic lupus erythematosus  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX  Rheumatology (Oxford)  Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort  Mycophenolate mofetil is as efficacious as",systemic lupus erythematosus,lupus
503461332,7/16/2014 13:48:28,,1324260586,7/16/2014 13:48:01,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,224,143,,,252,148,SYSTEMIC LUPUS ERYTHEMATOSUS,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,224-233-239,134-143-149,systemic LUPUS erythematosus,"Development of autoantibodies before the clinical onset of systemic lupus erythematosus  Premature coronary-artery atherosclerosis in systemic lupus erythematosus  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus  Lineage-specific hematopoietic growth factors  Combined oral contraceptives in women with systemic lupus erythematosus  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX  Rheumatology (Oxford)  Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort  Mycophenolate mofetil is as efficacious as.",224 233 239,143,224,143,252,148,-1,RO-has_manifestation,906287,"Development of autoantibodies before the clinical onset of systemic lupus erythematosus  Premature coronary-artery atherosclerosis in systemic lupus erythematosus  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus  Lineage-specific hematopoietic growth factors  Combined oral contraceptives in women with systemic lupus erythematosus  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX  Rheumatology (Oxford)  Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort  Mycophenolate mofetil is as efficacious as",systemic lupus erythematosus,lupus
503461332,7/16/2014 14:01:15,,1324265516,7/16/2014 13:59:09,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,224,143,,,252,148,SYSTEMIC LUPUS ERYTHEMATOSUS,LUPUS,"autoantibodies clinical onset systemic lupus erythematosus Premature coronary artery atherosclerosis systemic lupus erythematosus Prevalence correlates accelerated atherosclerosis in SYSTEMIC LUPUS ERYTHEMATOSUS Lineage specific hematopoietic growth factors Combined oral contraceptives systemic lupus erythematosus Association systemic lupus erythematosus C8orf13 - BLK ITGAM ITGAX Rheumatology (Oxford) Fatigue systemic lupus erythematosus: randomized controlled trial exercise Predictors cardiovascular damage systemic lupus erythematosus: LUMINA (LXVIII), Mycophenolate mofetil",15-41-50-59-68-74-89-99-108-115-134-143-149-164-179-193-205-221-224-233-239-254-262-271-285-292-301-310-315-344-353-359-374-389-398-404-423-430-431-439-445-452-465-475-486-495-501-518-529-540-549-559-573-588-612-621-627-652-659-694-708,15-41-50-59-68-74-89-99-108-115-131-134-143-149-164-193-205-221-224-233-239-254-262-271-310-315-344-353-359-374-389-398-404-423-431-439-445-452-465-475-486-495-501-573-588-612-621-627-652-659-694-708-179,"autoantibodies clinical onset systemic lupus erythematosus Premature coronary artery atherosclerosis in systemic LUPUS erythematosus Prevalence correlates accelerated atherosclerosis in systemic lupus erythematosus Lineage specific hematopoietic oral contraceptives systemic lupus erythematosus Association systemic lupus erythematosus C8orf13 BLK ITGAM ITGAX Rheumatology (Oxford) Fatigue systemic lupus erythematosus: cardiovascular damage systemic lupus erythematosus: LUMINA (LXVIII), Mycophenolate mofetil","Development of autoantibodies before the clinical onset of systemic lupus erythematosus  Premature coronary-artery atherosclerosis in systemic lupus erythematosus  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus  Lineage-specific hematopoietic growth factors  Combined oral contraceptives in women with systemic lupus erythematosus  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX  Rheumatology (Oxford)  Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort  Mycophenolate mofetil is as efficacious as.",224 233 239,143,224,143,252,148,-1,RO-has_manifestation,906287,"Development of autoantibodies before the clinical onset of systemic lupus erythematosus  Premature coronary-artery atherosclerosis in systemic lupus erythematosus  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus  Lineage-specific hematopoietic growth factors  Combined oral contraceptives in women with systemic lupus erythematosus  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX  Rheumatology (Oxford)  Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort  Mycophenolate mofetil is as efficacious as",systemic lupus erythematosus,lupus
503461332,7/16/2014 14:17:11,,1324272383,7/16/2014 14:16:58,prodege,1.0,17932518,GBR,"","",81.133.61.60,224,143,,,252,148,SYSTEMIC LUPUS ERYTHEMATOSUS,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,224-233-239,143-149,LUPUS erythematosus,"Development of autoantibodies before the clinical onset of systemic lupus erythematosus  Premature coronary-artery atherosclerosis in systemic lupus erythematosus  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus  Lineage-specific hematopoietic growth factors  Combined oral contraceptives in women with systemic lupus erythematosus  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX  Rheumatology (Oxford)  Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort  Mycophenolate mofetil is as efficacious as.",224 233 239,143,224,143,252,148,-1,RO-has_manifestation,906287,"Development of autoantibodies before the clinical onset of systemic lupus erythematosus  Premature coronary-artery atherosclerosis in systemic lupus erythematosus  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus  Lineage-specific hematopoietic growth factors  Combined oral contraceptives in women with systemic lupus erythematosus  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX  Rheumatology (Oxford)  Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort  Mycophenolate mofetil is as efficacious as",systemic lupus erythematosus,lupus
503461332,7/16/2014 14:20:56,,1324273946,7/16/2014 14:20:07,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,224,143,,,252,148,SYSTEMIC LUPUS ERYTHEMATOSUS,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,224-233-239,134-143-149,systemic LUPUS erythematosus,"Development of autoantibodies before the clinical onset of systemic lupus erythematosus  Premature coronary-artery atherosclerosis in systemic lupus erythematosus  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus  Lineage-specific hematopoietic growth factors  Combined oral contraceptives in women with systemic lupus erythematosus  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX  Rheumatology (Oxford)  Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort  Mycophenolate mofetil is as efficacious as.",224 233 239,143,224,143,252,148,-1,RO-has_manifestation,906287,"Development of autoantibodies before the clinical onset of systemic lupus erythematosus  Premature coronary-artery atherosclerosis in systemic lupus erythematosus  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus  Lineage-specific hematopoietic growth factors  Combined oral contraceptives in women with systemic lupus erythematosus  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX  Rheumatology (Oxford)  Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort  Mycophenolate mofetil is as efficacious as",systemic lupus erythematosus,lupus
503461332,7/16/2014 14:25:02,,1324275572,7/16/2014 14:24:06,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,224,143,,,252,148,SYSTEMIC LUPUS ERYTHEMATOSUS,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,224-233-239,143,LUPUS,"Development of autoantibodies before the clinical onset of systemic lupus erythematosus  Premature coronary-artery atherosclerosis in systemic lupus erythematosus  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus  Lineage-specific hematopoietic growth factors  Combined oral contraceptives in women with systemic lupus erythematosus  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX  Rheumatology (Oxford)  Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort  Mycophenolate mofetil is as efficacious as.",224 233 239,143,224,143,252,148,-1,RO-has_manifestation,906287,"Development of autoantibodies before the clinical onset of systemic lupus erythematosus  Premature coronary-artery atherosclerosis in systemic lupus erythematosus  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus  Lineage-specific hematopoietic growth factors  Combined oral contraceptives in women with systemic lupus erythematosus  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX  Rheumatology (Oxford)  Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort  Mycophenolate mofetil is as efficacious as",systemic lupus erythematosus,lupus
503461332,7/16/2014 14:29:09,,1324277227,7/16/2014 14:28:41,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,224,143,,,252,148,SYSTEMIC LUPUS ERYTHEMATOSUS,LUPUS,lupus SYSTEMIC LUPUS ERYTHEMATOSUS,143-224-233-239,143-224-233-239,LUPUS systemic lupus erythematosus,"Development of autoantibodies before the clinical onset of systemic lupus erythematosus  Premature coronary-artery atherosclerosis in systemic lupus erythematosus  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus  Lineage-specific hematopoietic growth factors  Combined oral contraceptives in women with systemic lupus erythematosus  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX  Rheumatology (Oxford)  Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort  Mycophenolate mofetil is as efficacious as.",224 233 239,143,224,143,252,148,-1,RO-has_manifestation,906287,"Development of autoantibodies before the clinical onset of systemic lupus erythematosus  Premature coronary-artery atherosclerosis in systemic lupus erythematosus  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus  Lineage-specific hematopoietic growth factors  Combined oral contraceptives in women with systemic lupus erythematosus  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX  Rheumatology (Oxford)  Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort  Mycophenolate mofetil is as efficacious as",systemic lupus erythematosus,lupus
503461332,7/16/2014 14:38:22,,1324281055,7/16/2014 14:37:58,prodege,1.0,6316959,GBR,"","",46.208.145.114,224,143,,,252,148,SYSTEMIC LUPUS ERYTHEMATOSUS,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,224-233-239,134-143-149,systemic LUPUS erythematosus,"Development of autoantibodies before the clinical onset of systemic lupus erythematosus  Premature coronary-artery atherosclerosis in systemic lupus erythematosus  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus  Lineage-specific hematopoietic growth factors  Combined oral contraceptives in women with systemic lupus erythematosus  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX  Rheumatology (Oxford)  Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort  Mycophenolate mofetil is as efficacious as.",224 233 239,143,224,143,252,148,-1,RO-has_manifestation,906287,"Development of autoantibodies before the clinical onset of systemic lupus erythematosus  Premature coronary-artery atherosclerosis in systemic lupus erythematosus  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus  Lineage-specific hematopoietic growth factors  Combined oral contraceptives in women with systemic lupus erythematosus  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX  Rheumatology (Oxford)  Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort  Mycophenolate mofetil is as efficacious as",systemic lupus erythematosus,lupus
503461332,7/16/2014 14:39:39,,1324281515,7/16/2014 14:39:08,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,224,143,,,252,148,SYSTEMIC LUPUS ERYTHEMATOSUS,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,224-233-239,134-143-149,systemic LUPUS erythematosus,"Development of autoantibodies before the clinical onset of systemic lupus erythematosus  Premature coronary-artery atherosclerosis in systemic lupus erythematosus  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus  Lineage-specific hematopoietic growth factors  Combined oral contraceptives in women with systemic lupus erythematosus  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX  Rheumatology (Oxford)  Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort  Mycophenolate mofetil is as efficacious as.",224 233 239,143,224,143,252,148,-1,RO-has_manifestation,906287,"Development of autoantibodies before the clinical onset of systemic lupus erythematosus  Premature coronary-artery atherosclerosis in systemic lupus erythematosus  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus  Lineage-specific hematopoietic growth factors  Combined oral contraceptives in women with systemic lupus erythematosus  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX  Rheumatology (Oxford)  Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort  Mycophenolate mofetil is as efficacious as",systemic lupus erythematosus,lupus
503461332,7/16/2014 14:43:52,,1324282701,7/16/2014 14:41:38,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,224,143,,,252,148,SYSTEMIC LUPUS ERYTHEMATOSUS,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,224-233-239,134-143-149,systemic LUPUS erythematosus,"Development of autoantibodies before the clinical onset of systemic lupus erythematosus  Premature coronary-artery atherosclerosis in systemic lupus erythematosus  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus  Lineage-specific hematopoietic growth factors  Combined oral contraceptives in women with systemic lupus erythematosus  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX  Rheumatology (Oxford)  Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort  Mycophenolate mofetil is as efficacious as.",224 233 239,143,224,143,252,148,-1,RO-has_manifestation,906287,"Development of autoantibodies before the clinical onset of systemic lupus erythematosus  Premature coronary-artery atherosclerosis in systemic lupus erythematosus  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus  Lineage-specific hematopoietic growth factors  Combined oral contraceptives in women with systemic lupus erythematosus  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX  Rheumatology (Oxford)  Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort  Mycophenolate mofetil is as efficacious as",systemic lupus erythematosus,lupus
503461333,7/16/2014 13:49:52,,1324261024,7/16/2014 13:49:35,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,61,4,,,73,12,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,61,4,GLUCAGON,"The glucagon and norepinephrine responses to insulin-induced hypoglycemia are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",61,4,61,4,73,12,1,RO-may_treat,908243,"The glucagon and norepinephrine responses to insulin-induced hypoglycemia are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose",hypoglycemia,glucagon
503461333,7/16/2014 13:56:23,,1324263602,7/16/2014 13:56:12,instagc,1.0,18960682,GBR,"","",86.29.147.112,61,4,,,73,12,HYPOGLYCEMIA,GLUCAGON,insulin induced HYPOGLYCEMIA,45-53-61,4,GLUCAGON,"The glucagon and norepinephrine responses to insulin-induced hypoglycemia are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",61,4,61,4,73,12,1,RO-may_treat,908243,"The glucagon and norepinephrine responses to insulin-induced hypoglycemia are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose",hypoglycemia,glucagon
503461333,7/16/2014 13:57:31,,1324264083,7/16/2014 13:57:11,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,61,4,,,73,12,HYPOGLYCEMIA,GLUCAGON,insulin induced HYPOGLYCEMIA,45-53-61,4-13-17,GLUCAGON and norepinephrine,"The glucagon and norepinephrine responses to insulin-induced hypoglycemia are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",61,4,61,4,73,12,1,RO-may_treat,908243,"The glucagon and norepinephrine responses to insulin-induced hypoglycemia are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose",hypoglycemia,glucagon
503461333,7/16/2014 14:15:32,,1324271681,7/16/2014 14:14:49,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,61,4,,,73,12,HYPOGLYCEMIA,GLUCAGON,insulin induced HYPOGLYCEMIA,45-53-61,4,GLUCAGON,"The glucagon and norepinephrine responses to insulin-induced hypoglycemia are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",61,4,61,4,73,12,1,RO-may_treat,908243,"The glucagon and norepinephrine responses to insulin-induced hypoglycemia are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose",hypoglycemia,glucagon
503461333,7/16/2014 14:21:11,,1324274066,7/16/2014 14:20:51,vivatic,1.0,25451531,GBR,"","",83.67.28.193,61,4,,,73,12,HYPOGLYCEMIA,GLUCAGON,insulin induced HYPOGLYCEMIA,45-53-61,4,GLUCAGON,"The glucagon and norepinephrine responses to insulin-induced hypoglycemia are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",61,4,61,4,73,12,1,RO-may_treat,908243,"The glucagon and norepinephrine responses to insulin-induced hypoglycemia are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose",hypoglycemia,glucagon
503461333,7/16/2014 14:24:23,,1324275281,7/16/2014 14:24:08,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,61,4,,,73,12,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,61,4,GLUCAGON,"The glucagon and norepinephrine responses to insulin-induced hypoglycemia are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",61,4,61,4,73,12,1,RO-may_treat,908243,"The glucagon and norepinephrine responses to insulin-induced hypoglycemia are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose",hypoglycemia,glucagon
503461333,7/16/2014 14:29:01,,1324277181,7/16/2014 14:28:39,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,61,4,,,73,12,HYPOGLYCEMIA,GLUCAGON,insulin induced HYPOGLYCEMIA,45-53-61,4,GLUCAGON,"The glucagon and norepinephrine responses to insulin-induced hypoglycemia are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",61,4,61,4,73,12,1,RO-may_treat,908243,"The glucagon and norepinephrine responses to insulin-induced hypoglycemia are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose",hypoglycemia,glucagon
503461333,7/16/2014 14:51:58,,1324285050,7/16/2014 14:51:47,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,61,4,,,73,12,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,61,4,GLUCAGON,"The glucagon and norepinephrine responses to insulin-induced hypoglycemia are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",61,4,61,4,73,12,1,RO-may_treat,908243,"The glucagon and norepinephrine responses to insulin-induced hypoglycemia are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose",hypoglycemia,glucagon
503461333,7/16/2014 14:52:18,,1324285139,7/16/2014 14:52:09,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,61,4,,,73,12,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,61,4,GLUCAGON,"The glucagon and norepinephrine responses to insulin-induced hypoglycemia are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",61,4,61,4,73,12,1,RO-may_treat,908243,"The glucagon and norepinephrine responses to insulin-induced hypoglycemia are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose",hypoglycemia,glucagon
503461333,7/16/2014 14:57:14,,1324286950,7/16/2014 14:57:01,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,61,4,,,73,12,HYPOGLYCEMIA,GLUCAGON,insulin induced HYPOGLYCEMIA,45-53-61,4,GLUCAGON,"The glucagon and norepinephrine responses to insulin-induced hypoglycemia are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",61,4,61,4,73,12,1,RO-may_treat,908243,"The glucagon and norepinephrine responses to insulin-induced hypoglycemia are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose",hypoglycemia,glucagon
503461334,7/16/2014 13:48:07,,1324260466,7/16/2014 13:47:56,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,93,45,,,102,56,SINUSITIS,AMOXICILLIN,acute maxillary SINUSITIS.,77-83-93,45,AMOXICILLIN,Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis.,93,45,93,45,102,56,1,RO-may_treat,907639,Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis,sinusitis,amoxicillin
503461334,7/16/2014 13:48:11,,1324260492,7/16/2014 13:47:50,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,93,45,,,102,56,SINUSITIS,AMOXICILLIN,acute maxillary SINUSITIS.,77-83-93,26-41-45,clarithromycin and AMOXICILLIN,Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis.,93,45,93,45,102,56,1,RO-may_treat,907639,Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis,sinusitis,amoxicillin
503461334,7/16/2014 13:54:55,,1324262970,7/16/2014 13:54:42,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,93,45,,,102,56,SINUSITIS,AMOXICILLIN,acute maxillary SINUSITIS.,83-93-77,45,AMOXICILLIN,Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis.,93,45,93,45,102,56,1,RO-may_treat,907639,Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis,sinusitis,amoxicillin
503461334,7/16/2014 13:55:33,,1324263224,7/16/2014 13:55:10,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,93,45,,,102,56,SINUSITIS,AMOXICILLIN,SINUSITIS.,93,45,AMOXICILLIN,Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis.,93,45,93,45,102,56,1,RO-may_treat,907639,Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis,sinusitis,amoxicillin
503461334,7/16/2014 14:02:42,,1324266229,7/16/2014 14:02:28,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,93,45,,,102,56,SINUSITIS,AMOXICILLIN,clarithromycin amoxicillin acute maxillary SINUSITIS.,26-45-77-83-93,26-45-77-93-83,clarithromycin AMOXICILLIN acute maxillary sinusitis.,Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis.,93,45,93,45,102,56,1,RO-may_treat,907639,Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis,sinusitis,amoxicillin
503461334,7/16/2014 14:07:23,,1324268288,7/16/2014 14:07:12,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,93,45,,,102,56,SINUSITIS,AMOXICILLIN,acute maxillary SINUSITIS.,77-83-93,45,AMOXICILLIN,Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis.,93,45,93,45,102,56,1,RO-may_treat,907639,Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis,sinusitis,amoxicillin
503461334,7/16/2014 14:19:25,,1324273346,7/16/2014 14:19:09,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,93,45,,,102,56,SINUSITIS,AMOXICILLIN,acute maxillary SINUSITIS.,77-83-93,45,AMOXICILLIN,Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis.,93,45,93,45,102,56,1,RO-may_treat,907639,Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis,sinusitis,amoxicillin
503461334,7/16/2014 14:24:22,,1324275290,7/16/2014 14:24:07,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,93,45,,,102,56,SINUSITIS,AMOXICILLIN,acute maxillary SINUSITIS.,77-83-93,45,AMOXICILLIN,Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis.,93,45,93,45,102,56,1,RO-may_treat,907639,Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis,sinusitis,amoxicillin
503461334,7/16/2014 14:25:35,,1324275787,7/16/2014 14:25:22,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,93,45,,,102,56,SINUSITIS,AMOXICILLIN,SINUSITIS.,93,45,AMOXICILLIN,Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis.,93,45,93,45,102,56,1,RO-may_treat,907639,Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis,sinusitis,amoxicillin
503461334,7/16/2014 14:31:10,,1324278169,7/16/2014 14:30:44,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,93,45,,,102,56,SINUSITIS,AMOXICILLIN,SINUSITIS.,93,45,AMOXICILLIN,Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis.,93,45,93,45,102,56,1,RO-may_treat,907639,Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis,sinusitis,amoxicillin
503461335,7/16/2014 13:53:06,,1324262235,7/16/2014 13:52:36,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,103,31,,,114,36,HAEMOPHILIA,FVIII,HAEMOPHILIA,103,30,(FVIII),"The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",103,,103,31,114,36,-1,RO-has_manifestation,906352,"The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors",haemophilia,FVIII
503461335,7/16/2014 13:53:30,,1324262372,7/16/2014 13:53:00,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,103,31,,,114,36,HAEMOPHILIA,FVIII,HAEMOPHILIA A.,103-115,18-25-30,factor VIII (FVIII),"The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",103,,103,31,114,36,-1,RO-has_manifestation,906352,"The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors",haemophilia,FVIII
503461335,7/16/2014 14:03:52,,1324266763,7/16/2014 14:03:43,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,103,31,,,114,36,HAEMOPHILIA,FVIII,HAEMOPHILIA A.,103-115,18-25-30-38,factor VIII (FVIII) inhibitors,"The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",103,,103,31,114,36,-1,RO-has_manifestation,906352,"The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors",haemophilia,FVIII
503461335,7/16/2014 14:23:05,,1324274808,7/16/2014 14:22:46,vivatic,1.0,25451531,GBR,"","",83.67.28.193,103,31,,,114,36,HAEMOPHILIA,FVIII,HAEMOPHILIA A.,103-115,18-25-30-38,factor VIII (FVIII) inhibitors,"The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",103,,103,31,114,36,-1,RO-has_manifestation,906352,"The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors",haemophilia,FVIII
503461335,7/16/2014 14:37:42,,1324280874,7/16/2014 14:37:30,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,103,31,,,114,36,HAEMOPHILIA,FVIII,HAEMOPHILIA A.,103-115,18-25-30-38,factor VIII (FVIII) inhibitors,"The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",103,,103,31,114,36,-1,RO-has_manifestation,906352,"The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors",haemophilia,FVIII
503461335,7/16/2014 14:45:16,,1324283040,7/16/2014 14:44:57,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,103,31,,,114,36,HAEMOPHILIA,FVIII,HAEMOPHILIA A.,103-115,18-25-30-38,factor VIII (FVIII) inhibitors,"The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",103,,103,31,114,36,-1,RO-has_manifestation,906352,"The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors",haemophilia,FVIII
503461335,7/16/2014 14:46:49,,1324283484,7/16/2014 14:46:40,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,103,31,,,114,36,HAEMOPHILIA,FVIII,HAEMOPHILIA,103,30-38,(FVIII) inhibitors,"The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",103,,103,31,114,36,-1,RO-has_manifestation,906352,"The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors",haemophilia,FVIII
503461335,7/16/2014 14:49:57,,1324284463,7/16/2014 14:49:33,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,103,31,,,114,36,HAEMOPHILIA,FVIII,HAEMOPHILIA A.,103-115,18-25-30,factor VIII (FVIII),"The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",103,,103,31,114,36,-1,RO-has_manifestation,906352,"The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors",haemophilia,FVIII
503461335,7/16/2014 14:54:56,,1324285993,7/16/2014 14:54:54,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,103,31,,,114,36,HAEMOPHILIA,FVIII,the treatment of HAEMOPHILIA A. We present,86-90-100-103-115-118-121,18-25-30-38-49-52,factor VIII (FVIII) inhibitors is one,"The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",103,,103,31,114,36,-1,RO-has_manifestation,906352,"The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors",haemophilia,FVIII
503461335,7/16/2014 14:55:15,,1324286110,7/16/2014 14:54:49,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,103,31,,,114,36,HAEMOPHILIA,FVIII,HAEMOPHILIA A.,103-115,18-25-30,factor VIII (FVIII),"The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",103,,103,31,114,36,-1,RO-has_manifestation,906352,"The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors",haemophilia,FVIII
503461336,7/16/2014 13:44:47,,1324259370,7/16/2014 13:44:39,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,220,200,,,225,204,BRAIN,SSPE,BRAIN cultures,220-226,200-205-211,"SSPE brain tissues,","Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE brain tissues, brain cultures derived from them, and CV-1 cells infected with SSPE viruses.",220,200,220,200,225,204,1,RO-disease_has_primary_anatomic_site,902239,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE brain tissues, brain cultures derived from them, and CV-1 cells infected with SSPE viruses",brain,SSPE
503461336,7/16/2014 13:50:29,,1324261277,7/16/2014 13:50:19,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,220,200,,,225,204,BRAIN,SSPE,BRAIN cultures,220-226,200-205-211,"SSPE brain tissues,","Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE brain tissues, brain cultures derived from them, and CV-1 cells infected with SSPE viruses.",220,200,220,200,225,204,1,RO-disease_has_primary_anatomic_site,902239,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE brain tissues, brain cultures derived from them, and CV-1 cells infected with SSPE viruses",brain,SSPE
503461336,7/16/2014 13:51:30,,1324261652,7/16/2014 13:51:14,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,220,200,,,225,204,BRAIN,SSPE,BRAIN,220,200,SSPE,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE brain tissues, brain cultures derived from them, and CV-1 cells infected with SSPE viruses.",220,200,220,200,225,204,1,RO-disease_has_primary_anatomic_site,902239,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE brain tissues, brain cultures derived from them, and CV-1 cells infected with SSPE viruses",brain,SSPE
503461336,7/16/2014 13:54:21,,1324262782,7/16/2014 13:54:02,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,220,200,,,225,204,BRAIN,SSPE,"SSPE brain tissues, BRAIN",200-205-211-220,200-205-211,"SSPE brain tissues,","Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE brain tissues, brain cultures derived from them, and CV-1 cells infected with SSPE viruses.",220,200,220,200,225,204,1,RO-disease_has_primary_anatomic_site,902239,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE brain tissues, brain cultures derived from them, and CV-1 cells infected with SSPE viruses",brain,SSPE
503461336,7/16/2014 13:55:17,,1324263073,7/16/2014 13:54:48,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,220,200,,,225,204,BRAIN,SSPE,"SSPE brain tissues, BRAIN",200-205-211-220,200-205-211-220,"SSPE brain tissues, brain","Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE brain tissues, brain cultures derived from them, and CV-1 cells infected with SSPE viruses.",220,200,220,200,225,204,1,RO-disease_has_primary_anatomic_site,902239,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE brain tissues, brain cultures derived from them, and CV-1 cells infected with SSPE viruses",brain,SSPE
503461336,7/16/2014 13:57:47,,1324264234,7/16/2014 13:57:34,instagc,1.0,18960682,GBR,"","",86.29.147.112,220,200,,,225,204,BRAIN,SSPE,BRAIN,220,200-205-211,"SSPE brain tissues,","Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE brain tissues, brain cultures derived from them, and CV-1 cells infected with SSPE viruses.",220,200,220,200,225,204,1,RO-disease_has_primary_anatomic_site,902239,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE brain tissues, brain cultures derived from them, and CV-1 cells infected with SSPE viruses",brain,SSPE
503461336,7/16/2014 14:06:11,,1324267822,7/16/2014 14:05:54,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,220,200,,,225,204,BRAIN,SSPE,SSPE BRAIN,200-220,200,SSPE,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE brain tissues, brain cultures derived from them, and CV-1 cells infected with SSPE viruses.",220,200,220,200,225,204,1,RO-disease_has_primary_anatomic_site,902239,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE brain tissues, brain cultures derived from them, and CV-1 cells infected with SSPE viruses",brain,SSPE
503461336,7/16/2014 14:08:12,,1324268639,7/16/2014 14:07:39,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,220,200,,,225,204,BRAIN,SSPE,BRAIN cultures,220-226,200-205-211,"SSPE brain tissues,","Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE brain tissues, brain cultures derived from them, and CV-1 cells infected with SSPE viruses.",220,200,220,200,225,204,1,RO-disease_has_primary_anatomic_site,902239,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE brain tissues, brain cultures derived from them, and CV-1 cells infected with SSPE viruses",brain,SSPE
503461336,7/16/2014 14:09:13,,1324269107,7/16/2014 14:08:56,instagc,1.0,13763729,USA,"","",75.182.89.225,220,200,,,225,204,BRAIN,SSPE,BRAIN,220,200-205-211,"SSPE brain tissues,","Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE brain tissues, brain cultures derived from them, and CV-1 cells infected with SSPE viruses.",220,200,220,200,225,204,1,RO-disease_has_primary_anatomic_site,902239,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE brain tissues, brain cultures derived from them, and CV-1 cells infected with SSPE viruses",brain,SSPE
503461336,7/16/2014 14:13:52,,1324271116,7/16/2014 14:13:43,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,220,200,,,225,204,BRAIN,SSPE,"SSPE brain tissues, BRAIN cultures derived from",200-205-211-220-226-235-243,181-192-197-200-205-211-220,"invariably seen in SSPE brain tissues, brain","Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE brain tissues, brain cultures derived from them, and CV-1 cells infected with SSPE viruses.",220,200,220,200,225,204,1,RO-disease_has_primary_anatomic_site,902239,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE brain tissues, brain cultures derived from them, and CV-1 cells infected with SSPE viruses",brain,SSPE
503461337,7/16/2014 13:45:34,,1324259641,7/16/2014 13:45:23,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,31,68,,,42,84,INFERTILITY,MALE INFERTILITY,INFERTILITY,31,68-73-85,MALE INFERTILITY clinic.,More than 800 men referred for infertility have been evaluated in a male infertility clinic.,31,68 73,31,68,42,84,-1,RO-has_definitional_manifestation,904935,More than 800 men referred for infertility have been evaluated in a male infertility clinic,infertility,male infertility
503461337,7/16/2014 14:11:15,,1324269994,7/16/2014 14:11:07,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,31,68,,,42,84,INFERTILITY,MALE INFERTILITY,men referred for INFERTILITY have been evaluated,14-18-27-31-43-48-53,53-63-66-68-73-85,evaluated in a MALE INFERTILITY clinic.,More than 800 men referred for infertility have been evaluated in a male infertility clinic.,31,68 73,31,68,42,84,-1,RO-has_definitional_manifestation,904935,More than 800 men referred for infertility have been evaluated in a male infertility clinic,infertility,male infertility
503461337,7/16/2014 14:12:24,,1324270540,7/16/2014 14:12:11,prodege,1.0,17932518,GBR,"","",81.133.61.60,31,68,,,42,84,INFERTILITY,MALE INFERTILITY,INFERTILITY,31,68-73,MALE INFERTILITY,More than 800 men referred for infertility have been evaluated in a male infertility clinic.,31,68 73,31,68,42,84,-1,RO-has_definitional_manifestation,904935,More than 800 men referred for infertility have been evaluated in a male infertility clinic,infertility,male infertility
503461337,7/16/2014 14:17:15,,1324272409,7/16/2014 14:16:48,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,31,68,,,42,84,INFERTILITY,MALE INFERTILITY,INFERTILITY,31,68-73,MALE INFERTILITY,More than 800 men referred for infertility have been evaluated in a male infertility clinic.,31,68 73,31,68,42,84,-1,RO-has_definitional_manifestation,904935,More than 800 men referred for infertility have been evaluated in a male infertility clinic,infertility,male infertility
503461337,7/16/2014 14:23:35,,1324275004,7/16/2014 14:23:21,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,31,68,,,42,84,INFERTILITY,MALE INFERTILITY,INFERTILITY,31,68-73,MALE INFERTILITY,More than 800 men referred for infertility have been evaluated in a male infertility clinic.,31,68 73,31,68,42,84,-1,RO-has_definitional_manifestation,904935,More than 800 men referred for infertility have been evaluated in a male infertility clinic,infertility,male infertility
503461337,7/16/2014 14:36:24,,1324280315,7/16/2014 14:36:09,prodege,1.0,6316959,GBR,"","",46.208.145.114,31,68,,,42,84,INFERTILITY,MALE INFERTILITY,INFERTILITY,31,68-73-85,MALE INFERTILITY clinic.,More than 800 men referred for infertility have been evaluated in a male infertility clinic.,31,68 73,31,68,42,84,-1,RO-has_definitional_manifestation,904935,More than 800 men referred for infertility have been evaluated in a male infertility clinic,infertility,male infertility
503461337,7/16/2014 14:36:45,,1324280460,7/16/2014 14:36:31,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,31,68,,,42,84,INFERTILITY,MALE INFERTILITY,INFERTILITY,31,68-73-85,MALE INFERTILITY clinic.,More than 800 men referred for infertility have been evaluated in a male infertility clinic.,31,68 73,31,68,42,84,-1,RO-has_definitional_manifestation,904935,More than 800 men referred for infertility have been evaluated in a male infertility clinic,infertility,male infertility
503461337,7/16/2014 14:44:37,,1324282899,7/16/2014 14:44:25,neodev,1.0,28336203,USA,PA,Harrisburg,50.149.53.150,31,68,,,42,84,INFERTILITY,MALE INFERTILITY,INFERTILITY,31,68-73,MALE INFERTILITY,More than 800 men referred for infertility have been evaluated in a male infertility clinic.,31,68 73,31,68,42,84,-1,RO-has_definitional_manifestation,904935,More than 800 men referred for infertility have been evaluated in a male infertility clinic,infertility,male infertility
503461337,7/16/2014 14:51:30,,1324284904,7/16/2014 14:51:12,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,31,68,,,42,84,INFERTILITY,MALE INFERTILITY,INFERTILITY,31,68-73,MALE INFERTILITY,More than 800 men referred for infertility have been evaluated in a male infertility clinic.,31,68 73,31,68,42,84,-1,RO-has_definitional_manifestation,904935,More than 800 men referred for infertility have been evaluated in a male infertility clinic,infertility,male infertility
503461337,7/16/2014 14:55:17,,1324286114,7/16/2014 14:55:06,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,31,68,,,42,84,INFERTILITY,MALE INFERTILITY,INFERTILITY,31,68-73,MALE INFERTILITY,More than 800 men referred for infertility have been evaluated in a male infertility clinic.,31,68 73,31,68,42,84,-1,RO-has_definitional_manifestation,904935,More than 800 men referred for infertility have been evaluated in a male infertility clinic,infertility,male infertility
503461338,7/16/2014 13:41:08,,1324258053,7/16/2014 13:40:57,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,110,62,,,120,86,MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,sporadic MENINGIOMA.,101-110,62-80-85-87-93,NEUROFIBROMATOSIS TYPE 2 (NF2) gene,The authors investigated the role of somatic mutations of the neurofibromatosis type 2 (NF2) gene in sporadic meningioma.,110,62 80 85,110,62,120,86,-1,RO-has_manifestation,906483,The authors investigated the role of somatic mutations of the neurofibromatosis type 2 (NF2) gene in sporadic meningioma,meningioma,neurofibromatosis type 2
503461338,7/16/2014 13:47:55,,1324260401,7/16/2014 13:47:43,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,110,62,,,120,86,MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,MENINGIOMA.,110,62-80-85,NEUROFIBROMATOSIS TYPE 2,The authors investigated the role of somatic mutations of the neurofibromatosis type 2 (NF2) gene in sporadic meningioma.,110,62 80 85,110,62,120,86,-1,RO-has_manifestation,906483,The authors investigated the role of somatic mutations of the neurofibromatosis type 2 (NF2) gene in sporadic meningioma,meningioma,neurofibromatosis type 2
503461338,7/16/2014 13:48:17,,1324260519,7/16/2014 13:48:10,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,110,62,,,120,86,MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,sporadic MENINGIOMA.,101-110,62-80-85,NEUROFIBROMATOSIS TYPE 2,The authors investigated the role of somatic mutations of the neurofibromatosis type 2 (NF2) gene in sporadic meningioma.,110,62 80 85,110,62,120,86,-1,RO-has_manifestation,906483,The authors investigated the role of somatic mutations of the neurofibromatosis type 2 (NF2) gene in sporadic meningioma,meningioma,neurofibromatosis type 2
503461338,7/16/2014 13:54:21,,1324262778,7/16/2014 13:54:09,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,110,62,,,120,86,MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,sporadic MENINGIOMA.,101-110,62-80-85-87,NEUROFIBROMATOSIS TYPE 2 (NF2),The authors investigated the role of somatic mutations of the neurofibromatosis type 2 (NF2) gene in sporadic meningioma.,110,62 80 85,110,62,120,86,-1,RO-has_manifestation,906483,The authors investigated the role of somatic mutations of the neurofibromatosis type 2 (NF2) gene in sporadic meningioma,meningioma,neurofibromatosis type 2
503461338,7/16/2014 13:57:25,,1324264065,7/16/2014 13:57:10,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,110,62,,,120,86,MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,MENINGIOMA.,110,62-80-85,NEUROFIBROMATOSIS TYPE 2,The authors investigated the role of somatic mutations of the neurofibromatosis type 2 (NF2) gene in sporadic meningioma.,110,62 80 85,110,62,120,86,-1,RO-has_manifestation,906483,The authors investigated the role of somatic mutations of the neurofibromatosis type 2 (NF2) gene in sporadic meningioma,meningioma,neurofibromatosis type 2
503461338,7/16/2014 14:12:13,,1324270442,7/16/2014 14:11:56,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,110,62,,,120,86,MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,gene in sporadic MENINGIOMA.,93-98-101-110,45-55-58-62-80-85-93-98,mutations of the NEUROFIBROMATOSIS TYPE 2 gene in,The authors investigated the role of somatic mutations of the neurofibromatosis type 2 (NF2) gene in sporadic meningioma.,110,62 80 85,110,62,120,86,-1,RO-has_manifestation,906483,The authors investigated the role of somatic mutations of the neurofibromatosis type 2 (NF2) gene in sporadic meningioma,meningioma,neurofibromatosis type 2
503461338,7/16/2014 14:12:38,,1324270647,7/16/2014 14:12:23,instagc,1.0,13763729,USA,"","",75.182.89.225,110,62,,,120,86,MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,MENINGIOMA.,110,62-80-85,NEUROFIBROMATOSIS TYPE 2,The authors investigated the role of somatic mutations of the neurofibromatosis type 2 (NF2) gene in sporadic meningioma.,110,62 80 85,110,62,120,86,-1,RO-has_manifestation,906483,The authors investigated the role of somatic mutations of the neurofibromatosis type 2 (NF2) gene in sporadic meningioma,meningioma,neurofibromatosis type 2
503461338,7/16/2014 14:16:48,,1324272195,7/16/2014 14:16:37,prodege,1.0,17932518,GBR,"","",81.133.61.60,110,62,,,120,86,MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,sporadic MENINGIOMA.,110-101,62-80-85,NEUROFIBROMATOSIS TYPE 2,The authors investigated the role of somatic mutations of the neurofibromatosis type 2 (NF2) gene in sporadic meningioma.,110,62 80 85,110,62,120,86,-1,RO-has_manifestation,906483,The authors investigated the role of somatic mutations of the neurofibromatosis type 2 (NF2) gene in sporadic meningioma,meningioma,neurofibromatosis type 2
503461338,7/16/2014 14:20:26,,1324273704,7/16/2014 14:20:13,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,110,62,,,120,86,MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,sporadic MENINGIOMA.,101-110,62-80-85,NEUROFIBROMATOSIS TYPE 2,The authors investigated the role of somatic mutations of the neurofibromatosis type 2 (NF2) gene in sporadic meningioma.,110,62 80 85,110,62,120,86,-1,RO-has_manifestation,906483,The authors investigated the role of somatic mutations of the neurofibromatosis type 2 (NF2) gene in sporadic meningioma,meningioma,neurofibromatosis type 2
503461338,7/16/2014 14:22:13,,1324274464,7/16/2014 14:21:47,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,110,62,,,120,86,MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,MENINGIOMA.,110,62-80-85,NEUROFIBROMATOSIS TYPE 2,The authors investigated the role of somatic mutations of the neurofibromatosis type 2 (NF2) gene in sporadic meningioma.,110,62 80 85,110,62,120,86,-1,RO-has_manifestation,906483,The authors investigated the role of somatic mutations of the neurofibromatosis type 2 (NF2) gene in sporadic meningioma,meningioma,neurofibromatosis type 2
503461339,7/16/2014 13:48:26,,1324260580,7/16/2014 13:48:18,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,33,63,,,51,76,CUSHING'S SYNDROME,DEXAMETHASONE,"CUSHING'S SYNDROME,",33-43,63-53,exogenous DEXAMETHASONE,"However, in 75% of the dogs with Cushing's syndrome, exogenous dexamethasone was cleared completely in the 3-hour test.",33 43,63,33,63,51,76,1,RO-may_diagnose,906695,"However, in 75% of the dogs with Cushing's syndrome, exogenous dexamethasone was cleared completely in the 3-hour test",Cushing's syndrome,dexamethasone
503461339,7/16/2014 13:51:32,,1324261667,7/16/2014 13:51:16,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,33,63,,,51,76,CUSHING'S SYNDROME,DEXAMETHASONE,"CUSHING'S SYNDROME,",33-43,53-63,exogenous DEXAMETHASONE,"However, in 75% of the dogs with Cushing's syndrome, exogenous dexamethasone was cleared completely in the 3-hour test.",33 43,63,33,63,51,76,1,RO-may_diagnose,906695,"However, in 75% of the dogs with Cushing's syndrome, exogenous dexamethasone was cleared completely in the 3-hour test",Cushing's syndrome,dexamethasone
503461339,7/16/2014 14:05:11,,1324267346,7/16/2014 14:05:00,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,33,63,,,51,76,CUSHING'S SYNDROME,DEXAMETHASONE,"CUSHING'S SYNDROME,",33-43,53-63,exogenous DEXAMETHASONE,"However, in 75% of the dogs with Cushing's syndrome, exogenous dexamethasone was cleared completely in the 3-hour test.",33 43,63,33,63,51,76,1,RO-may_diagnose,906695,"However, in 75% of the dogs with Cushing's syndrome, exogenous dexamethasone was cleared completely in the 3-hour test",Cushing's syndrome,dexamethasone
503461339,7/16/2014 14:12:29,,1324270564,7/16/2014 14:12:16,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,33,63,,,51,76,CUSHING'S SYNDROME,DEXAMETHASONE,"the dogs with CUSHING'S SYNDROME, exogenous dexamethasone was",19-23-28-33-43-53-63-77,33-43-53-63-77-81-89,"Cushing's syndrome, exogenous DEXAMETHASONE was cleared completely","However, in 75% of the dogs with Cushing's syndrome, exogenous dexamethasone was cleared completely in the 3-hour test.",33 43,63,33,63,51,76,1,RO-may_diagnose,906695,"However, in 75% of the dogs with Cushing's syndrome, exogenous dexamethasone was cleared completely in the 3-hour test",Cushing's syndrome,dexamethasone
503461339,7/16/2014 14:30:37,,1324277919,7/16/2014 14:30:16,prodege,1.0,6316959,GBR,"","",46.208.145.114,33,63,,,51,76,CUSHING'S SYNDROME,DEXAMETHASONE,"CUSHING'S SYNDROME,",33-43,53-63,exogenous DEXAMETHASONE,"However, in 75% of the dogs with Cushing's syndrome, exogenous dexamethasone was cleared completely in the 3-hour test.",33 43,63,33,63,51,76,1,RO-may_diagnose,906695,"However, in 75% of the dogs with Cushing's syndrome, exogenous dexamethasone was cleared completely in the 3-hour test",Cushing's syndrome,dexamethasone
503461339,7/16/2014 14:31:02,,1324278094,7/16/2014 14:30:43,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,33,63,,,51,76,CUSHING'S SYNDROME,DEXAMETHASONE,"CUSHING'S SYNDROME,",33-43,53-63,exogenous DEXAMETHASONE,"However, in 75% of the dogs with Cushing's syndrome, exogenous dexamethasone was cleared completely in the 3-hour test.",33 43,63,33,63,51,76,1,RO-may_diagnose,906695,"However, in 75% of the dogs with Cushing's syndrome, exogenous dexamethasone was cleared completely in the 3-hour test",Cushing's syndrome,dexamethasone
503461339,7/16/2014 14:34:07,,1324279248,7/16/2014 14:33:49,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,33,63,,,51,76,CUSHING'S SYNDROME,DEXAMETHASONE,"CUSHING'S SYNDROME,",33-43,63,DEXAMETHASONE,"However, in 75% of the dogs with Cushing's syndrome, exogenous dexamethasone was cleared completely in the 3-hour test.",33 43,63,33,63,51,76,1,RO-may_diagnose,906695,"However, in 75% of the dogs with Cushing's syndrome, exogenous dexamethasone was cleared completely in the 3-hour test",Cushing's syndrome,dexamethasone
503461339,7/16/2014 14:54:26,,1324285821,7/16/2014 14:54:08,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,33,63,,,51,76,CUSHING'S SYNDROME,DEXAMETHASONE,"CUSHING'S SYNDROME,",33-43,53-63,exogenous DEXAMETHASONE,"However, in 75% of the dogs with Cushing's syndrome, exogenous dexamethasone was cleared completely in the 3-hour test.",33 43,63,33,63,51,76,1,RO-may_diagnose,906695,"However, in 75% of the dogs with Cushing's syndrome, exogenous dexamethasone was cleared completely in the 3-hour test",Cushing's syndrome,dexamethasone
503461339,7/16/2014 14:55:03,,1324286068,7/16/2014 14:54:59,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,33,63,,,51,76,CUSHING'S SYNDROME,DEXAMETHASONE,"the dogs with CUSHING'S SYNDROME, exogenous dexamethasone was",19-23-28-33-43-53-63-77,33-43-53-63-77-81-89,"Cushing's syndrome, exogenous DEXAMETHASONE was cleared completely","However, in 75% of the dogs with Cushing's syndrome, exogenous dexamethasone was cleared completely in the 3-hour test.",33 43,63,33,63,51,76,1,RO-may_diagnose,906695,"However, in 75% of the dogs with Cushing's syndrome, exogenous dexamethasone was cleared completely in the 3-hour test",Cushing's syndrome,dexamethasone
503461339,7/16/2014 14:56:36,,1324286667,7/16/2014 14:56:14,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,33,63,,,51,76,CUSHING'S SYNDROME,DEXAMETHASONE,"CUSHING'S SYNDROME,",33-43,63,DEXAMETHASONE,"However, in 75% of the dogs with Cushing's syndrome, exogenous dexamethasone was cleared completely in the 3-hour test.",33 43,63,33,63,51,76,1,RO-may_diagnose,906695,"However, in 75% of the dogs with Cushing's syndrome, exogenous dexamethasone was cleared completely in the 3-hour test",Cushing's syndrome,dexamethasone
503461340,7/16/2014 13:51:09,,1324261533,7/16/2014 13:50:36,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,100,53,,,111,65,ELEVATED BP,HYPERTENSION,"ELEVATED BP,",100-109,53,HYPERTENSION,"We conclude that symptoms putatively associated with hypertension are common among ED patients with elevated BP, and their prevalence appears unrelated to BP value.",100 109,53,100,53,111,65,-1,RO-has_definitional_manifestation,904506,"We conclude that symptoms putatively associated with hypertension are common among ED patients with elevated BP, and their prevalence appears unrelated to BP value",elevated BP,hypertension
503461340,7/16/2014 13:51:41,,1324261690,7/16/2014 13:51:21,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,100,53,,,111,65,ELEVATED BP,HYPERTENSION,"ELEVATED BP,",100-109,53,HYPERTENSION,"We conclude that symptoms putatively associated with hypertension are common among ED patients with elevated BP, and their prevalence appears unrelated to BP value.",100 109,53,100,53,111,65,-1,RO-has_definitional_manifestation,904506,"We conclude that symptoms putatively associated with hypertension are common among ED patients with elevated BP, and their prevalence appears unrelated to BP value",elevated BP,hypertension
503461340,7/16/2014 13:56:48,,1324263754,7/16/2014 13:56:34,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,100,53,,,111,65,ELEVATED BP,HYPERTENSION,"ELEVATED BP,",100-109,53,HYPERTENSION,"We conclude that symptoms putatively associated with hypertension are common among ED patients with elevated BP, and their prevalence appears unrelated to BP value.",100 109,53,100,53,111,65,-1,RO-has_definitional_manifestation,904506,"We conclude that symptoms putatively associated with hypertension are common among ED patients with elevated BP, and their prevalence appears unrelated to BP value",elevated BP,hypertension
503461340,7/16/2014 14:00:04,,1324265252,7/16/2014 13:59:24,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,100,53,,,111,65,ELEVATED BP,HYPERTENSION,"ELEVATED BP,",100-109,53,HYPERTENSION,"We conclude that symptoms putatively associated with hypertension are common among ED patients with elevated BP, and their prevalence appears unrelated to BP value.",100 109,53,100,53,111,65,-1,RO-has_definitional_manifestation,904506,"We conclude that symptoms putatively associated with hypertension are common among ED patients with elevated BP, and their prevalence appears unrelated to BP value",elevated BP,hypertension
503461340,7/16/2014 14:05:35,,1324267514,7/16/2014 14:05:22,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,100,53,,,111,65,ELEVATED BP,HYPERTENSION,"hypertension ELEVATED BP,",53-100-109,53,HYPERTENSION,"We conclude that symptoms putatively associated with hypertension are common among ED patients with elevated BP, and their prevalence appears unrelated to BP value.",100 109,53,100,53,111,65,-1,RO-has_definitional_manifestation,904506,"We conclude that symptoms putatively associated with hypertension are common among ED patients with elevated BP, and their prevalence appears unrelated to BP value",elevated BP,hypertension
503461340,7/16/2014 14:22:50,,1324274708,7/16/2014 14:22:31,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,100,53,,,111,65,ELEVATED BP,HYPERTENSION,"ELEVATED BP,",100-109,53,HYPERTENSION,"We conclude that symptoms putatively associated with hypertension are common among ED patients with elevated BP, and their prevalence appears unrelated to BP value.",100 109,53,100,53,111,65,-1,RO-has_definitional_manifestation,904506,"We conclude that symptoms putatively associated with hypertension are common among ED patients with elevated BP, and their prevalence appears unrelated to BP value",elevated BP,hypertension
503461340,7/16/2014 14:25:25,,1324275691,7/16/2014 14:25:00,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,100,53,,,111,65,ELEVATED BP,HYPERTENSION,"hypertension ELEVATED BP,",100-109-53,53-100-109,"HYPERTENSION elevated BP,","We conclude that symptoms putatively associated with hypertension are common among ED patients with elevated BP, and their prevalence appears unrelated to BP value.",100 109,53,100,53,111,65,-1,RO-has_definitional_manifestation,904506,"We conclude that symptoms putatively associated with hypertension are common among ED patients with elevated BP, and their prevalence appears unrelated to BP value",elevated BP,hypertension
503461340,7/16/2014 14:36:31,,1324280358,7/16/2014 14:36:08,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,100,53,,,111,65,ELEVATED BP,HYPERTENSION,"ELEVATED BP,",100-109,53,HYPERTENSION,"We conclude that symptoms putatively associated with hypertension are common among ED patients with elevated BP, and their prevalence appears unrelated to BP value.",100 109,53,100,53,111,65,-1,RO-has_definitional_manifestation,904506,"We conclude that symptoms putatively associated with hypertension are common among ED patients with elevated BP, and their prevalence appears unrelated to BP value",elevated BP,hypertension
503461340,7/16/2014 14:37:55,,1324280928,7/16/2014 14:37:38,prodege,1.0,26790109,USA,"","",23.125.64.233,100,53,,,111,65,ELEVATED BP,HYPERTENSION,"ED patients with ELEVATED BP, and their prevalence appears unrelated to BP value.",83-86-95-100-109-113-117-123-134-142-152-155-158,26-37-48-53-66-70-77-83-86-95-100-109,"putatively associated with HYPERTENSION are common among ED patients with elevated BP,","We conclude that symptoms putatively associated with hypertension are common among ED patients with elevated BP, and their prevalence appears unrelated to BP value.",100 109,53,100,53,111,65,-1,RO-has_definitional_manifestation,904506,"We conclude that symptoms putatively associated with hypertension are common among ED patients with elevated BP, and their prevalence appears unrelated to BP value",elevated BP,hypertension
503461340,7/16/2014 14:40:37,,1324281811,7/16/2014 14:39:45,neodev,1.0,28336203,USA,PA,Harrisburg,50.149.53.150,100,53,,,111,65,ELEVATED BP,HYPERTENSION,"ELEVATED BP,",100-109,53,HYPERTENSION,"We conclude that symptoms putatively associated with hypertension are common among ED patients with elevated BP, and their prevalence appears unrelated to BP value.",100 109,53,100,53,111,65,-1,RO-has_definitional_manifestation,904506,"We conclude that symptoms putatively associated with hypertension are common among ED patients with elevated BP, and their prevalence appears unrelated to BP value",elevated BP,hypertension
503461341,7/16/2014 13:46:59,,1324260092,7/16/2014 13:46:51,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,218,151,,,239,170,HEPATITIS B INFECTION,HEPATITIS B VACCINE,HEPATITIS B INFECTION,218-228-230,151-161-163,HEPATITIS B VACCINE,"The protocols for the practical management of these cases, including the immunisation of susceptible non-human primates and the staff with recombinant hepatitis B vaccine are described, and the origin and evolution of hepatitis B infection in primates are discussed.",218 228 230,151 161 163,218,151,239,170,1,RO-may_prevent,907208,"The protocols for the practical management of these cases, including the immunisation of susceptible non-human primates and the staff with recombinant hepatitis B vaccine are described, and the origin and evolution of hepatitis B infection in primates are discussed",hepatitis B infection,hepatitis B vaccine
503461341,7/16/2014 13:50:03,,1324261087,7/16/2014 13:49:21,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,218,151,,,239,170,HEPATITIS B INFECTION,HEPATITIS B VACCINE,HEPATITIS B INFECTION,218-228-230,151-161-163-230,HEPATITIS B VACCINE infection,"The protocols for the practical management of these cases, including the immunisation of susceptible non-human primates and the staff with recombinant hepatitis B vaccine are described, and the origin and evolution of hepatitis B infection in primates are discussed.",218 228 230,151 161 163,218,151,239,170,1,RO-may_prevent,907208,"The protocols for the practical management of these cases, including the immunisation of susceptible non-human primates and the staff with recombinant hepatitis B vaccine are described, and the origin and evolution of hepatitis B infection in primates are discussed",hepatitis B infection,hepatitis B vaccine
503461341,7/16/2014 13:50:48,,1324261437,7/16/2014 13:50:24,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,218,151,,,239,170,HEPATITIS B INFECTION,HEPATITIS B VACCINE,HEPATITIS B INFECTION,218-228-230,139-151-161-163,recombinant HEPATITIS B VACCINE,"The protocols for the practical management of these cases, including the immunisation of susceptible non-human primates and the staff with recombinant hepatitis B vaccine are described, and the origin and evolution of hepatitis B infection in primates are discussed.",218 228 230,151 161 163,218,151,239,170,1,RO-may_prevent,907208,"The protocols for the practical management of these cases, including the immunisation of susceptible non-human primates and the staff with recombinant hepatitis B vaccine are described, and the origin and evolution of hepatitis B infection in primates are discussed",hepatitis B infection,hepatitis B vaccine
503461341,7/16/2014 13:54:39,,1324262870,7/16/2014 13:54:19,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,218,151,,,239,170,HEPATITIS B INFECTION,HEPATITIS B VACCINE,HEPATITIS B INFECTION,218-228-230,151-161-163,HEPATITIS B VACCINE,"The protocols for the practical management of these cases, including the immunisation of susceptible non-human primates and the staff with recombinant hepatitis B vaccine are described, and the origin and evolution of hepatitis B infection in primates are discussed.",218 228 230,151 161 163,218,151,239,170,1,RO-may_prevent,907208,"The protocols for the practical management of these cases, including the immunisation of susceptible non-human primates and the staff with recombinant hepatitis B vaccine are described, and the origin and evolution of hepatitis B infection in primates are discussed",hepatitis B infection,hepatitis B vaccine
503461341,7/16/2014 14:04:00,,1324266844,7/16/2014 14:03:48,instagc,1.0,18960682,GBR,"","",86.29.147.112,218,151,,,239,170,HEPATITIS B INFECTION,HEPATITIS B VACCINE,HEPATITIS B INFECTION,218-228-230,151-161-163,HEPATITIS B VACCINE,"The protocols for the practical management of these cases, including the immunisation of susceptible non-human primates and the staff with recombinant hepatitis B vaccine are described, and the origin and evolution of hepatitis B infection in primates are discussed.",218 228 230,151 161 163,218,151,239,170,1,RO-may_prevent,907208,"The protocols for the practical management of these cases, including the immunisation of susceptible non-human primates and the staff with recombinant hepatitis B vaccine are described, and the origin and evolution of hepatitis B infection in primates are discussed",hepatitis B infection,hepatitis B vaccine
503461341,7/16/2014 14:10:06,,1324269502,7/16/2014 14:09:51,instagc,1.0,13763729,USA,"","",75.182.89.225,218,151,,,239,170,HEPATITIS B INFECTION,HEPATITIS B VACCINE,HEPATITIS B INFECTION,218-228-230,151-161-163,HEPATITIS B VACCINE,"The protocols for the practical management of these cases, including the immunisation of susceptible non-human primates and the staff with recombinant hepatitis B vaccine are described, and the origin and evolution of hepatitis B infection in primates are discussed.",218 228 230,151 161 163,218,151,239,170,1,RO-may_prevent,907208,"The protocols for the practical management of these cases, including the immunisation of susceptible non-human primates and the staff with recombinant hepatitis B vaccine are described, and the origin and evolution of hepatitis B infection in primates are discussed",hepatitis B infection,hepatitis B vaccine
503461341,7/16/2014 14:12:10,,1324270403,7/16/2014 14:11:55,prodege,1.0,17932518,GBR,"","",81.133.61.60,218,151,,,239,170,HEPATITIS B INFECTION,HEPATITIS B VACCINE,HEPATITIS B INFECTION,218-228-230,151-161-163,HEPATITIS B VACCINE,"The protocols for the practical management of these cases, including the immunisation of susceptible non-human primates and the staff with recombinant hepatitis B vaccine are described, and the origin and evolution of hepatitis B infection in primates are discussed.",218 228 230,151 161 163,218,151,239,170,1,RO-may_prevent,907208,"The protocols for the practical management of these cases, including the immunisation of susceptible non-human primates and the staff with recombinant hepatitis B vaccine are described, and the origin and evolution of hepatitis B infection in primates are discussed",hepatitis B infection,hepatitis B vaccine
503461341,7/16/2014 14:22:14,,1324274470,7/16/2014 14:21:40,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,218,151,,,239,170,HEPATITIS B INFECTION,HEPATITIS B VACCINE,HEPATITIS B INFECTION,218-228-230,139-151-161-163,recombinant HEPATITIS B VACCINE,"The protocols for the practical management of these cases, including the immunisation of susceptible non-human primates and the staff with recombinant hepatitis B vaccine are described, and the origin and evolution of hepatitis B infection in primates are discussed.",218 228 230,151 161 163,218,151,239,170,1,RO-may_prevent,907208,"The protocols for the practical management of these cases, including the immunisation of susceptible non-human primates and the staff with recombinant hepatitis B vaccine are described, and the origin and evolution of hepatitis B infection in primates are discussed",hepatitis B infection,hepatitis B vaccine
503461341,7/16/2014 14:30:17,,1324277723,7/16/2014 14:30:00,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,218,151,,,239,170,HEPATITIS B INFECTION,HEPATITIS B VACCINE,HEPATITIS B INFECTION,218-228-230,151-161-163,HEPATITIS B VACCINE,"The protocols for the practical management of these cases, including the immunisation of susceptible non-human primates and the staff with recombinant hepatitis B vaccine are described, and the origin and evolution of hepatitis B infection in primates are discussed.",218 228 230,151 161 163,218,151,239,170,1,RO-may_prevent,907208,"The protocols for the practical management of these cases, including the immunisation of susceptible non-human primates and the staff with recombinant hepatitis B vaccine are described, and the origin and evolution of hepatitis B infection in primates are discussed",hepatitis B infection,hepatitis B vaccine
503461341,7/16/2014 14:39:36,,1324281497,7/16/2014 14:39:01,prodege,1.0,26790109,USA,"","",23.125.64.233,218,151,,,239,170,HEPATITIS B INFECTION,HEPATITIS B VACCINE,and evolution of HEPATITIS B INFECTION in primates are,201-205-215-218-228-230-240-243-252,128-134-139-151-161-163-171-175-186-190-194-201-205-215-218-228-230-240-243-252-256,"staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of hepatitis B infection in primates are discussed.","The protocols for the practical management of these cases, including the immunisation of susceptible non-human primates and the staff with recombinant hepatitis B vaccine are described, and the origin and evolution of hepatitis B infection in primates are discussed.",218 228 230,151 161 163,218,151,239,170,1,RO-may_prevent,907208,"The protocols for the practical management of these cases, including the immunisation of susceptible non-human primates and the staff with recombinant hepatitis B vaccine are described, and the origin and evolution of hepatitis B infection in primates are discussed",hepatitis B infection,hepatitis B vaccine
503461342,7/16/2014 13:43:41,,1324258976,7/16/2014 13:43:26,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,35,118,,,51,140,THROMBOCYTOPENIA,PLATELET SEQUESTRATION,THROMBOCYTOPENIA,35,118-127,PLATELET SEQUESTRATION,"In most recently infected patients thrombocytopenia is due to accelerated platelet destruction; in these patients the platelet sequestration is predominantly splenic, and splenectomy is usually effective.",35,118 127,35,118,51,140,-1,RO-has_definitional_manifestation,904751,"In most recently infected patients thrombocytopenia is due to accelerated platelet destruction; in these patients the platelet sequestration is predominantly splenic, and splenectomy is usually effective",thrombocytopenia,platelet sequestration
503461342,7/16/2014 13:52:32,,1324261986,7/16/2014 13:52:03,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,35,118,,,51,140,THROMBOCYTOPENIA,PLATELET SEQUESTRATION,THROMBOCYTOPENIA platelet sequestration,35-127-118,35-118-127,thrombocytopenia PLATELET SEQUESTRATION,"In most recently infected patients thrombocytopenia is due to accelerated platelet destruction; in these patients the platelet sequestration is predominantly splenic, and splenectomy is usually effective.",35,118 127,35,118,51,140,-1,RO-has_definitional_manifestation,904751,"In most recently infected patients thrombocytopenia is due to accelerated platelet destruction; in these patients the platelet sequestration is predominantly splenic, and splenectomy is usually effective",thrombocytopenia,platelet sequestration
503461342,7/16/2014 13:53:33,,1324262401,7/16/2014 13:53:18,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,35,118,,,51,140,THROMBOCYTOPENIA,PLATELET SEQUESTRATION,THROMBOCYTOPENIA,35,118-127,PLATELET SEQUESTRATION,"In most recently infected patients thrombocytopenia is due to accelerated platelet destruction; in these patients the platelet sequestration is predominantly splenic, and splenectomy is usually effective.",35,118 127,35,118,51,140,-1,RO-has_definitional_manifestation,904751,"In most recently infected patients thrombocytopenia is due to accelerated platelet destruction; in these patients the platelet sequestration is predominantly splenic, and splenectomy is usually effective",thrombocytopenia,platelet sequestration
503461342,7/16/2014 14:04:45,,1324267143,7/16/2014 14:04:29,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,35,118,,,51,140,THROMBOCYTOPENIA,PLATELET SEQUESTRATION,THROMBOCYTOPENIA,35,118-127,PLATELET SEQUESTRATION,"In most recently infected patients thrombocytopenia is due to accelerated platelet destruction; in these patients the platelet sequestration is predominantly splenic, and splenectomy is usually effective.",35,118 127,35,118,51,140,-1,RO-has_definitional_manifestation,904751,"In most recently infected patients thrombocytopenia is due to accelerated platelet destruction; in these patients the platelet sequestration is predominantly splenic, and splenectomy is usually effective",thrombocytopenia,platelet sequestration
503461342,7/16/2014 14:24:06,,1324275147,7/16/2014 14:23:47,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,35,118,,,51,140,THROMBOCYTOPENIA,PLATELET SEQUESTRATION,THROMBOCYTOPENIA,35,118-127,PLATELET SEQUESTRATION,"In most recently infected patients thrombocytopenia is due to accelerated platelet destruction; in these patients the platelet sequestration is predominantly splenic, and splenectomy is usually effective.",35,118 127,35,118,51,140,-1,RO-has_definitional_manifestation,904751,"In most recently infected patients thrombocytopenia is due to accelerated platelet destruction; in these patients the platelet sequestration is predominantly splenic, and splenectomy is usually effective",thrombocytopenia,platelet sequestration
503461342,7/16/2014 14:39:55,,1324281640,7/16/2014 14:39:40,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,35,118,,,51,140,THROMBOCYTOPENIA,PLATELET SEQUESTRATION,THROMBOCYTOPENIA,35,118-127,PLATELET SEQUESTRATION,"In most recently infected patients thrombocytopenia is due to accelerated platelet destruction; in these patients the platelet sequestration is predominantly splenic, and splenectomy is usually effective.",35,118 127,35,118,51,140,-1,RO-has_definitional_manifestation,904751,"In most recently infected patients thrombocytopenia is due to accelerated platelet destruction; in these patients the platelet sequestration is predominantly splenic, and splenectomy is usually effective",thrombocytopenia,platelet sequestration
503461342,7/16/2014 14:43:44,,1324282654,7/16/2014 14:43:36,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,35,118,,,51,140,THROMBOCYTOPENIA,PLATELET SEQUESTRATION,THROMBOCYTOPENIA,35,114-118-127,the PLATELET SEQUESTRATION,"In most recently infected patients thrombocytopenia is due to accelerated platelet destruction; in these patients the platelet sequestration is predominantly splenic, and splenectomy is usually effective.",35,118 127,35,118,51,140,-1,RO-has_definitional_manifestation,904751,"In most recently infected patients thrombocytopenia is due to accelerated platelet destruction; in these patients the platelet sequestration is predominantly splenic, and splenectomy is usually effective",thrombocytopenia,platelet sequestration
503461342,7/16/2014 14:59:44,,1324287827,7/16/2014 14:59:28,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,35,118,,,51,140,THROMBOCYTOPENIA,PLATELET SEQUESTRATION,THROMBOCYTOPENIA,35,118-127,PLATELET SEQUESTRATION,"In most recently infected patients thrombocytopenia is due to accelerated platelet destruction; in these patients the platelet sequestration is predominantly splenic, and splenectomy is usually effective.",35,118 127,35,118,51,140,-1,RO-has_definitional_manifestation,904751,"In most recently infected patients thrombocytopenia is due to accelerated platelet destruction; in these patients the platelet sequestration is predominantly splenic, and splenectomy is usually effective",thrombocytopenia,platelet sequestration
503461342,7/16/2014 14:59:51,,1324287856,7/16/2014 14:59:31,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,35,118,,,51,140,THROMBOCYTOPENIA,PLATELET SEQUESTRATION,THROMBOCYTOPENIA,35,118-127,PLATELET SEQUESTRATION,"In most recently infected patients thrombocytopenia is due to accelerated platelet destruction; in these patients the platelet sequestration is predominantly splenic, and splenectomy is usually effective.",35,118 127,35,118,51,140,-1,RO-has_definitional_manifestation,904751,"In most recently infected patients thrombocytopenia is due to accelerated platelet destruction; in these patients the platelet sequestration is predominantly splenic, and splenectomy is usually effective",thrombocytopenia,platelet sequestration
503461342,7/16/2014 15:01:10,,1324288390,7/16/2014 15:00:49,irazoo,1.0,7022810,USA,IA,Ankeny,216.161.121.1,35,118,,,51,140,THROMBOCYTOPENIA,PLATELET SEQUESTRATION,THROMBOCYTOPENIA,35,118-127,PLATELET SEQUESTRATION,"In most recently infected patients thrombocytopenia is due to accelerated platelet destruction; in these patients the platelet sequestration is predominantly splenic, and splenectomy is usually effective.",35,118 127,35,118,51,140,-1,RO-has_definitional_manifestation,904751,"In most recently infected patients thrombocytopenia is due to accelerated platelet destruction; in these patients the platelet sequestration is predominantly splenic, and splenectomy is usually effective",thrombocytopenia,platelet sequestration
503461343,7/16/2014 13:41:31,,1324258179,7/16/2014 13:41:23,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,146,122,,,163,128,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS.,146-153,122-129,ATOPIC diseases,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of atopic diseases (mostly atopic dermatitis.,146 153,122,146,122,163,128,-1,RO-cause_of,900445,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of atopic diseases (mostly atopic dermatitis,atopic dermatitis,atopic
503461343,7/16/2014 13:46:28,,1324259906,7/16/2014 13:46:22,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,146,122,,,163,128,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS.,146-153,122-129,ATOPIC diseases,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of atopic diseases (mostly atopic dermatitis.,146 153,122,146,122,163,128,-1,RO-cause_of,900445,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of atopic diseases (mostly atopic dermatitis,atopic dermatitis,atopic
503461343,7/16/2014 13:52:27,,1324261959,7/16/2014 13:52:17,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,146,122,,,163,128,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS.,146-153,122,ATOPIC,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of atopic diseases (mostly atopic dermatitis.,146 153,122,146,122,163,128,-1,RO-cause_of,900445,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of atopic diseases (mostly atopic dermatitis,atopic dermatitis,atopic
503461343,7/16/2014 13:52:29,,1324261977,7/16/2014 13:52:17,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,146,122,,,163,128,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS.,146-153,122-129,ATOPIC diseases,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of atopic diseases (mostly atopic dermatitis.,146 153,122,146,122,163,128,-1,RO-cause_of,900445,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of atopic diseases (mostly atopic dermatitis,atopic dermatitis,atopic
503461343,7/16/2014 13:52:32,,1324261988,7/16/2014 13:52:06,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,146,122,,,163,128,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS.,146-153,122-129,ATOPIC diseases,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of atopic diseases (mostly atopic dermatitis.,146 153,122,146,122,163,128,-1,RO-cause_of,900445,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of atopic diseases (mostly atopic dermatitis,atopic dermatitis,atopic
503461343,7/16/2014 13:57:33,,1324264108,7/16/2014 13:56:25,instagc,1.0,18960682,GBR,"","",86.29.147.112,146,122,,,163,128,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS.,146-153,122-129,ATOPIC diseases,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of atopic diseases (mostly atopic dermatitis.,146 153,122,146,122,163,128,-1,RO-cause_of,900445,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of atopic diseases (mostly atopic dermatitis,atopic dermatitis,atopic
503461343,7/16/2014 14:04:17,,1324266933,7/16/2014 14:04:06,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,146,122,,,163,128,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS.,146-153,122-146-153,ATOPIC atopic dermatitis.,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of atopic diseases (mostly atopic dermatitis.,146 153,122,146,122,163,128,-1,RO-cause_of,900445,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of atopic diseases (mostly atopic dermatitis,atopic dermatitis,atopic
503461343,7/16/2014 14:10:31,,1324269678,7/16/2014 14:10:15,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,146,122,,,163,128,ATOPIC DERMATITIS,ATOPIC,atopic diseases (mostly ATOPIC DERMATITIS.,122-129-138-146-153,99-108-119-122-129-146,familial occurrence of ATOPIC diseases atopic,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of atopic diseases (mostly atopic dermatitis.,146 153,122,146,122,163,128,-1,RO-cause_of,900445,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of atopic diseases (mostly atopic dermatitis,atopic dermatitis,atopic
503461343,7/16/2014 14:11:11,,1324269970,7/16/2014 14:10:59,instagc,1.0,13763729,USA,"","",75.182.89.225,146,122,,,163,128,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS.,146-153,122-129,ATOPIC diseases,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of atopic diseases (mostly atopic dermatitis.,146 153,122,146,122,163,128,-1,RO-cause_of,900445,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of atopic diseases (mostly atopic dermatitis,atopic dermatitis,atopic
503461343,7/16/2014 14:15:02,,1324271548,7/16/2014 14:14:54,prodege,1.0,17932518,GBR,"","",81.133.61.60,146,122,,,163,128,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS.,146-153,122-129,ATOPIC diseases,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of atopic diseases (mostly atopic dermatitis.,146 153,122,146,122,163,128,-1,RO-cause_of,900445,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of atopic diseases (mostly atopic dermatitis,atopic dermatitis,atopic
503461344,7/16/2014 13:45:44,,1324259699,7/16/2014 13:45:34,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,54,17,,,62,40,ARTERIES,FIBROMUSCULAR DYSPLASIA,renal ARTERIES,48-54,17-31,FIBROMUSCULAR DYSPLASIA,Imaging revealed fibromuscular dysplasia of the renal arteries and the superior mesentery artery.,54,17 31,54,17,62,40,1,RO-has_finding_site,905441,Imaging revealed fibromuscular dysplasia of the renal arteries and the superior mesentery artery,arteries,fibromuscular dysplasia
503461344,7/16/2014 13:46:43,,1324260002,7/16/2014 13:46:26,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,54,17,,,62,40,ARTERIES,FIBROMUSCULAR DYSPLASIA,ARTERIES,54,17-31,FIBROMUSCULAR DYSPLASIA,Imaging revealed fibromuscular dysplasia of the renal arteries and the superior mesentery artery.,54,17 31,54,17,62,40,1,RO-has_finding_site,905441,Imaging revealed fibromuscular dysplasia of the renal arteries and the superior mesentery artery,arteries,fibromuscular dysplasia
503461344,7/16/2014 13:55:36,,1324263234,7/16/2014 13:55:23,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,54,17,,,62,40,ARTERIES,FIBROMUSCULAR DYSPLASIA,renal ARTERIES,48-54,17-31,FIBROMUSCULAR DYSPLASIA,Imaging revealed fibromuscular dysplasia of the renal arteries and the superior mesentery artery.,54,17 31,54,17,62,40,1,RO-has_finding_site,905441,Imaging revealed fibromuscular dysplasia of the renal arteries and the superior mesentery artery,arteries,fibromuscular dysplasia
503461344,7/16/2014 14:07:11,,1324268183,7/16/2014 14:06:49,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,54,17,,,62,40,ARTERIES,FIBROMUSCULAR DYSPLASIA,Imaging fibromuscular dysplasia renal ARTERIES superior mesentery artery.,17-31-48-54-71-80-90-0,0-17-31-48-71-80-90-54,Imaging FIBROMUSCULAR DYSPLASIA renal arteries superior mesentery artery.,Imaging revealed fibromuscular dysplasia of the renal arteries and the superior mesentery artery.,54,17 31,54,17,62,40,1,RO-has_finding_site,905441,Imaging revealed fibromuscular dysplasia of the renal arteries and the superior mesentery artery,arteries,fibromuscular dysplasia
503461344,7/16/2014 14:31:03,,1324278139,7/16/2014 14:30:52,prodege,1.0,6316959,GBR,"","",46.208.145.114,54,17,,,62,40,ARTERIES,FIBROMUSCULAR DYSPLASIA,renal ARTERIES,48-54,17-31,FIBROMUSCULAR DYSPLASIA,Imaging revealed fibromuscular dysplasia of the renal arteries and the superior mesentery artery.,54,17 31,54,17,62,40,1,RO-has_finding_site,905441,Imaging revealed fibromuscular dysplasia of the renal arteries and the superior mesentery artery,arteries,fibromuscular dysplasia
503461344,7/16/2014 14:33:30,,1324278986,7/16/2014 14:33:09,prodege,1.0,26790109,USA,"","",23.125.64.233,54,17,,,62,40,ARTERIES,FIBROMUSCULAR DYSPLASIA,fibromuscular dysplasia of the renal ARTERIES and the superior mesentery artery.,17-31-41-44-48-54-63-67-71-80-90,0-8-17-31-41-44-48-54-63-67-71-80-90,Imaging revealed FIBROMUSCULAR DYSPLASIA of the renal arteries and the superior mesentery artery.,Imaging revealed fibromuscular dysplasia of the renal arteries and the superior mesentery artery.,54,17 31,54,17,62,40,1,RO-has_finding_site,905441,Imaging revealed fibromuscular dysplasia of the renal arteries and the superior mesentery artery,arteries,fibromuscular dysplasia
503461344,7/16/2014 14:37:29,,1324280762,7/16/2014 14:36:46,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,54,17,,,62,40,ARTERIES,FIBROMUSCULAR DYSPLASIA,renal ARTERIES,48-54,17-31,FIBROMUSCULAR DYSPLASIA,Imaging revealed fibromuscular dysplasia of the renal arteries and the superior mesentery artery.,54,17 31,54,17,62,40,1,RO-has_finding_site,905441,Imaging revealed fibromuscular dysplasia of the renal arteries and the superior mesentery artery,arteries,fibromuscular dysplasia
503461344,7/16/2014 14:41:59,,1324282175,7/16/2014 14:41:45,neodev,1.0,28336203,USA,PA,Harrisburg,50.149.53.150,54,17,,,62,40,ARTERIES,FIBROMUSCULAR DYSPLASIA,renal ARTERIES,48-54,17-31,FIBROMUSCULAR DYSPLASIA,Imaging revealed fibromuscular dysplasia of the renal arteries and the superior mesentery artery.,54,17 31,54,17,62,40,1,RO-has_finding_site,905441,Imaging revealed fibromuscular dysplasia of the renal arteries and the superior mesentery artery,arteries,fibromuscular dysplasia
503461344,7/16/2014 14:47:16,,1324283612,7/16/2014 14:47:10,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,54,17,,,62,40,ARTERIES,FIBROMUSCULAR DYSPLASIA,renal ARTERIES,48-54,17-31,FIBROMUSCULAR DYSPLASIA,Imaging revealed fibromuscular dysplasia of the renal arteries and the superior mesentery artery.,54,17 31,54,17,62,40,1,RO-has_finding_site,905441,Imaging revealed fibromuscular dysplasia of the renal arteries and the superior mesentery artery,arteries,fibromuscular dysplasia
503461344,7/16/2014 14:47:44,,1324283761,7/16/2014 14:47:12,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,54,17,,,62,40,ARTERIES,FIBROMUSCULAR DYSPLASIA,fibromuscular dysplasia ARTERIES,17-31-54,17-31,FIBROMUSCULAR DYSPLASIA,Imaging revealed fibromuscular dysplasia of the renal arteries and the superior mesentery artery.,54,17 31,54,17,62,40,1,RO-has_finding_site,905441,Imaging revealed fibromuscular dysplasia of the renal arteries and the superior mesentery artery,arteries,fibromuscular dysplasia
503461345,7/16/2014 13:40:09,,1324257686,7/16/2014 13:39:43,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,483,498,,,488,507,JOINT,ARTHRITIS,JOINT exam for arthritis,483-489-494-498,483-489-494-498,Joint exam for ARTHRITIS,"History and Physical Examination Elements for Psoriasis  Normal;           History and Physical Examination Elements for Psoriasis Category  Element  Notes History  Chronic areas of redness, scaling, and itching History  Positive family history for psoriasis History  Positive history for joint symptoms  20%-30% of patients with psoriasis complain of arthralgias (tvml 30tvml ) History  Koebner phenomenon  The development of psoriasis at the site of physical trauma Physical exam  Joint exam for arthritis  Look for swelling and redness of the soft tissues around the joints, especially the fingers and toes.",483,498,483,498,488,507,1,RO-disease_has_primary_anatomic_site,902283,"History and Physical Examination Elements for Psoriasis  Normal;           History and Physical Examination Elements for Psoriasis Category  Element  Notes History  Chronic areas of redness, scaling, and itching History  Positive family history for psoriasis History  Positive history for joint symptoms  20%-30% of patients with psoriasis complain of arthralgias (tvml 30tvml ) History  Koebner phenomenon  The development of psoriasis at the site of physical trauma Physical exam  Joint exam for arthritis  Look for swelling and redness of the soft tissues around the joints, especially the fingers and toes",Joint,arthritis
503461345,7/16/2014 13:44:58,,1324259427,7/16/2014 13:44:27,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,483,498,,,488,507,JOINT,ARTHRITIS,JOINT,483,498,ARTHRITIS,"History and Physical Examination Elements for Psoriasis  Normal;           History and Physical Examination Elements for Psoriasis Category  Element  Notes History  Chronic areas of redness, scaling, and itching History  Positive family history for psoriasis History  Positive history for joint symptoms  20%-30% of patients with psoriasis complain of arthralgias (tvml 30tvml ) History  Koebner phenomenon  The development of psoriasis at the site of physical trauma Physical exam  Joint exam for arthritis  Look for swelling and redness of the soft tissues around the joints, especially the fingers and toes.",483,498,483,498,488,507,1,RO-disease_has_primary_anatomic_site,902283,"History and Physical Examination Elements for Psoriasis  Normal;           History and Physical Examination Elements for Psoriasis Category  Element  Notes History  Chronic areas of redness, scaling, and itching History  Positive family history for psoriasis History  Positive history for joint symptoms  20%-30% of patients with psoriasis complain of arthralgias (tvml 30tvml ) History  Koebner phenomenon  The development of psoriasis at the site of physical trauma Physical exam  Joint exam for arthritis  Look for swelling and redness of the soft tissues around the joints, especially the fingers and toes",Joint,arthritis
503461345,7/16/2014 13:49:12,,1324260816,7/16/2014 13:48:43,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,483,498,,,488,507,JOINT,ARTHRITIS,trauma Physical exam JOINT exam for arthritis,461-468-477-483-489-494-498,483-489-494-498,Joint exam for ARTHRITIS,"History and Physical Examination Elements for Psoriasis  Normal;           History and Physical Examination Elements for Psoriasis Category  Element  Notes History  Chronic areas of redness, scaling, and itching History  Positive family history for psoriasis History  Positive history for joint symptoms  20%-30% of patients with psoriasis complain of arthralgias (tvml 30tvml ) History  Koebner phenomenon  The development of psoriasis at the site of physical trauma Physical exam  Joint exam for arthritis  Look for swelling and redness of the soft tissues around the joints, especially the fingers and toes.",483,498,483,498,488,507,1,RO-disease_has_primary_anatomic_site,902283,"History and Physical Examination Elements for Psoriasis  Normal;           History and Physical Examination Elements for Psoriasis Category  Element  Notes History  Chronic areas of redness, scaling, and itching History  Positive family history for psoriasis History  Positive history for joint symptoms  20%-30% of patients with psoriasis complain of arthralgias (tvml 30tvml ) History  Koebner phenomenon  The development of psoriasis at the site of physical trauma Physical exam  Joint exam for arthritis  Look for swelling and redness of the soft tissues around the joints, especially the fingers and toes",Joint,arthritis
503461345,7/16/2014 13:58:12,,1324264394,7/16/2014 13:57:59,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,483,498,,,488,507,JOINT,ARTHRITIS,JOINT exam for arthritis,483-489-494-498,483-489-494-498,Joint exam for ARTHRITIS,"History and Physical Examination Elements for Psoriasis  Normal;           History and Physical Examination Elements for Psoriasis Category  Element  Notes History  Chronic areas of redness, scaling, and itching History  Positive family history for psoriasis History  Positive history for joint symptoms  20%-30% of patients with psoriasis complain of arthralgias (tvml 30tvml ) History  Koebner phenomenon  The development of psoriasis at the site of physical trauma Physical exam  Joint exam for arthritis  Look for swelling and redness of the soft tissues around the joints, especially the fingers and toes.",483,498,483,498,488,507,1,RO-disease_has_primary_anatomic_site,902283,"History and Physical Examination Elements for Psoriasis  Normal;           History and Physical Examination Elements for Psoriasis Category  Element  Notes History  Chronic areas of redness, scaling, and itching History  Positive family history for psoriasis History  Positive history for joint symptoms  20%-30% of patients with psoriasis complain of arthralgias (tvml 30tvml ) History  Koebner phenomenon  The development of psoriasis at the site of physical trauma Physical exam  Joint exam for arthritis  Look for swelling and redness of the soft tissues around the joints, especially the fingers and toes",Joint,arthritis
503461345,7/16/2014 14:00:40,,1324265406,7/16/2014 13:58:59,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,483,498,,,488,507,JOINT,ARTHRITIS,JOINT exam,483-489,498,ARTHRITIS,"History and Physical Examination Elements for Psoriasis  Normal;           History and Physical Examination Elements for Psoriasis Category  Element  Notes History  Chronic areas of redness, scaling, and itching History  Positive family history for psoriasis History  Positive history for joint symptoms  20%-30% of patients with psoriasis complain of arthralgias (tvml 30tvml ) History  Koebner phenomenon  The development of psoriasis at the site of physical trauma Physical exam  Joint exam for arthritis  Look for swelling and redness of the soft tissues around the joints, especially the fingers and toes.",483,498,483,498,488,507,1,RO-disease_has_primary_anatomic_site,902283,"History and Physical Examination Elements for Psoriasis  Normal;           History and Physical Examination Elements for Psoriasis Category  Element  Notes History  Chronic areas of redness, scaling, and itching History  Positive family history for psoriasis History  Positive history for joint symptoms  20%-30% of patients with psoriasis complain of arthralgias (tvml 30tvml ) History  Koebner phenomenon  The development of psoriasis at the site of physical trauma Physical exam  Joint exam for arthritis  Look for swelling and redness of the soft tissues around the joints, especially the fingers and toes",Joint,arthritis
503461345,7/16/2014 14:17:55,,1324272695,7/16/2014 14:17:42,prodege,1.0,17932518,GBR,"","",81.133.61.60,483,498,,,488,507,JOINT,ARTHRITIS,JOINT,483,498,ARTHRITIS,"History and Physical Examination Elements for Psoriasis  Normal;           History and Physical Examination Elements for Psoriasis Category  Element  Notes History  Chronic areas of redness, scaling, and itching History  Positive family history for psoriasis History  Positive history for joint symptoms  20%-30% of patients with psoriasis complain of arthralgias (tvml 30tvml ) History  Koebner phenomenon  The development of psoriasis at the site of physical trauma Physical exam  Joint exam for arthritis  Look for swelling and redness of the soft tissues around the joints, especially the fingers and toes.",483,498,483,498,488,507,1,RO-disease_has_primary_anatomic_site,902283,"History and Physical Examination Elements for Psoriasis  Normal;           History and Physical Examination Elements for Psoriasis Category  Element  Notes History  Chronic areas of redness, scaling, and itching History  Positive family history for psoriasis History  Positive history for joint symptoms  20%-30% of patients with psoriasis complain of arthralgias (tvml 30tvml ) History  Koebner phenomenon  The development of psoriasis at the site of physical trauma Physical exam  Joint exam for arthritis  Look for swelling and redness of the soft tissues around the joints, especially the fingers and toes",Joint,arthritis
503461345,7/16/2014 14:24:28,,1324275313,7/16/2014 14:23:57,vivatic,1.0,25451531,GBR,"","",83.67.28.193,483,498,,,488,507,JOINT,ARTHRITIS,JOINT exam for arthritis,483-489-494-498,483-489-494-498,Joint exam for ARTHRITIS,"History and Physical Examination Elements for Psoriasis  Normal;           History and Physical Examination Elements for Psoriasis Category  Element  Notes History  Chronic areas of redness, scaling, and itching History  Positive family history for psoriasis History  Positive history for joint symptoms  20%-30% of patients with psoriasis complain of arthralgias (tvml 30tvml ) History  Koebner phenomenon  The development of psoriasis at the site of physical trauma Physical exam  Joint exam for arthritis  Look for swelling and redness of the soft tissues around the joints, especially the fingers and toes.",483,498,483,498,488,507,1,RO-disease_has_primary_anatomic_site,902283,"History and Physical Examination Elements for Psoriasis  Normal;           History and Physical Examination Elements for Psoriasis Category  Element  Notes History  Chronic areas of redness, scaling, and itching History  Positive family history for psoriasis History  Positive history for joint symptoms  20%-30% of patients with psoriasis complain of arthralgias (tvml 30tvml ) History  Koebner phenomenon  The development of psoriasis at the site of physical trauma Physical exam  Joint exam for arthritis  Look for swelling and redness of the soft tissues around the joints, especially the fingers and toes",Joint,arthritis
503461345,7/16/2014 14:25:20,,1324275653,7/16/2014 14:25:02,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,483,498,,,488,507,JOINT,ARTHRITIS,JOINT,483,498,ARTHRITIS,"History and Physical Examination Elements for Psoriasis  Normal;           History and Physical Examination Elements for Psoriasis Category  Element  Notes History  Chronic areas of redness, scaling, and itching History  Positive family history for psoriasis History  Positive history for joint symptoms  20%-30% of patients with psoriasis complain of arthralgias (tvml 30tvml ) History  Koebner phenomenon  The development of psoriasis at the site of physical trauma Physical exam  Joint exam for arthritis  Look for swelling and redness of the soft tissues around the joints, especially the fingers and toes.",483,498,483,498,488,507,1,RO-disease_has_primary_anatomic_site,902283,"History and Physical Examination Elements for Psoriasis  Normal;           History and Physical Examination Elements for Psoriasis Category  Element  Notes History  Chronic areas of redness, scaling, and itching History  Positive family history for psoriasis History  Positive history for joint symptoms  20%-30% of patients with psoriasis complain of arthralgias (tvml 30tvml ) History  Koebner phenomenon  The development of psoriasis at the site of physical trauma Physical exam  Joint exam for arthritis  Look for swelling and redness of the soft tissues around the joints, especially the fingers and toes",Joint,arthritis
503461345,7/16/2014 14:29:38,,1324277462,7/16/2014 14:28:30,prodege,1.0,26790109,USA,"","",23.125.64.233,483,498,,,488,507,JOINT,ARTHRITIS,trauma Physical exam JOINT exam for arthritis Look for swelling and redness of the soft tissues around,461-468-477-483-489-494-509-514-518-527-531-539-542-546-551-559-498,483-489-494-498-509-514-518-527-531-539-542-546-551-559-566-570-578-589-593-605-601,"Joint exam for ARTHRITIS Look for swelling and redness of the soft tissues around the joints, especially the fingers and toes.","History and Physical Examination Elements for Psoriasis  Normal;           History and Physical Examination Elements for Psoriasis Category  Element  Notes History  Chronic areas of redness, scaling, and itching History  Positive family history for psoriasis History  Positive history for joint symptoms  20%-30% of patients with psoriasis complain of arthralgias (tvml 30tvml ) History  Koebner phenomenon  The development of psoriasis at the site of physical trauma Physical exam  Joint exam for arthritis  Look for swelling and redness of the soft tissues around the joints, especially the fingers and toes.",483,498,483,498,488,507,1,RO-disease_has_primary_anatomic_site,902283,"History and Physical Examination Elements for Psoriasis  Normal;           History and Physical Examination Elements for Psoriasis Category  Element  Notes History  Chronic areas of redness, scaling, and itching History  Positive family history for psoriasis History  Positive history for joint symptoms  20%-30% of patients with psoriasis complain of arthralgias (tvml 30tvml ) History  Koebner phenomenon  The development of psoriasis at the site of physical trauma Physical exam  Joint exam for arthritis  Look for swelling and redness of the soft tissues around the joints, especially the fingers and toes",Joint,arthritis
503461345,7/16/2014 14:37:15,,1324280612,7/16/2014 14:36:58,prodege,1.0,6316959,GBR,"","",46.208.145.114,483,498,,,488,507,JOINT,ARTHRITIS,JOINT,483,498,ARTHRITIS,"History and Physical Examination Elements for Psoriasis  Normal;           History and Physical Examination Elements for Psoriasis Category  Element  Notes History  Chronic areas of redness, scaling, and itching History  Positive family history for psoriasis History  Positive history for joint symptoms  20%-30% of patients with psoriasis complain of arthralgias (tvml 30tvml ) History  Koebner phenomenon  The development of psoriasis at the site of physical trauma Physical exam  Joint exam for arthritis  Look for swelling and redness of the soft tissues around the joints, especially the fingers and toes.",483,498,483,498,488,507,1,RO-disease_has_primary_anatomic_site,902283,"History and Physical Examination Elements for Psoriasis  Normal;           History and Physical Examination Elements for Psoriasis Category  Element  Notes History  Chronic areas of redness, scaling, and itching History  Positive family history for psoriasis History  Positive history for joint symptoms  20%-30% of patients with psoriasis complain of arthralgias (tvml 30tvml ) History  Koebner phenomenon  The development of psoriasis at the site of physical trauma Physical exam  Joint exam for arthritis  Look for swelling and redness of the soft tissues around the joints, especially the fingers and toes",Joint,arthritis
503461346,7/16/2014 13:44:08,,1324259154,7/16/2014 13:43:52,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,166,78,,,182,95,SEVERE DYSPLASIA,CARCINOMA IN SITU,DYSPLASIA),173,88-91,IN SITU),"Only two premalignant lesions showed absence of p16 expression, of which one (carcinoma in situ) was hypermethylated at the p16(INK4a) promoter region and the other (severe dysplasia) showed BMI-1 expression.",173,88 91,166,78,182,95,-1,RO-disease_has_finding,901932,"Only two premalignant lesions showed absence of p16 expression, of which one (carcinoma in situ) was hypermethylated at the p16(INK4a) promoter region and the other (severe dysplasia) showed BMI-1 expression",severe dysplasia,carcinoma in situ
503461346,7/16/2014 13:47:00,,1324260095,7/16/2014 13:46:44,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,166,78,,,182,95,SEVERE DYSPLASIA,CARCINOMA IN SITU,DYSPLASIA),173,88-91,IN SITU),"Only two premalignant lesions showed absence of p16 expression, of which one (carcinoma in situ) was hypermethylated at the p16(INK4a) promoter region and the other (severe dysplasia) showed BMI-1 expression.",173,88 91,166,78,182,95,-1,RO-disease_has_finding,901932,"Only two premalignant lesions showed absence of p16 expression, of which one (carcinoma in situ) was hypermethylated at the p16(INK4a) promoter region and the other (severe dysplasia) showed BMI-1 expression",severe dysplasia,carcinoma in situ
503461346,7/16/2014 13:53:13,,1324262267,7/16/2014 13:52:48,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,166,78,,,182,95,SEVERE DYSPLASIA,CARCINOMA IN SITU,(SEVERE DYSPLASIA) showed BMI 1 expression.,165-173-184-191-195-197,77-88-91,(CARCINOMA IN SITU),"Only two premalignant lesions showed absence of p16 expression, of which one (carcinoma in situ) was hypermethylated at the p16(INK4a) promoter region and the other (severe dysplasia) showed BMI-1 expression.",173,88 91,166,78,182,95,-1,RO-disease_has_finding,901932,"Only two premalignant lesions showed absence of p16 expression, of which one (carcinoma in situ) was hypermethylated at the p16(INK4a) promoter region and the other (severe dysplasia) showed BMI-1 expression",severe dysplasia,carcinoma in situ
503461346,7/16/2014 13:55:03,,1324263013,7/16/2014 13:54:42,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,166,78,,,182,95,SEVERE DYSPLASIA,CARCINOMA IN SITU,(SEVERE DYSPLASIA),165-173,77-88-91,(CARCINOMA IN SITU),"Only two premalignant lesions showed absence of p16 expression, of which one (carcinoma in situ) was hypermethylated at the p16(INK4a) promoter region and the other (severe dysplasia) showed BMI-1 expression.",173,88 91,166,78,182,95,-1,RO-disease_has_finding,901932,"Only two premalignant lesions showed absence of p16 expression, of which one (carcinoma in situ) was hypermethylated at the p16(INK4a) promoter region and the other (severe dysplasia) showed BMI-1 expression",severe dysplasia,carcinoma in situ
503461346,7/16/2014 14:00:57,,1324265459,7/16/2014 14:00:32,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,166,78,,,182,95,SEVERE DYSPLASIA,CARCINOMA IN SITU,(SEVERE DYSPLASIA),173-165,88-91-165-173,IN SITU) (severe dysplasia),"Only two premalignant lesions showed absence of p16 expression, of which one (carcinoma in situ) was hypermethylated at the p16(INK4a) promoter region and the other (severe dysplasia) showed BMI-1 expression.",173,88 91,166,78,182,95,-1,RO-disease_has_finding,901932,"Only two premalignant lesions showed absence of p16 expression, of which one (carcinoma in situ) was hypermethylated at the p16(INK4a) promoter region and the other (severe dysplasia) showed BMI-1 expression",severe dysplasia,carcinoma in situ
503461346,7/16/2014 14:02:09,,1324265987,7/16/2014 14:01:52,instagc,1.0,18960682,GBR,"","",86.29.147.112,166,78,,,182,95,SEVERE DYSPLASIA,CARCINOMA IN SITU,(SEVERE DYSPLASIA),165-173,77-88-91,(CARCINOMA IN SITU),"Only two premalignant lesions showed absence of p16 expression, of which one (carcinoma in situ) was hypermethylated at the p16(INK4a) promoter region and the other (severe dysplasia) showed BMI-1 expression.",173,88 91,166,78,182,95,-1,RO-disease_has_finding,901932,"Only two premalignant lesions showed absence of p16 expression, of which one (carcinoma in situ) was hypermethylated at the p16(INK4a) promoter region and the other (severe dysplasia) showed BMI-1 expression",severe dysplasia,carcinoma in situ
503461346,7/16/2014 14:31:08,,1324278150,7/16/2014 14:30:39,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,166,78,,,182,95,SEVERE DYSPLASIA,CARCINOMA IN SITU,in situ) DYSPLASIA),91-173-88,88-91-173,IN SITU) dysplasia),"Only two premalignant lesions showed absence of p16 expression, of which one (carcinoma in situ) was hypermethylated at the p16(INK4a) promoter region and the other (severe dysplasia) showed BMI-1 expression.",173,88 91,166,78,182,95,-1,RO-disease_has_finding,901932,"Only two premalignant lesions showed absence of p16 expression, of which one (carcinoma in situ) was hypermethylated at the p16(INK4a) promoter region and the other (severe dysplasia) showed BMI-1 expression",severe dysplasia,carcinoma in situ
503461346,7/16/2014 14:34:34,,1324279432,7/16/2014 14:34:12,prodege,1.0,6316959,GBR,"","",46.208.145.114,166,78,,,182,95,SEVERE DYSPLASIA,CARCINOMA IN SITU,(SEVERE DYSPLASIA),165-173,77-88-91,(CARCINOMA IN SITU),"Only two premalignant lesions showed absence of p16 expression, of which one (carcinoma in situ) was hypermethylated at the p16(INK4a) promoter region and the other (severe dysplasia) showed BMI-1 expression.",173,88 91,166,78,182,95,-1,RO-disease_has_finding,901932,"Only two premalignant lesions showed absence of p16 expression, of which one (carcinoma in situ) was hypermethylated at the p16(INK4a) promoter region and the other (severe dysplasia) showed BMI-1 expression",severe dysplasia,carcinoma in situ
503461346,7/16/2014 14:44:58,,1324282984,7/16/2014 14:44:49,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,166,78,,,182,95,SEVERE DYSPLASIA,CARCINOMA IN SITU,(SEVERE DYSPLASIA),165-173,77-88-91,(CARCINOMA IN SITU),"Only two premalignant lesions showed absence of p16 expression, of which one (carcinoma in situ) was hypermethylated at the p16(INK4a) promoter region and the other (severe dysplasia) showed BMI-1 expression.",173,88 91,166,78,182,95,-1,RO-disease_has_finding,901932,"Only two premalignant lesions showed absence of p16 expression, of which one (carcinoma in situ) was hypermethylated at the p16(INK4a) promoter region and the other (severe dysplasia) showed BMI-1 expression",severe dysplasia,carcinoma in situ
503461346,7/16/2014 14:55:08,,1324286109,7/16/2014 14:55:05,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,166,78,,,182,95,SEVERE DYSPLASIA,CARCINOMA IN SITU,the other (SEVERE DYSPLASIA) showed BMI 1,155-159-165-173-184-191-195,67-73-77-88-91-97-101-117,which one (CARCINOMA IN SITU) was hypermethylated at,"Only two premalignant lesions showed absence of p16 expression, of which one (carcinoma in situ) was hypermethylated at the p16(INK4a) promoter region and the other (severe dysplasia) showed BMI-1 expression.",173,88 91,166,78,182,95,-1,RO-disease_has_finding,901932,"Only two premalignant lesions showed absence of p16 expression, of which one (carcinoma in situ) was hypermethylated at the p16(INK4a) promoter region and the other (severe dysplasia) showed BMI-1 expression",severe dysplasia,carcinoma in situ
503461347,7/16/2014 13:52:17,,1324261886,7/16/2014 13:52:02,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,146,201,,,153,209,SEIZURE,EPILEPSY,SEIZURE,146,201,EPILEPSY;,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of epileptic activity attenuated seizure responses under conditions of animal models of epilepsy; pharmacological blocking of galanin receptors exerted proconvulsant effects.",146,201,146,201,153,209,-1,RO-has_definitional_manifestation,904940,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of epileptic activity attenuated seizure responses under conditions of animal models of epilepsy; pharmacological blocking of galanin receptors exerted proconvulsant effects",seizure,epilepsy
503461347,7/16/2014 13:57:52,,1324264249,7/16/2014 13:57:34,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,146,201,,,153,209,SEIZURE,EPILEPSY,epileptic activity attenuated SEIZURE,116-126-135-146,201,EPILEPSY;,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of epileptic activity attenuated seizure responses under conditions of animal models of epilepsy; pharmacological blocking of galanin receptors exerted proconvulsant effects.",146,201,146,201,153,209,-1,RO-has_definitional_manifestation,904940,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of epileptic activity attenuated seizure responses under conditions of animal models of epilepsy; pharmacological blocking of galanin receptors exerted proconvulsant effects",seizure,epilepsy
503461347,7/16/2014 14:05:10,,1324267337,7/16/2014 14:04:32,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,146,201,,,153,209,SEIZURE,EPILEPSY,galanin receptor agonists brain epileptic activity SEIZURE epilepsy; pharmacological galanin receptors exerted proconvulsant effects.,26-34-43-57-116-126-146-201-211-239-247-257-265-279,26-34-57-116-126-146-201-211-239-247-257-265-279,galanin receptor brain epileptic activity seizure EPILEPSY; pharmacological galanin receptors exerted proconvulsant effects.,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of epileptic activity attenuated seizure responses under conditions of animal models of epilepsy; pharmacological blocking of galanin receptors exerted proconvulsant effects.",146,201,146,201,153,209,-1,RO-has_definitional_manifestation,904940,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of epileptic activity attenuated seizure responses under conditions of animal models of epilepsy; pharmacological blocking of galanin receptors exerted proconvulsant effects",seizure,epilepsy
503461347,7/16/2014 14:07:37,,1324268384,7/16/2014 14:07:29,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,146,201,,,153,209,SEIZURE,EPILEPSY,epileptic activity attenuated SEIZURE responses under conditions,116-126-135-146-154-164-170,184-191-198-201-211-227-236,animal models of EPILEPSY; pharmacological blocking of,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of epileptic activity attenuated seizure responses under conditions of animal models of epilepsy; pharmacological blocking of galanin receptors exerted proconvulsant effects.",146,201,146,201,153,209,-1,RO-has_definitional_manifestation,904940,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of epileptic activity attenuated seizure responses under conditions of animal models of epilepsy; pharmacological blocking of galanin receptors exerted proconvulsant effects",seizure,epilepsy
503461347,7/16/2014 14:29:12,,1324277248,7/16/2014 14:28:56,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,146,201,,,153,209,SEIZURE,EPILEPSY,SEIZURE,146,201,EPILEPSY;,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of epileptic activity attenuated seizure responses under conditions of animal models of epilepsy; pharmacological blocking of galanin receptors exerted proconvulsant effects.",146,201,146,201,153,209,-1,RO-has_definitional_manifestation,904940,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of epileptic activity attenuated seizure responses under conditions of animal models of epilepsy; pharmacological blocking of galanin receptors exerted proconvulsant effects",seizure,epilepsy
503461347,7/16/2014 14:30:17,,1324277725,7/16/2014 14:29:58,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,146,201,,,153,209,SEIZURE,EPILEPSY,SEIZURE epilepsy;,146-201,146-201,seizure EPILEPSY;,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of epileptic activity attenuated seizure responses under conditions of animal models of epilepsy; pharmacological blocking of galanin receptors exerted proconvulsant effects.",146,201,146,201,153,209,-1,RO-has_definitional_manifestation,904940,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of epileptic activity attenuated seizure responses under conditions of animal models of epilepsy; pharmacological blocking of galanin receptors exerted proconvulsant effects",seizure,epilepsy
503461347,7/16/2014 14:38:44,,1324281169,7/16/2014 14:38:10,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,146,201,,,153,209,SEIZURE,EPILEPSY,epileptic activity attenuated SEIZURE responses,116-126-135-146-154,201,EPILEPSY;,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of epileptic activity attenuated seizure responses under conditions of animal models of epilepsy; pharmacological blocking of galanin receptors exerted proconvulsant effects.",146,201,146,201,153,209,-1,RO-has_definitional_manifestation,904940,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of epileptic activity attenuated seizure responses under conditions of animal models of epilepsy; pharmacological blocking of galanin receptors exerted proconvulsant effects",seizure,epilepsy
503461347,7/16/2014 14:46:38,,1324283421,7/16/2014 14:46:29,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,146,201,,,153,209,SEIZURE,EPILEPSY,SEIZURE,146,201,EPILEPSY;,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of epileptic activity attenuated seizure responses under conditions of animal models of epilepsy; pharmacological blocking of galanin receptors exerted proconvulsant effects.",146,201,146,201,153,209,-1,RO-has_definitional_manifestation,904940,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of epileptic activity attenuated seizure responses under conditions of animal models of epilepsy; pharmacological blocking of galanin receptors exerted proconvulsant effects",seizure,epilepsy
503461347,7/16/2014 14:55:20,,1324286151,7/16/2014 14:54:14,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.72,146,201,,,153,209,SEIZURE,EPILEPSY,epileptic activity attenuated SEIZURE responses,116-126-146-154-135,201,EPILEPSY;,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of epileptic activity attenuated seizure responses under conditions of animal models of epilepsy; pharmacological blocking of galanin receptors exerted proconvulsant effects.",146,201,146,201,153,209,-1,RO-has_definitional_manifestation,904940,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of epileptic activity attenuated seizure responses under conditions of animal models of epilepsy; pharmacological blocking of galanin receptors exerted proconvulsant effects",seizure,epilepsy
503461347,7/16/2014 14:58:07,,1324287275,7/16/2014 14:57:19,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,146,201,,,153,209,SEIZURE,EPILEPSY,SEIZURE,146,201,EPILEPSY;,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of epileptic activity attenuated seizure responses under conditions of animal models of epilepsy; pharmacological blocking of galanin receptors exerted proconvulsant effects.",146,201,146,201,153,209,-1,RO-has_definitional_manifestation,904940,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of epileptic activity attenuated seizure responses under conditions of animal models of epilepsy; pharmacological blocking of galanin receptors exerted proconvulsant effects",seizure,epilepsy
503461348,7/16/2014 13:40:23,,1324257813,7/16/2014 13:40:10,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,170,190,,,179,195,ARTHRITIS,LUPUS,"(rheumatoid ARTHRITIS,",158-170,181-190-196,systemic LUPUS erythematosus),"? Note that patients at potential increased risk of hematogenous infection of their total joint replacements include those with: ? Inflammatory arthropathies (rheumatoid arthritis, systemic lupus erythematosus) ? Disease-, drug-, or radiation-induced immunosuppression ? Insulin-dependent (type 1) diabetes mellitus ? Joint replacement within previous 2 years ? Previous prosthetic infections ? Malnourishment ? Hemophilia ? Counsel patients about the risk of developing an infection in prosthetic joints and the risk of adverse effects in taking antibiotic prophylaxis; if the risk of infection is greater, offer antibiotic.",170,190,170,190,179,195,-1,RO-has_manifestation,906335,"? Note that patients at potential increased risk of hematogenous infection of their total joint replacements include those with: ? Inflammatory arthropathies (rheumatoid arthritis, systemic lupus erythematosus) ? Disease-, drug-, or radiation-induced immunosuppression ? Insulin-dependent (type 1) diabetes mellitus ? Joint replacement within previous 2 years ? Previous prosthetic infections ? Malnourishment ? Hemophilia ? Counsel patients about the risk of developing an infection in prosthetic joints and the risk of adverse effects in taking antibiotic prophylaxis; if the risk of infection is greater, offer antibiotic",arthritis,lupus
503461348,7/16/2014 13:47:42,,1324260335,7/16/2014 13:47:29,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,170,190,,,179,195,ARTHRITIS,LUPUS,"(rheumatoid ARTHRITIS,",158-170,181-190,systemic LUPUS,"? Note that patients at potential increased risk of hematogenous infection of their total joint replacements include those with: ? Inflammatory arthropathies (rheumatoid arthritis, systemic lupus erythematosus) ? Disease-, drug-, or radiation-induced immunosuppression ? Insulin-dependent (type 1) diabetes mellitus ? Joint replacement within previous 2 years ? Previous prosthetic infections ? Malnourishment ? Hemophilia ? Counsel patients about the risk of developing an infection in prosthetic joints and the risk of adverse effects in taking antibiotic prophylaxis; if the risk of infection is greater, offer antibiotic.",170,190,170,190,179,195,-1,RO-has_manifestation,906335,"? Note that patients at potential increased risk of hematogenous infection of their total joint replacements include those with: ? Inflammatory arthropathies (rheumatoid arthritis, systemic lupus erythematosus) ? Disease-, drug-, or radiation-induced immunosuppression ? Insulin-dependent (type 1) diabetes mellitus ? Joint replacement within previous 2 years ? Previous prosthetic infections ? Malnourishment ? Hemophilia ? Counsel patients about the risk of developing an infection in prosthetic joints and the risk of adverse effects in taking antibiotic prophylaxis; if the risk of infection is greater, offer antibiotic",arthritis,lupus
503461348,7/16/2014 13:50:08,,1324261146,7/16/2014 13:49:50,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,170,190,,,179,195,ARTHRITIS,LUPUS,"Inflammatory arthropathies (rheumatoid ARTHRITIS, systemic lupus erythematosus)",131-144-158-170-181-190-196,158-170-181-190-196,"(rheumatoid arthritis, systemic LUPUS erythematosus)","? Note that patients at potential increased risk of hematogenous infection of their total joint replacements include those with: ? Inflammatory arthropathies (rheumatoid arthritis, systemic lupus erythematosus) ? Disease-, drug-, or radiation-induced immunosuppression ? Insulin-dependent (type 1) diabetes mellitus ? Joint replacement within previous 2 years ? Previous prosthetic infections ? Malnourishment ? Hemophilia ? Counsel patients about the risk of developing an infection in prosthetic joints and the risk of adverse effects in taking antibiotic prophylaxis; if the risk of infection is greater, offer antibiotic.",170,190,170,190,179,195,-1,RO-has_manifestation,906335,"? Note that patients at potential increased risk of hematogenous infection of their total joint replacements include those with: ? Inflammatory arthropathies (rheumatoid arthritis, systemic lupus erythematosus) ? Disease-, drug-, or radiation-induced immunosuppression ? Insulin-dependent (type 1) diabetes mellitus ? Joint replacement within previous 2 years ? Previous prosthetic infections ? Malnourishment ? Hemophilia ? Counsel patients about the risk of developing an infection in prosthetic joints and the risk of adverse effects in taking antibiotic prophylaxis; if the risk of infection is greater, offer antibiotic",arthritis,lupus
503461348,7/16/2014 13:52:34,,1324262018,7/16/2014 13:52:01,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,170,190,,,179,195,ARTHRITIS,LUPUS,"ARTHRITIS,",170,190,LUPUS,"? Note that patients at potential increased risk of hematogenous infection of their total joint replacements include those with: ? Inflammatory arthropathies (rheumatoid arthritis, systemic lupus erythematosus) ? Disease-, drug-, or radiation-induced immunosuppression ? Insulin-dependent (type 1) diabetes mellitus ? Joint replacement within previous 2 years ? Previous prosthetic infections ? Malnourishment ? Hemophilia ? Counsel patients about the risk of developing an infection in prosthetic joints and the risk of adverse effects in taking antibiotic prophylaxis; if the risk of infection is greater, offer antibiotic.",170,190,170,190,179,195,-1,RO-has_manifestation,906335,"? Note that patients at potential increased risk of hematogenous infection of their total joint replacements include those with: ? Inflammatory arthropathies (rheumatoid arthritis, systemic lupus erythematosus) ? Disease-, drug-, or radiation-induced immunosuppression ? Insulin-dependent (type 1) diabetes mellitus ? Joint replacement within previous 2 years ? Previous prosthetic infections ? Malnourishment ? Hemophilia ? Counsel patients about the risk of developing an infection in prosthetic joints and the risk of adverse effects in taking antibiotic prophylaxis; if the risk of infection is greater, offer antibiotic",arthritis,lupus
503461348,7/16/2014 13:58:20,,1324264445,7/16/2014 13:58:00,instagc,1,18960682,GBR,"","",86.29.147.112,170,190,,,179,195,ARTHRITIS,LUPUS,"(rheumatoid ARTHRITIS,",158-170,181-190-196,systemic LUPUS erythematosus),"? Note that patients at potential increased risk of hematogenous infection of their total joint replacements include those with: ? Inflammatory arthropathies (rheumatoid arthritis, systemic lupus erythematosus) ? Disease-, drug-, or radiation-induced immunosuppression ? Insulin-dependent (type 1) diabetes mellitus ? Joint replacement within previous 2 years ? Previous prosthetic infections ? Malnourishment ? Hemophilia ? Counsel patients about the risk of developing an infection in prosthetic joints and the risk of adverse effects in taking antibiotic prophylaxis; if the risk of infection is greater, offer antibiotic.",170,190,170,190,179,195,-1,RO-has_manifestation,906335,"? Note that patients at potential increased risk of hematogenous infection of their total joint replacements include those with: ? Inflammatory arthropathies (rheumatoid arthritis, systemic lupus erythematosus) ? Disease-, drug-, or radiation-induced immunosuppression ? Insulin-dependent (type 1) diabetes mellitus ? Joint replacement within previous 2 years ? Previous prosthetic infections ? Malnourishment ? Hemophilia ? Counsel patients about the risk of developing an infection in prosthetic joints and the risk of adverse effects in taking antibiotic prophylaxis; if the risk of infection is greater, offer antibiotic",arthritis,lupus
503461348,7/16/2014 14:06:29,,1324267915,7/16/2014 14:05:12,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,170,190,,,179,195,ARTHRITIS,LUPUS,"hematogenous infection total joint replacements Inflammatory arthropathies (rheumatoid ARTHRITIS, systemic lupus erythematosus) Disease drug - radiation induced immunosuppression Insulin - dependent (type 1) diabetes mellitus Joint replacement prosthetic infections Malnourishment Hemophilia infection prosthetic joints adverse effects antibiotic prophylaxis; infection antibiotic.",52-65-84-90-96-131-144-158-170-181-190-196-213-223-227-233-243-251-271-278-279-289-295-298-307-318-324-371-382-395-412-474-487-498-521-547-558-586-614-529,52-65-84-90-96-131-144-158-170-181-190-196-213-223-233-243-251-271-279-289-295-298-307-318-324-371-382-395-412-474-487-498-521-529-547-558-614-586,"hematogenous infection total joint replacements Inflammatory arthropathies (rheumatoid arthritis, systemic LUPUS erythematosus) Disease drug radiation induced immunosuppression Insulin dependent (type 1) diabetes mellitus Joint replacement prosthetic infections Malnourishment Hemophilia infection prosthetic joints adverse effects antibiotic prophylaxis; infection antibiotic.","? Note that patients at potential increased risk of hematogenous infection of their total joint replacements include those with: ? Inflammatory arthropathies (rheumatoid arthritis, systemic lupus erythematosus) ? Disease-, drug-, or radiation-induced immunosuppression ? Insulin-dependent (type 1) diabetes mellitus ? Joint replacement within previous 2 years ? Previous prosthetic infections ? Malnourishment ? Hemophilia ? Counsel patients about the risk of developing an infection in prosthetic joints and the risk of adverse effects in taking antibiotic prophylaxis; if the risk of infection is greater, offer antibiotic.",170,190,170,190,179,195,-1,RO-has_manifestation,906335,"? Note that patients at potential increased risk of hematogenous infection of their total joint replacements include those with: ? Inflammatory arthropathies (rheumatoid arthritis, systemic lupus erythematosus) ? Disease-, drug-, or radiation-induced immunosuppression ? Insulin-dependent (type 1) diabetes mellitus ? Joint replacement within previous 2 years ? Previous prosthetic infections ? Malnourishment ? Hemophilia ? Counsel patients about the risk of developing an infection in prosthetic joints and the risk of adverse effects in taking antibiotic prophylaxis; if the risk of infection is greater, offer antibiotic",arthritis,lupus
503461348,7/16/2014 14:32:02,,1324278426,7/16/2014 14:31:40,prodege,1,26790109,USA,"","",23.125.64.233,170,190,,,179,195,ARTHRITIS,LUPUS,"Inflammatory arthropathies (rheumatoid ARTHRITIS, systemic lupus erythematosus)",131-144-158-170-181-190-196,158-170-181-190-196-213-223,"(rheumatoid arthritis, systemic LUPUS erythematosus) Disease drug","? Note that patients at potential increased risk of hematogenous infection of their total joint replacements include those with: ? Inflammatory arthropathies (rheumatoid arthritis, systemic lupus erythematosus) ? Disease-, drug-, or radiation-induced immunosuppression ? Insulin-dependent (type 1) diabetes mellitus ? Joint replacement within previous 2 years ? Previous prosthetic infections ? Malnourishment ? Hemophilia ? Counsel patients about the risk of developing an infection in prosthetic joints and the risk of adverse effects in taking antibiotic prophylaxis; if the risk of infection is greater, offer antibiotic.",170,190,170,190,179,195,-1,RO-has_manifestation,906335,"? Note that patients at potential increased risk of hematogenous infection of their total joint replacements include those with: ? Inflammatory arthropathies (rheumatoid arthritis, systemic lupus erythematosus) ? Disease-, drug-, or radiation-induced immunosuppression ? Insulin-dependent (type 1) diabetes mellitus ? Joint replacement within previous 2 years ? Previous prosthetic infections ? Malnourishment ? Hemophilia ? Counsel patients about the risk of developing an infection in prosthetic joints and the risk of adverse effects in taking antibiotic prophylaxis; if the risk of infection is greater, offer antibiotic",arthritis,lupus
503461348,7/16/2014 14:36:06,,1324280173,7/16/2014 14:35:47,prodege,1.0,6316959,GBR,"","",46.208.145.114,170,190,,,179,195,ARTHRITIS,LUPUS,"(rheumatoid ARTHRITIS,",158-170,181-190-196,systemic LUPUS erythematosus),"? Note that patients at potential increased risk of hematogenous infection of their total joint replacements include those with: ? Inflammatory arthropathies (rheumatoid arthritis, systemic lupus erythematosus) ? Disease-, drug-, or radiation-induced immunosuppression ? Insulin-dependent (type 1) diabetes mellitus ? Joint replacement within previous 2 years ? Previous prosthetic infections ? Malnourishment ? Hemophilia ? Counsel patients about the risk of developing an infection in prosthetic joints and the risk of adverse effects in taking antibiotic prophylaxis; if the risk of infection is greater, offer antibiotic.",170,190,170,190,179,195,-1,RO-has_manifestation,906335,"? Note that patients at potential increased risk of hematogenous infection of their total joint replacements include those with: ? Inflammatory arthropathies (rheumatoid arthritis, systemic lupus erythematosus) ? Disease-, drug-, or radiation-induced immunosuppression ? Insulin-dependent (type 1) diabetes mellitus ? Joint replacement within previous 2 years ? Previous prosthetic infections ? Malnourishment ? Hemophilia ? Counsel patients about the risk of developing an infection in prosthetic joints and the risk of adverse effects in taking antibiotic prophylaxis; if the risk of infection is greater, offer antibiotic",arthritis,lupus
503461348,7/16/2014 14:47:25,,1324283682,7/16/2014 14:47:17,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,170,190,,,179,195,ARTHRITIS,LUPUS,"Inflammatory arthropathies (rheumatoid ARTHRITIS, systemic lupus erythematosus)",131-144-158-170-181-190-196,158-170-181-190-196,"(rheumatoid arthritis, systemic LUPUS erythematosus)","? Note that patients at potential increased risk of hematogenous infection of their total joint replacements include those with: ? Inflammatory arthropathies (rheumatoid arthritis, systemic lupus erythematosus) ? Disease-, drug-, or radiation-induced immunosuppression ? Insulin-dependent (type 1) diabetes mellitus ? Joint replacement within previous 2 years ? Previous prosthetic infections ? Malnourishment ? Hemophilia ? Counsel patients about the risk of developing an infection in prosthetic joints and the risk of adverse effects in taking antibiotic prophylaxis; if the risk of infection is greater, offer antibiotic.",170,190,170,190,179,195,-1,RO-has_manifestation,906335,"? Note that patients at potential increased risk of hematogenous infection of their total joint replacements include those with: ? Inflammatory arthropathies (rheumatoid arthritis, systemic lupus erythematosus) ? Disease-, drug-, or radiation-induced immunosuppression ? Insulin-dependent (type 1) diabetes mellitus ? Joint replacement within previous 2 years ? Previous prosthetic infections ? Malnourishment ? Hemophilia ? Counsel patients about the risk of developing an infection in prosthetic joints and the risk of adverse effects in taking antibiotic prophylaxis; if the risk of infection is greater, offer antibiotic",arthritis,lupus
503461348,7/16/2014 14:53:00,,1324285329,7/16/2014 14:52:42,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,170,190,,,179,195,ARTHRITIS,LUPUS,"(rheumatoid ARTHRITIS,",170-158,181-190-196,systemic LUPUS erythematosus),"? Note that patients at potential increased risk of hematogenous infection of their total joint replacements include those with: ? Inflammatory arthropathies (rheumatoid arthritis, systemic lupus erythematosus) ? Disease-, drug-, or radiation-induced immunosuppression ? Insulin-dependent (type 1) diabetes mellitus ? Joint replacement within previous 2 years ? Previous prosthetic infections ? Malnourishment ? Hemophilia ? Counsel patients about the risk of developing an infection in prosthetic joints and the risk of adverse effects in taking antibiotic prophylaxis; if the risk of infection is greater, offer antibiotic.",170,190,170,190,179,195,-1,RO-has_manifestation,906335,"? Note that patients at potential increased risk of hematogenous infection of their total joint replacements include those with: ? Inflammatory arthropathies (rheumatoid arthritis, systemic lupus erythematosus) ? Disease-, drug-, or radiation-induced immunosuppression ? Insulin-dependent (type 1) diabetes mellitus ? Joint replacement within previous 2 years ? Previous prosthetic infections ? Malnourishment ? Hemophilia ? Counsel patients about the risk of developing an infection in prosthetic joints and the risk of adverse effects in taking antibiotic prophylaxis; if the risk of infection is greater, offer antibiotic",arthritis,lupus
503461349,7/16/2014 14:25:56,,1324275935,7/16/2014 14:25:14,vivatic,1.0,25451531,GBR,"","",83.67.28.193,90,52,,,102,61,INFLAMMATION,IBUPROFEN,INFLAMMATION,90,52-41,"metabolite IBUPROFEN,","In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model.",90,52,90,52,102,61,1,RO-may_treat,908045,"In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model",inflammation,ibuprofen
503461349,7/16/2014 14:28:58,,1324277163,7/16/2014 14:28:43,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,90,52,,,102,61,INFLAMMATION,IBUPROFEN,INFLAMMATION,90,52,"IBUPROFEN,","In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model.",90,52,90,52,102,61,1,RO-may_treat,908045,"In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model",inflammation,ibuprofen
503461349,7/16/2014 14:35:16,,1324279775,7/16/2014 14:34:59,prodege,1.0,6316959,GBR,"","",46.208.145.114,90,52,,,102,61,INFLAMMATION,IBUPROFEN,INFLAMMATION,90,52,"IBUPROFEN,","In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model.",90,52,90,52,102,61,1,RO-may_treat,908045,"In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model",inflammation,ibuprofen
503461349,7/16/2014 14:53:17,,1324285471,7/16/2014 14:52:55,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,90,52,,,102,61,INFLAMMATION,IBUPROFEN,INFLAMMATION,90,52,"IBUPROFEN,","In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model.",90,52,90,52,102,61,1,RO-may_treat,908045,"In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model",inflammation,ibuprofen
503461349,7/16/2014 14:55:31,,1324286239,7/16/2014 14:55:04,irazoo,1.0,7022810,USA,IA,Ankeny,216.161.121.1,90,52,,,102,61,INFLAMMATION,IBUPROFEN,INFLAMMATION,90,41-52,"metabolite IBUPROFEN,","In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model.",90,52,90,52,102,61,1,RO-may_treat,908045,"In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model",inflammation,ibuprofen
503461349,7/16/2014 14:57:16,,1324286953,7/16/2014 14:57:06,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,90,52,,,102,61,INFLAMMATION,IBUPROFEN,INFLAMMATION,90,52,"IBUPROFEN,","In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model.",90,52,90,52,102,61,1,RO-may_treat,908045,"In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model",inflammation,ibuprofen
503461349,7/16/2014 14:57:52,,1324287184,7/16/2014 14:56:00,onestopgpt,1,21275875,CAN,ON,Hamilton,216.209.129.72,90,52,,,102,61,INFLAMMATION,IBUPROFEN,INFLAMMATION,90,52,"IBUPROFEN,","In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model.",90,52,90,52,102,61,1,RO-may_treat,908045,"In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model",inflammation,ibuprofen
503461349,7/16/2014 14:58:34,,1324287404,7/16/2014 14:58:17,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,90,52,,,102,61,INFLAMMATION,IBUPROFEN,INFLAMMATION,90,52,"IBUPROFEN,","In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model.",90,52,90,52,102,61,1,RO-may_treat,908045,"In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model",inflammation,ibuprofen
503461349,7/16/2014 15:00:13,,1324288044,7/16/2014 14:59:55,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,90,52,,,102,61,INFLAMMATION,IBUPROFEN,enhance INFLAMMATION,82-90,52,"IBUPROFEN,","In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model.",90,52,90,52,102,61,1,RO-may_treat,908045,"In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model",inflammation,ibuprofen
503461349,7/16/2014 15:07:09,,1324291067,7/16/2014 15:06:48,elite,1,28276268,USA,MI,Fenton,68.188.185.225,90,52,,,102,61,INFLAMMATION,IBUPROFEN,INFLAMMATION,90,52,"IBUPROFEN,","In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model.",90,52,90,52,102,61,1,RO-may_treat,908045,"In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model",inflammation,ibuprofen
503461350,7/16/2014 13:57:22,,1324264001,7/16/2014 13:57:09,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,43,82,,,47,86,OPCA,SCA1,sporadic OPCA,34-43,82,"SCA1,","In contrast, in two patients with sporadic OPCA and in four of five patients with SCA1, the fibres were not identified.",43,82,43,82,47,86,-1,RO-has_manifestation,906113,"In contrast, in two patients with sporadic OPCA and in four of five patients with SCA1, the fibres were not identified",OPCA,SCA1
503461350,7/16/2014 13:58:26,,1324264484,7/16/2014 13:58:05,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,43,82,,,47,86,OPCA,SCA1,OPCA,43,82,"SCA1,","In contrast, in two patients with sporadic OPCA and in four of five patients with SCA1, the fibres were not identified.",43,82,43,82,47,86,-1,RO-has_manifestation,906113,"In contrast, in two patients with sporadic OPCA and in four of five patients with SCA1, the fibres were not identified",OPCA,SCA1
503461350,7/16/2014 14:07:05,,1324268122,7/16/2014 14:06:48,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,43,82,,,47,86,OPCA,SCA1,sporadic OPCA,34-43,34-43-82,"sporadic OPCA SCA1,","In contrast, in two patients with sporadic OPCA and in four of five patients with SCA1, the fibres were not identified.",43,82,43,82,47,86,-1,RO-has_manifestation,906113,"In contrast, in two patients with sporadic OPCA and in four of five patients with SCA1, the fibres were not identified",OPCA,SCA1
503461350,7/16/2014 14:26:19,,1324276051,7/16/2014 14:25:57,vivatic,1.0,25451531,GBR,"","",83.67.28.193,43,82,,,47,86,OPCA,SCA1,sporadic OPCA,34-43,82,"SCA1,","In contrast, in two patients with sporadic OPCA and in four of five patients with SCA1, the fibres were not identified.",43,82,43,82,47,86,-1,RO-has_manifestation,906113,"In contrast, in two patients with sporadic OPCA and in four of five patients with SCA1, the fibres were not identified",OPCA,SCA1
503461350,7/16/2014 14:43:25,,1324282584,7/16/2014 14:43:10,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,43,82,,,47,86,OPCA,SCA1,sporadic OPCA,34-43,82,"SCA1,","In contrast, in two patients with sporadic OPCA and in four of five patients with SCA1, the fibres were not identified.",43,82,43,82,47,86,-1,RO-has_manifestation,906113,"In contrast, in two patients with sporadic OPCA and in four of five patients with SCA1, the fibres were not identified",OPCA,SCA1
503461350,7/16/2014 14:46:28,,1324283372,7/16/2014 14:46:18,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,43,82,,,47,86,OPCA,SCA1,sporadic OPCA,34-43,82,"SCA1,","In contrast, in two patients with sporadic OPCA and in four of five patients with SCA1, the fibres were not identified.",43,82,43,82,47,86,-1,RO-has_manifestation,906113,"In contrast, in two patients with sporadic OPCA and in four of five patients with SCA1, the fibres were not identified",OPCA,SCA1
503461350,7/16/2014 14:50:07,,1324284529,7/16/2014 14:49:58,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,43,82,,,47,86,OPCA,SCA1,OPCA,43,82,"SCA1,","In contrast, in two patients with sporadic OPCA and in four of five patients with SCA1, the fibres were not identified.",43,82,43,82,47,86,-1,RO-has_manifestation,906113,"In contrast, in two patients with sporadic OPCA and in four of five patients with SCA1, the fibres were not identified",OPCA,SCA1
503461350,7/16/2014 14:53:53,,1324285657,7/16/2014 14:53:38,irazoo,1.0,7022810,USA,IA,Ankeny,216.161.121.1,43,82,,,47,86,OPCA,SCA1,sporadic OPCA,34-43,82,"SCA1,","In contrast, in two patients with sporadic OPCA and in four of five patients with SCA1, the fibres were not identified.",43,82,43,82,47,86,-1,RO-has_manifestation,906113,"In contrast, in two patients with sporadic OPCA and in four of five patients with SCA1, the fibres were not identified",OPCA,SCA1
503461350,7/16/2014 14:54:30,,1324285858,7/16/2014 14:54:08,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,43,82,,,47,86,OPCA,SCA1,sporadic OPCA,34-43,82,"SCA1,","In contrast, in two patients with sporadic OPCA and in four of five patients with SCA1, the fibres were not identified.",43,82,43,82,47,86,-1,RO-has_manifestation,906113,"In contrast, in two patients with sporadic OPCA and in four of five patients with SCA1, the fibres were not identified",OPCA,SCA1
503461350,7/16/2014 14:54:31,,1324285864,7/16/2014 14:54:21,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,43,82,,,47,86,OPCA,SCA1,sporadic OPCA,34-43,82,"SCA1,","In contrast, in two patients with sporadic OPCA and in four of five patients with SCA1, the fibres were not identified.",43,82,43,82,47,86,-1,RO-has_manifestation,906113,"In contrast, in two patients with sporadic OPCA and in four of five patients with SCA1, the fibres were not identified",OPCA,SCA1
503461351,7/16/2014 13:40:46,,1324257923,7/16/2014 13:40:37,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,107,79,,,125,88,TUBEROUS SCLEROSIS,HAMARTOMA,TUBEROUS SCLEROSIS.,107-116,79,HAMARTOMA,"To the best of our knowledge, this is the first reported case of a tongue-base hamartoma in a patient with tuberous sclerosis.",107 116,79,107,79,125,88,-1,RO-cause_of,900150,"To the best of our knowledge, this is the first reported case of a tongue-base hamartoma in a patient with tuberous sclerosis",tuberous sclerosis,hamartoma
503461351,7/16/2014 13:41:45,,1324258281,7/16/2014 13:41:32,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,107,79,,,125,88,TUBEROUS SCLEROSIS,HAMARTOMA,TUBEROUS SCLEROSIS.,107-116,79,HAMARTOMA,"To the best of our knowledge, this is the first reported case of a tongue-base hamartoma in a patient with tuberous sclerosis.",107 116,79,107,79,125,88,-1,RO-cause_of,900150,"To the best of our knowledge, this is the first reported case of a tongue-base hamartoma in a patient with tuberous sclerosis",tuberous sclerosis,hamartoma
503461351,7/16/2014 13:48:58,,1324260755,7/16/2014 13:48:48,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,107,79,,,125,88,TUBEROUS SCLEROSIS,HAMARTOMA,TUBEROUS SCLEROSIS.,107-116,67-73-74-79,tongue - base HAMARTOMA,"To the best of our knowledge, this is the first reported case of a tongue-base hamartoma in a patient with tuberous sclerosis.",107 116,79,107,79,125,88,-1,RO-cause_of,900150,"To the best of our knowledge, this is the first reported case of a tongue-base hamartoma in a patient with tuberous sclerosis",tuberous sclerosis,hamartoma
503461351,7/16/2014 13:51:47,,1324261736,7/16/2014 13:51:10,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,107,79,,,125,88,TUBEROUS SCLEROSIS,HAMARTOMA,TUBEROUS SCLEROSIS.,107-116,79,HAMARTOMA,"To the best of our knowledge, this is the first reported case of a tongue-base hamartoma in a patient with tuberous sclerosis.",107 116,79,107,79,125,88,-1,RO-cause_of,900150,"To the best of our knowledge, this is the first reported case of a tongue-base hamartoma in a patient with tuberous sclerosis",tuberous sclerosis,hamartoma
503461351,7/16/2014 13:52:23,,1324261947,7/16/2014 13:52:07,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,107,79,,,125,88,TUBEROUS SCLEROSIS,HAMARTOMA,TUBEROUS SCLEROSIS.,107-116,65-67-74-79,a tongue base HAMARTOMA,"To the best of our knowledge, this is the first reported case of a tongue-base hamartoma in a patient with tuberous sclerosis.",107 116,79,107,79,125,88,-1,RO-cause_of,900150,"To the best of our knowledge, this is the first reported case of a tongue-base hamartoma in a patient with tuberous sclerosis",tuberous sclerosis,hamartoma
503461351,7/16/2014 13:57:08,,1324263900,7/16/2014 13:56:51,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,107,79,,,125,88,TUBEROUS SCLEROSIS,HAMARTOMA,TUBEROUS SCLEROSIS.,107-116,79,HAMARTOMA,"To the best of our knowledge, this is the first reported case of a tongue-base hamartoma in a patient with tuberous sclerosis.",107 116,79,107,79,125,88,-1,RO-cause_of,900150,"To the best of our knowledge, this is the first reported case of a tongue-base hamartoma in a patient with tuberous sclerosis",tuberous sclerosis,hamartoma
503461351,7/16/2014 14:04:07,,1324266870,7/16/2014 14:03:53,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,107,79,,,125,88,TUBEROUS SCLEROSIS,HAMARTOMA,a TUBEROUS SCLEROSIS.,92-107-116,67-74-79,tongue base HAMARTOMA,"To the best of our knowledge, this is the first reported case of a tongue-base hamartoma in a patient with tuberous sclerosis.",107 116,79,107,79,125,88,-1,RO-cause_of,900150,"To the best of our knowledge, this is the first reported case of a tongue-base hamartoma in a patient with tuberous sclerosis",tuberous sclerosis,hamartoma
503461351,7/16/2014 14:13:39,,1324271001,7/16/2014 14:13:28,instagc,1.0,13763729,USA,"","",75.182.89.225,107,79,,,125,88,TUBEROUS SCLEROSIS,HAMARTOMA,TUBEROUS SCLEROSIS.,107-116,67-74-79,tongue base HAMARTOMA,"To the best of our knowledge, this is the first reported case of a tongue-base hamartoma in a patient with tuberous sclerosis.",107 116,79,107,79,125,88,-1,RO-cause_of,900150,"To the best of our knowledge, this is the first reported case of a tongue-base hamartoma in a patient with tuberous sclerosis",tuberous sclerosis,hamartoma
503461351,7/16/2014 14:16:46,,1324272166,7/16/2014 14:16:03,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,107,79,,,125,88,TUBEROUS SCLEROSIS,HAMARTOMA,TUBEROUS SCLEROSIS.,107-116,67-74-79,tongue base HAMARTOMA,"To the best of our knowledge, this is the first reported case of a tongue-base hamartoma in a patient with tuberous sclerosis.",107 116,79,107,79,125,88,-1,RO-cause_of,900150,"To the best of our knowledge, this is the first reported case of a tongue-base hamartoma in a patient with tuberous sclerosis",tuberous sclerosis,hamartoma
503461351,7/16/2014 14:19:41,,1324273416,7/16/2014 14:19:27,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,107,79,,,125,88,TUBEROUS SCLEROSIS,HAMARTOMA,TUBEROUS SCLEROSIS.,107-116,67-74-79,tongue base HAMARTOMA,"To the best of our knowledge, this is the first reported case of a tongue-base hamartoma in a patient with tuberous sclerosis.",107 116,79,107,79,125,88,-1,RO-cause_of,900150,"To the best of our knowledge, this is the first reported case of a tongue-base hamartoma in a patient with tuberous sclerosis",tuberous sclerosis,hamartoma
503461352,7/16/2014 13:39:16,,1324257361,7/16/2014 13:38:20,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,72,109,,,92,118,HYPERCHOLESTEROLEMIA,EZETIMIBE,with homozygous familial HYPERCHOLESTEROLEMIA the addition of,47-52-63-72-93-97-106,109,EZETIMIBE,"In other studies by the same team, in patients with homozygous familial hypercholesterolemia the addition of ezetimibe to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",72,109,72,109,92,118,1,RO-may_treat,907719,"In other studies by the same team, in patients with homozygous familial hypercholesterolemia the addition of ezetimibe to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2)",hypercholesterolemia,ezetimibe
503461352,7/16/2014 13:45:56,,1324259742,7/16/2014 13:45:45,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,72,109,,,92,118,HYPERCHOLESTEROLEMIA,EZETIMIBE,homozygous familial HYPERCHOLESTEROLEMIA,52-63-72,109,EZETIMIBE,"In other studies by the same team, in patients with homozygous familial hypercholesterolemia the addition of ezetimibe to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",72,109,72,109,92,118,1,RO-may_treat,907719,"In other studies by the same team, in patients with homozygous familial hypercholesterolemia the addition of ezetimibe to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2)",hypercholesterolemia,ezetimibe
503461352,7/16/2014 13:52:47,,1324262112,7/16/2014 13:52:24,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,72,109,,,92,118,HYPERCHOLESTEROLEMIA,EZETIMIBE,homozygous familial HYPERCHOLESTEROLEMIA,52-63-72,109,EZETIMIBE,"In other studies by the same team, in patients with homozygous familial hypercholesterolemia the addition of ezetimibe to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",72,109,72,109,92,118,1,RO-may_treat,907719,"In other studies by the same team, in patients with homozygous familial hypercholesterolemia the addition of ezetimibe to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2)",hypercholesterolemia,ezetimibe
503461352,7/16/2014 13:53:11,,1324262259,7/16/2014 13:52:39,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,72,109,,,92,118,HYPERCHOLESTEROLEMIA,EZETIMIBE,homozygous familial HYPERCHOLESTEROLEMIA ezetimibe simvastatin atorvastatin statin dosage,52-63-72-109-140-155-232-239,52-63-72-109-140-155-232-239,homozygous familial hypercholesterolemia EZETIMIBE simvastatin atorvastatin statin dosage,"In other studies by the same team, in patients with homozygous familial hypercholesterolemia the addition of ezetimibe to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",72,109,72,109,92,118,1,RO-may_treat,907719,"In other studies by the same team, in patients with homozygous familial hypercholesterolemia the addition of ezetimibe to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2)",hypercholesterolemia,ezetimibe
503461352,7/16/2014 13:56:22,,1324263582,7/16/2014 13:55:52,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,72,109,,,92,118,HYPERCHOLESTEROLEMIA,EZETIMIBE,HYPERCHOLESTEROLEMIA ezetimibe,72-109,72-109,hypercholesterolemia EZETIMIBE,"In other studies by the same team, in patients with homozygous familial hypercholesterolemia the addition of ezetimibe to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",72,109,72,109,92,118,1,RO-may_treat,907719,"In other studies by the same team, in patients with homozygous familial hypercholesterolemia the addition of ezetimibe to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2)",hypercholesterolemia,ezetimibe
503461352,7/16/2014 14:09:47,,1324269332,7/16/2014 14:09:38,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,72,109,,,92,118,HYPERCHOLESTEROLEMIA,EZETIMIBE,with homozygous familial HYPERCHOLESTEROLEMIA the addition of,47-52-63-72-93-97-106,93-97-106-109-119-122-125,the addition of EZETIMIBE to 40 mg,"In other studies by the same team, in patients with homozygous familial hypercholesterolemia the addition of ezetimibe to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",72,109,72,109,92,118,1,RO-may_treat,907719,"In other studies by the same team, in patients with homozygous familial hypercholesterolemia the addition of ezetimibe to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2)",hypercholesterolemia,ezetimibe
503461352,7/16/2014 14:11:03,,1324269913,7/16/2014 14:10:26,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,72,109,,,92,118,HYPERCHOLESTEROLEMIA,EZETIMIBE,homozygous familial HYPERCHOLESTEROLEMIA,52-63-72,109,EZETIMIBE,"In other studies by the same team, in patients with homozygous familial hypercholesterolemia the addition of ezetimibe to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",72,109,72,109,92,118,1,RO-may_treat,907719,"In other studies by the same team, in patients with homozygous familial hypercholesterolemia the addition of ezetimibe to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2)",hypercholesterolemia,ezetimibe
503461352,7/16/2014 14:11:29,,1324270097,7/16/2014 14:11:11,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,72,109,,,92,118,HYPERCHOLESTEROLEMIA,EZETIMIBE,homozygous familial HYPERCHOLESTEROLEMIA,52-63-72,109,EZETIMIBE,"In other studies by the same team, in patients with homozygous familial hypercholesterolemia the addition of ezetimibe to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",72,109,72,109,92,118,1,RO-may_treat,907719,"In other studies by the same team, in patients with homozygous familial hypercholesterolemia the addition of ezetimibe to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2)",hypercholesterolemia,ezetimibe
503461352,7/16/2014 14:14:03,,1324271217,7/16/2014 14:13:26,vivatic,1.0,25451531,GBR,"","",83.67.28.193,72,109,,,92,118,HYPERCHOLESTEROLEMIA,EZETIMIBE,homozygous familial HYPERCHOLESTEROLEMIA,52-63-72,109-119-122-125-128-130-133-140-152-155,EZETIMIBE to 40 mg d of either simvastatin or atorvastatin,"In other studies by the same team, in patients with homozygous familial hypercholesterolemia the addition of ezetimibe to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",72,109,72,109,92,118,1,RO-may_treat,907719,"In other studies by the same team, in patients with homozygous familial hypercholesterolemia the addition of ezetimibe to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2)",hypercholesterolemia,ezetimibe
503461352,7/16/2014 14:28:34,,1324276912,7/16/2014 14:28:16,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,72,109,,,92,118,HYPERCHOLESTEROLEMIA,EZETIMIBE,HYPERCHOLESTEROLEMIA,72,109,EZETIMIBE,"In other studies by the same team, in patients with homozygous familial hypercholesterolemia the addition of ezetimibe to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",72,109,72,109,92,118,1,RO-may_treat,907719,"In other studies by the same team, in patients with homozygous familial hypercholesterolemia the addition of ezetimibe to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2)",hypercholesterolemia,ezetimibe
503461353,7/16/2014 13:43:41,,1324258977,7/16/2014 13:43:33,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,33,0,,,37,31,GIST,GASTROINTESTINAL STROMAL TUMORS,stromal tumors (GIST),17-25-32,0-17-25,GASTROINTESTINAL STROMAL TUMORS,"Gastrointestinal stromal tumors (GIST) have been recognized in humans, more recently in dogs and nonhuman primates, and now in equids.",,0 17 25,33,0,37,31,-1,RO-has_manifestation,906025,"Gastrointestinal stromal tumors (GIST) have been recognized in humans, more recently in dogs and nonhuman primates, and now in equids",GIST,Gastrointestinal stromal tumors
503461353,7/16/2014 13:44:35,,1324259315,7/16/2014 13:44:19,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,33,0,,,37,31,GIST,GASTROINTESTINAL STROMAL TUMORS,stromal tumors (GIST),17-25-32,0-17-25,GASTROINTESTINAL STROMAL TUMORS,"Gastrointestinal stromal tumors (GIST) have been recognized in humans, more recently in dogs and nonhuman primates, and now in equids.",,0 17 25,33,0,37,31,-1,RO-has_manifestation,906025,"Gastrointestinal stromal tumors (GIST) have been recognized in humans, more recently in dogs and nonhuman primates, and now in equids",GIST,Gastrointestinal stromal tumors
503461353,7/16/2014 14:01:14,,1324265502,7/16/2014 14:00:40,instagc,1.0,18960682,GBR,"","",86.29.147.112,33,0,,,37,31,GIST,GASTROINTESTINAL STROMAL TUMORS,Gastrointestinal stromal tumors (GIST),0-17-25-32,0-17-25-32,GASTROINTESTINAL STROMAL TUMORS (GIST),"Gastrointestinal stromal tumors (GIST) have been recognized in humans, more recently in dogs and nonhuman primates, and now in equids.",,0 17 25,33,0,37,31,-1,RO-has_manifestation,906025,"Gastrointestinal stromal tumors (GIST) have been recognized in humans, more recently in dogs and nonhuman primates, and now in equids",GIST,Gastrointestinal stromal tumors
503461353,7/16/2014 14:08:15,,1324268658,7/16/2014 14:08:04,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,33,0,,,37,31,GIST,GASTROINTESTINAL STROMAL TUMORS,Gastrointestinal stromal tumors (GIST),17-25-32-0,0-17-25-32,GASTROINTESTINAL STROMAL TUMORS (GIST),"Gastrointestinal stromal tumors (GIST) have been recognized in humans, more recently in dogs and nonhuman primates, and now in equids.",,0 17 25,33,0,37,31,-1,RO-has_manifestation,906025,"Gastrointestinal stromal tumors (GIST) have been recognized in humans, more recently in dogs and nonhuman primates, and now in equids",GIST,Gastrointestinal stromal tumors
503461353,7/16/2014 14:10:59,,1324269886,7/16/2014 14:10:45,instagc,1.0,13763729,USA,"","",75.182.89.225,33,0,,,37,31,GIST,GASTROINTESTINAL STROMAL TUMORS,(GIST),32,0-17-25,GASTROINTESTINAL STROMAL TUMORS,"Gastrointestinal stromal tumors (GIST) have been recognized in humans, more recently in dogs and nonhuman primates, and now in equids.",,0 17 25,33,0,37,31,-1,RO-has_manifestation,906025,"Gastrointestinal stromal tumors (GIST) have been recognized in humans, more recently in dogs and nonhuman primates, and now in equids",GIST,Gastrointestinal stromal tumors
503461353,7/16/2014 14:15:30,,1324271675,7/16/2014 14:15:18,prodege,1.0,17932518,GBR,"","",81.133.61.60,33,0,,,37,31,GIST,GASTROINTESTINAL STROMAL TUMORS,Gastrointestinal stromal tumors (GIST),17-25-32-0,0-17-25,GASTROINTESTINAL STROMAL TUMORS,"Gastrointestinal stromal tumors (GIST) have been recognized in humans, more recently in dogs and nonhuman primates, and now in equids.",,0 17 25,33,0,37,31,-1,RO-has_manifestation,906025,"Gastrointestinal stromal tumors (GIST) have been recognized in humans, more recently in dogs and nonhuman primates, and now in equids",GIST,Gastrointestinal stromal tumors
503461353,7/16/2014 14:18:54,,1324273098,7/16/2014 14:17:59,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,33,0,,,37,31,GIST,GASTROINTESTINAL STROMAL TUMORS,Gastrointestinal stromal tumors (GIST),0-17-25-32,0-17-25-32,GASTROINTESTINAL STROMAL TUMORS (GIST),"Gastrointestinal stromal tumors (GIST) have been recognized in humans, more recently in dogs and nonhuman primates, and now in equids.",,0 17 25,33,0,37,31,-1,RO-has_manifestation,906025,"Gastrointestinal stromal tumors (GIST) have been recognized in humans, more recently in dogs and nonhuman primates, and now in equids",GIST,Gastrointestinal stromal tumors
503461353,7/16/2014 14:21:32,,1324274192,7/16/2014 14:21:12,vivatic,1.0,25451531,GBR,"","",83.67.28.193,33,0,,,37,31,GIST,GASTROINTESTINAL STROMAL TUMORS,Gastrointestinal stromal tumors (GIST),0-17-25-32,0-17-25-32,GASTROINTESTINAL STROMAL TUMORS (GIST),"Gastrointestinal stromal tumors (GIST) have been recognized in humans, more recently in dogs and nonhuman primates, and now in equids.",,0 17 25,33,0,37,31,-1,RO-has_manifestation,906025,"Gastrointestinal stromal tumors (GIST) have been recognized in humans, more recently in dogs and nonhuman primates, and now in equids",GIST,Gastrointestinal stromal tumors
503461353,7/16/2014 14:26:00,,1324275948,7/16/2014 14:25:50,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,33,0,,,37,31,GIST,GASTROINTESTINAL STROMAL TUMORS,(GIST),32,0-17-25,GASTROINTESTINAL STROMAL TUMORS,"Gastrointestinal stromal tumors (GIST) have been recognized in humans, more recently in dogs and nonhuman primates, and now in equids.",,0 17 25,33,0,37,31,-1,RO-has_manifestation,906025,"Gastrointestinal stromal tumors (GIST) have been recognized in humans, more recently in dogs and nonhuman primates, and now in equids",GIST,Gastrointestinal stromal tumors
503461353,7/16/2014 14:33:25,,1324278966,7/16/2014 14:33:12,prodege,1.0,6316959,GBR,"","",46.208.145.114,33,0,,,37,31,GIST,GASTROINTESTINAL STROMAL TUMORS,Gastrointestinal stromal tumors (GIST),17-25-32-0,0-17-25-32,GASTROINTESTINAL STROMAL TUMORS (GIST),"Gastrointestinal stromal tumors (GIST) have been recognized in humans, more recently in dogs and nonhuman primates, and now in equids.",,0 17 25,33,0,37,31,-1,RO-has_manifestation,906025,"Gastrointestinal stromal tumors (GIST) have been recognized in humans, more recently in dogs and nonhuman primates, and now in equids",GIST,Gastrointestinal stromal tumors
503461354,7/16/2014 13:43:51,,1324259037,7/16/2014 13:43:41,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,91,16,,,98,39,THYROID,HASHIMOTO'S THYROIDITIS,THYROID.,91,16-28,HASHIMOTO'S THYROIDITIS,Pathogenesis of Hashimoto's thyroiditis is largely cell-mediated immune destruction of the thyroid.,91,16 28,91,16,98,39,1,RO-disease_has_primary_anatomic_site,902140,Pathogenesis of Hashimoto's thyroiditis is largely cell-mediated immune destruction of the thyroid,thyroid,Hashimoto's thyroiditis
503461354,7/16/2014 13:54:23,,1324262799,7/16/2014 13:54:14,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,91,16,,,98,39,THYROID,HASHIMOTO'S THYROIDITIS,THYROID.,91,16-28,HASHIMOTO'S THYROIDITIS,Pathogenesis of Hashimoto's thyroiditis is largely cell-mediated immune destruction of the thyroid.,91,16 28,91,16,98,39,1,RO-disease_has_primary_anatomic_site,902140,Pathogenesis of Hashimoto's thyroiditis is largely cell-mediated immune destruction of the thyroid,thyroid,Hashimoto's thyroiditis
503461354,7/16/2014 14:00:38,,1324265383,7/16/2014 14:00:29,instagc,1.0,18960682,GBR,"","",86.29.147.112,91,16,,,98,39,THYROID,HASHIMOTO'S THYROIDITIS,THYROID.,91,0-13-16-28,Pathogenesis of HASHIMOTO'S THYROIDITIS,Pathogenesis of Hashimoto's thyroiditis is largely cell-mediated immune destruction of the thyroid.,91,16 28,91,16,98,39,1,RO-disease_has_primary_anatomic_site,902140,Pathogenesis of Hashimoto's thyroiditis is largely cell-mediated immune destruction of the thyroid,thyroid,Hashimoto's thyroiditis
503461354,7/16/2014 14:04:15,,1324266926,7/16/2014 14:02:46,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,91,16,,,98,39,THYROID,HASHIMOTO'S THYROIDITIS,Hashimoto's thyroiditis THYROID.,28-91-16,16-28-91,HASHIMOTO'S THYROIDITIS thyroid.,Pathogenesis of Hashimoto's thyroiditis is largely cell-mediated immune destruction of the thyroid.,91,16 28,91,16,98,39,1,RO-disease_has_primary_anatomic_site,902140,Pathogenesis of Hashimoto's thyroiditis is largely cell-mediated immune destruction of the thyroid,thyroid,Hashimoto's thyroiditis
503461354,7/16/2014 14:06:47,,1324268019,7/16/2014 14:06:33,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,91,16,,,98,39,THYROID,HASHIMOTO'S THYROIDITIS,Hashimoto's thyroiditis THYROID.,16-28-91,16-28,HASHIMOTO'S THYROIDITIS,Pathogenesis of Hashimoto's thyroiditis is largely cell-mediated immune destruction of the thyroid.,91,16 28,91,16,98,39,1,RO-disease_has_primary_anatomic_site,902140,Pathogenesis of Hashimoto's thyroiditis is largely cell-mediated immune destruction of the thyroid,thyroid,Hashimoto's thyroiditis
503461354,7/16/2014 14:07:49,,1324268465,7/16/2014 14:07:41,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,91,16,,,98,39,THYROID,HASHIMOTO'S THYROIDITIS,destruction of the THYROID.,72-84-87-91,0-13-16-28-40-43-51,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell,Pathogenesis of Hashimoto's thyroiditis is largely cell-mediated immune destruction of the thyroid.,91,16 28,91,16,98,39,1,RO-disease_has_primary_anatomic_site,902140,Pathogenesis of Hashimoto's thyroiditis is largely cell-mediated immune destruction of the thyroid,thyroid,Hashimoto's thyroiditis
503461354,7/16/2014 14:09:22,,1324269164,7/16/2014 14:09:10,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,91,16,,,98,39,THYROID,HASHIMOTO'S THYROIDITIS,destruction of the THYROID.,72-84-87-91,0-13-16-28,Pathogenesis of HASHIMOTO'S THYROIDITIS,Pathogenesis of Hashimoto's thyroiditis is largely cell-mediated immune destruction of the thyroid.,91,16 28,91,16,98,39,1,RO-disease_has_primary_anatomic_site,902140,Pathogenesis of Hashimoto's thyroiditis is largely cell-mediated immune destruction of the thyroid,thyroid,Hashimoto's thyroiditis
503461354,7/16/2014 14:23:06,,1324274810,7/16/2014 14:22:52,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,91,16,,,98,39,THYROID,HASHIMOTO'S THYROIDITIS,THYROID.,91,16-28,HASHIMOTO'S THYROIDITIS,Pathogenesis of Hashimoto's thyroiditis is largely cell-mediated immune destruction of the thyroid.,91,16 28,91,16,98,39,1,RO-disease_has_primary_anatomic_site,902140,Pathogenesis of Hashimoto's thyroiditis is largely cell-mediated immune destruction of the thyroid,thyroid,Hashimoto's thyroiditis
503461354,7/16/2014 14:37:29,,1324280758,7/16/2014 14:37:17,prodege,1.0,6316959,GBR,"","",46.208.145.114,91,16,,,98,39,THYROID,HASHIMOTO'S THYROIDITIS,THYROID.,91,16-28,HASHIMOTO'S THYROIDITIS,Pathogenesis of Hashimoto's thyroiditis is largely cell-mediated immune destruction of the thyroid.,91,16 28,91,16,98,39,1,RO-disease_has_primary_anatomic_site,902140,Pathogenesis of Hashimoto's thyroiditis is largely cell-mediated immune destruction of the thyroid,thyroid,Hashimoto's thyroiditis
503461354,7/16/2014 14:43:23,,1324282576,7/16/2014 14:43:04,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,91,16,,,98,39,THYROID,HASHIMOTO'S THYROIDITIS,THYROID.,91,16-28,HASHIMOTO'S THYROIDITIS,Pathogenesis of Hashimoto's thyroiditis is largely cell-mediated immune destruction of the thyroid.,91,16 28,91,16,98,39,1,RO-disease_has_primary_anatomic_site,902140,Pathogenesis of Hashimoto's thyroiditis is largely cell-mediated immune destruction of the thyroid,thyroid,Hashimoto's thyroiditis
503461355,7/16/2014 13:43:50,,1324259038,7/16/2014 13:43:42,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,87,0,,,91,23,BONE,OSTEOGENESIS IMPERFECTA,low BONE mass.,83-87-92,0-13,OSTEOGENESIS IMPERFECTA,"Osteogenesis imperfecta (OI) is a genetic disorder of increased bone fragility and low bone mass. Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",87,0 13,87,0,91,23,1,RO-disease_has_primary_anatomic_site,902453,"Osteogenesis imperfecta (OI) is a genetic disorder of increased bone fragility and low bone mass. Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures",bone,Osteogenesis imperfecta
503461355,7/16/2014 13:46:25,,1324259893,7/16/2014 13:45:01,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,87,0,,,91,23,BONE,OSTEOGENESIS IMPERFECTA,low BONE mass.,83-87-92,0-13,OSTEOGENESIS IMPERFECTA,"Osteogenesis imperfecta (OI) is a genetic disorder of increased bone fragility and low bone mass. Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",87,0 13,87,0,91,23,1,RO-disease_has_primary_anatomic_site,902453,"Osteogenesis imperfecta (OI) is a genetic disorder of increased bone fragility and low bone mass. Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures",bone,Osteogenesis imperfecta
503461355,7/16/2014 13:51:17,,1324261580,7/16/2014 13:51:02,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,87,0,,,91,23,BONE,OSTEOGENESIS IMPERFECTA,fragility and low BONE mass.,69-79-83-87-92,0-13,OSTEOGENESIS IMPERFECTA,"Osteogenesis imperfecta (OI) is a genetic disorder of increased bone fragility and low bone mass. Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",87,0 13,87,0,91,23,1,RO-disease_has_primary_anatomic_site,902453,"Osteogenesis imperfecta (OI) is a genetic disorder of increased bone fragility and low bone mass. Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures",bone,Osteogenesis imperfecta
503461355,7/16/2014 14:06:09,,1324267792,7/16/2014 14:05:44,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,87,0,,,91,23,BONE,OSTEOGENESIS IMPERFECTA,BONE mass.,87-92,0-13,OSTEOGENESIS IMPERFECTA,"Osteogenesis imperfecta (OI) is a genetic disorder of increased bone fragility and low bone mass. Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",87,0 13,87,0,91,23,1,RO-disease_has_primary_anatomic_site,902453,"Osteogenesis imperfecta (OI) is a genetic disorder of increased bone fragility and low bone mass. Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures",bone,Osteogenesis imperfecta
503461355,7/16/2014 14:26:46,,1324276172,7/16/2014 14:26:31,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,87,0,,,91,23,BONE,OSTEOGENESIS IMPERFECTA,BONE,87,0-13,OSTEOGENESIS IMPERFECTA,"Osteogenesis imperfecta (OI) is a genetic disorder of increased bone fragility and low bone mass. Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",87,0 13,87,0,91,23,1,RO-disease_has_primary_anatomic_site,902453,"Osteogenesis imperfecta (OI) is a genetic disorder of increased bone fragility and low bone mass. Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures",bone,Osteogenesis imperfecta
503461355,7/16/2014 14:31:15,,1324278193,7/16/2014 14:31:00,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,87,0,,,91,23,BONE,OSTEOGENESIS IMPERFECTA,BONE,87,0-13,OSTEOGENESIS IMPERFECTA,"Osteogenesis imperfecta (OI) is a genetic disorder of increased bone fragility and low bone mass. Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",87,0 13,87,0,91,23,1,RO-disease_has_primary_anatomic_site,902453,"Osteogenesis imperfecta (OI) is a genetic disorder of increased bone fragility and low bone mass. Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures",bone,Osteogenesis imperfecta
503461355,7/16/2014 14:37:25,,1324280706,7/16/2014 14:37:08,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,87,0,,,91,23,BONE,OSTEOGENESIS IMPERFECTA,Osteogenesis imperfecta BONE,13-87-0,0-13-87,OSTEOGENESIS IMPERFECTA bone,"Osteogenesis imperfecta (OI) is a genetic disorder of increased bone fragility and low bone mass. Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",87,0 13,87,0,91,23,1,RO-disease_has_primary_anatomic_site,902453,"Osteogenesis imperfecta (OI) is a genetic disorder of increased bone fragility and low bone mass. Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures",bone,Osteogenesis imperfecta
503461355,7/16/2014 14:39:26,,1324281407,7/16/2014 14:39:12,prodege,1.0,6316959,GBR,"","",46.208.145.114,87,0,,,91,23,BONE,OSTEOGENESIS IMPERFECTA,low BONE mass.,83-87-92,0-13-24,OSTEOGENESIS IMPERFECTA (OI),"Osteogenesis imperfecta (OI) is a genetic disorder of increased bone fragility and low bone mass. Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",87,0 13,87,0,91,23,1,RO-disease_has_primary_anatomic_site,902453,"Osteogenesis imperfecta (OI) is a genetic disorder of increased bone fragility and low bone mass. Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures",bone,Osteogenesis imperfecta
503461355,7/16/2014 14:44:31,,1324282881,7/16/2014 14:44:21,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,87,0,,,91,23,BONE,OSTEOGENESIS IMPERFECTA,low BONE mass.,83-87-92,0-13,OSTEOGENESIS IMPERFECTA,"Osteogenesis imperfecta (OI) is a genetic disorder of increased bone fragility and low bone mass. Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",87,0 13,87,0,91,23,1,RO-disease_has_primary_anatomic_site,902453,"Osteogenesis imperfecta (OI) is a genetic disorder of increased bone fragility and low bone mass. Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures",bone,Osteogenesis imperfecta
503461355,7/16/2014 14:52:54,,1324285301,7/16/2014 14:52:14,irazoo,1.0,7022810,USA,IA,Ankeny,216.161.121.1,87,0,,,91,23,BONE,OSTEOGENESIS IMPERFECTA,low BONE mass.,83-87-92,0-13,OSTEOGENESIS IMPERFECTA,"Osteogenesis imperfecta (OI) is a genetic disorder of increased bone fragility and low bone mass. Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",87,0 13,87,0,91,23,1,RO-disease_has_primary_anatomic_site,902453,"Osteogenesis imperfecta (OI) is a genetic disorder of increased bone fragility and low bone mass. Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures",bone,Osteogenesis imperfecta
503461356,7/16/2014 13:48:09,,1324260488,7/16/2014 13:48:00,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,76,36,,,82,45,JOINTS,ARTHRITIS,medium - sized JOINTS,63-69-70-76,36,ARTHRITIS,"Among them, the most common include arthritis of the large and medium-sized joints in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo-fasciitis in TRAPS.",76,36,76,36,82,45,1,RO-has_finding_site,905445,"Among them, the most common include arthritis of the large and medium-sized joints in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo-fasciitis in TRAPS",joints,arthritis
503461356,7/16/2014 13:54:29,,1324262822,7/16/2014 13:53:59,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,76,36,,,82,45,JOINTS,ARTHRITIS,"arthritis JOINTS FMF CINCA, arthralgia HIDS, myalgia pseudo fasciitis TRAPS.",36-76-86-94-101-115-125-136-143-156,36-76-86-94-101-115-125-136-143-156,"ARTHRITIS joints FMF CINCA, arthralgia HIDS, myalgia pseudo fasciitis TRAPS.","Among them, the most common include arthritis of the large and medium-sized joints in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo-fasciitis in TRAPS.",76,36,76,36,82,45,1,RO-has_finding_site,905445,"Among them, the most common include arthritis of the large and medium-sized joints in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo-fasciitis in TRAPS",joints,arthritis
503461356,7/16/2014 14:08:24,,1324268756,7/16/2014 14:08:15,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,76,36,,,82,45,JOINTS,ARTHRITIS,and medium sized JOINTS in FMF and,59-63-70-76-83-86-90,16-21-28-36-46-49-53,most common include ARTHRITIS of the large,"Among them, the most common include arthritis of the large and medium-sized joints in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo-fasciitis in TRAPS.",76,36,76,36,82,45,1,RO-has_finding_site,905445,"Among them, the most common include arthritis of the large and medium-sized joints in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo-fasciitis in TRAPS",joints,arthritis
503461356,7/16/2014 14:09:30,,1324269220,7/16/2014 14:09:14,instagc,1.0,13763729,USA,"","",75.182.89.225,76,36,,,82,45,JOINTS,ARTHRITIS,JOINTS,76,36,ARTHRITIS,"Among them, the most common include arthritis of the large and medium-sized joints in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo-fasciitis in TRAPS.",76,36,76,36,82,45,1,RO-has_finding_site,905445,"Among them, the most common include arthritis of the large and medium-sized joints in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo-fasciitis in TRAPS",joints,arthritis
503461356,7/16/2014 14:11:54,,1324270313,7/16/2014 14:11:41,prodege,1.0,17932518,GBR,"","",81.133.61.60,76,36,,,82,45,JOINTS,ARTHRITIS,JOINTS,76,36,ARTHRITIS,"Among them, the most common include arthritis of the large and medium-sized joints in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo-fasciitis in TRAPS.",76,36,76,36,82,45,1,RO-has_finding_site,905445,"Among them, the most common include arthritis of the large and medium-sized joints in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo-fasciitis in TRAPS",joints,arthritis
503461356,7/16/2014 14:18:47,,1324273051,7/16/2014 14:18:29,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,76,36,,,82,45,JOINTS,ARTHRITIS,medium sized JOINTS,63-70-76,36,ARTHRITIS,"Among them, the most common include arthritis of the large and medium-sized joints in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo-fasciitis in TRAPS.",76,36,76,36,82,45,1,RO-has_finding_site,905445,"Among them, the most common include arthritis of the large and medium-sized joints in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo-fasciitis in TRAPS",joints,arthritis
503461356,7/16/2014 14:25:40,,1324275814,7/16/2014 14:25:24,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,76,36,,,82,45,JOINTS,ARTHRITIS,JOINTS,76,36,ARTHRITIS,"Among them, the most common include arthritis of the large and medium-sized joints in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo-fasciitis in TRAPS.",76,36,76,36,82,45,1,RO-has_finding_site,905445,"Among them, the most common include arthritis of the large and medium-sized joints in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo-fasciitis in TRAPS",joints,arthritis
503461356,7/16/2014 14:26:46,,1324276189,7/16/2014 14:26:21,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,76,36,,,82,45,JOINTS,ARTHRITIS,arthritis JOINTS,76-36,36-76,ARTHRITIS joints,"Among them, the most common include arthritis of the large and medium-sized joints in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo-fasciitis in TRAPS.",76,36,76,36,82,45,1,RO-has_finding_site,905445,"Among them, the most common include arthritis of the large and medium-sized joints in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo-fasciitis in TRAPS",joints,arthritis
503461356,7/16/2014 14:28:28,,1324276887,7/16/2014 14:28:13,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,76,36,,,82,45,JOINTS,ARTHRITIS,JOINTS,76,36,ARTHRITIS,"Among them, the most common include arthritis of the large and medium-sized joints in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo-fasciitis in TRAPS.",76,36,76,36,82,45,1,RO-has_finding_site,905445,"Among them, the most common include arthritis of the large and medium-sized joints in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo-fasciitis in TRAPS",joints,arthritis
503461356,7/16/2014 14:28:29,,1324276904,7/16/2014 14:27:48,prodege,1.0,26790109,USA,"","",23.125.64.233,76,36,,,82,45,JOINTS,ARTHRITIS,"large and medium sized JOINTS in FMF and CINCA,",53-59-63-70-76-83-86-90-94,36-46-49-53-59-63-70-76-83-86-90-94-101-112-115-121-125-133-136-143-153-156,"ARTHRITIS of the large and medium sized joints in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.","Among them, the most common include arthritis of the large and medium-sized joints in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo-fasciitis in TRAPS.",76,36,76,36,82,45,1,RO-has_finding_site,905445,"Among them, the most common include arthritis of the large and medium-sized joints in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo-fasciitis in TRAPS",joints,arthritis
503461357,7/16/2014 13:52:59,,1324262167,7/16/2014 13:52:34,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,182,157,,,191,169,CIRRHOSIS,MILK THISTLE,"(hepatitis, CIRRHOSIS),",170-182,157-162,MILK THISTLE,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals Milk thistle (hepatitis, cirrhosis), 70-140 mg t.i.d.",182,157 162,182,157,191,169,1,RO-may_treat,907669,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals Milk thistle (hepatitis, cirrhosis), 70-140 mg t.i.d",cirrhosis,Milk thistle
503461357,7/16/2014 13:53:31,,1324262393,7/16/2014 13:53:08,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,182,157,,,191,169,CIRRHOSIS,MILK THISTLE,"CIRRHOSIS),",182,157-162,MILK THISTLE,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals Milk thistle (hepatitis, cirrhosis), 70-140 mg t.i.d.",182,157 162,182,157,191,169,1,RO-may_treat,907669,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals Milk thistle (hepatitis, cirrhosis), 70-140 mg t.i.d",cirrhosis,Milk thistle
503461357,7/16/2014 13:56:18,,1324263556,7/16/2014 13:55:53,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,182,157,,,191,169,CIRRHOSIS,MILK THISTLE,"CIRRHOSIS),",182,157-162,MILK THISTLE,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals Milk thistle (hepatitis, cirrhosis), 70-140 mg t.i.d.",182,157 162,182,157,191,169,1,RO-may_treat,907669,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals Milk thistle (hepatitis, cirrhosis), 70-140 mg t.i.d",cirrhosis,Milk thistle
503461357,7/16/2014 14:04:35,,1324267028,7/16/2014 14:03:47,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,182,157,,,191,169,CIRRHOSIS,MILK THISTLE,"CIRRHOSIS),",182,157-162,MILK THISTLE,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals Milk thistle (hepatitis, cirrhosis), 70-140 mg t.i.d.",182,157 162,182,157,191,169,1,RO-may_treat,907669,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals Milk thistle (hepatitis, cirrhosis), 70-140 mg t.i.d",cirrhosis,Milk thistle
503461357,7/16/2014 14:04:58,,1324267233,7/16/2014 14:03:54,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,182,157,,,191,169,CIRRHOSIS,MILK THISTLE,"CIRRHOSIS),",182,157-162,MILK THISTLE,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals Milk thistle (hepatitis, cirrhosis), 70-140 mg t.i.d.",182,157 162,182,157,191,169,1,RO-may_treat,907669,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals Milk thistle (hepatitis, cirrhosis), 70-140 mg t.i.d",cirrhosis,Milk thistle
503461357,7/16/2014 14:05:33,,1324267500,7/16/2014 14:04:57,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,182,157,,,191,169,CIRRHOSIS,MILK THISTLE,"Milk thistle CIRRHOSIS),",157-162-182,157-162-182,"MILK THISTLE cirrhosis),","Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals Milk thistle (hepatitis, cirrhosis), 70-140 mg t.i.d.",182,157 162,182,157,191,169,1,RO-may_treat,907669,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals Milk thistle (hepatitis, cirrhosis), 70-140 mg t.i.d",cirrhosis,Milk thistle
503461357,7/16/2014 14:10:31,,1324269709,7/16/2014 14:10:07,instagc,1.0,13763729,USA,"","",75.182.89.225,182,157,,,191,169,CIRRHOSIS,MILK THISTLE,"CIRRHOSIS),",182,157-162,MILK THISTLE,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals Milk thistle (hepatitis, cirrhosis), 70-140 mg t.i.d.",182,157 162,182,157,191,169,1,RO-may_treat,907669,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals Milk thistle (hepatitis, cirrhosis), 70-140 mg t.i.d",cirrhosis,Milk thistle
503461357,7/16/2014 14:26:09,,1324275978,7/16/2014 14:25:31,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,182,157,,,191,169,CIRRHOSIS,MILK THISTLE,"CIRRHOSIS),",182,157-162,MILK THISTLE,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals Milk thistle (hepatitis, cirrhosis), 70-140 mg t.i.d.",182,157 162,182,157,191,169,1,RO-may_treat,907669,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals Milk thistle (hepatitis, cirrhosis), 70-140 mg t.i.d",cirrhosis,Milk thistle
503461357,7/16/2014 14:40:57,,1324281910,7/16/2014 14:40:33,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,182,157,,,191,169,CIRRHOSIS,MILK THISTLE,"CIRRHOSIS),",182,157-162,MILK THISTLE,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals Milk thistle (hepatitis, cirrhosis), 70-140 mg t.i.d.",182,157 162,182,157,191,169,1,RO-may_treat,907669,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals Milk thistle (hepatitis, cirrhosis), 70-140 mg t.i.d",cirrhosis,Milk thistle
503461357,7/16/2014 14:41:45,,1324282123,7/16/2014 14:40:37,neodev,1.0,28336203,USA,PA,Harrisburg,50.149.53.150,182,157,,,191,169,CIRRHOSIS,MILK THISTLE,"Evidencec Herbals Milk thistle (hepatitis, CIRRHOSIS),",131-149-157-170-182-162,149-157-162-170-182-131,"Evidencec Herbals MILK THISTLE (hepatitis, cirrhosis),","Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals Milk thistle (hepatitis, cirrhosis), 70-140 mg t.i.d.",182,157 162,182,157,191,169,1,RO-may_treat,907669,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals Milk thistle (hepatitis, cirrhosis), 70-140 mg t.i.d",cirrhosis,Milk thistle
503461358,7/16/2014 13:44:14,,1324259216,7/16/2014 13:44:03,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,23,46,,,29,57,EMESIS,ONDANSETRON,EMESIS,23,46,ONDANSETRON,The lower incidence of emesis recorded by the ondansetron groups compared with the droperidol group was not statistically significant.,23,46,23,46,29,57,1,RO-may_prevent,907449,The lower incidence of emesis recorded by the ondansetron groups compared with the droperidol group was not statistically significant,emesis,ondansetron
503461358,7/16/2014 13:49:48,,1324260999,7/16/2014 13:49:38,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,23,46,,,29,57,EMESIS,ONDANSETRON,EMESIS,23,46-58,ONDANSETRON groups,The lower incidence of emesis recorded by the ondansetron groups compared with the droperidol group was not statistically significant.,23,46,23,46,29,57,1,RO-may_prevent,907449,The lower incidence of emesis recorded by the ondansetron groups compared with the droperidol group was not statistically significant,emesis,ondansetron
503461358,7/16/2014 13:51:25,,1324261612,7/16/2014 13:51:04,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,23,46,,,29,57,EMESIS,ONDANSETRON,EMESIS,23,46-58,ONDANSETRON groups,The lower incidence of emesis recorded by the ondansetron groups compared with the droperidol group was not statistically significant.,23,46,23,46,29,57,1,RO-may_prevent,907449,The lower incidence of emesis recorded by the ondansetron groups compared with the droperidol group was not statistically significant,emesis,ondansetron
503461358,7/16/2014 13:57:27,,1324264074,7/16/2014 13:57:10,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,23,46,,,29,57,EMESIS,ONDANSETRON,lower incidence of EMESIS,4-10-20-23,46,ONDANSETRON,The lower incidence of emesis recorded by the ondansetron groups compared with the droperidol group was not statistically significant.,23,46,23,46,29,57,1,RO-may_prevent,907449,The lower incidence of emesis recorded by the ondansetron groups compared with the droperidol group was not statistically significant,emesis,ondansetron
503461358,7/16/2014 14:00:18,,1324265294,7/16/2014 14:00:00,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,23,46,,,29,57,EMESIS,ONDANSETRON,incidence of EMESIS,10-20-23,46-58,ONDANSETRON groups,The lower incidence of emesis recorded by the ondansetron groups compared with the droperidol group was not statistically significant.,23,46,23,46,29,57,1,RO-may_prevent,907449,The lower incidence of emesis recorded by the ondansetron groups compared with the droperidol group was not statistically significant,emesis,ondansetron
503461358,7/16/2014 14:21:38,,1324274234,7/16/2014 14:21:25,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,23,46,,,29,57,EMESIS,ONDANSETRON,EMESIS,23,46,ONDANSETRON,The lower incidence of emesis recorded by the ondansetron groups compared with the droperidol group was not statistically significant.,23,46,23,46,29,57,1,RO-may_prevent,907449,The lower incidence of emesis recorded by the ondansetron groups compared with the droperidol group was not statistically significant,emesis,ondansetron
503461358,7/16/2014 14:29:17,,1324277316,7/16/2014 14:29:00,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,23,46,,,29,57,EMESIS,ONDANSETRON,EMESIS,23,46,ONDANSETRON,The lower incidence of emesis recorded by the ondansetron groups compared with the droperidol group was not statistically significant.,23,46,23,46,29,57,1,RO-may_prevent,907449,The lower incidence of emesis recorded by the ondansetron groups compared with the droperidol group was not statistically significant,emesis,ondansetron
503461358,7/16/2014 14:42:45,,1324282406,7/16/2014 14:42:35,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,23,46,,,29,57,EMESIS,ONDANSETRON,EMESIS,23,46,ONDANSETRON,The lower incidence of emesis recorded by the ondansetron groups compared with the droperidol group was not statistically significant.,23,46,23,46,29,57,1,RO-may_prevent,907449,The lower incidence of emesis recorded by the ondansetron groups compared with the droperidol group was not statistically significant,emesis,ondansetron
503461358,7/16/2014 14:50:18,,1324284580,7/16/2014 14:50:08,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,23,46,,,29,57,EMESIS,ONDANSETRON,EMESIS,23,46,ONDANSETRON,The lower incidence of emesis recorded by the ondansetron groups compared with the droperidol group was not statistically significant.,23,46,23,46,29,57,1,RO-may_prevent,907449,The lower incidence of emesis recorded by the ondansetron groups compared with the droperidol group was not statistically significant,emesis,ondansetron
503461358,7/16/2014 14:52:10,,1324285080,7/16/2014 14:51:57,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,23,46,,,29,57,EMESIS,ONDANSETRON,EMESIS,23,46,ONDANSETRON,The lower incidence of emesis recorded by the ondansetron groups compared with the droperidol group was not statistically significant.,23,46,23,46,29,57,1,RO-may_prevent,907449,The lower incidence of emesis recorded by the ondansetron groups compared with the droperidol group was not statistically significant,emesis,ondansetron
503461359,7/16/2014 13:43:12,,1324258818,7/16/2014 13:43:02,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,114,124,,,122,141,JAUNDICE,HEPATIC CARCINOMA,"JAUNDICE,",114,124-132,"HEPATIC CARCINOMA,","There are numerous side-effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, jaundice, hepatic carcinoma, tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",114,124 132,114,124,122,141,-1,RO-disease_may_have_finding,902602,"There are numerous side-effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, jaundice, hepatic carcinoma, tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia",jaundice,hepatic carcinoma
503461359,7/16/2014 13:46:50,,1324260059,7/16/2014 13:46:39,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,114,124,,,122,141,JAUNDICE,HEPATIC CARCINOMA,"JAUNDICE,",114,124-132,"HEPATIC CARCINOMA,","There are numerous side-effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, jaundice, hepatic carcinoma, tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",114,124 132,114,124,122,141,-1,RO-disease_may_have_finding,902602,"There are numerous side-effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, jaundice, hepatic carcinoma, tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia",jaundice,hepatic carcinoma
503461359,7/16/2014 13:48:23,,1324260544,7/16/2014 13:48:12,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,114,124,,,122,141,JAUNDICE,HEPATIC CARCINOMA,"atherosclerosis, blood clotting, JAUNDICE, hepatic carcinoma, tendon",81-98-104-114-124-132-143,98-104-114-124-132-143-150-158,"blood clotting, jaundice, HEPATIC CARCINOMA, tendon damage, psychiatric","There are numerous side-effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, jaundice, hepatic carcinoma, tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",114,124 132,114,124,122,141,-1,RO-disease_may_have_finding,902602,"There are numerous side-effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, jaundice, hepatic carcinoma, tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia",jaundice,hepatic carcinoma
503461359,7/16/2014 13:57:33,,1324264114,7/16/2014 13:57:17,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,114,124,,,122,141,JAUNDICE,HEPATIC CARCINOMA,"JAUNDICE,",114,124-132,"HEPATIC CARCINOMA,","There are numerous side-effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, jaundice, hepatic carcinoma, tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",114,124 132,114,124,122,141,-1,RO-disease_may_have_finding,902602,"There are numerous side-effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, jaundice, hepatic carcinoma, tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia",jaundice,hepatic carcinoma
503461359,7/16/2014 14:01:45,,1324265848,7/16/2014 14:01:21,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,114,124,,,122,141,JAUNDICE,HEPATIC CARCINOMA,"side effects anabolic steroids, hypertension atherosclerosis, blood clotting, JAUNDICE, hepatic carcinoma, tendon damage, psychiatric behavioural effects reduced fertility gynaccomastia.",19-35-44-64-81-98-104-114-124-132-143-150-158-174-186-209-217-231-24,19-24-35-44-64-81-98-104-114-124-132-143-150-158-174-186-209-217-231,"side effects anabolic steroids, hypertension atherosclerosis, blood clotting, jaundice, HEPATIC CARCINOMA, tendon damage, psychiatric behavioural effects reduced fertility gynaccomastia.","There are numerous side-effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, jaundice, hepatic carcinoma, tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",114,124 132,114,124,122,141,-1,RO-disease_may_have_finding,902602,"There are numerous side-effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, jaundice, hepatic carcinoma, tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia",jaundice,hepatic carcinoma
503461359,7/16/2014 14:03:51,,1324266749,7/16/2014 14:03:33,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,114,124,,,122,141,JAUNDICE,HEPATIC CARCINOMA,"JAUNDICE,",114,114-124-132,"jaundice, HEPATIC CARCINOMA,","There are numerous side-effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, jaundice, hepatic carcinoma, tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",114,124 132,114,124,122,141,-1,RO-disease_may_have_finding,902602,"There are numerous side-effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, jaundice, hepatic carcinoma, tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia",jaundice,hepatic carcinoma
503461359,7/16/2014 14:08:49,,1324268893,7/16/2014 14:08:30,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,114,124,,,122,141,JAUNDICE,HEPATIC CARCINOMA,"JAUNDICE,",114,124-132,"HEPATIC CARCINOMA,","There are numerous side-effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, jaundice, hepatic carcinoma, tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",114,124 132,114,124,122,141,-1,RO-disease_may_have_finding,902602,"There are numerous side-effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, jaundice, hepatic carcinoma, tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia",jaundice,hepatic carcinoma
503461359,7/16/2014 14:10:04,,1324269513,7/16/2014 14:09:43,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,114,124,,,122,141,JAUNDICE,HEPATIC CARCINOMA,"JAUNDICE,",114,124-132,"HEPATIC CARCINOMA,","There are numerous side-effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, jaundice, hepatic carcinoma, tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",114,124 132,114,124,122,141,-1,RO-disease_may_have_finding,902602,"There are numerous side-effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, jaundice, hepatic carcinoma, tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia",jaundice,hepatic carcinoma
503461359,7/16/2014 14:12:33,,1324270594,7/16/2014 14:11:56,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,114,124,,,122,141,JAUNDICE,HEPATIC CARCINOMA,"JAUNDICE,",114,124-132,"HEPATIC CARCINOMA,","There are numerous side-effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, jaundice, hepatic carcinoma, tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",114,124 132,114,124,122,141,-1,RO-disease_may_have_finding,902602,"There are numerous side-effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, jaundice, hepatic carcinoma, tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia",jaundice,hepatic carcinoma
503461359,7/16/2014 14:28:39,,1324276935,7/16/2014 14:28:22,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,114,124,,,122,141,JAUNDICE,HEPATIC CARCINOMA,"JAUNDICE, hepatic carcinoma,",114-124-132,114-124-132,"jaundice, HEPATIC CARCINOMA,","There are numerous side-effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, jaundice, hepatic carcinoma, tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",114,124 132,114,124,122,141,-1,RO-disease_may_have_finding,902602,"There are numerous side-effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, jaundice, hepatic carcinoma, tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia",jaundice,hepatic carcinoma
503461360,7/16/2014 13:42:44,,1324258697,7/16/2014 13:42:32,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,55,100,,,67,108,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,55,100,GLUCAGON,"For patients who are unconscious or unable to swallow, hypoglycemia can be treated immediately with glucagon 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",55,100,55,100,67,108,1,RO-may_treat,907911,"For patients who are unconscious or unable to swallow, hypoglycemia can be treated immediately with glucagon 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels",hypoglycemia,glucagon
503461360,7/16/2014 13:58:49,,1324264672,7/16/2014 13:58:14,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,55,100,,,67,108,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,55,100-109-111-114,GLUCAGON 1 mg sc,"For patients who are unconscious or unable to swallow, hypoglycemia can be treated immediately with glucagon 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",55,100,55,100,67,108,1,RO-may_treat,907911,"For patients who are unconscious or unable to swallow, hypoglycemia can be treated immediately with glucagon 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels",hypoglycemia,glucagon
503461360,7/16/2014 14:04:59,,1324267224,7/16/2014 14:04:43,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,55,100,,,67,108,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,55,55-100,hypoglycemia GLUCAGON,"For patients who are unconscious or unable to swallow, hypoglycemia can be treated immediately with glucagon 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",55,100,55,100,67,108,1,RO-may_treat,907911,"For patients who are unconscious or unable to swallow, hypoglycemia can be treated immediately with glucagon 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels",hypoglycemia,glucagon
503461360,7/16/2014 14:27:37,,1324276535,7/16/2014 14:27:21,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,55,100,,,67,108,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,55,100,GLUCAGON,"For patients who are unconscious or unable to swallow, hypoglycemia can be treated immediately with glucagon 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",55,100,55,100,67,108,1,RO-may_treat,907911,"For patients who are unconscious or unable to swallow, hypoglycemia can be treated immediately with glucagon 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels",hypoglycemia,glucagon
503461360,7/16/2014 14:35:39,,1324279953,7/16/2014 14:35:23,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,55,100,,,67,108,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,55,100,GLUCAGON,"For patients who are unconscious or unable to swallow, hypoglycemia can be treated immediately with glucagon 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",55,100,55,100,67,108,1,RO-may_treat,907911,"For patients who are unconscious or unable to swallow, hypoglycemia can be treated immediately with glucagon 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels",hypoglycemia,glucagon
503461360,7/16/2014 14:37:37,,1324280844,7/16/2014 14:37:06,prodege,1.0,26790109,USA,"","",23.125.64.233,55,100,,,67,108,HYPOGLYCEMIA,GLUCAGON,"unable to swallow, HYPOGLYCEMIA can be treated immediately with glucagon 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g),",36-43-46-55-68-72-75-83-95-100-109-111-114-117-120-123-126-128-132-141-150-153-156-159-163,75-83-95-100-109-111-114,treated immediately with GLUCAGON 1 mg sc,"For patients who are unconscious or unable to swallow, hypoglycemia can be treated immediately with glucagon 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",55,100,55,100,67,108,1,RO-may_treat,907911,"For patients who are unconscious or unable to swallow, hypoglycemia can be treated immediately with glucagon 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels",hypoglycemia,glucagon
503461360,7/16/2014 14:38:08,,1324280984,7/16/2014 14:37:51,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,55,100,,,67,108,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA glucagon,55-100,55-100,hypoglycemia GLUCAGON,"For patients who are unconscious or unable to swallow, hypoglycemia can be treated immediately with glucagon 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",55,100,55,100,67,108,1,RO-may_treat,907911,"For patients who are unconscious or unable to swallow, hypoglycemia can be treated immediately with glucagon 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels",hypoglycemia,glucagon
503461360,7/16/2014 14:53:37,,1324285574,7/16/2014 14:53:18,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,55,100,,,67,108,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,55,100,GLUCAGON,"For patients who are unconscious or unable to swallow, hypoglycemia can be treated immediately with glucagon 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",55,100,55,100,67,108,1,RO-may_treat,907911,"For patients who are unconscious or unable to swallow, hypoglycemia can be treated immediately with glucagon 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels",hypoglycemia,glucagon
503461360,7/16/2014 14:57:53,,1324287192,7/16/2014 14:57:41,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,55,100,,,67,108,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,55,100,GLUCAGON,"For patients who are unconscious or unable to swallow, hypoglycemia can be treated immediately with glucagon 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",55,100,55,100,67,108,1,RO-may_treat,907911,"For patients who are unconscious or unable to swallow, hypoglycemia can be treated immediately with glucagon 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels",hypoglycemia,glucagon
503461360,7/16/2014 14:59:47,,1324287845,7/16/2014 14:59:27,irazoo,1.0,7022810,USA,IA,Ankeny,216.161.121.1,55,100,,,67,108,HYPOGLYCEMIA,GLUCAGON,HYPOGLYCEMIA,55,100-109-111-114,GLUCAGON 1 mg sc,"For patients who are unconscious or unable to swallow, hypoglycemia can be treated immediately with glucagon 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",55,100,55,100,67,108,1,RO-may_treat,907911,"For patients who are unconscious or unable to swallow, hypoglycemia can be treated immediately with glucagon 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels",hypoglycemia,glucagon
503461361,7/16/2014 13:53:50,,1324262560,7/16/2014 13:53:32,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,0,32,,,27,44,PROTEIN ENERGY MALNUTRITION,DEFICIENCIES,PROTEIN ENERGY MALNUTRITION,0-8-15,32,DEFICIENCIES,"Protein energy malnutrition and deficiencies of iron, vitamin A and iodine affect millions of people in developing countries.",0 8 15,32,0,32,27,44,-1,RO-cause_of,900464,"Protein energy malnutrition and deficiencies of iron, vitamin A and iodine affect millions of people in developing countries",Protein energy malnutrition,deficiencies
503461361,7/16/2014 14:00:01,,1324265243,7/16/2014 13:59:49,instagc,1.0,18960682,GBR,"","",86.29.147.112,0,32,,,27,44,PROTEIN ENERGY MALNUTRITION,DEFICIENCIES,PROTEIN ENERGY MALNUTRITION,0-8-15,32-45-48,"DEFICIENCIES of iron,","Protein energy malnutrition and deficiencies of iron, vitamin A and iodine affect millions of people in developing countries.",0 8 15,32,0,32,27,44,-1,RO-cause_of,900464,"Protein energy malnutrition and deficiencies of iron, vitamin A and iodine affect millions of people in developing countries",Protein energy malnutrition,deficiencies
503461361,7/16/2014 14:12:53,,1324270717,7/16/2014 14:12:40,instagc,1.0,13763729,USA,"","",75.182.89.225,0,32,,,27,44,PROTEIN ENERGY MALNUTRITION,DEFICIENCIES,PROTEIN ENERGY MALNUTRITION,0-8-15,32,DEFICIENCIES,"Protein energy malnutrition and deficiencies of iron, vitamin A and iodine affect millions of people in developing countries.",0 8 15,32,0,32,27,44,-1,RO-cause_of,900464,"Protein energy malnutrition and deficiencies of iron, vitamin A and iodine affect millions of people in developing countries",Protein energy malnutrition,deficiencies
503461361,7/16/2014 14:15:15,,1324271599,7/16/2014 14:14:56,vivatic,1.0,25451531,GBR,"","",83.67.28.193,0,32,,,27,44,PROTEIN ENERGY MALNUTRITION,DEFICIENCIES,PROTEIN ENERGY MALNUTRITION,0-8-15,32-45-48-54-62-64-68,"DEFICIENCIES of iron, vitamin A and iodine","Protein energy malnutrition and deficiencies of iron, vitamin A and iodine affect millions of people in developing countries.",0 8 15,32,0,32,27,44,-1,RO-cause_of,900464,"Protein energy malnutrition and deficiencies of iron, vitamin A and iodine affect millions of people in developing countries",Protein energy malnutrition,deficiencies
503461361,7/16/2014 14:23:42,,1324275029,7/16/2014 14:23:11,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,0,32,,,27,44,PROTEIN ENERGY MALNUTRITION,DEFICIENCIES,PROTEIN ENERGY MALNUTRITION,0-8-15,32,DEFICIENCIES,"Protein energy malnutrition and deficiencies of iron, vitamin A and iodine affect millions of people in developing countries.",0 8 15,32,0,32,27,44,-1,RO-cause_of,900464,"Protein energy malnutrition and deficiencies of iron, vitamin A and iodine affect millions of people in developing countries",Protein energy malnutrition,deficiencies
503461361,7/16/2014 14:30:10,,1324277674,7/16/2014 14:29:56,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,0,32,,,27,44,PROTEIN ENERGY MALNUTRITION,DEFICIENCIES,PROTEIN ENERGY MALNUTRITION,0-8-15,32,DEFICIENCIES,"Protein energy malnutrition and deficiencies of iron, vitamin A and iodine affect millions of people in developing countries.",0 8 15,32,0,32,27,44,-1,RO-cause_of,900464,"Protein energy malnutrition and deficiencies of iron, vitamin A and iodine affect millions of people in developing countries",Protein energy malnutrition,deficiencies
503461361,7/16/2014 14:30:41,,1324277951,7/16/2014 14:30:18,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,0,32,,,27,44,PROTEIN ENERGY MALNUTRITION,DEFICIENCIES,PROTEIN ENERGY MALNUTRITION,0-8-15,32,DEFICIENCIES,"Protein energy malnutrition and deficiencies of iron, vitamin A and iodine affect millions of people in developing countries.",0 8 15,32,0,32,27,44,-1,RO-cause_of,900464,"Protein energy malnutrition and deficiencies of iron, vitamin A and iodine affect millions of people in developing countries",Protein energy malnutrition,deficiencies
503461361,7/16/2014 14:41:16,,1324282011,7/16/2014 14:40:42,prodege,1.0,26790109,USA,"","",23.125.64.233,0,32,,,27,44,PROTEIN ENERGY MALNUTRITION,DEFICIENCIES,"PROTEIN ENERGY MALNUTRITION and deficiencies of iron, vitamin A and iodine affect millions of people in developing countries.",0-8-15-28-32-45-48-54-62-64-68-75-82-91-94-101-104-115,32-45-48-54-62-64-68-75-82-91-94-101-104-115,"DEFICIENCIES of iron, vitamin A and iodine affect millions of people in developing countries.","Protein energy malnutrition and deficiencies of iron, vitamin A and iodine affect millions of people in developing countries.",0 8 15,32,0,32,27,44,-1,RO-cause_of,900464,"Protein energy malnutrition and deficiencies of iron, vitamin A and iodine affect millions of people in developing countries",Protein energy malnutrition,deficiencies
503461361,7/16/2014 14:49:44,,1324284407,7/16/2014 14:49:23,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,0,32,,,27,44,PROTEIN ENERGY MALNUTRITION,DEFICIENCIES,PROTEIN ENERGY MALNUTRITION,0-8-15,32,DEFICIENCIES,"Protein energy malnutrition and deficiencies of iron, vitamin A and iodine affect millions of people in developing countries.",0 8 15,32,0,32,27,44,-1,RO-cause_of,900464,"Protein energy malnutrition and deficiencies of iron, vitamin A and iodine affect millions of people in developing countries",Protein energy malnutrition,deficiencies
503461361,7/16/2014 14:51:48,,1324284998,7/16/2014 14:51:17,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,0,32,,,27,44,PROTEIN ENERGY MALNUTRITION,DEFICIENCIES,PROTEIN ENERGY MALNUTRITION,0-8-15,32,DEFICIENCIES,"Protein energy malnutrition and deficiencies of iron, vitamin A and iodine affect millions of people in developing countries.",0 8 15,32,0,32,27,44,-1,RO-cause_of,900464,"Protein energy malnutrition and deficiencies of iron, vitamin A and iodine affect millions of people in developing countries",Protein energy malnutrition,deficiencies
503461362,7/16/2014 13:46:38,,1324259968,7/16/2014 13:46:29,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,23,84,,,40,95,MYASTHENIA GRAVIS,NEOSTIGMINE,MYASTHENIA GRAVIS,23-34,84,"NEOSTIGMINE,","A 52 year old man with myasthenia gravis and normal liver function was treated with neostigmine, prednisolone and azathioprine.",23 34,84,23,84,40,95,1,RO-may_diagnose,906775,"A 52 year old man with myasthenia gravis and normal liver function was treated with neostigmine, prednisolone and azathioprine",myasthenia gravis,neostigmine
503461362,7/16/2014 13:52:43,,1324262076,7/16/2014 13:52:28,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,23,84,,,40,95,MYASTHENIA GRAVIS,NEOSTIGMINE,MYASTHENIA GRAVIS,23-34,84,"NEOSTIGMINE,","A 52 year old man with myasthenia gravis and normal liver function was treated with neostigmine, prednisolone and azathioprine.",23 34,84,23,84,40,95,1,RO-may_diagnose,906775,"A 52 year old man with myasthenia gravis and normal liver function was treated with neostigmine, prednisolone and azathioprine",myasthenia gravis,neostigmine
503461362,7/16/2014 13:56:50,,1324263761,7/16/2014 13:56:32,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,23,84,,,40,95,MYASTHENIA GRAVIS,NEOSTIGMINE,MYASTHENIA GRAVIS,23-34,84,"NEOSTIGMINE,","A 52 year old man with myasthenia gravis and normal liver function was treated with neostigmine, prednisolone and azathioprine.",23 34,84,23,84,40,95,1,RO-may_diagnose,906775,"A 52 year old man with myasthenia gravis and normal liver function was treated with neostigmine, prednisolone and azathioprine",myasthenia gravis,neostigmine
503461362,7/16/2014 14:23:43,,1324275032,7/16/2014 14:23:25,vivatic,1.0,25451531,GBR,"","",83.67.28.193,23,84,,,40,95,MYASTHENIA GRAVIS,NEOSTIGMINE,MYASTHENIA GRAVIS,23-34,84,"NEOSTIGMINE,","A 52 year old man with myasthenia gravis and normal liver function was treated with neostigmine, prednisolone and azathioprine.",23 34,84,23,84,40,95,1,RO-may_diagnose,906775,"A 52 year old man with myasthenia gravis and normal liver function was treated with neostigmine, prednisolone and azathioprine",myasthenia gravis,neostigmine
503461362,7/16/2014 14:35:14,,1324279728,7/16/2014 14:34:54,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,23,84,,,40,95,MYASTHENIA GRAVIS,NEOSTIGMINE,"MYASTHENIA GRAVIS neostigmine,",23-34-84,23-34-84,"myasthenia gravis NEOSTIGMINE,","A 52 year old man with myasthenia gravis and normal liver function was treated with neostigmine, prednisolone and azathioprine.",23 34,84,23,84,40,95,1,RO-may_diagnose,906775,"A 52 year old man with myasthenia gravis and normal liver function was treated with neostigmine, prednisolone and azathioprine",myasthenia gravis,neostigmine
503461362,7/16/2014 14:47:33,,1324283729,7/16/2014 14:47:13,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,23,84,,,40,95,MYASTHENIA GRAVIS,NEOSTIGMINE,MYASTHENIA GRAVIS,23-34,84,"NEOSTIGMINE,","A 52 year old man with myasthenia gravis and normal liver function was treated with neostigmine, prednisolone and azathioprine.",23 34,84,23,84,40,95,1,RO-may_diagnose,906775,"A 52 year old man with myasthenia gravis and normal liver function was treated with neostigmine, prednisolone and azathioprine",myasthenia gravis,neostigmine
503461362,7/16/2014 14:52:41,,1324285239,7/16/2014 14:52:32,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,23,84,,,40,95,MYASTHENIA GRAVIS,NEOSTIGMINE,MYASTHENIA GRAVIS,23-34,84,"NEOSTIGMINE,","A 52 year old man with myasthenia gravis and normal liver function was treated with neostigmine, prednisolone and azathioprine.",23 34,84,23,84,40,95,1,RO-may_diagnose,906775,"A 52 year old man with myasthenia gravis and normal liver function was treated with neostigmine, prednisolone and azathioprine",myasthenia gravis,neostigmine
503461362,7/16/2014 14:55:13,,1324286111,7/16/2014 14:55:12,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,23,84,,,40,95,MYASTHENIA GRAVIS,NEOSTIGMINE,old man with MYASTHENIA GRAVIS and normal liver,10-14-18-23-34-41-45-52,67-71-79-84-97-110-114,"was treated with NEOSTIGMINE, prednisolone and azathioprine.","A 52 year old man with myasthenia gravis and normal liver function was treated with neostigmine, prednisolone and azathioprine.",23 34,84,23,84,40,95,1,RO-may_diagnose,906775,"A 52 year old man with myasthenia gravis and normal liver function was treated with neostigmine, prednisolone and azathioprine",myasthenia gravis,neostigmine
503461362,7/16/2014 14:57:42,,1324287114,7/16/2014 14:57:19,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,23,84,,,40,95,MYASTHENIA GRAVIS,NEOSTIGMINE,MYASTHENIA GRAVIS,23-34,84,"NEOSTIGMINE,","A 52 year old man with myasthenia gravis and normal liver function was treated with neostigmine, prednisolone and azathioprine.",23 34,84,23,84,40,95,1,RO-may_diagnose,906775,"A 52 year old man with myasthenia gravis and normal liver function was treated with neostigmine, prednisolone and azathioprine",myasthenia gravis,neostigmine
503461362,7/16/2014 14:57:59,,1324287248,7/16/2014 14:57:40,irazoo,1.0,7022810,USA,IA,Ankeny,216.161.121.1,23,84,,,40,95,MYASTHENIA GRAVIS,NEOSTIGMINE,MYASTHENIA GRAVIS,23-34,84,"NEOSTIGMINE,","A 52 year old man with myasthenia gravis and normal liver function was treated with neostigmine, prednisolone and azathioprine.",23 34,84,23,84,40,95,1,RO-may_diagnose,906775,"A 52 year old man with myasthenia gravis and normal liver function was treated with neostigmine, prednisolone and azathioprine",myasthenia gravis,neostigmine
503461363,7/16/2014 13:56:30,,1324263635,7/16/2014 13:56:12,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,227,151,,,235,167,SEIZURES,INFANTILE SPASMS,SEIZURES,227,151-161,INFANTILE SPASMS,"Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X-linked infantile spasms sharing the common features of generally intractable early seizures and mental retardation.",227,151 161,227,151,235,167,-1,RO-has_definitional_manifestation,904552,"Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X-linked infantile spasms sharing the common features of generally intractable early seizures and mental retardation",seizures,infantile spasms
503461363,7/16/2014 14:02:11,,1324266024,7/16/2014 14:01:46,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,227,151,,,235,167,SEIZURES,INFANTILE SPASMS,"Rett syndrome, West syndrome, SEIZURES",108-113-123-128-227,108-113-123-128-151-161,"Rett syndrome, West syndrome, INFANTILE SPASMS","Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X-linked infantile spasms sharing the common features of generally intractable early seizures and mental retardation.",227,151 161,227,151,235,167,-1,RO-has_definitional_manifestation,904552,"Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X-linked infantile spasms sharing the common features of generally intractable early seizures and mental retardation",seizures,infantile spasms
503461363,7/16/2014 14:08:55,,1324268944,7/16/2014 14:08:38,instagc,1.0,13763729,USA,"","",75.182.89.225,227,151,,,235,167,SEIZURES,INFANTILE SPASMS,SEIZURES,227,142-144-151-161,X linked INFANTILE SPASMS,"Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X-linked infantile spasms sharing the common features of generally intractable early seizures and mental retardation.",227,151 161,227,151,235,167,-1,RO-has_definitional_manifestation,904552,"Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X-linked infantile spasms sharing the common features of generally intractable early seizures and mental retardation",seizures,infantile spasms
503461363,7/16/2014 14:25:11,,1324275616,7/16/2014 14:24:50,vivatic,1.0,25451531,GBR,"","",83.67.28.193,227,151,,,235,167,SEIZURES,INFANTILE SPASMS,intractable early SEIZURES,209-221-227,142-144-151-161,X linked INFANTILE SPASMS,"Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X-linked infantile spasms sharing the common features of generally intractable early seizures and mental retardation.",227,151 161,227,151,235,167,-1,RO-has_definitional_manifestation,904552,"Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X-linked infantile spasms sharing the common features of generally intractable early seizures and mental retardation",seizures,infantile spasms
503461363,7/16/2014 14:29:30,,1324277400,7/16/2014 14:29:02,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,227,151,,,235,167,SEIZURES,INFANTILE SPASMS,SEIZURES,227,151-161,INFANTILE SPASMS,"Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X-linked infantile spasms sharing the common features of generally intractable early seizures and mental retardation.",227,151 161,227,151,235,167,-1,RO-has_definitional_manifestation,904552,"Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X-linked infantile spasms sharing the common features of generally intractable early seizures and mental retardation",seizures,infantile spasms
503461363,7/16/2014 14:29:59,,1324277598,7/16/2014 14:29:38,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,227,151,,,235,167,SEIZURES,INFANTILE SPASMS,SEIZURES,227,151-161,INFANTILE SPASMS,"Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X-linked infantile spasms sharing the common features of generally intractable early seizures and mental retardation.",227,151 161,227,151,235,167,-1,RO-has_definitional_manifestation,904552,"Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X-linked infantile spasms sharing the common features of generally intractable early seizures and mental retardation",seizures,infantile spasms
503461363,7/16/2014 14:31:36,,1324278333,7/16/2014 14:31:05,prodege,1.0,6316959,GBR,"","",46.208.145.114,227,151,,,235,167,SEIZURES,INFANTILE SPASMS,SEIZURES,227,142-143-151-161-144,X - linked INFANTILE SPASMS,"Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X-linked infantile spasms sharing the common features of generally intractable early seizures and mental retardation.",227,151 161,227,151,235,167,-1,RO-has_definitional_manifestation,904552,"Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X-linked infantile spasms sharing the common features of generally intractable early seizures and mental retardation",seizures,infantile spasms
503461363,7/16/2014 14:33:51,,1324279157,7/16/2014 14:33:31,prodege,1.0,26790109,USA,"","",23.125.64.233,227,151,,,235,167,SEIZURES,INFANTILE SPASMS,generally intractable early SEIZURES and mental retardation.,199-209-221-227-236-240-247,138-142-144-151-161-168-176-180-187-196-199-209-221-227-236-240-247,and X linked INFANTILE SPASMS sharing the common features of generally intractable early seizures and mental retardation.,"Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X-linked infantile spasms sharing the common features of generally intractable early seizures and mental retardation.",227,151 161,227,151,235,167,-1,RO-has_definitional_manifestation,904552,"Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X-linked infantile spasms sharing the common features of generally intractable early seizures and mental retardation",seizures,infantile spasms
503461363,7/16/2014 14:41:15,,1324281992,7/16/2014 14:41:05,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,227,151,,,235,167,SEIZURES,INFANTILE SPASMS,SEIZURES mental retardation.,227-240-247,151-161,INFANTILE SPASMS,"Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X-linked infantile spasms sharing the common features of generally intractable early seizures and mental retardation.",227,151 161,227,151,235,167,-1,RO-has_definitional_manifestation,904552,"Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X-linked infantile spasms sharing the common features of generally intractable early seizures and mental retardation",seizures,infantile spasms
503461363,7/16/2014 14:53:45,,1324285611,7/16/2014 14:53:31,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,227,151,,,235,167,SEIZURES,INFANTILE SPASMS,SEIZURES,227,142-144-151-161,X linked INFANTILE SPASMS,"Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X-linked infantile spasms sharing the common features of generally intractable early seizures and mental retardation.",227,151 161,227,151,235,167,-1,RO-has_definitional_manifestation,904552,"Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X-linked infantile spasms sharing the common features of generally intractable early seizures and mental retardation",seizures,infantile spasms
503461364,7/16/2014 13:39:29,,1324257406,7/16/2014 13:39:21,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,71,110,,,76,127,BRAIN,CEREBRAL ISCHEMIA,BRAIN,71,110-119,CEREBRAL ISCHEMIA.,The results indicate that the function of the inhibitory system in the brain is selectively vulnerable during cerebral ischemia.,71,110 119,71,110,76,127,1,RO-disease_has_primary_anatomic_site,902113,The results indicate that the function of the inhibitory system in the brain is selectively vulnerable during cerebral ischemia,brain,cerebral ischemia
503461364,7/16/2014 14:02:28,,1324266114,7/16/2014 14:02:09,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,71,110,,,76,127,BRAIN,CEREBRAL ISCHEMIA,inhibitory system BRAIN cerebral ischemia.,46-57-71-110-119,46-57-110-119-71,inhibitory system brain CEREBRAL ISCHEMIA.,The results indicate that the function of the inhibitory system in the brain is selectively vulnerable during cerebral ischemia.,71,110 119,71,110,76,127,1,RO-disease_has_primary_anatomic_site,902113,The results indicate that the function of the inhibitory system in the brain is selectively vulnerable during cerebral ischemia,brain,cerebral ischemia
503461364,7/16/2014 14:13:06,,1324270778,7/16/2014 14:12:54,instagc,1.0,13763729,USA,"","",75.182.89.225,71,110,,,76,127,BRAIN,CEREBRAL ISCHEMIA,BRAIN,71,110-119,CEREBRAL ISCHEMIA.,The results indicate that the function of the inhibitory system in the brain is selectively vulnerable during cerebral ischemia.,71,110 119,71,110,76,127,1,RO-disease_has_primary_anatomic_site,902113,The results indicate that the function of the inhibitory system in the brain is selectively vulnerable during cerebral ischemia,brain,cerebral ischemia
503461364,7/16/2014 14:26:56,,1324276226,7/16/2014 14:26:23,prodege,1.0,26790109,USA,"","",23.125.64.233,71,110,,,76,127,BRAIN,CEREBRAL ISCHEMIA,function of the inhibitory system in the BRAIN is selectively vulnerable during cerebral ischemia.,30-39-42-46-57-64-67-71-77-80-92-103-110-119,30-39-42-46-57-64-67-71-80-92-103-110-119-77,function of the inhibitory system in the brain is selectively vulnerable during CEREBRAL ISCHEMIA.,The results indicate that the function of the inhibitory system in the brain is selectively vulnerable during cerebral ischemia.,71,110 119,71,110,76,127,1,RO-disease_has_primary_anatomic_site,902113,The results indicate that the function of the inhibitory system in the brain is selectively vulnerable during cerebral ischemia,brain,cerebral ischemia
503461364,7/16/2014 14:30:43,,1324277985,7/16/2014 14:30:30,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,71,110,,,76,127,BRAIN,CEREBRAL ISCHEMIA,BRAIN,71,110-119,CEREBRAL ISCHEMIA.,The results indicate that the function of the inhibitory system in the brain is selectively vulnerable during cerebral ischemia.,71,110 119,71,110,76,127,1,RO-disease_has_primary_anatomic_site,902113,The results indicate that the function of the inhibitory system in the brain is selectively vulnerable during cerebral ischemia,brain,cerebral ischemia
503461364,7/16/2014 14:34:52,,1324279579,7/16/2014 14:34:36,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,71,110,,,76,127,BRAIN,CEREBRAL ISCHEMIA,BRAIN cerebral ischemia.,71-110-119,71-110-119,brain CEREBRAL ISCHEMIA.,The results indicate that the function of the inhibitory system in the brain is selectively vulnerable during cerebral ischemia.,71,110 119,71,110,76,127,1,RO-disease_has_primary_anatomic_site,902113,The results indicate that the function of the inhibitory system in the brain is selectively vulnerable during cerebral ischemia,brain,cerebral ischemia
503461364,7/16/2014 14:50:41,,1324284688,7/16/2014 14:50:27,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,71,110,,,76,127,BRAIN,CEREBRAL ISCHEMIA,BRAIN,71,110-119,CEREBRAL ISCHEMIA.,The results indicate that the function of the inhibitory system in the brain is selectively vulnerable during cerebral ischemia.,71,110 119,71,110,76,127,1,RO-disease_has_primary_anatomic_site,902113,The results indicate that the function of the inhibitory system in the brain is selectively vulnerable during cerebral ischemia,brain,cerebral ischemia
503461364,7/16/2014 14:55:10,,1324286104,7/16/2014 14:54:55,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,71,110,,,76,127,BRAIN,CEREBRAL ISCHEMIA,BRAIN,71,110-119,CEREBRAL ISCHEMIA.,The results indicate that the function of the inhibitory system in the brain is selectively vulnerable during cerebral ischemia.,71,110 119,71,110,76,127,1,RO-disease_has_primary_anatomic_site,902113,The results indicate that the function of the inhibitory system in the brain is selectively vulnerable during cerebral ischemia,brain,cerebral ischemia
503461364,7/16/2014 14:55:33,,1324286252,7/16/2014 14:55:16,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,71,110,,,76,127,BRAIN,CEREBRAL ISCHEMIA,BRAIN,71,110-119,CEREBRAL ISCHEMIA.,The results indicate that the function of the inhibitory system in the brain is selectively vulnerable during cerebral ischemia.,71,110 119,71,110,76,127,1,RO-disease_has_primary_anatomic_site,902113,The results indicate that the function of the inhibitory system in the brain is selectively vulnerable during cerebral ischemia,brain,cerebral ischemia
503461364,7/16/2014 14:57:38,,1324287093,7/16/2014 14:57:13,irazoo,1.0,7022810,USA,IA,Ankeny,216.161.121.1,71,110,,,76,127,BRAIN,CEREBRAL ISCHEMIA,BRAIN,71,110-119,CEREBRAL ISCHEMIA.,The results indicate that the function of the inhibitory system in the brain is selectively vulnerable during cerebral ischemia.,71,110 119,71,110,76,127,1,RO-disease_has_primary_anatomic_site,902113,The results indicate that the function of the inhibitory system in the brain is selectively vulnerable during cerebral ischemia,brain,cerebral ischemia
503461365,7/16/2014 13:51:43,,1324261716,7/16/2014 13:51:17,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,49,84,,,64,91,TYPE 2 DIABETES,INSULIN,CKD patients with TYPE 2 DIABETES,31-35-44-49-54-56,84-92,INSULIN therapy.,"Unfortunately, the majority of CKD patients with type 2 diabetes eventually require insulin therapy.",49 54 56,84,49,84,64,91,1,RO-may_treat,907826,"Unfortunately, the majority of CKD patients with type 2 diabetes eventually require insulin therapy",type 2 diabetes,insulin
503461365,7/16/2014 13:59:08,,1324264823,7/16/2014 13:58:47,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,49,84,,,64,91,TYPE 2 DIABETES,INSULIN,CKD patients TYPE 2 DIABETES insulin therapy.,31-35-49-54-56-84-92,31-35-49-54-56-84-92,CKD patients type 2 diabetes INSULIN therapy.,"Unfortunately, the majority of CKD patients with type 2 diabetes eventually require insulin therapy.",49 54 56,84,49,84,64,91,1,RO-may_treat,907826,"Unfortunately, the majority of CKD patients with type 2 diabetes eventually require insulin therapy",type 2 diabetes,insulin
503461365,7/16/2014 14:15:14,,1324271594,7/16/2014 14:14:53,instagc,1.0,13763729,USA,"","",75.182.89.225,49,84,,,64,91,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,49-54-56,84,INSULIN,"Unfortunately, the majority of CKD patients with type 2 diabetes eventually require insulin therapy.",49 54 56,84,49,84,64,91,1,RO-may_treat,907826,"Unfortunately, the majority of CKD patients with type 2 diabetes eventually require insulin therapy",type 2 diabetes,insulin
503461365,7/16/2014 14:23:23,,1324274893,7/16/2014 14:23:07,vivatic,1.0,25451531,GBR,"","",83.67.28.193,49,84,,,64,91,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,49-54-56,84-92,INSULIN therapy.,"Unfortunately, the majority of CKD patients with type 2 diabetes eventually require insulin therapy.",49 54 56,84,49,84,64,91,1,RO-may_treat,907826,"Unfortunately, the majority of CKD patients with type 2 diabetes eventually require insulin therapy",type 2 diabetes,insulin
503461365,7/16/2014 14:36:00,,1324280122,7/16/2014 14:35:34,prodege,1.0,26790109,USA,"","",23.125.64.233,49,84,,,64,91,TYPE 2 DIABETES,INSULIN,CKD patients with TYPE 2 DIABETES eventually require insulin therapy.,31-35-44-49-54-56-65-76-84-92,31-35-44-54-56-65-76-84-92-49,CKD patients with type 2 diabetes eventually require INSULIN therapy.,"Unfortunately, the majority of CKD patients with type 2 diabetes eventually require insulin therapy.",49 54 56,84,49,84,64,91,1,RO-may_treat,907826,"Unfortunately, the majority of CKD patients with type 2 diabetes eventually require insulin therapy",type 2 diabetes,insulin
503461365,7/16/2014 14:39:11,,1324281351,7/16/2014 14:38:53,prodege,1.0,6316959,GBR,"","",46.208.145.114,49,84,,,64,91,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,49-54-56,84-92,INSULIN therapy.,"Unfortunately, the majority of CKD patients with type 2 diabetes eventually require insulin therapy.",49 54 56,84,49,84,64,91,1,RO-may_treat,907826,"Unfortunately, the majority of CKD patients with type 2 diabetes eventually require insulin therapy",type 2 diabetes,insulin
503461365,7/16/2014 14:45:52,,1324283187,7/16/2014 14:45:47,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,49,84,,,64,91,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,49-54-56,84,INSULIN,"Unfortunately, the majority of CKD patients with type 2 diabetes eventually require insulin therapy.",49 54 56,84,49,84,64,91,1,RO-may_treat,907826,"Unfortunately, the majority of CKD patients with type 2 diabetes eventually require insulin therapy",type 2 diabetes,insulin
503461365,7/16/2014 14:48:01,,1324283854,7/16/2014 14:47:51,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,49,84,,,64,91,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,49-54-56,84-92,INSULIN therapy.,"Unfortunately, the majority of CKD patients with type 2 diabetes eventually require insulin therapy.",49 54 56,84,49,84,64,91,1,RO-may_treat,907826,"Unfortunately, the majority of CKD patients with type 2 diabetes eventually require insulin therapy",type 2 diabetes,insulin
503461365,7/16/2014 14:54:06,,1324285716,7/16/2014 14:53:57,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,49,84,,,64,91,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,49-54-56,84-92,INSULIN therapy.,"Unfortunately, the majority of CKD patients with type 2 diabetes eventually require insulin therapy.",49 54 56,84,49,84,64,91,1,RO-may_treat,907826,"Unfortunately, the majority of CKD patients with type 2 diabetes eventually require insulin therapy",type 2 diabetes,insulin
503461365,7/16/2014 14:54:48,,1324285941,7/16/2014 14:54:31,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,49,84,,,64,91,TYPE 2 DIABETES,INSULIN,TYPE 2 DIABETES,49-54-56,84,INSULIN,"Unfortunately, the majority of CKD patients with type 2 diabetes eventually require insulin therapy.",49 54 56,84,49,84,64,91,1,RO-may_treat,907826,"Unfortunately, the majority of CKD patients with type 2 diabetes eventually require insulin therapy",type 2 diabetes,insulin
503461366,7/16/2014 13:50:42,,1324261371,7/16/2014 13:50:29,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,139,191,,,145,199,ANGINA,BEPRIDIL,ANGINA,139,-1,0.9,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of angina during exercise was 5.7 +/- 0.9 minutes with bepridil as opposed to 4.5 +/- 0.8 minutes with placebo (p less than 0.05.",139,,139,191,145,199,1,RO-may_treat,908351,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of angina during exercise was 5.7 +/- 0.9 minutes with bepridil as opposed to 4.5 +/- 0.8 minutes with placebo (p less than 0.05",angina,bepridil
503461366,7/16/2014 13:50:57,,1324261486,7/16/2014 13:50:30,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,139,191,,,145,199,ANGINA,BEPRIDIL,ANGINA,139,-1,0.9,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of angina during exercise was 5.7 +/- 0.9 minutes with bepridil as opposed to 4.5 +/- 0.8 minutes with placebo (p less than 0.05.",139,,139,191,145,199,1,RO-may_treat,908351,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of angina during exercise was 5.7 +/- 0.9 minutes with bepridil as opposed to 4.5 +/- 0.8 minutes with placebo (p less than 0.05",angina,bepridil
503461366,7/16/2014 13:58:58,,1324264757,7/16/2014 13:57:17,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,139,191,,,145,199,ANGINA,BEPRIDIL,ANGINA,139,,,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of angina during exercise was 5.7 +/- 0.9 minutes with bepridil as opposed to 4.5 +/- 0.8 minutes with placebo (p less than 0.05.",139,,139,191,145,199,1,RO-may_treat,908351,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of angina during exercise was 5.7 +/- 0.9 minutes with bepridil as opposed to 4.5 +/- 0.8 minutes with placebo (p less than 0.05",angina,bepridil
503461366,7/16/2014 13:59:14,,1324264863,7/16/2014 13:58:48,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,139,191,,,145,199,ANGINA,BEPRIDIL,ANGINA,139,139,angina,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of angina during exercise was 5.7 +/- 0.9 minutes with bepridil as opposed to 4.5 +/- 0.8 minutes with placebo (p less than 0.05.",139,,139,191,145,199,1,RO-may_treat,908351,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of angina during exercise was 5.7 +/- 0.9 minutes with bepridil as opposed to 4.5 +/- 0.8 minutes with placebo (p less than 0.05",angina,bepridil
503461366,7/16/2014 14:04:45,,1324267137,7/16/2014 14:03:35,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,139,191,,,145,199,ANGINA,BEPRIDIL,onset of ANGINA,130-136-139,,,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of angina during exercise was 5.7 +/- 0.9 minutes with bepridil as opposed to 4.5 +/- 0.8 minutes with placebo (p less than 0.05.",139,,139,191,145,199,1,RO-may_treat,908351,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of angina during exercise was 5.7 +/- 0.9 minutes with bepridil as opposed to 4.5 +/- 0.8 minutes with placebo (p less than 0.05",angina,bepridil
503461366,7/16/2014 14:20:54,,1324273934,7/16/2014 14:20:41,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,139,191,,,145,199,ANGINA,BEPRIDIL,ANGINA,139,,,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of angina during exercise was 5.7 +/- 0.9 minutes with bepridil as opposed to 4.5 +/- 0.8 minutes with placebo (p less than 0.05.",139,,139,191,145,199,1,RO-may_treat,908351,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of angina during exercise was 5.7 +/- 0.9 minutes with bepridil as opposed to 4.5 +/- 0.8 minutes with placebo (p less than 0.05",angina,bepridil
503461366,7/16/2014 14:34:45,,1324279505,7/16/2014 14:34:22,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,139,191,,,145,199,ANGINA,BEPRIDIL,ANGINA,139,,,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of angina during exercise was 5.7 +/- 0.9 minutes with bepridil as opposed to 4.5 +/- 0.8 minutes with placebo (p less than 0.05.",139,,139,191,145,199,1,RO-may_treat,908351,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of angina during exercise was 5.7 +/- 0.9 minutes with bepridil as opposed to 4.5 +/- 0.8 minutes with placebo (p less than 0.05",angina,bepridil
503461366,7/16/2014 14:54:59,,1324286005,7/16/2014 14:54:57,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,139,191,,,145,199,ANGINA,BEPRIDIL,to onset of ANGINA during exercise was,127-130-136-139-146-153-162,,,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of angina during exercise was 5.7 +/- 0.9 minutes with bepridil as opposed to 4.5 +/- 0.8 minutes with placebo (p less than 0.05.",139,,139,191,145,199,1,RO-may_treat,908351,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of angina during exercise was 5.7 +/- 0.9 minutes with bepridil as opposed to 4.5 +/- 0.8 minutes with placebo (p less than 0.05",angina,bepridil
503461366,7/16/2014 14:55:54,,1324286356,7/16/2014 14:55:27,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.72,139,191,,,145,199,ANGINA,BEPRIDIL,ANGINA,139,139,angina,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of angina during exercise was 5.7 +/- 0.9 minutes with bepridil as opposed to 4.5 +/- 0.8 minutes with placebo (p less than 0.05.",139,,139,191,145,199,1,RO-may_treat,908351,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of angina during exercise was 5.7 +/- 0.9 minutes with bepridil as opposed to 4.5 +/- 0.8 minutes with placebo (p less than 0.05",angina,bepridil
503461366,7/16/2014 14:59:53,,1324287890,7/16/2014 14:59:12,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,139,191,,,145,199,ANGINA,BEPRIDIL,ANGINA,139,58,angina,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of angina during exercise was 5.7 +/- 0.9 minutes with bepridil as opposed to 4.5 +/- 0.8 minutes with placebo (p less than 0.05.",139,,139,191,145,199,1,RO-may_treat,908351,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of angina during exercise was 5.7 +/- 0.9 minutes with bepridil as opposed to 4.5 +/- 0.8 minutes with placebo (p less than 0.05",angina,bepridil
503461367,7/16/2014 13:49:33,,1324260925,7/16/2014 13:49:14,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,56,102,,,74,123,METASTATIC LESIONS,LYMPH NODE METASTASIS,METASTATIC LESIONS,56-67,102-108-113,"LYMPH NODE METASTASIS,","When TM expression was compared between the primary and metastatic lesions in the 39 patients who had lymph node metastasis, 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the metastatic lesions.",56 67,102 108 113,56,102,74,123,-1,RO-disease_has_finding,901642,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had lymph node metastasis, 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the metastatic lesions",metastatic lesions,lymph node metastasis
503461367,7/16/2014 13:58:59,,1324264765,7/16/2014 13:58:33,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,56,102,,,74,123,METASTATIC LESIONS,LYMPH NODE METASTASIS,primary and METASTATIC LESIONS,44-52-56-67,102-108-113,"LYMPH NODE METASTASIS,","When TM expression was compared between the primary and metastatic lesions in the 39 patients who had lymph node metastasis, 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the metastatic lesions.",56 67,102 108 113,56,102,74,123,-1,RO-disease_has_finding,901642,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had lymph node metastasis, 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the metastatic lesions",metastatic lesions,lymph node metastasis
503461367,7/16/2014 14:01:51,,1324265887,7/16/2014 14:01:22,instagc,1.0,18960682,GBR,"","",86.29.147.112,56,102,,,74,123,METASTATIC LESIONS,LYMPH NODE METASTASIS,primary and METASTATIC LESIONS,44-52-56-67,102-108-113,"LYMPH NODE METASTASIS,","When TM expression was compared between the primary and metastatic lesions in the 39 patients who had lymph node metastasis, 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the metastatic lesions.",56 67,102 108 113,56,102,74,123,-1,RO-disease_has_finding,901642,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had lymph node metastasis, 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the metastatic lesions",metastatic lesions,lymph node metastasis
503461367,7/16/2014 14:03:10,,1324266471,7/16/2014 14:02:48,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,56,102,,,74,123,METASTATIC LESIONS,LYMPH NODE METASTASIS,METASTATIC LESIONS,56-67,102-108-113,"LYMPH NODE METASTASIS,","When TM expression was compared between the primary and metastatic lesions in the 39 patients who had lymph node metastasis, 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the metastatic lesions.",56 67,102 108 113,56,102,74,123,-1,RO-disease_has_finding,901642,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had lymph node metastasis, 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the metastatic lesions",metastatic lesions,lymph node metastasis
503461367,7/16/2014 14:03:38,,1324266653,7/16/2014 14:01:53,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,56,102,,,74,123,METASTATIC LESIONS,LYMPH NODE METASTASIS,METASTATIC LESIONS,56-67,102-108-113,"LYMPH NODE METASTASIS,","When TM expression was compared between the primary and metastatic lesions in the 39 patients who had lymph node metastasis, 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the metastatic lesions.",56 67,102 108 113,56,102,74,123,-1,RO-disease_has_finding,901642,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had lymph node metastasis, 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the metastatic lesions",metastatic lesions,lymph node metastasis
503461367,7/16/2014 14:27:48,,1324276628,7/16/2014 14:27:18,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,56,102,,,74,123,METASTATIC LESIONS,LYMPH NODE METASTASIS,METASTATIC LESIONS,56-67,102-108-113,"LYMPH NODE METASTASIS,","When TM expression was compared between the primary and metastatic lesions in the 39 patients who had lymph node metastasis, 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the metastatic lesions.",56 67,102 108 113,56,102,74,123,-1,RO-disease_has_finding,901642,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had lymph node metastasis, 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the metastatic lesions",metastatic lesions,lymph node metastasis
503461367,7/16/2014 14:50:50,,1324284725,7/16/2014 14:50:30,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,56,102,,,74,123,METASTATIC LESIONS,LYMPH NODE METASTASIS,METASTATIC LESIONS,56-67,102-108-113,"LYMPH NODE METASTASIS,","When TM expression was compared between the primary and metastatic lesions in the 39 patients who had lymph node metastasis, 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the metastatic lesions.",56 67,102 108 113,56,102,74,123,-1,RO-disease_has_finding,901642,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had lymph node metastasis, 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the metastatic lesions",metastatic lesions,lymph node metastasis
503461367,7/16/2014 14:51:43,,1324284965,7/16/2014 14:51:33,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,56,102,,,74,123,METASTATIC LESIONS,LYMPH NODE METASTASIS,METASTATIC LESIONS,56-67,102-108-113,"LYMPH NODE METASTASIS,","When TM expression was compared between the primary and metastatic lesions in the 39 patients who had lymph node metastasis, 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the metastatic lesions.",56 67,102 108 113,56,102,74,123,-1,RO-disease_has_finding,901642,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had lymph node metastasis, 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the metastatic lesions",metastatic lesions,lymph node metastasis
503461367,7/16/2014 14:53:50,,1324285646,7/16/2014 14:52:46,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,56,102,,,74,123,METASTATIC LESIONS,LYMPH NODE METASTASIS,METASTATIC LESIONS,56-67,102-108-113,"LYMPH NODE METASTASIS,","When TM expression was compared between the primary and metastatic lesions in the 39 patients who had lymph node metastasis, 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the metastatic lesions.",56 67,102 108 113,56,102,74,123,-1,RO-disease_has_finding,901642,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had lymph node metastasis, 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the metastatic lesions",metastatic lesions,lymph node metastasis
503461367,7/16/2014 14:55:25,,1324286171,7/16/2014 14:55:04,tremorgames,1.0,25257192,CAN,ON,Toronto,68.68.13.209,56,102,,,74,123,METASTATIC LESIONS,LYMPH NODE METASTASIS,METASTATIC LESIONS,56-67,102-108-113,"LYMPH NODE METASTASIS,","When TM expression was compared between the primary and metastatic lesions in the 39 patients who had lymph node metastasis, 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the metastatic lesions.",56 67,102 108 113,56,102,74,123,-1,RO-disease_has_finding,901642,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had lymph node metastasis, 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the metastatic lesions",metastatic lesions,lymph node metastasis
503461368,7/16/2014 13:56:31,,1324263636,7/16/2014 13:56:15,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,73,49,,,79,57,CARIES,FLUORIDE,CARIES,73,49-58,FLUORIDE supplements,The scientific evidence supports the efficacy of fluoride supplements in caries prevention but there is weaker support for their effectiveness.,73,49,73,49,79,57,1,RO-may_prevent,907310,The scientific evidence supports the efficacy of fluoride supplements in caries prevention but there is weaker support for their effectiveness,caries,fluoride
503461368,7/16/2014 13:59:17,,1324264884,7/16/2014 13:59:05,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,73,49,,,79,57,CARIES,FLUORIDE,CARIES,73,49-73,FLUORIDE caries,The scientific evidence supports the efficacy of fluoride supplements in caries prevention but there is weaker support for their effectiveness.,73,49,73,49,79,57,1,RO-may_prevent,907310,The scientific evidence supports the efficacy of fluoride supplements in caries prevention but there is weaker support for their effectiveness,caries,fluoride
503461368,7/16/2014 14:10:28,,1324269659,7/16/2014 14:10:12,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,73,49,,,79,57,CARIES,FLUORIDE,CARIES prevention,73-80,49-58,FLUORIDE supplements,The scientific evidence supports the efficacy of fluoride supplements in caries prevention but there is weaker support for their effectiveness.,73,49,73,49,79,57,1,RO-may_prevent,907310,The scientific evidence supports the efficacy of fluoride supplements in caries prevention but there is weaker support for their effectiveness,caries,fluoride
503461368,7/16/2014 14:16:24,,1324272039,7/16/2014 14:16:09,instagc,1.0,13763729,USA,"","",75.182.89.225,73,49,,,79,57,CARIES,FLUORIDE,CARIES,73,49-58,FLUORIDE supplements,The scientific evidence supports the efficacy of fluoride supplements in caries prevention but there is weaker support for their effectiveness.,73,49,73,49,79,57,1,RO-may_prevent,907310,The scientific evidence supports the efficacy of fluoride supplements in caries prevention but there is weaker support for their effectiveness,caries,fluoride
503461368,7/16/2014 14:19:16,,1324273269,7/16/2014 14:19:05,prodege,1.0,17932518,GBR,"","",81.133.61.60,73,49,,,79,57,CARIES,FLUORIDE,CARIES,73,49,FLUORIDE,The scientific evidence supports the efficacy of fluoride supplements in caries prevention but there is weaker support for their effectiveness.,73,49,73,49,79,57,1,RO-may_prevent,907310,The scientific evidence supports the efficacy of fluoride supplements in caries prevention but there is weaker support for their effectiveness,caries,fluoride
503461368,7/16/2014 14:26:16,,1324276003,7/16/2014 14:25:42,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,73,49,,,79,57,CARIES,FLUORIDE,CARIES,73,49-58,FLUORIDE supplements,The scientific evidence supports the efficacy of fluoride supplements in caries prevention but there is weaker support for their effectiveness.,73,49,73,49,79,57,1,RO-may_prevent,907310,The scientific evidence supports the efficacy of fluoride supplements in caries prevention but there is weaker support for their effectiveness,caries,fluoride
503461368,7/16/2014 14:44:12,,1324282807,7/16/2014 14:44:02,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,73,49,,,79,57,CARIES,FLUORIDE,CARIES,73,49,FLUORIDE,The scientific evidence supports the efficacy of fluoride supplements in caries prevention but there is weaker support for their effectiveness.,73,49,73,49,79,57,1,RO-may_prevent,907310,The scientific evidence supports the efficacy of fluoride supplements in caries prevention but there is weaker support for their effectiveness,caries,fluoride
503461368,7/16/2014 14:51:46,,1324284986,7/16/2014 14:51:34,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,73,49,,,79,57,CARIES,FLUORIDE,CARIES,73,49,FLUORIDE,The scientific evidence supports the efficacy of fluoride supplements in caries prevention but there is weaker support for their effectiveness.,73,49,73,49,79,57,1,RO-may_prevent,907310,The scientific evidence supports the efficacy of fluoride supplements in caries prevention but there is weaker support for their effectiveness,caries,fluoride
503461368,7/16/2014 14:52:05,,1324285067,7/16/2014 14:51:32,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.72,73,49,,,79,57,CARIES,FLUORIDE,CARIES,73,49-58,FLUORIDE supplements,The scientific evidence supports the efficacy of fluoride supplements in caries prevention but there is weaker support for their effectiveness.,73,49,73,49,79,57,1,RO-may_prevent,907310,The scientific evidence supports the efficacy of fluoride supplements in caries prevention but there is weaker support for their effectiveness,caries,fluoride
503461368,7/16/2014 14:53:36,,1324285571,7/16/2014 14:52:55,irazoo,1.0,7022810,USA,IA,Ankeny,216.161.121.1,73,49,,,79,57,CARIES,FLUORIDE,CARIES prevention,73-80,49-58,FLUORIDE supplements,The scientific evidence supports the efficacy of fluoride supplements in caries prevention but there is weaker support for their effectiveness.,73,49,73,49,79,57,1,RO-may_prevent,907310,The scientific evidence supports the efficacy of fluoride supplements in caries prevention but there is weaker support for their effectiveness,caries,fluoride
503461369,7/16/2014 13:49:49,,1324261001,7/16/2014 13:49:37,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,76,42,,,86,52,GONORRHOEA,AMPICILLIN,ampicillin treating uncomplicated GONORRHOEA.,42-53-62-76,37-42-53-62-76,oral AMPICILLIN treating uncomplicated gonorrhoea.,Oral cefuroxime axetil compared with oral ampicillin treating uncomplicated gonorrhoea.,76,42,76,42,86,52,1,RO-may_treat,907528,Oral cefuroxime axetil compared with oral ampicillin treating uncomplicated gonorrhoea,gonorrhoea,ampicillin
503461369,7/16/2014 13:52:08,,1324261842,7/16/2014 13:51:46,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,76,42,,,86,52,GONORRHOEA,AMPICILLIN,GONORRHOEA.,76,37-42,oral AMPICILLIN,Oral cefuroxime axetil compared with oral ampicillin treating uncomplicated gonorrhoea.,76,42,76,42,86,52,1,RO-may_treat,907528,Oral cefuroxime axetil compared with oral ampicillin treating uncomplicated gonorrhoea,gonorrhoea,ampicillin
503461369,7/16/2014 13:52:17,,1324261883,7/16/2014 13:51:48,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,76,42,,,86,52,GONORRHOEA,AMPICILLIN,GONORRHOEA.,76,42,AMPICILLIN,Oral cefuroxime axetil compared with oral ampicillin treating uncomplicated gonorrhoea.,76,42,76,42,86,52,1,RO-may_treat,907528,Oral cefuroxime axetil compared with oral ampicillin treating uncomplicated gonorrhoea,gonorrhoea,ampicillin
503461369,7/16/2014 13:53:58,,1324262608,7/16/2014 13:53:41,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,76,42,,,86,52,GONORRHOEA,AMPICILLIN,Oral cefuroxime axetil oral ampicillin uncomplicated GONORRHOEA.,0-5-16-37-42-62-76,0-5-16-37-42-62-76,Oral cefuroxime axetil oral AMPICILLIN uncomplicated gonorrhoea.,Oral cefuroxime axetil compared with oral ampicillin treating uncomplicated gonorrhoea.,76,42,76,42,86,52,1,RO-may_treat,907528,Oral cefuroxime axetil compared with oral ampicillin treating uncomplicated gonorrhoea,gonorrhoea,ampicillin
503461369,7/16/2014 13:58:19,,1324264457,7/16/2014 13:58:08,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,76,42,,,86,52,GONORRHOEA,AMPICILLIN,GONORRHOEA.,76,42-76,AMPICILLIN gonorrhoea.,Oral cefuroxime axetil compared with oral ampicillin treating uncomplicated gonorrhoea.,76,42,76,42,86,52,1,RO-may_treat,907528,Oral cefuroxime axetil compared with oral ampicillin treating uncomplicated gonorrhoea,gonorrhoea,ampicillin
503461369,7/16/2014 14:11:52,,1324270293,7/16/2014 14:11:44,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,76,42,,,86,52,GONORRHOEA,AMPICILLIN,ampicillin treating uncomplicated GONORRHOEA.,42-53-62-76,23-32-37-42-53-62-76,compared with oral AMPICILLIN treating uncomplicated gonorrhoea.,Oral cefuroxime axetil compared with oral ampicillin treating uncomplicated gonorrhoea.,76,42,76,42,86,52,1,RO-may_treat,907528,Oral cefuroxime axetil compared with oral ampicillin treating uncomplicated gonorrhoea,gonorrhoea,ampicillin
503461369,7/16/2014 14:14:22,,1324271346,7/16/2014 14:14:04,vivatic,1.0,25451531,GBR,"","",83.67.28.193,76,42,,,86,52,GONORRHOEA,AMPICILLIN,uncomplicated GONORRHOEA.,62-76,37-42,oral AMPICILLIN,Oral cefuroxime axetil compared with oral ampicillin treating uncomplicated gonorrhoea.,76,42,76,42,86,52,1,RO-may_treat,907528,Oral cefuroxime axetil compared with oral ampicillin treating uncomplicated gonorrhoea,gonorrhoea,ampicillin
503461369,7/16/2014 14:18:28,,1324272917,7/16/2014 14:18:15,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,76,42,,,86,52,GONORRHOEA,AMPICILLIN,uncomplicated GONORRHOEA.,62-76,42-76-37,oral AMPICILLIN gonorrhoea.,Oral cefuroxime axetil compared with oral ampicillin treating uncomplicated gonorrhoea.,76,42,76,42,86,52,1,RO-may_treat,907528,Oral cefuroxime axetil compared with oral ampicillin treating uncomplicated gonorrhoea,gonorrhoea,ampicillin
503461369,7/16/2014 14:25:29,,1324275744,7/16/2014 14:25:09,prodege,1.0,26790109,USA,"","",23.125.64.233,76,42,,,86,52,GONORRHOEA,AMPICILLIN,ampicillin treating uncomplicated GONORRHOEA.,42-53-62-76,23-32-37-42-53-62-76,compared with oral AMPICILLIN treating uncomplicated gonorrhoea.,Oral cefuroxime axetil compared with oral ampicillin treating uncomplicated gonorrhoea.,76,42,76,42,86,52,1,RO-may_treat,907528,Oral cefuroxime axetil compared with oral ampicillin treating uncomplicated gonorrhoea,gonorrhoea,ampicillin
503461369,7/16/2014 14:52:35,,1324285226,7/16/2014 14:52:17,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,76,42,,,86,52,GONORRHOEA,AMPICILLIN,uncomplicated GONORRHOEA.,62-76,42,AMPICILLIN,Oral cefuroxime axetil compared with oral ampicillin treating uncomplicated gonorrhoea.,76,42,76,42,86,52,1,RO-may_treat,907528,Oral cefuroxime axetil compared with oral ampicillin treating uncomplicated gonorrhoea,gonorrhoea,ampicillin
503461370,7/16/2014 13:47:51,,1324260390,7/16/2014 13:47:44,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,90,18,,,112,28,SOFT TISSUE INFECTIONS,AMPICILLIN,SOFT TISSUE INFECTIONS.,90-95-102,0-4-14-18-29,The Sulbactam and AMPICILLIN combination,The Sulbactam and ampicillin combination is an effective combination for the treatment of soft tissue infections.,90 95 102,18,90,18,112,28,1,RO-may_treat,908272,The Sulbactam and ampicillin combination is an effective combination for the treatment of soft tissue infections,soft tissue infections,ampicillin
503461370,7/16/2014 13:57:25,,1324264061,7/16/2014 13:57:06,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,90,18,,,112,28,SOFT TISSUE INFECTIONS,AMPICILLIN,Sulbactam ampicillin combination treatment SOFT TISSUE INFECTIONS.,4-18-29-90-95-102-77,4-18-29-44-90-95-102-77,Sulbactam AMPICILLIN combination an treatment soft tissue infections.,The Sulbactam and ampicillin combination is an effective combination for the treatment of soft tissue infections.,90 95 102,18,90,18,112,28,1,RO-may_treat,908272,The Sulbactam and ampicillin combination is an effective combination for the treatment of soft tissue infections,soft tissue infections,ampicillin
503461370,7/16/2014 14:22:13,,1324274454,7/16/2014 14:21:53,vivatic,1.0,25451531,GBR,"","",83.67.28.193,90,18,,,112,28,SOFT TISSUE INFECTIONS,AMPICILLIN,SOFT TISSUE INFECTIONS.,90-95-102,4-14-18-29,Sulbactam and AMPICILLIN combination,The Sulbactam and ampicillin combination is an effective combination for the treatment of soft tissue infections.,90 95 102,18,90,18,112,28,1,RO-may_treat,908272,The Sulbactam and ampicillin combination is an effective combination for the treatment of soft tissue infections,soft tissue infections,ampicillin
503461370,7/16/2014 14:23:20,,1324274884,7/16/2014 14:23:07,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,90,18,,,112,28,SOFT TISSUE INFECTIONS,AMPICILLIN,SOFT TISSUE INFECTIONS.,90-95-102,18,AMPICILLIN,The Sulbactam and ampicillin combination is an effective combination for the treatment of soft tissue infections.,90 95 102,18,90,18,112,28,1,RO-may_treat,908272,The Sulbactam and ampicillin combination is an effective combination for the treatment of soft tissue infections,soft tissue infections,ampicillin
503461370,7/16/2014 14:30:51,,1324278049,7/16/2014 14:30:38,prodege,1.0,6316959,GBR,"","",46.208.145.114,90,18,,,112,28,SOFT TISSUE INFECTIONS,AMPICILLIN,SOFT TISSUE INFECTIONS.,90-95-102,4-14-18-29,Sulbactam and AMPICILLIN combination,The Sulbactam and ampicillin combination is an effective combination for the treatment of soft tissue infections.,90 95 102,18,90,18,112,28,1,RO-may_treat,908272,The Sulbactam and ampicillin combination is an effective combination for the treatment of soft tissue infections,soft tissue infections,ampicillin
503461370,7/16/2014 14:48:35,,1324284020,7/16/2014 14:48:02,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,90,18,,,112,28,SOFT TISSUE INFECTIONS,AMPICILLIN,SOFT TISSUE INFECTIONS.,90-95-102,0-4-14-18-29,The Sulbactam and AMPICILLIN combination,The Sulbactam and ampicillin combination is an effective combination for the treatment of soft tissue infections.,90 95 102,18,90,18,112,28,1,RO-may_treat,908272,The Sulbactam and ampicillin combination is an effective combination for the treatment of soft tissue infections,soft tissue infections,ampicillin
503461370,7/16/2014 14:56:53,,1324286801,7/16/2014 14:56:40,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,90,18,,,112,28,SOFT TISSUE INFECTIONS,AMPICILLIN,SOFT TISSUE INFECTIONS.,90-95-102,18,AMPICILLIN,The Sulbactam and ampicillin combination is an effective combination for the treatment of soft tissue infections.,90 95 102,18,90,18,112,28,1,RO-may_treat,908272,The Sulbactam and ampicillin combination is an effective combination for the treatment of soft tissue infections,soft tissue infections,ampicillin
503461370,7/16/2014 14:58:05,,1324287273,7/16/2014 14:57:54,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,90,18,,,112,28,SOFT TISSUE INFECTIONS,AMPICILLIN,SOFT TISSUE INFECTIONS.,90-95-102,18,AMPICILLIN,The Sulbactam and ampicillin combination is an effective combination for the treatment of soft tissue infections.,90 95 102,18,90,18,112,28,1,RO-may_treat,908272,The Sulbactam and ampicillin combination is an effective combination for the treatment of soft tissue infections,soft tissue infections,ampicillin
503461370,7/16/2014 15:00:36,,1324288161,7/16/2014 15:00:15,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.72,90,18,,,112,28,SOFT TISSUE INFECTIONS,AMPICILLIN,SOFT TISSUE INFECTIONS.,90-95-102,18,AMPICILLIN,The Sulbactam and ampicillin combination is an effective combination for the treatment of soft tissue infections.,90 95 102,18,90,18,112,28,1,RO-may_treat,908272,The Sulbactam and ampicillin combination is an effective combination for the treatment of soft tissue infections,soft tissue infections,ampicillin
503461370,7/16/2014 15:00:48,,1324288266,7/16/2014 15:00:29,irazoo,1.0,7022810,USA,IA,Ankeny,216.161.121.1,90,18,,,112,28,SOFT TISSUE INFECTIONS,AMPICILLIN,SOFT TISSUE INFECTIONS.,90-95-102,4-14-18-29,Sulbactam and AMPICILLIN combination,The Sulbactam and ampicillin combination is an effective combination for the treatment of soft tissue infections.,90 95 102,18,90,18,112,28,1,RO-may_treat,908272,The Sulbactam and ampicillin combination is an effective combination for the treatment of soft tissue infections,soft tissue infections,ampicillin
503461371,7/16/2014 13:52:06,,1324261833,7/16/2014 13:51:44,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,221,152,,,230,169,KERATOSIS,ACTINIC KERATOSIS,"arsenical keratosis, radiation KERATOSIS, Bowen disease, bowenoid papulosis,",190-200-211-221-232-238-247-256,135-141-151-160-171-178-190-200,"solar keratosis (ACTINIC KERATOSIS, senile keratosis), arsenical keratosis,","This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous-cell carcinoma as disparate as solar keratosis (actinic keratosis, senile keratosis), arsenical keratosis, radiation keratosis, Bowen disease, bowenoid papulosis, squamous-cell carcinoma in situ, as well as variations on the theme of ""keratinocytic intraepidermal neoplasia"" and ""dysplasia,"" and in the cervix by squamous-cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I-III, as well as variations on the theme of ""squamous dysplasia ().",221,160,221,152,230,169,-1,RO-disease_has_finding,901786,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous-cell carcinoma as disparate as solar keratosis (actinic keratosis, senile keratosis), arsenical keratosis, radiation keratosis, Bowen disease, bowenoid papulosis, squamous-cell carcinoma in situ, as well as variations on the theme of &quot;keratinocytic intraepidermal neoplasia&quot; and &quot;dysplasia,&quot; and in the cervix by squamous-cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I-III, as well as variations on the theme of &quot;squamous dysplasia ()",keratosis,actinic keratosis
503461371,7/16/2014 14:02:43,,1324266230,7/16/2014 14:02:16,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,221,152,,,230,169,KERATOSIS,ACTINIC KERATOSIS,"radiation KERATOSIS,",211-221,151-160,"(ACTINIC KERATOSIS,","This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous-cell carcinoma as disparate as solar keratosis (actinic keratosis, senile keratosis), arsenical keratosis, radiation keratosis, Bowen disease, bowenoid papulosis, squamous-cell carcinoma in situ, as well as variations on the theme of ""keratinocytic intraepidermal neoplasia"" and ""dysplasia,"" and in the cervix by squamous-cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I-III, as well as variations on the theme of ""squamous dysplasia ().",221,160,221,152,230,169,-1,RO-disease_has_finding,901786,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous-cell carcinoma as disparate as solar keratosis (actinic keratosis, senile keratosis), arsenical keratosis, radiation keratosis, Bowen disease, bowenoid papulosis, squamous-cell carcinoma in situ, as well as variations on the theme of &quot;keratinocytic intraepidermal neoplasia&quot; and &quot;dysplasia,&quot; and in the cervix by squamous-cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I-III, as well as variations on the theme of &quot;squamous dysplasia ()",keratosis,actinic keratosis
503461371,7/16/2014 14:07:37,,1324268414,7/16/2014 14:06:59,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,221,152,,,230,169,KERATOSIS,ACTINIC KERATOSIS,"radiation KERATOSIS,",211-221,160-171-178-151,"(ACTINIC KERATOSIS, senile keratosis),","This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous-cell carcinoma as disparate as solar keratosis (actinic keratosis, senile keratosis), arsenical keratosis, radiation keratosis, Bowen disease, bowenoid papulosis, squamous-cell carcinoma in situ, as well as variations on the theme of ""keratinocytic intraepidermal neoplasia"" and ""dysplasia,"" and in the cervix by squamous-cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I-III, as well as variations on the theme of ""squamous dysplasia ().",221,160,221,152,230,169,-1,RO-disease_has_finding,901786,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous-cell carcinoma as disparate as solar keratosis (actinic keratosis, senile keratosis), arsenical keratosis, radiation keratosis, Bowen disease, bowenoid papulosis, squamous-cell carcinoma in situ, as well as variations on the theme of &quot;keratinocytic intraepidermal neoplasia&quot; and &quot;dysplasia,&quot; and in the cervix by squamous-cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I-III, as well as variations on the theme of &quot;squamous dysplasia ()",keratosis,actinic keratosis
503461371,7/16/2014 14:08:48,,1324268894,7/16/2014 14:08:39,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,221,152,,,230,169,KERATOSIS,ACTINIC KERATOSIS,"arsenical keratosis, radiation KERATOSIS, Bowen disease, bowenoid",190-200-211-221-232-238-247,135-141-151-160-171-178-190,"solar keratosis (ACTINIC KERATOSIS, senile keratosis), arsenical","This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous-cell carcinoma as disparate as solar keratosis (actinic keratosis, senile keratosis), arsenical keratosis, radiation keratosis, Bowen disease, bowenoid papulosis, squamous-cell carcinoma in situ, as well as variations on the theme of ""keratinocytic intraepidermal neoplasia"" and ""dysplasia,"" and in the cervix by squamous-cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I-III, as well as variations on the theme of ""squamous dysplasia ().",221,160,221,152,230,169,-1,RO-disease_has_finding,901786,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous-cell carcinoma as disparate as solar keratosis (actinic keratosis, senile keratosis), arsenical keratosis, radiation keratosis, Bowen disease, bowenoid papulosis, squamous-cell carcinoma in situ, as well as variations on the theme of &quot;keratinocytic intraepidermal neoplasia&quot; and &quot;dysplasia,&quot; and in the cervix by squamous-cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I-III, as well as variations on the theme of &quot;squamous dysplasia ()",keratosis,actinic keratosis
503461371,7/16/2014 14:10:10,,1324269546,7/16/2014 14:09:52,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,221,152,,,230,169,KERATOSIS,ACTINIC KERATOSIS,"radiation KERATOSIS,",211-221,151-160,"(ACTINIC KERATOSIS,","This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous-cell carcinoma as disparate as solar keratosis (actinic keratosis, senile keratosis), arsenical keratosis, radiation keratosis, Bowen disease, bowenoid papulosis, squamous-cell carcinoma in situ, as well as variations on the theme of ""keratinocytic intraepidermal neoplasia"" and ""dysplasia,"" and in the cervix by squamous-cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I-III, as well as variations on the theme of ""squamous dysplasia ().",221,160,221,152,230,169,-1,RO-disease_has_finding,901786,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous-cell carcinoma as disparate as solar keratosis (actinic keratosis, senile keratosis), arsenical keratosis, radiation keratosis, Bowen disease, bowenoid papulosis, squamous-cell carcinoma in situ, as well as variations on the theme of &quot;keratinocytic intraepidermal neoplasia&quot; and &quot;dysplasia,&quot; and in the cervix by squamous-cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I-III, as well as variations on the theme of &quot;squamous dysplasia ()",keratosis,actinic keratosis
503461371,7/16/2014 14:18:20,,1324272857,7/16/2014 14:17:34,vivatic,1.0,25451531,GBR,"","",83.67.28.193,221,152,,,230,169,KERATOSIS,ACTINIC KERATOSIS,"radiation KERATOSIS,",211-221,151-160,"(ACTINIC KERATOSIS,","This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous-cell carcinoma as disparate as solar keratosis (actinic keratosis, senile keratosis), arsenical keratosis, radiation keratosis, Bowen disease, bowenoid papulosis, squamous-cell carcinoma in situ, as well as variations on the theme of ""keratinocytic intraepidermal neoplasia"" and ""dysplasia,"" and in the cervix by squamous-cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I-III, as well as variations on the theme of ""squamous dysplasia ().",221,160,221,152,230,169,-1,RO-disease_has_finding,901786,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous-cell carcinoma as disparate as solar keratosis (actinic keratosis, senile keratosis), arsenical keratosis, radiation keratosis, Bowen disease, bowenoid papulosis, squamous-cell carcinoma in situ, as well as variations on the theme of &quot;keratinocytic intraepidermal neoplasia&quot; and &quot;dysplasia,&quot; and in the cervix by squamous-cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I-III, as well as variations on the theme of &quot;squamous dysplasia ()",keratosis,actinic keratosis
503461371,7/16/2014 14:27:19,,1324276392,7/16/2014 14:26:57,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,221,152,,,230,169,KERATOSIS,ACTINIC KERATOSIS,"KERATOSIS,",221,151-160,"(ACTINIC KERATOSIS,","This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous-cell carcinoma as disparate as solar keratosis (actinic keratosis, senile keratosis), arsenical keratosis, radiation keratosis, Bowen disease, bowenoid papulosis, squamous-cell carcinoma in situ, as well as variations on the theme of ""keratinocytic intraepidermal neoplasia"" and ""dysplasia,"" and in the cervix by squamous-cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I-III, as well as variations on the theme of ""squamous dysplasia ().",221,160,221,152,230,169,-1,RO-disease_has_finding,901786,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous-cell carcinoma as disparate as solar keratosis (actinic keratosis, senile keratosis), arsenical keratosis, radiation keratosis, Bowen disease, bowenoid papulosis, squamous-cell carcinoma in situ, as well as variations on the theme of &quot;keratinocytic intraepidermal neoplasia&quot; and &quot;dysplasia,&quot; and in the cervix by squamous-cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I-III, as well as variations on the theme of &quot;squamous dysplasia ()",keratosis,actinic keratosis
503461371,7/16/2014 14:31:43,,1324278347,7/16/2014 14:31:12,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,221,152,,,230,169,KERATOSIS,ACTINIC KERATOSIS,"KERATOSIS,",221,151-160,"(ACTINIC KERATOSIS,","This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous-cell carcinoma as disparate as solar keratosis (actinic keratosis, senile keratosis), arsenical keratosis, radiation keratosis, Bowen disease, bowenoid papulosis, squamous-cell carcinoma in situ, as well as variations on the theme of ""keratinocytic intraepidermal neoplasia"" and ""dysplasia,"" and in the cervix by squamous-cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I-III, as well as variations on the theme of ""squamous dysplasia ().",221,160,221,152,230,169,-1,RO-disease_has_finding,901786,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous-cell carcinoma as disparate as solar keratosis (actinic keratosis, senile keratosis), arsenical keratosis, radiation keratosis, Bowen disease, bowenoid papulosis, squamous-cell carcinoma in situ, as well as variations on the theme of &quot;keratinocytic intraepidermal neoplasia&quot; and &quot;dysplasia,&quot; and in the cervix by squamous-cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I-III, as well as variations on the theme of &quot;squamous dysplasia ()",keratosis,actinic keratosis
503461371,7/16/2014 14:41:42,,1324282106,7/16/2014 14:41:16,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,221,152,,,230,169,KERATOSIS,ACTINIC KERATOSIS,"arsenical keratosis, radiation KERATOSIS,",190-200-211-221,135-141-151-160-171-178-190-200-211-221,"solar keratosis (ACTINIC KERATOSIS, senile keratosis), arsenical keratosis, radiation keratosis,","This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous-cell carcinoma as disparate as solar keratosis (actinic keratosis, senile keratosis), arsenical keratosis, radiation keratosis, Bowen disease, bowenoid papulosis, squamous-cell carcinoma in situ, as well as variations on the theme of ""keratinocytic intraepidermal neoplasia"" and ""dysplasia,"" and in the cervix by squamous-cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I-III, as well as variations on the theme of ""squamous dysplasia ().",221,160,221,152,230,169,-1,RO-disease_has_finding,901786,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous-cell carcinoma as disparate as solar keratosis (actinic keratosis, senile keratosis), arsenical keratosis, radiation keratosis, Bowen disease, bowenoid papulosis, squamous-cell carcinoma in situ, as well as variations on the theme of &quot;keratinocytic intraepidermal neoplasia&quot; and &quot;dysplasia,&quot; and in the cervix by squamous-cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I-III, as well as variations on the theme of &quot;squamous dysplasia ()",keratosis,actinic keratosis
503461371,7/16/2014 14:49:45,,1324284408,7/16/2014 14:49:26,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,221,152,,,230,169,KERATOSIS,ACTINIC KERATOSIS,"radiation KERATOSIS,",211-221,135-141-151-160-171-178,"solar keratosis (ACTINIC KERATOSIS, senile keratosis),","This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous-cell carcinoma as disparate as solar keratosis (actinic keratosis, senile keratosis), arsenical keratosis, radiation keratosis, Bowen disease, bowenoid papulosis, squamous-cell carcinoma in situ, as well as variations on the theme of ""keratinocytic intraepidermal neoplasia"" and ""dysplasia,"" and in the cervix by squamous-cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I-III, as well as variations on the theme of ""squamous dysplasia ().",221,160,221,152,230,169,-1,RO-disease_has_finding,901786,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous-cell carcinoma as disparate as solar keratosis (actinic keratosis, senile keratosis), arsenical keratosis, radiation keratosis, Bowen disease, bowenoid papulosis, squamous-cell carcinoma in situ, as well as variations on the theme of &quot;keratinocytic intraepidermal neoplasia&quot; and &quot;dysplasia,&quot; and in the cervix by squamous-cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I-III, as well as variations on the theme of &quot;squamous dysplasia ()",keratosis,actinic keratosis
503461372,7/16/2014 13:46:11,,1324259811,7/16/2014 13:45:16,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,12,74,,,24,104,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS,COLON CANCER,12-18,74-83-95,FAMILIAL ADENOMATOUS POLYPOSIS,The risk of colon cancer is extreme in the rare colon cancer syndromes of familial adenomatous polyposis and hereditary nonpolyposis colon cancer.,12 18,74 83 95,12,74,24,104,-1,RO-has_manifestation,906092,The risk of colon cancer is extreme in the rare colon cancer syndromes of familial adenomatous polyposis and hereditary nonpolyposis colon cancer,colon cancer,familial adenomatous polyposis
503461372,7/16/2014 13:49:35,,1324260937,7/16/2014 13:49:20,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,12,74,,,24,104,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS,COLON CANCER,12-18,74-83-95,FAMILIAL ADENOMATOUS POLYPOSIS,The risk of colon cancer is extreme in the rare colon cancer syndromes of familial adenomatous polyposis and hereditary nonpolyposis colon cancer.,12 18,74 83 95,12,74,24,104,-1,RO-has_manifestation,906092,The risk of colon cancer is extreme in the rare colon cancer syndromes of familial adenomatous polyposis and hereditary nonpolyposis colon cancer,colon cancer,familial adenomatous polyposis
503461372,7/16/2014 13:50:34,,1324261313,7/16/2014 13:50:04,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,12,74,,,24,104,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS,COLON CANCER,12-18,74-83-95-109-120-105,FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis,The risk of colon cancer is extreme in the rare colon cancer syndromes of familial adenomatous polyposis and hereditary nonpolyposis colon cancer.,12 18,74 83 95,12,74,24,104,-1,RO-has_manifestation,906092,The risk of colon cancer is extreme in the rare colon cancer syndromes of familial adenomatous polyposis and hereditary nonpolyposis colon cancer,colon cancer,familial adenomatous polyposis
503461372,7/16/2014 13:51:13,,1324261554,7/16/2014 13:50:50,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,12,74,,,24,104,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS,COLON CANCER,12-18,74-83-95,FAMILIAL ADENOMATOUS POLYPOSIS,The risk of colon cancer is extreme in the rare colon cancer syndromes of familial adenomatous polyposis and hereditary nonpolyposis colon cancer.,12 18,74 83 95,12,74,24,104,-1,RO-has_manifestation,906092,The risk of colon cancer is extreme in the rare colon cancer syndromes of familial adenomatous polyposis and hereditary nonpolyposis colon cancer,colon cancer,familial adenomatous polyposis
503461372,7/16/2014 14:03:45,,1324266709,7/16/2014 14:03:33,instagc,1.0,18960682,GBR,"","",86.29.147.112,12,74,,,24,104,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS,COLON CANCER,12-18,74-83-95,FAMILIAL ADENOMATOUS POLYPOSIS,The risk of colon cancer is extreme in the rare colon cancer syndromes of familial adenomatous polyposis and hereditary nonpolyposis colon cancer.,12 18,74 83 95,12,74,24,104,-1,RO-has_manifestation,906092,The risk of colon cancer is extreme in the rare colon cancer syndromes of familial adenomatous polyposis and hereditary nonpolyposis colon cancer,colon cancer,familial adenomatous polyposis
503461372,7/16/2014 14:29:37,,1324277458,7/16/2014 14:29:13,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,12,74,,,24,104,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS,COLON CANCER,12-18,74-83-95,FAMILIAL ADENOMATOUS POLYPOSIS,The risk of colon cancer is extreme in the rare colon cancer syndromes of familial adenomatous polyposis and hereditary nonpolyposis colon cancer.,12 18,74 83 95,12,74,24,104,-1,RO-has_manifestation,906092,The risk of colon cancer is extreme in the rare colon cancer syndromes of familial adenomatous polyposis and hereditary nonpolyposis colon cancer,colon cancer,familial adenomatous polyposis
503461372,7/16/2014 14:50:08,,1324284531,7/16/2014 14:49:47,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,12,74,,,24,104,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS,COLON CANCER,12-18,74-83-95,FAMILIAL ADENOMATOUS POLYPOSIS,The risk of colon cancer is extreme in the rare colon cancer syndromes of familial adenomatous polyposis and hereditary nonpolyposis colon cancer.,12 18,74 83 95,12,74,24,104,-1,RO-has_manifestation,906092,The risk of colon cancer is extreme in the rare colon cancer syndromes of familial adenomatous polyposis and hereditary nonpolyposis colon cancer,colon cancer,familial adenomatous polyposis
503461372,7/16/2014 14:51:00,,1324284786,7/16/2014 14:50:42,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,12,74,,,24,104,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS,COLON CANCER,12-18,74-83-95,FAMILIAL ADENOMATOUS POLYPOSIS,The risk of colon cancer is extreme in the rare colon cancer syndromes of familial adenomatous polyposis and hereditary nonpolyposis colon cancer.,12 18,74 83 95,12,74,24,104,-1,RO-has_manifestation,906092,The risk of colon cancer is extreme in the rare colon cancer syndromes of familial adenomatous polyposis and hereditary nonpolyposis colon cancer,colon cancer,familial adenomatous polyposis
503461372,7/16/2014 14:56:54,,1324286819,7/16/2014 14:56:34,irazoo,1.0,7022810,USA,IA,Ankeny,216.161.121.1,12,74,,,24,104,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS,COLON CANCER,12-18,74-83-95,FAMILIAL ADENOMATOUS POLYPOSIS,The risk of colon cancer is extreme in the rare colon cancer syndromes of familial adenomatous polyposis and hereditary nonpolyposis colon cancer.,12 18,74 83 95,12,74,24,104,-1,RO-has_manifestation,906092,The risk of colon cancer is extreme in the rare colon cancer syndromes of familial adenomatous polyposis and hereditary nonpolyposis colon cancer,colon cancer,familial adenomatous polyposis
503461372,7/16/2014 14:57:01,,1324286841,7/16/2014 14:56:46,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,12,74,,,24,104,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS,COLON CANCER,12-18,74-83-95,FAMILIAL ADENOMATOUS POLYPOSIS,The risk of colon cancer is extreme in the rare colon cancer syndromes of familial adenomatous polyposis and hereditary nonpolyposis colon cancer.,12 18,74 83 95,12,74,24,104,-1,RO-has_manifestation,906092,The risk of colon cancer is extreme in the rare colon cancer syndromes of familial adenomatous polyposis and hereditary nonpolyposis colon cancer,colon cancer,familial adenomatous polyposis
503461373,7/16/2014 13:46:20,,1324259845,7/16/2014 13:46:09,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,82,126,,,90,134,HEADACHE,MIGRAINE,HEADACHE,82,116-126,childhood MIGRAINE),"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, headache and other equivalents of childhood migraine) is often related in the literature to a ""neuro-vegetative dysfunction"", by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",82,126,82,126,90,134,-1,RO-has_definitional_manifestation,904903,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, headache and other equivalents of childhood migraine) is often related in the literature to a &quot;neuro-vegetative dysfunction&quot;, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression",headache,migraine
503461373,7/16/2014 13:55:51,,1324263329,7/16/2014 13:55:38,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,82,126,,,90,134,HEADACHE,MIGRAINE,HEADACHE,82,116-126,childhood MIGRAINE),"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, headache and other equivalents of childhood migraine) is often related in the literature to a ""neuro-vegetative dysfunction"", by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",82,126,82,126,90,134,-1,RO-has_definitional_manifestation,904903,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, headache and other equivalents of childhood migraine) is often related in the literature to a &quot;neuro-vegetative dysfunction&quot;, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression",headache,migraine
503461373,7/16/2014 13:58:18,,1324264454,7/16/2014 13:57:57,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,82,126,,,90,134,HEADACHE,MIGRAINE,"pain, cyclic vomiting, HEADACHE and other equivalents",59-65-72-82-91-95-101,101-113-116-126,equivalents of childhood MIGRAINE),"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, headache and other equivalents of childhood migraine) is often related in the literature to a ""neuro-vegetative dysfunction"", by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",82,126,82,126,90,134,-1,RO-has_definitional_manifestation,904903,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, headache and other equivalents of childhood migraine) is often related in the literature to a &quot;neuro-vegetative dysfunction&quot;, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression",headache,migraine
503461373,7/16/2014 14:11:06,,1324269957,7/16/2014 14:10:45,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,82,126,,,90,134,HEADACHE,MIGRAINE,HEADACHE,82,126,MIGRAINE),"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, headache and other equivalents of childhood migraine) is often related in the literature to a ""neuro-vegetative dysfunction"", by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",82,126,82,126,90,134,-1,RO-has_definitional_manifestation,904903,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, headache and other equivalents of childhood migraine) is often related in the literature to a &quot;neuro-vegetative dysfunction&quot;, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression",headache,migraine
503461373,7/16/2014 14:16:26,,1324272051,7/16/2014 14:15:52,vivatic,1.0,25451531,GBR,"","",83.67.28.193,82,126,,,90,134,HEADACHE,MIGRAINE,HEADACHE and other equivalents of childhood migraine),82-91-95-101-113-116-126,82-91-101-113-116-126-95,headache and other equivalents of childhood MIGRAINE),"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, headache and other equivalents of childhood migraine) is often related in the literature to a ""neuro-vegetative dysfunction"", by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",82,126,82,126,90,134,-1,RO-has_definitional_manifestation,904903,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, headache and other equivalents of childhood migraine) is often related in the literature to a &quot;neuro-vegetative dysfunction&quot;, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression",headache,migraine
503461373,7/16/2014 14:23:02,,1324274793,7/16/2014 14:22:47,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,82,126,,,90,134,HEADACHE,MIGRAINE,HEADACHE,82,126-116,childhood MIGRAINE),"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, headache and other equivalents of childhood migraine) is often related in the literature to a ""neuro-vegetative dysfunction"", by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",82,126,82,126,90,134,-1,RO-has_definitional_manifestation,904903,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, headache and other equivalents of childhood migraine) is often related in the literature to a &quot;neuro-vegetative dysfunction&quot;, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression",headache,migraine
503461373,7/16/2014 14:31:49,,1324278364,7/16/2014 14:31:34,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,82,126,,,90,134,HEADACHE,MIGRAINE,HEADACHE,82,116-126,childhood MIGRAINE),"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, headache and other equivalents of childhood migraine) is often related in the literature to a ""neuro-vegetative dysfunction"", by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",82,126,82,126,90,134,-1,RO-has_definitional_manifestation,904903,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, headache and other equivalents of childhood migraine) is often related in the literature to a &quot;neuro-vegetative dysfunction&quot;, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression",headache,migraine
503461373,7/16/2014 14:32:23,,1324278590,7/16/2014 14:31:04,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,82,126,,,90,134,HEADACHE,MIGRAINE,HEADACHE,82,126,MIGRAINE),"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, headache and other equivalents of childhood migraine) is often related in the literature to a ""neuro-vegetative dysfunction"", by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",82,126,82,126,90,134,-1,RO-has_definitional_manifestation,904903,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, headache and other equivalents of childhood migraine) is often related in the literature to a &quot;neuro-vegetative dysfunction&quot;, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression",headache,migraine
503461373,7/16/2014 14:39:42,,1324281547,7/16/2014 14:39:27,prodege,1.0,6316959,GBR,"","",46.208.145.114,82,126,,,90,134,HEADACHE,MIGRAINE,HEADACHE,82,116-126,childhood MIGRAINE),"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, headache and other equivalents of childhood migraine) is often related in the literature to a ""neuro-vegetative dysfunction"", by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",82,126,82,126,90,134,-1,RO-has_definitional_manifestation,904903,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, headache and other equivalents of childhood migraine) is often related in the literature to a &quot;neuro-vegetative dysfunction&quot;, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression",headache,migraine
503461373,7/16/2014 14:47:11,,1324283594,7/16/2014 14:45:06,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,82,126,,,90,134,HEADACHE,MIGRAINE,"abdominal pain, cyclic vomiting, HEADACHE childhood migraine)",49-59-65-72-82-116-126,20-29-49-59-65-72-82-116-126,"periodic syndrome abdominal pain, cyclic vomiting, headache childhood MIGRAINE)","The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, headache and other equivalents of childhood migraine) is often related in the literature to a ""neuro-vegetative dysfunction"", by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",82,126,82,126,90,134,-1,RO-has_definitional_manifestation,904903,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, headache and other equivalents of childhood migraine) is often related in the literature to a &quot;neuro-vegetative dysfunction&quot;, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression",headache,migraine
503461374,7/16/2014 13:45:16,,1324259541,7/16/2014 13:44:59,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,48,15,,,55,32,ANXIETY,ANXIETY DISORDERS,ANXIETY,48,15-23,ANXIETY DISORDERS,"a ,   b ,   c  Anxiety Disorders  Management of anxiety disorders and short-term relief of anxiety or anxiety associated with depressive symptoms.",48,15 23,48,15,55,32,-1,RO-has_definitional_manifestation,904525,"a ,   b ,   c  Anxiety Disorders  Management of anxiety disorders and short-term relief of anxiety or anxiety associated with depressive symptoms",anxiety,Anxiety Disorders
503461374,7/16/2014 13:47:17,,1324260194,7/16/2014 13:47:00,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,48,15,,,55,32,ANXIETY,ANXIETY DISORDERS,ANXIETY disorders,48-56,15-23,ANXIETY DISORDERS,"a ,   b ,   c  Anxiety Disorders  Management of anxiety disorders and short-term relief of anxiety or anxiety associated with depressive symptoms.",48,15 23,48,15,55,32,-1,RO-has_definitional_manifestation,904525,"a ,   b ,   c  Anxiety Disorders  Management of anxiety disorders and short-term relief of anxiety or anxiety associated with depressive symptoms",anxiety,Anxiety Disorders
503461374,7/16/2014 14:01:50,,1324265876,7/16/2014 14:01:22,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,48,15,,,55,32,ANXIETY,ANXIETY DISORDERS,ANXIETY,48,15-23,ANXIETY DISORDERS,"a ,   b ,   c  Anxiety Disorders  Management of anxiety disorders and short-term relief of anxiety or anxiety associated with depressive symptoms.",48,15 23,48,15,55,32,-1,RO-has_definitional_manifestation,904525,"a ,   b ,   c  Anxiety Disorders  Management of anxiety disorders and short-term relief of anxiety or anxiety associated with depressive symptoms",anxiety,Anxiety Disorders
503461374,7/16/2014 14:12:25,,1324270542,7/16/2014 14:11:45,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,48,15,,,55,32,ANXIETY,ANXIETY DISORDERS,ANXIETY disorders,48-56,15-23,ANXIETY DISORDERS,"a ,   b ,   c  Anxiety Disorders  Management of anxiety disorders and short-term relief of anxiety or anxiety associated with depressive symptoms.",48,15 23,48,15,55,32,-1,RO-has_definitional_manifestation,904525,"a ,   b ,   c  Anxiety Disorders  Management of anxiety disorders and short-term relief of anxiety or anxiety associated with depressive symptoms",anxiety,Anxiety Disorders
503461374,7/16/2014 14:18:40,,1324273014,7/16/2014 14:18:21,vivatic,1.0,25451531,GBR,"","",83.67.28.193,48,15,,,55,32,ANXIETY,ANXIETY DISORDERS,ANXIETY disorders,48-56,15-23,ANXIETY DISORDERS,"a ,   b ,   c  Anxiety Disorders  Management of anxiety disorders and short-term relief of anxiety or anxiety associated with depressive symptoms.",48,15 23,48,15,55,32,-1,RO-has_definitional_manifestation,904525,"a ,   b ,   c  Anxiety Disorders  Management of anxiety disorders and short-term relief of anxiety or anxiety associated with depressive symptoms",anxiety,Anxiety Disorders
503461374,7/16/2014 14:22:46,,1324274680,7/16/2014 14:22:29,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,48,15,,,55,32,ANXIETY,ANXIETY DISORDERS,ANXIETY disorders,48-56,15-23,ANXIETY DISORDERS,"a ,   b ,   c  Anxiety Disorders  Management of anxiety disorders and short-term relief of anxiety or anxiety associated with depressive symptoms.",48,15 23,48,15,55,32,-1,RO-has_definitional_manifestation,904525,"a ,   b ,   c  Anxiety Disorders  Management of anxiety disorders and short-term relief of anxiety or anxiety associated with depressive symptoms",anxiety,Anxiety Disorders
503461374,7/16/2014 14:25:22,,1324275686,7/16/2014 14:24:58,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,48,15,,,55,32,ANXIETY,ANXIETY DISORDERS,ANXIETY disorders,48-56,8-15-23,", ANXIETY DISORDERS","a ,   b ,   c  Anxiety Disorders  Management of anxiety disorders and short-term relief of anxiety or anxiety associated with depressive symptoms.",48,15 23,48,15,55,32,-1,RO-has_definitional_manifestation,904525,"a ,   b ,   c  Anxiety Disorders  Management of anxiety disorders and short-term relief of anxiety or anxiety associated with depressive symptoms",anxiety,Anxiety Disorders
503461374,7/16/2014 14:26:17,,1324276014,7/16/2014 14:25:55,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,48,15,,,55,32,ANXIETY,ANXIETY DISORDERS,Anxiety Disorders ANXIETY,15-48-23,8-15-23-48,", ANXIETY DISORDERS anxiety","a ,   b ,   c  Anxiety Disorders  Management of anxiety disorders and short-term relief of anxiety or anxiety associated with depressive symptoms.",48,15 23,48,15,55,32,-1,RO-has_definitional_manifestation,904525,"a ,   b ,   c  Anxiety Disorders  Management of anxiety disorders and short-term relief of anxiety or anxiety associated with depressive symptoms",anxiety,Anxiety Disorders
503461374,7/16/2014 14:32:52,,1324278762,7/16/2014 14:32:22,prodege,1.0,6316959,GBR,"","",46.208.145.114,48,15,,,55,32,ANXIETY,ANXIETY DISORDERS,ANXIETY disorders,48-56,8-15-23-34,", ANXIETY DISORDERS Management","a ,   b ,   c  Anxiety Disorders  Management of anxiety disorders and short-term relief of anxiety or anxiety associated with depressive symptoms.",48,15 23,48,15,55,32,-1,RO-has_definitional_manifestation,904525,"a ,   b ,   c  Anxiety Disorders  Management of anxiety disorders and short-term relief of anxiety or anxiety associated with depressive symptoms",anxiety,Anxiety Disorders
503461374,7/16/2014 14:40:32,,1324281777,7/16/2014 14:40:17,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,48,15,,,55,32,ANXIETY,ANXIETY DISORDERS,ANXIETY disorders,48-56,8-15-23,", ANXIETY DISORDERS","a ,   b ,   c  Anxiety Disorders  Management of anxiety disorders and short-term relief of anxiety or anxiety associated with depressive symptoms.",48,15 23,48,15,55,32,-1,RO-has_definitional_manifestation,904525,"a ,   b ,   c  Anxiety Disorders  Management of anxiety disorders and short-term relief of anxiety or anxiety associated with depressive symptoms",anxiety,Anxiety Disorders
503461375,7/16/2014 13:43:00,,1324258737,7/16/2014 13:42:46,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,0,54,,,9,79,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA,DYSPLASIA,0,54-70,INTRAEPITHELIAL NEOPLASIA,Dysplasia in the gastrointestinal tract is defined as intraepithelial neoplasia (IEN) according to the WHO nomenclature.,0,54 70,0,54,9,79,-1,RO-disease_has_finding,901698,Dysplasia in the gastrointestinal tract is defined as intraepithelial neoplasia (IEN) according to the WHO nomenclature,Dysplasia,intraepithelial neoplasia
503461375,7/16/2014 13:44:52,,1324259391,7/16/2014 13:44:44,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,0,54,,,9,79,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA,DYSPLASIA,0,54-70,INTRAEPITHELIAL NEOPLASIA,Dysplasia in the gastrointestinal tract is defined as intraepithelial neoplasia (IEN) according to the WHO nomenclature.,0,54 70,0,54,9,79,-1,RO-disease_has_finding,901698,Dysplasia in the gastrointestinal tract is defined as intraepithelial neoplasia (IEN) according to the WHO nomenclature,Dysplasia,intraepithelial neoplasia
503461375,7/16/2014 13:46:26,,1324259891,7/16/2014 13:46:12,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,0,54,,,9,79,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA,DYSPLASIA,0,54-70,INTRAEPITHELIAL NEOPLASIA,Dysplasia in the gastrointestinal tract is defined as intraepithelial neoplasia (IEN) according to the WHO nomenclature.,0,54 70,0,54,9,79,-1,RO-disease_has_finding,901698,Dysplasia in the gastrointestinal tract is defined as intraepithelial neoplasia (IEN) according to the WHO nomenclature,Dysplasia,intraepithelial neoplasia
503461375,7/16/2014 13:51:22,,1324261600,7/16/2014 13:51:02,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,0,54,,,9,79,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA,DYSPLASIA gastrointestinal tract intraepithelial neoplasia (IEN) nomenclature.,0-17-34-54-70-80-107,0-17-54-70-107-34,Dysplasia gastrointestinal tract INTRAEPITHELIAL NEOPLASIA nomenclature.,Dysplasia in the gastrointestinal tract is defined as intraepithelial neoplasia (IEN) according to the WHO nomenclature.,0,54 70,0,54,9,79,-1,RO-disease_has_finding,901698,Dysplasia in the gastrointestinal tract is defined as intraepithelial neoplasia (IEN) according to the WHO nomenclature,Dysplasia,intraepithelial neoplasia
503461375,7/16/2014 13:51:22,,1324261617,7/16/2014 13:50:43,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,0,54,,,9,79,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA,DYSPLASIA gastrointestinal intraepithelial neoplasia (IEN),0-17-54-70-80,0-54-70-80-17,Dysplasia gastrointestinal INTRAEPITHELIAL NEOPLASIA (IEN),Dysplasia in the gastrointestinal tract is defined as intraepithelial neoplasia (IEN) according to the WHO nomenclature.,0,54 70,0,54,9,79,-1,RO-disease_has_finding,901698,Dysplasia in the gastrointestinal tract is defined as intraepithelial neoplasia (IEN) according to the WHO nomenclature,Dysplasia,intraepithelial neoplasia
503461375,7/16/2014 13:53:24,,1324262336,7/16/2014 13:53:12,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,0,54,,,9,79,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA,DYSPLASIA,0,54-70-80,INTRAEPITHELIAL NEOPLASIA (IEN),Dysplasia in the gastrointestinal tract is defined as intraepithelial neoplasia (IEN) according to the WHO nomenclature.,0,54 70,0,54,9,79,-1,RO-disease_has_finding,901698,Dysplasia in the gastrointestinal tract is defined as intraepithelial neoplasia (IEN) according to the WHO nomenclature,Dysplasia,intraepithelial neoplasia
503461375,7/16/2014 13:55:25,,1324263142,7/16/2014 13:55:01,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,0,54,,,9,79,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA,DYSPLASIA in the gastrointestinal tract,0-10-13-17-34,54-70-80,INTRAEPITHELIAL NEOPLASIA (IEN),Dysplasia in the gastrointestinal tract is defined as intraepithelial neoplasia (IEN) according to the WHO nomenclature.,0,54 70,0,54,9,79,-1,RO-disease_has_finding,901698,Dysplasia in the gastrointestinal tract is defined as intraepithelial neoplasia (IEN) according to the WHO nomenclature,Dysplasia,intraepithelial neoplasia
503461375,7/16/2014 14:00:14,,1324265281,7/16/2014 14:00:03,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,0,54,,,9,79,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA,DYSPLASIA,0,0-54-70,Dysplasia INTRAEPITHELIAL NEOPLASIA,Dysplasia in the gastrointestinal tract is defined as intraepithelial neoplasia (IEN) according to the WHO nomenclature.,0,54 70,0,54,9,79,-1,RO-disease_has_finding,901698,Dysplasia in the gastrointestinal tract is defined as intraepithelial neoplasia (IEN) according to the WHO nomenclature,Dysplasia,intraepithelial neoplasia
503461375,7/16/2014 14:15:42,,1324271787,7/16/2014 14:15:28,instagc,1.0,13763729,USA,"","",75.182.89.225,0,54,,,9,79,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA,DYSPLASIA,0,54-70,INTRAEPITHELIAL NEOPLASIA,Dysplasia in the gastrointestinal tract is defined as intraepithelial neoplasia (IEN) according to the WHO nomenclature.,0,54 70,0,54,9,79,-1,RO-disease_has_finding,901698,Dysplasia in the gastrointestinal tract is defined as intraepithelial neoplasia (IEN) according to the WHO nomenclature,Dysplasia,intraepithelial neoplasia
503461375,7/16/2014 14:16:01,,1324271903,7/16/2014 14:15:34,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,0,54,,,9,79,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA,DYSPLASIA,0,54-70,INTRAEPITHELIAL NEOPLASIA,Dysplasia in the gastrointestinal tract is defined as intraepithelial neoplasia (IEN) according to the WHO nomenclature.,0,54 70,0,54,9,79,-1,RO-disease_has_finding,901698,Dysplasia in the gastrointestinal tract is defined as intraepithelial neoplasia (IEN) according to the WHO nomenclature,Dysplasia,intraepithelial neoplasia
503461376,7/16/2014 13:47:49,,1324260360,7/16/2014 13:47:09,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,67,15,,,95,27,PROTEIN-CALORIE MALNUTRITION,MALNUTRITION,"PROTEIN ENERGY MALNUTRITION PROTEIN CALORIE MALNUTRITION,",0-8-15-67-75-83,0-8-15-67-75-83,"PROTEIN ENERGY MALNUTRITION protein calorie malnutrition,","PROTEIN-ENERGY MALNUTRITION  Protein-energy malnutrition (PEM), or protein-calorie malnutrition, is an energy deficit due to chronic deficiency of all macronutrients.",67 75 83,15,67,15,95,27,-1,RO-cause_of,900144,"PROTEIN-ENERGY MALNUTRITION  Protein-energy malnutrition (PEM), or protein-calorie malnutrition, is an energy deficit due to chronic deficiency of all macronutrients",protein-calorie malnutrition,MALNUTRITION
503461376,7/16/2014 13:50:19,,1324261215,7/16/2014 13:50:05,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,67,15,,,95,27,PROTEIN-CALORIE MALNUTRITION,MALNUTRITION,"PROTEIN - CALORIE MALNUTRITION,",67-74-75-83,0-7-8-15,PROTEIN - ENERGY MALNUTRITION,"PROTEIN-ENERGY MALNUTRITION  Protein-energy malnutrition (PEM), or protein-calorie malnutrition, is an energy deficit due to chronic deficiency of all macronutrients.",67 75 83,15,67,15,95,27,-1,RO-cause_of,900144,"PROTEIN-ENERGY MALNUTRITION  Protein-energy malnutrition (PEM), or protein-calorie malnutrition, is an energy deficit due to chronic deficiency of all macronutrients",protein-calorie malnutrition,MALNUTRITION
503461376,7/16/2014 13:52:11,,1324261872,7/16/2014 13:51:54,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,67,15,,,95,27,PROTEIN-CALORIE MALNUTRITION,MALNUTRITION,"PROTEIN CALORIE MALNUTRITION,",67-75-83,0-8-15,PROTEIN ENERGY MALNUTRITION,"PROTEIN-ENERGY MALNUTRITION  Protein-energy malnutrition (PEM), or protein-calorie malnutrition, is an energy deficit due to chronic deficiency of all macronutrients.",67 75 83,15,67,15,95,27,-1,RO-cause_of,900144,"PROTEIN-ENERGY MALNUTRITION  Protein-energy malnutrition (PEM), or protein-calorie malnutrition, is an energy deficit due to chronic deficiency of all macronutrients",protein-calorie malnutrition,MALNUTRITION
503461376,7/16/2014 14:04:42,,1324267111,7/16/2014 14:04:18,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,67,15,,,95,27,PROTEIN-CALORIE MALNUTRITION,MALNUTRITION,"Protein energy malnutrition (PEM), PROTEIN CALORIE MALNUTRITION,",29-37-44-57-67-75-83,15-29-37-44-67-75-83-57,"MALNUTRITION Protein energy malnutrition (PEM), protein calorie malnutrition,","PROTEIN-ENERGY MALNUTRITION  Protein-energy malnutrition (PEM), or protein-calorie malnutrition, is an energy deficit due to chronic deficiency of all macronutrients.",67 75 83,15,67,15,95,27,-1,RO-cause_of,900144,"PROTEIN-ENERGY MALNUTRITION  Protein-energy malnutrition (PEM), or protein-calorie malnutrition, is an energy deficit due to chronic deficiency of all macronutrients",protein-calorie malnutrition,MALNUTRITION
503461376,7/16/2014 14:05:08,,1324267327,7/16/2014 14:04:46,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,67,15,,,95,27,PROTEIN-CALORIE MALNUTRITION,MALNUTRITION,"PROTEIN CALORIE MALNUTRITION,",67-75-83,0-8-15,PROTEIN ENERGY MALNUTRITION,"PROTEIN-ENERGY MALNUTRITION  Protein-energy malnutrition (PEM), or protein-calorie malnutrition, is an energy deficit due to chronic deficiency of all macronutrients.",67 75 83,15,67,15,95,27,-1,RO-cause_of,900144,"PROTEIN-ENERGY MALNUTRITION  Protein-energy malnutrition (PEM), or protein-calorie malnutrition, is an energy deficit due to chronic deficiency of all macronutrients",protein-calorie malnutrition,MALNUTRITION
503461376,7/16/2014 14:06:52,,1324268047,7/16/2014 14:06:34,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,67,15,,,95,27,PROTEIN-CALORIE MALNUTRITION,MALNUTRITION,"PROTEIN CALORIE MALNUTRITION,",67-75-83,0-8-15,PROTEIN ENERGY MALNUTRITION,"PROTEIN-ENERGY MALNUTRITION  Protein-energy malnutrition (PEM), or protein-calorie malnutrition, is an energy deficit due to chronic deficiency of all macronutrients.",67 75 83,15,67,15,95,27,-1,RO-cause_of,900144,"PROTEIN-ENERGY MALNUTRITION  Protein-energy malnutrition (PEM), or protein-calorie malnutrition, is an energy deficit due to chronic deficiency of all macronutrients",protein-calorie malnutrition,MALNUTRITION
503461376,7/16/2014 14:21:39,,1324274241,7/16/2014 14:21:16,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,67,15,,,95,27,PROTEIN-CALORIE MALNUTRITION,MALNUTRITION,"PROTEIN CALORIE MALNUTRITION,",67-75-83,0-8-15,PROTEIN ENERGY MALNUTRITION,"PROTEIN-ENERGY MALNUTRITION  Protein-energy malnutrition (PEM), or protein-calorie malnutrition, is an energy deficit due to chronic deficiency of all macronutrients.",67 75 83,15,67,15,95,27,-1,RO-cause_of,900144,"PROTEIN-ENERGY MALNUTRITION  Protein-energy malnutrition (PEM), or protein-calorie malnutrition, is an energy deficit due to chronic deficiency of all macronutrients",protein-calorie malnutrition,MALNUTRITION
503461376,7/16/2014 14:34:11,,1324279262,7/16/2014 14:33:42,prodege,1.0,6316959,GBR,"","",46.208.145.114,67,15,,,95,27,PROTEIN-CALORIE MALNUTRITION,MALNUTRITION,"PROTEIN CALORIE MALNUTRITION,",67-75-83,0-8-15-57,"PROTEIN ENERGY MALNUTRITION (PEM),","PROTEIN-ENERGY MALNUTRITION  Protein-energy malnutrition (PEM), or protein-calorie malnutrition, is an energy deficit due to chronic deficiency of all macronutrients.",67 75 83,15,67,15,95,27,-1,RO-cause_of,900144,"PROTEIN-ENERGY MALNUTRITION  Protein-energy malnutrition (PEM), or protein-calorie malnutrition, is an energy deficit due to chronic deficiency of all macronutrients",protein-calorie malnutrition,MALNUTRITION
503461376,7/16/2014 14:35:39,,1324279945,7/16/2014 14:35:16,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,67,15,,,95,27,PROTEIN-CALORIE MALNUTRITION,MALNUTRITION,"MALNUTRITION PROTEIN CALORIE MALNUTRITION,",15-67-75-83,15-67-75-83,"MALNUTRITION protein calorie malnutrition,","PROTEIN-ENERGY MALNUTRITION  Protein-energy malnutrition (PEM), or protein-calorie malnutrition, is an energy deficit due to chronic deficiency of all macronutrients.",67 75 83,15,67,15,95,27,-1,RO-cause_of,900144,"PROTEIN-ENERGY MALNUTRITION  Protein-energy malnutrition (PEM), or protein-calorie malnutrition, is an energy deficit due to chronic deficiency of all macronutrients",protein-calorie malnutrition,MALNUTRITION
503461376,7/16/2014 14:44:44,,1324282928,7/16/2014 14:44:20,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,67,15,,,95,27,PROTEIN-CALORIE MALNUTRITION,MALNUTRITION,"PROTEIN CALORIE MALNUTRITION,",67-75-83,0-8-15-57,"PROTEIN ENERGY MALNUTRITION (PEM),","PROTEIN-ENERGY MALNUTRITION  Protein-energy malnutrition (PEM), or protein-calorie malnutrition, is an energy deficit due to chronic deficiency of all macronutrients.",67 75 83,15,67,15,95,27,-1,RO-cause_of,900144,"PROTEIN-ENERGY MALNUTRITION  Protein-energy malnutrition (PEM), or protein-calorie malnutrition, is an energy deficit due to chronic deficiency of all macronutrients",protein-calorie malnutrition,MALNUTRITION
503461377,7/16/2014 13:42:03,,1324258461,7/16/2014 13:41:55,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,121,92,,,136,119,CBS) DEFICIENCY,CYSTATHIONINE BETA-SYNTHASE,DEFICIENCY.,126,92-106-111,CYSTATHIONINE BETA SYNTHASE,We have investigated 31 subjects from five unrelated families with one or more members with cystathionine beta-synthase (CBS) deficiency.,126,92 106 111,121,92,136,119,-1,RO-has_manifestation,906361,We have investigated 31 subjects from five unrelated families with one or more members with cystathionine beta-synthase (CBS) deficiency,CBS) deficiency,cystathionine beta-synthase
503461377,7/16/2014 13:55:32,,1324263225,7/16/2014 13:55:05,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,121,92,,,136,119,CBS) DEFICIENCY,CYSTATHIONINE BETA-SYNTHASE,cystathionine beta synthase (CBS) DEFICIENCY.,106-111-120-126-92,92-106-111-120-126,CYSTATHIONINE BETA SYNTHASE (CBS) deficiency.,We have investigated 31 subjects from five unrelated families with one or more members with cystathionine beta-synthase (CBS) deficiency.,126,92 106 111,121,92,136,119,-1,RO-has_manifestation,906361,We have investigated 31 subjects from five unrelated families with one or more members with cystathionine beta-synthase (CBS) deficiency,CBS) deficiency,cystathionine beta-synthase
503461377,7/16/2014 13:59:57,,1324265209,7/16/2014 13:59:30,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,121,92,,,136,119,CBS) DEFICIENCY,CYSTATHIONINE BETA-SYNTHASE,cystathionine beta synthase (CBS) DEFICIENCY.,106-111-120-126-92,92-106-111-126-120,CYSTATHIONINE BETA SYNTHASE (CBS) deficiency.,We have investigated 31 subjects from five unrelated families with one or more members with cystathionine beta-synthase (CBS) deficiency.,126,92 106 111,121,92,136,119,-1,RO-has_manifestation,906361,We have investigated 31 subjects from five unrelated families with one or more members with cystathionine beta-synthase (CBS) deficiency,CBS) deficiency,cystathionine beta-synthase
503461377,7/16/2014 14:04:31,,1324266993,7/16/2014 14:04:17,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,121,92,,,136,119,CBS) DEFICIENCY,CYSTATHIONINE BETA-SYNTHASE,cystathionine beta synthase (CBS) DEFICIENCY.,106-111-120-126-92,92-106-111-126-120,CYSTATHIONINE BETA SYNTHASE (CBS) deficiency.,We have investigated 31 subjects from five unrelated families with one or more members with cystathionine beta-synthase (CBS) deficiency.,126,92 106 111,121,92,136,119,-1,RO-has_manifestation,906361,We have investigated 31 subjects from five unrelated families with one or more members with cystathionine beta-synthase (CBS) deficiency,CBS) deficiency,cystathionine beta-synthase
503461377,7/16/2014 14:13:22,,1324270885,7/16/2014 14:13:13,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,121,92,,,136,119,CBS) DEFICIENCY,CYSTATHIONINE BETA-SYNTHASE,beta synthase (CBS) DEFICIENCY.,106-111-120-126,74-79-87-92-106-111-126,more members with CYSTATHIONINE BETA SYNTHASE deficiency.,We have investigated 31 subjects from five unrelated families with one or more members with cystathionine beta-synthase (CBS) deficiency.,126,92 106 111,121,92,136,119,-1,RO-has_manifestation,906361,We have investigated 31 subjects from five unrelated families with one or more members with cystathionine beta-synthase (CBS) deficiency,CBS) deficiency,cystathionine beta-synthase
503461377,7/16/2014 14:24:03,,1324275137,7/16/2014 14:23:50,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,121,92,,,136,119,CBS) DEFICIENCY,CYSTATHIONINE BETA-SYNTHASE,beta synthase (CBS) DEFICIENCY.,106-111-120-126,92-106-111,CYSTATHIONINE BETA SYNTHASE,We have investigated 31 subjects from five unrelated families with one or more members with cystathionine beta-synthase (CBS) deficiency.,126,92 106 111,121,92,136,119,-1,RO-has_manifestation,906361,We have investigated 31 subjects from five unrelated families with one or more members with cystathionine beta-synthase (CBS) deficiency,CBS) deficiency,cystathionine beta-synthase
503461377,7/16/2014 14:31:37,,1324278323,7/16/2014 14:31:17,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,121,92,,,136,119,CBS) DEFICIENCY,CYSTATHIONINE BETA-SYNTHASE,(CBS) DEFICIENCY.,120-126,92-106-111,CYSTATHIONINE BETA SYNTHASE,We have investigated 31 subjects from five unrelated families with one or more members with cystathionine beta-synthase (CBS) deficiency.,126,92 106 111,121,92,136,119,-1,RO-has_manifestation,906361,We have investigated 31 subjects from five unrelated families with one or more members with cystathionine beta-synthase (CBS) deficiency,CBS) deficiency,cystathionine beta-synthase
503461377,7/16/2014 14:31:39,,1324278339,7/16/2014 14:31:12,prodege,1.0,26790109,USA,"","",23.125.64.233,121,92,,,136,119,CBS) DEFICIENCY,CYSTATHIONINE BETA-SYNTHASE,cystathionine beta synthase (CBS) DEFICIENCY.,106-111-120-126-92,38-43-53-62-67-71-74-79-87-92-106-111-126-120,five unrelated families with one or more members with CYSTATHIONINE BETA SYNTHASE (CBS) deficiency.,We have investigated 31 subjects from five unrelated families with one or more members with cystathionine beta-synthase (CBS) deficiency.,126,92 106 111,121,92,136,119,-1,RO-has_manifestation,906361,We have investigated 31 subjects from five unrelated families with one or more members with cystathionine beta-synthase (CBS) deficiency,CBS) deficiency,cystathionine beta-synthase
503461377,7/16/2014 14:34:34,,1324279415,7/16/2014 14:34:08,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,121,92,,,136,119,CBS) DEFICIENCY,CYSTATHIONINE BETA-SYNTHASE,cystathionine beta synthase (CBS) DEFICIENCY.,106-111-120-126-92,92-106-111-120-126,CYSTATHIONINE BETA SYNTHASE (CBS) deficiency.,We have investigated 31 subjects from five unrelated families with one or more members with cystathionine beta-synthase (CBS) deficiency.,126,92 106 111,121,92,136,119,-1,RO-has_manifestation,906361,We have investigated 31 subjects from five unrelated families with one or more members with cystathionine beta-synthase (CBS) deficiency,CBS) deficiency,cystathionine beta-synthase
503461377,7/16/2014 14:46:04,,1324283238,7/16/2014 14:45:53,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,121,92,,,136,119,CBS) DEFICIENCY,CYSTATHIONINE BETA-SYNTHASE,cystathionine beta synthase (CBS) DEFICIENCY.,92-106-111-126-120,92-106-111-126-120,CYSTATHIONINE BETA SYNTHASE (CBS) deficiency.,We have investigated 31 subjects from five unrelated families with one or more members with cystathionine beta-synthase (CBS) deficiency.,126,92 106 111,121,92,136,119,-1,RO-has_manifestation,906361,We have investigated 31 subjects from five unrelated families with one or more members with cystathionine beta-synthase (CBS) deficiency,CBS) deficiency,cystathionine beta-synthase
503461378,7/16/2014 13:45:58,,1324259748,7/16/2014 13:45:47,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,48,136,,,65,153,PANCREATIC ISLETS,DIABETES MELLITUS,PANCREATIC ISLETS,48-59,136-145,DIABETES MELLITUS.,Cytokines produced by immune cells infiltrating pancreatic islets are important mediators of beta-cell destruction in insulin-dependent diabetes mellitus.,48 59,136 145,48,136,65,153,1,RO-disease_has_primary_anatomic_site,902058,Cytokines produced by immune cells infiltrating pancreatic islets are important mediators of beta-cell destruction in insulin-dependent diabetes mellitus,pancreatic islets,diabetes mellitus
503461378,7/16/2014 13:53:37,,1324262433,7/16/2014 13:53:25,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,48,136,,,65,153,PANCREATIC ISLETS,DIABETES MELLITUS,PANCREATIC ISLETS,48-59,118-126-136-145,insulin dependent DIABETES MELLITUS.,Cytokines produced by immune cells infiltrating pancreatic islets are important mediators of beta-cell destruction in insulin-dependent diabetes mellitus.,48 59,136 145,48,136,65,153,1,RO-disease_has_primary_anatomic_site,902058,Cytokines produced by immune cells infiltrating pancreatic islets are important mediators of beta-cell destruction in insulin-dependent diabetes mellitus,pancreatic islets,diabetes mellitus
503461378,7/16/2014 13:59:21,,1324264945,7/16/2014 13:58:28,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,48,136,,,65,153,PANCREATIC ISLETS,DIABETES MELLITUS,PANCREATIC ISLETS,48-59,136-145,DIABETES MELLITUS.,Cytokines produced by immune cells infiltrating pancreatic islets are important mediators of beta-cell destruction in insulin-dependent diabetes mellitus.,48 59,136 145,48,136,65,153,1,RO-disease_has_primary_anatomic_site,902058,Cytokines produced by immune cells infiltrating pancreatic islets are important mediators of beta-cell destruction in insulin-dependent diabetes mellitus,pancreatic islets,diabetes mellitus
503461378,7/16/2014 14:05:43,,1324267557,7/16/2014 14:04:59,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,48,136,,,65,153,PANCREATIC ISLETS,DIABETES MELLITUS,PANCREATIC ISLETS,48-59,118-126-136-145,insulin dependent DIABETES MELLITUS.,Cytokines produced by immune cells infiltrating pancreatic islets are important mediators of beta-cell destruction in insulin-dependent diabetes mellitus.,48 59,136 145,48,136,65,153,1,RO-disease_has_primary_anatomic_site,902058,Cytokines produced by immune cells infiltrating pancreatic islets are important mediators of beta-cell destruction in insulin-dependent diabetes mellitus,pancreatic islets,diabetes mellitus
503461378,7/16/2014 14:08:32,,1324268797,7/16/2014 14:08:13,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,48,136,,,65,153,PANCREATIC ISLETS,DIABETES MELLITUS,infiltrating PANCREATIC ISLETS,48-59-35,118-126-136-145,insulin dependent DIABETES MELLITUS.,Cytokines produced by immune cells infiltrating pancreatic islets are important mediators of beta-cell destruction in insulin-dependent diabetes mellitus.,48 59,136 145,48,136,65,153,1,RO-disease_has_primary_anatomic_site,902058,Cytokines produced by immune cells infiltrating pancreatic islets are important mediators of beta-cell destruction in insulin-dependent diabetes mellitus,pancreatic islets,diabetes mellitus
503461378,7/16/2014 14:20:49,,1324273894,7/16/2014 14:20:40,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,48,136,,,65,153,PANCREATIC ISLETS,DIABETES MELLITUS,PANCREATIC ISLETS,48-59,118-126-136-145,insulin dependent DIABETES MELLITUS.,Cytokines produced by immune cells infiltrating pancreatic islets are important mediators of beta-cell destruction in insulin-dependent diabetes mellitus.,48 59,136 145,48,136,65,153,1,RO-disease_has_primary_anatomic_site,902058,Cytokines produced by immune cells infiltrating pancreatic islets are important mediators of beta-cell destruction in insulin-dependent diabetes mellitus,pancreatic islets,diabetes mellitus
503461378,7/16/2014 14:23:09,,1324274850,7/16/2014 14:22:51,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,48,136,,,65,153,PANCREATIC ISLETS,DIABETES MELLITUS,PANCREATIC ISLETS,48-59,118-126-136-145,insulin dependent DIABETES MELLITUS.,Cytokines produced by immune cells infiltrating pancreatic islets are important mediators of beta-cell destruction in insulin-dependent diabetes mellitus.,48 59,136 145,48,136,65,153,1,RO-disease_has_primary_anatomic_site,902058,Cytokines produced by immune cells infiltrating pancreatic islets are important mediators of beta-cell destruction in insulin-dependent diabetes mellitus,pancreatic islets,diabetes mellitus
503461378,7/16/2014 14:54:07,,1324285729,7/16/2014 14:53:51,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,48,136,,,65,153,PANCREATIC ISLETS,DIABETES MELLITUS,PANCREATIC ISLETS,48-59,118-126-136-145,insulin dependent DIABETES MELLITUS.,Cytokines produced by immune cells infiltrating pancreatic islets are important mediators of beta-cell destruction in insulin-dependent diabetes mellitus.,48 59,136 145,48,136,65,153,1,RO-disease_has_primary_anatomic_site,902058,Cytokines produced by immune cells infiltrating pancreatic islets are important mediators of beta-cell destruction in insulin-dependent diabetes mellitus,pancreatic islets,diabetes mellitus
503461378,7/16/2014 14:54:16,,1324285761,7/16/2014 14:54:07,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,48,136,,,65,153,PANCREATIC ISLETS,DIABETES MELLITUS,PANCREATIC ISLETS,48-59,118-136-145-126,insulin dependent DIABETES MELLITUS.,Cytokines produced by immune cells infiltrating pancreatic islets are important mediators of beta-cell destruction in insulin-dependent diabetes mellitus.,48 59,136 145,48,136,65,153,1,RO-disease_has_primary_anatomic_site,902058,Cytokines produced by immune cells infiltrating pancreatic islets are important mediators of beta-cell destruction in insulin-dependent diabetes mellitus,pancreatic islets,diabetes mellitus
503461378,7/16/2014 14:58:34,,1324287405,7/16/2014 14:58:13,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,48,136,,,65,153,PANCREATIC ISLETS,DIABETES MELLITUS,PANCREATIC ISLETS,48-59,118-126-136-145,insulin dependent DIABETES MELLITUS.,Cytokines produced by immune cells infiltrating pancreatic islets are important mediators of beta-cell destruction in insulin-dependent diabetes mellitus.,48 59,136 145,48,136,65,153,1,RO-disease_has_primary_anatomic_site,902058,Cytokines produced by immune cells infiltrating pancreatic islets are important mediators of beta-cell destruction in insulin-dependent diabetes mellitus,pancreatic islets,diabetes mellitus
503461379,7/16/2014 13:47:33,,1324260272,7/16/2014 13:47:27,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,0,80,,,10,90,SALMONELLA,AMPICILLIN,SALMONELLA isolates,0-11,80,AMPICILLIN,"Salmonella isolates were found to be susceptible to chloramphenicol, kanamycin, ampicillin and tetracycline.",0,80,0,80,10,90,1,RO-may_treat,908309,"Salmonella isolates were found to be susceptible to chloramphenicol, kanamycin, ampicillin and tetracycline",Salmonella,ampicillin
503461379,7/16/2014 13:52:15,,1324261881,7/16/2014 13:51:57,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,0,80,,,10,90,SALMONELLA,AMPICILLIN,"SALMONELLA isolates chloramphenicol, kanamycin, ampicillin tetracycline.",0-11-52-69-80-95,0-11-52-69-80-95,"Salmonella isolates chloramphenicol, kanamycin, AMPICILLIN tetracycline.","Salmonella isolates were found to be susceptible to chloramphenicol, kanamycin, ampicillin and tetracycline.",0,80,0,80,10,90,1,RO-may_treat,908309,"Salmonella isolates were found to be susceptible to chloramphenicol, kanamycin, ampicillin and tetracycline",Salmonella,ampicillin
503461379,7/16/2014 13:57:37,,1324264164,7/16/2014 13:57:23,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,0,80,,,10,90,SALMONELLA,AMPICILLIN,SALMONELLA isolates,0-11,80,AMPICILLIN,"Salmonella isolates were found to be susceptible to chloramphenicol, kanamycin, ampicillin and tetracycline.",0,80,0,80,10,90,1,RO-may_treat,908309,"Salmonella isolates were found to be susceptible to chloramphenicol, kanamycin, ampicillin and tetracycline",Salmonella,ampicillin
503461379,7/16/2014 14:10:56,,1324269873,7/16/2014 14:10:47,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,0,80,,,10,90,SALMONELLA,AMPICILLIN,SALMONELLA isolates,0-11,80,AMPICILLIN,"Salmonella isolates were found to be susceptible to chloramphenicol, kanamycin, ampicillin and tetracycline.",0,80,0,80,10,90,1,RO-may_treat,908309,"Salmonella isolates were found to be susceptible to chloramphenicol, kanamycin, ampicillin and tetracycline",Salmonella,ampicillin
503461379,7/16/2014 14:12:53,,1324270719,7/16/2014 14:12:43,prodege,1.0,17932518,GBR,"","",81.133.61.60,0,80,,,10,90,SALMONELLA,AMPICILLIN,SALMONELLA,0,80,AMPICILLIN,"Salmonella isolates were found to be susceptible to chloramphenicol, kanamycin, ampicillin and tetracycline.",0,80,0,80,10,90,1,RO-may_treat,908309,"Salmonella isolates were found to be susceptible to chloramphenicol, kanamycin, ampicillin and tetracycline",Salmonella,ampicillin
503461379,7/16/2014 14:16:09,,1324271955,7/16/2014 14:15:54,instagc,1.0,13763729,USA,"","",75.182.89.225,0,80,,,10,90,SALMONELLA,AMPICILLIN,SALMONELLA,0,80,AMPICILLIN,"Salmonella isolates were found to be susceptible to chloramphenicol, kanamycin, ampicillin and tetracycline.",0,80,0,80,10,90,1,RO-may_treat,908309,"Salmonella isolates were found to be susceptible to chloramphenicol, kanamycin, ampicillin and tetracycline",Salmonella,ampicillin
503461379,7/16/2014 14:25:21,,1324275652,7/16/2014 14:25:07,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,0,80,,,10,90,SALMONELLA,AMPICILLIN,SALMONELLA isolates,0-11,80,AMPICILLIN,"Salmonella isolates were found to be susceptible to chloramphenicol, kanamycin, ampicillin and tetracycline.",0,80,0,80,10,90,1,RO-may_treat,908309,"Salmonella isolates were found to be susceptible to chloramphenicol, kanamycin, ampicillin and tetracycline",Salmonella,ampicillin
503461379,7/16/2014 14:28:15,,1324276776,7/16/2014 14:27:50,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,0,80,,,10,90,SALMONELLA,AMPICILLIN,SALMONELLA,0,80,AMPICILLIN,"Salmonella isolates were found to be susceptible to chloramphenicol, kanamycin, ampicillin and tetracycline.",0,80,0,80,10,90,1,RO-may_treat,908309,"Salmonella isolates were found to be susceptible to chloramphenicol, kanamycin, ampicillin and tetracycline",Salmonella,ampicillin
503461379,7/16/2014 14:53:02,,1324285345,7/16/2014 14:52:51,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,0,80,,,10,90,SALMONELLA,AMPICILLIN,"SALMONELLA chloramphenicol, kanamycin, ampicillin tetracycline.",0-52-69-80-95,0-52-69-80-95,"Salmonella chloramphenicol, kanamycin, AMPICILLIN tetracycline.","Salmonella isolates were found to be susceptible to chloramphenicol, kanamycin, ampicillin and tetracycline.",0,80,0,80,10,90,1,RO-may_treat,908309,"Salmonella isolates were found to be susceptible to chloramphenicol, kanamycin, ampicillin and tetracycline",Salmonella,ampicillin
503461379,7/16/2014 14:58:46,,1324287504,7/16/2014 14:58:31,irazoo,1.0,7022810,USA,IA,Ankeny,216.161.121.1,0,80,,,10,90,SALMONELLA,AMPICILLIN,SALMONELLA isolates,0-11,80,AMPICILLIN,"Salmonella isolates were found to be susceptible to chloramphenicol, kanamycin, ampicillin and tetracycline.",0,80,0,80,10,90,1,RO-may_treat,908309,"Salmonella isolates were found to be susceptible to chloramphenicol, kanamycin, ampicillin and tetracycline",Salmonella,ampicillin
503461380,7/16/2014 13:42:51,,1324258713,7/16/2014 13:42:02,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,3,22,,,5,25,TB,PPD,TB,3,22,PPD,"If TB is a concern, a PPD is performed.",3,22,3,22,5,25,1,RO-may_diagnose,906829,"If TB is a concern, a PPD is performed",TB,PPD
503461380,7/16/2014 13:48:56,,1324260747,7/16/2014 13:48:40,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,3,22,,,5,25,TB,PPD,TB,3,22,PPD,"If TB is a concern, a PPD is performed.",3,22,3,22,5,25,1,RO-may_diagnose,906829,"If TB is a concern, a PPD is performed",TB,PPD
503461380,7/16/2014 13:51:03,,1324261500,7/16/2014 13:50:50,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,3,22,,,5,25,TB,PPD,TB,3,22,PPD,"If TB is a concern, a PPD is performed.",3,22,3,22,5,25,1,RO-may_diagnose,906829,"If TB is a concern, a PPD is performed",TB,PPD
503461380,7/16/2014 13:55:36,,1324263268,7/16/2014 13:55:12,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,3,22,,,5,25,TB,PPD,TB,3,22,PPD,"If TB is a concern, a PPD is performed.",3,22,3,22,5,25,1,RO-may_diagnose,906829,"If TB is a concern, a PPD is performed",TB,PPD
503461380,7/16/2014 13:59:07,,1324264818,7/16/2014 13:58:56,instagc,1.0,18960682,GBR,"","",86.29.147.112,3,22,,,5,25,TB,PPD,TB,3,22,PPD,"If TB is a concern, a PPD is performed.",3,22,3,22,5,25,1,RO-may_diagnose,906829,"If TB is a concern, a PPD is performed",TB,PPD
503461380,7/16/2014 14:04:58,,1324267225,7/16/2014 14:04:46,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,3,22,,,5,25,TB,PPD,TB,3,22,PPD,"If TB is a concern, a PPD is performed.",3,22,3,22,5,25,1,RO-may_diagnose,906829,"If TB is a concern, a PPD is performed",TB,PPD
503461380,7/16/2014 14:20:39,,1324273797,7/16/2014 14:20:28,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,3,22,,,5,25,TB,PPD,If TB,0-3,22,PPD,"If TB is a concern, a PPD is performed.",3,22,3,22,5,25,1,RO-may_diagnose,906829,"If TB is a concern, a PPD is performed",TB,PPD
503461380,7/16/2014 14:29:34,,1324277432,7/16/2014 14:29:12,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,3,22,,,5,25,TB,PPD,If TB PPD,0-3-22,3-22,TB PPD,"If TB is a concern, a PPD is performed.",3,22,3,22,5,25,1,RO-may_diagnose,906829,"If TB is a concern, a PPD is performed",TB,PPD
503461380,7/16/2014 14:44:47,,1324282943,7/16/2014 14:44:38,neodev,1.0,28336203,USA,PA,Harrisburg,50.149.53.150,3,22,,,5,25,TB,PPD,TB,3,22,PPD,"If TB is a concern, a PPD is performed.",3,22,3,22,5,25,1,RO-may_diagnose,906829,"If TB is a concern, a PPD is performed",TB,PPD
503461380,7/16/2014 14:44:48,,1324282949,7/16/2014 14:44:32,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,3,22,,,5,25,TB,PPD,TB,3,22,PPD,"If TB is a concern, a PPD is performed.",3,22,3,22,5,25,1,RO-may_diagnose,906829,"If TB is a concern, a PPD is performed",TB,PPD
503461381,7/16/2014 13:41:20,,1324258128,7/16/2014 13:41:11,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,34,68,,,40,95,TESTIS,TESTICULAR GERM CELL CANCER,TESTIS,34,68-79-84-89,TESTICULAR GERM CELL CANCER.,CIS is found in the contralateral testis in 5% of the patients with testicular germ cell cancer.,34,68 79 84 89,34,68,40,95,1,RO-disease_has_primary_anatomic_site,902445,CIS is found in the contralateral testis in 5% of the patients with testicular germ cell cancer,testis,testicular germ cell cancer
503461381,7/16/2014 13:48:28,,1324260589,7/16/2014 13:47:55,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,34,68,,,40,95,TESTIS,TESTICULAR GERM CELL CANCER,CIS contralateral TESTIS testicular germ cell cancer.,0-34-68-79-84-89-20,20-34-68-79-84-89-0,CIS contralateral testis TESTICULAR GERM CELL CANCER.,CIS is found in the contralateral testis in 5% of the patients with testicular germ cell cancer.,34,68 79 84 89,34,68,40,95,1,RO-disease_has_primary_anatomic_site,902445,CIS is found in the contralateral testis in 5% of the patients with testicular germ cell cancer,testis,testicular germ cell cancer
503461381,7/16/2014 13:52:47,,1324262113,7/16/2014 13:52:31,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,34,68,,,40,95,TESTIS,TESTICULAR GERM CELL CANCER,contralateral TESTIS,20-34,68-79-84-89,TESTICULAR GERM CELL CANCER.,CIS is found in the contralateral testis in 5% of the patients with testicular germ cell cancer.,34,68 79 84 89,34,68,40,95,1,RO-disease_has_primary_anatomic_site,902445,CIS is found in the contralateral testis in 5% of the patients with testicular germ cell cancer,testis,testicular germ cell cancer
503461381,7/16/2014 14:08:12,,1324268637,7/16/2014 14:08:04,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,34,68,,,40,95,TESTIS,TESTICULAR GERM CELL CANCER,in the contralateral TESTIS in 5% of,13-16-20-34-41-44-47,50-54-63-68-79-84-89,the patients with TESTICULAR GERM CELL CANCER.,CIS is found in the contralateral testis in 5% of the patients with testicular germ cell cancer.,34,68 79 84 89,34,68,40,95,1,RO-disease_has_primary_anatomic_site,902445,CIS is found in the contralateral testis in 5% of the patients with testicular germ cell cancer,testis,testicular germ cell cancer
503461381,7/16/2014 14:14:29,,1324271405,7/16/2014 14:14:18,prodege,1.0,17932518,GBR,"","",81.133.61.60,34,68,,,40,95,TESTIS,TESTICULAR GERM CELL CANCER,contralateral TESTIS,34-20,68-79-84-89,TESTICULAR GERM CELL CANCER.,CIS is found in the contralateral testis in 5% of the patients with testicular germ cell cancer.,34,68 79 84 89,34,68,40,95,1,RO-disease_has_primary_anatomic_site,902445,CIS is found in the contralateral testis in 5% of the patients with testicular germ cell cancer,testis,testicular germ cell cancer
503461381,7/16/2014 14:37:56,,1324280930,7/16/2014 14:37:43,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,34,68,,,40,95,TESTIS,TESTICULAR GERM CELL CANCER,contralateral TESTIS,20-34,68-79-84-89,TESTICULAR GERM CELL CANCER.,CIS is found in the contralateral testis in 5% of the patients with testicular germ cell cancer.,34,68 79 84 89,34,68,40,95,1,RO-disease_has_primary_anatomic_site,902445,CIS is found in the contralateral testis in 5% of the patients with testicular germ cell cancer,testis,testicular germ cell cancer
503461381,7/16/2014 14:45:22,,1324283064,7/16/2014 14:45:16,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,34,68,,,40,95,TESTIS,TESTICULAR GERM CELL CANCER,TESTIS,34,68-79-84-89,TESTICULAR GERM CELL CANCER.,CIS is found in the contralateral testis in 5% of the patients with testicular germ cell cancer.,34,68 79 84 89,34,68,40,95,1,RO-disease_has_primary_anatomic_site,902445,CIS is found in the contralateral testis in 5% of the patients with testicular germ cell cancer,testis,testicular germ cell cancer
503461381,7/16/2014 14:50:49,,1324284723,7/16/2014 14:50:21,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,34,68,,,40,95,TESTIS,TESTICULAR GERM CELL CANCER,TESTIS,34,68-79-84-89,TESTICULAR GERM CELL CANCER.,CIS is found in the contralateral testis in 5% of the patients with testicular germ cell cancer.,34,68 79 84 89,34,68,40,95,1,RO-disease_has_primary_anatomic_site,902445,CIS is found in the contralateral testis in 5% of the patients with testicular germ cell cancer,testis,testicular germ cell cancer
503461381,7/16/2014 14:51:57,,1324285038,7/16/2014 14:51:36,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,34,68,,,40,95,TESTIS,TESTICULAR GERM CELL CANCER,TESTIS of the testicular germ cell cancer.,34-47-50-68-79-84-89,68-79-84-89-0,CIS TESTICULAR GERM CELL CANCER.,CIS is found in the contralateral testis in 5% of the patients with testicular germ cell cancer.,34,68 79 84 89,34,68,40,95,1,RO-disease_has_primary_anatomic_site,902445,CIS is found in the contralateral testis in 5% of the patients with testicular germ cell cancer,testis,testicular germ cell cancer
503461381,7/16/2014 14:54:37,,1324285910,7/16/2014 14:54:27,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,34,68,,,40,95,TESTIS,TESTICULAR GERM CELL CANCER,contralateral TESTIS,20-34,68-79-84-89,TESTICULAR GERM CELL CANCER.,CIS is found in the contralateral testis in 5% of the patients with testicular germ cell cancer.,34,68 79 84 89,34,68,40,95,1,RO-disease_has_primary_anatomic_site,902445,CIS is found in the contralateral testis in 5% of the patients with testicular germ cell cancer,testis,testicular germ cell cancer
503461382,7/16/2014 13:49:09,,1324260811,7/16/2014 13:48:49,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,28,115,,,42,135,UTERINE CERVIX,CANCER OF THE CERVIX,UTERINE CERVIX,28-36,115-122-125-129,CANCER OF THE CERVIX.,Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix.,28 36,115 122 125 129,28,115,42,135,1,RO-disease_has_primary_anatomic_site,902354,Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix,uterine cervix,cancer of the cervix
503461382,7/16/2014 14:22:45,,1324274674,7/16/2014 14:22:14,vivatic,1.0,25451531,GBR,"","",83.67.28.193,28,115,,,42,135,UTERINE CERVIX,CANCER OF THE CERVIX,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV),0-11-21-24-28-36-43-48-53-58-64-81,115-122-125-129,CANCER OF THE CERVIX.,Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix.,28 36,115 122 125 129,28,115,42,135,1,RO-disease_has_primary_anatomic_site,902354,Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix,uterine cervix,cancer of the cervix
503461382,7/16/2014 14:26:33,,1324276104,7/16/2014 14:26:16,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,28,115,,,42,135,UTERINE CERVIX,CANCER OF THE CERVIX,UTERINE CERVIX,28-36,115-122-125-129,CANCER OF THE CERVIX.,Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix.,28 36,115 122 125 129,28,115,42,135,1,RO-disease_has_primary_anatomic_site,902354,Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix,uterine cervix,cancer of the cervix
503461382,7/16/2014 14:36:57,,1324280522,7/16/2014 14:36:46,prodege,1.0,6316959,GBR,"","",46.208.145.114,28,115,,,42,135,UTERINE CERVIX,CANCER OF THE CERVIX,UTERINE CERVIX,28-36,115-122-125-129,CANCER OF THE CERVIX.,Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix.,28 36,115 122 125 129,28,115,42,135,1,RO-disease_has_primary_anatomic_site,902354,Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix,uterine cervix,cancer of the cervix
503461382,7/16/2014 14:44:57,,1324282971,7/16/2014 14:44:45,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,28,115,,,42,135,UTERINE CERVIX,CANCER OF THE CERVIX,UTERINE CERVIX,28-36,115-122-125-129,CANCER OF THE CERVIX.,Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix.,28 36,115 122 125 129,28,115,42,135,1,RO-disease_has_primary_anatomic_site,902354,Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix,uterine cervix,cancer of the cervix
503461382,7/16/2014 14:51:57,,1324285044,7/16/2014 14:51:44,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,28,115,,,42,135,UTERINE CERVIX,CANCER OF THE CERVIX,UTERINE CERVIX,28-36,115-122-125-129,CANCER OF THE CERVIX.,Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix.,28 36,115 122 125 129,28,115,42,135,1,RO-disease_has_primary_anatomic_site,902354,Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix,uterine cervix,cancer of the cervix
503461382,7/16/2014 14:55:21,,1324286158,7/16/2014 14:55:19,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,28,115,,,42,135,UTERINE CERVIX,CANCER OF THE CERVIX,infection of the UTERINE CERVIX with high risk,11-21-24-28-36-43-48-53,90-99-110-115-122-125-129,causally associated with CANCER OF THE CERVIX.,Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix.,28 36,115 122 125 129,28,115,42,135,1,RO-disease_has_primary_anatomic_site,902354,Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix,uterine cervix,cancer of the cervix
503461382,7/16/2014 14:57:23,,1324287012,7/16/2014 14:57:07,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,28,115,,,42,135,UTERINE CERVIX,CANCER OF THE CERVIX,UTERINE CERVIX,28-36,115-122-125-129,CANCER OF THE CERVIX.,Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix.,28 36,115 122 125 129,28,115,42,135,1,RO-disease_has_primary_anatomic_site,902354,Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix,uterine cervix,cancer of the cervix
503461382,7/16/2014 14:58:16,,1324287319,7/16/2014 14:58:07,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,28,115,,,42,135,UTERINE CERVIX,CANCER OF THE CERVIX,UTERINE CERVIX,28-36,115-122-125-129,CANCER OF THE CERVIX.,Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix.,28 36,115 122 125 129,28,115,42,135,1,RO-disease_has_primary_anatomic_site,902354,Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix,uterine cervix,cancer of the cervix
503461382,7/16/2014 15:00:08,,1324287990,7/16/2014 14:59:52,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,28,115,,,42,135,UTERINE CERVIX,CANCER OF THE CERVIX,UTERINE CERVIX,28-36,115-122-125-129,CANCER OF THE CERVIX.,Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix.,28 36,115 122 125 129,28,115,42,135,1,RO-disease_has_primary_anatomic_site,902354,Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix,uterine cervix,cancer of the cervix
503461383,7/16/2014 13:49:37,,1324260946,7/16/2014 13:49:29,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,95,115,,,111,154,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX,SEVERE DYSPLASIA,95-102,115-125-128-133-136-140-148,CARCINOMA IN SITU OF THE UTERINE CERVIX,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of severe dysplasia or carcinoma in situ of the uterine cervix (CIN III) are presented.,95 102,115 125 128 133 136 140 148,95,115,111,154,-1,RO-disease_has_finding,901940,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of severe dysplasia or carcinoma in situ of the uterine cervix (CIN III) are presented,severe dysplasia,carcinoma in situ of the uterine cervix
503461383,7/16/2014 13:49:53,,1324261038,7/16/2014 13:49:36,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,95,115,,,111,154,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX,SEVERE DYSPLASIA,95-102,115-125-128-133-136-140-148-155-160,CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III),Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of severe dysplasia or carcinoma in situ of the uterine cervix (CIN III) are presented.,95 102,115 125 128 133 136 140 148,95,115,111,154,-1,RO-disease_has_finding,901940,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of severe dysplasia or carcinoma in situ of the uterine cervix (CIN III) are presented,severe dysplasia,carcinoma in situ of the uterine cervix
503461383,7/16/2014 13:50:28,,1324261281,7/16/2014 13:49:59,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,95,115,,,111,154,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX,SEVERE DYSPLASIA,95-102,115-125-128-133-136-140-148,CARCINOMA IN SITU OF THE UTERINE CERVIX,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of severe dysplasia or carcinoma in situ of the uterine cervix (CIN III) are presented.,95 102,115 125 128 133 136 140 148,95,115,111,154,-1,RO-disease_has_finding,901940,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of severe dysplasia or carcinoma in situ of the uterine cervix (CIN III) are presented,severe dysplasia,carcinoma in situ of the uterine cervix
503461383,7/16/2014 14:26:37,,1324276127,7/16/2014 14:26:16,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,95,115,,,111,154,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX,SEVERE DYSPLASIA,95-102,115-125-128-133-136-140-148,CARCINOMA IN SITU OF THE UTERINE CERVIX,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of severe dysplasia or carcinoma in situ of the uterine cervix (CIN III) are presented.,95 102,115 125 128 133 136 140 148,95,115,111,154,-1,RO-disease_has_finding,901940,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of severe dysplasia or carcinoma in situ of the uterine cervix (CIN III) are presented,severe dysplasia,carcinoma in situ of the uterine cervix
503461383,7/16/2014 14:32:00,,1324278417,7/16/2014 14:31:38,prodege,1.0,6316959,GBR,"","",46.208.145.114,95,115,,,111,154,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX,SEVERE DYSPLASIA,95-102,115-125-128-133-136-140-148-155-160,CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III),Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of severe dysplasia or carcinoma in situ of the uterine cervix (CIN III) are presented.,95 102,115 125 128 133 136 140 148,95,115,111,154,-1,RO-disease_has_finding,901940,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of severe dysplasia or carcinoma in situ of the uterine cervix (CIN III) are presented,severe dysplasia,carcinoma in situ of the uterine cervix
503461383,7/16/2014 14:33:51,,1324279156,7/16/2014 14:33:30,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,95,115,,,111,154,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX,SEVERE DYSPLASIA,95-102,115-125-128-133-136-140-148,CARCINOMA IN SITU OF THE UTERINE CERVIX,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of severe dysplasia or carcinoma in situ of the uterine cervix (CIN III) are presented.,95 102,115 125 128 133 136 140 148,95,115,111,154,-1,RO-disease_has_finding,901940,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of severe dysplasia or carcinoma in situ of the uterine cervix (CIN III) are presented,severe dysplasia,carcinoma in situ of the uterine cervix
503461383,7/16/2014 14:35:22,,1324279818,7/16/2014 14:34:45,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,95,115,,,111,154,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX,SEVERE DYSPLASIA,95-102,115-125-128-133-136-140-148-155-160,CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III),Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of severe dysplasia or carcinoma in situ of the uterine cervix (CIN III) are presented.,95 102,115 125 128 133 136 140 148,95,115,111,154,-1,RO-disease_has_finding,901940,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of severe dysplasia or carcinoma in situ of the uterine cervix (CIN III) are presented,severe dysplasia,carcinoma in situ of the uterine cervix
503461383,7/16/2014 14:37:05,,1324280561,7/16/2014 14:36:31,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,95,115,,,111,154,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX,SEVERE DYSPLASIA carcinoma in situ of the uterine cervix,95-102-115-125-128-133-136-140-148,95-102-115-125-128-133-136-140-148,severe dysplasia CARCINOMA IN SITU OF THE UTERINE CERVIX,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of severe dysplasia or carcinoma in situ of the uterine cervix (CIN III) are presented.,95 102,115 125 128 133 136 140 148,95,115,111,154,-1,RO-disease_has_finding,901940,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of severe dysplasia or carcinoma in situ of the uterine cervix (CIN III) are presented,severe dysplasia,carcinoma in situ of the uterine cervix
503461383,7/16/2014 14:45:57,,1324283201,7/16/2014 14:45:43,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,95,115,,,111,154,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX,SEVERE DYSPLASIA,95-102,115-125-128-133-136-140-148-155-160,CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III),Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of severe dysplasia or carcinoma in situ of the uterine cervix (CIN III) are presented.,95 102,115 125 128 133 136 140 148,95,115,111,154,-1,RO-disease_has_finding,901940,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of severe dysplasia or carcinoma in situ of the uterine cervix (CIN III) are presented,severe dysplasia,carcinoma in situ of the uterine cervix
503461383,7/16/2014 14:53:23,,1324285485,7/16/2014 14:53:03,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,95,115,,,111,154,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX,SEVERE DYSPLASIA carcinoma situ uterine cervix,95-102-115-128-140-148,95-102-115-125-128-133-136-140-148,severe dysplasia CARCINOMA IN SITU OF THE UTERINE CERVIX,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of severe dysplasia or carcinoma in situ of the uterine cervix (CIN III) are presented.,95 102,115 125 128 133 136 140 148,95,115,111,154,-1,RO-disease_has_finding,901940,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of severe dysplasia or carcinoma in situ of the uterine cervix (CIN III) are presented,severe dysplasia,carcinoma in situ of the uterine cervix
503461384,7/16/2014 13:44:37,,1324259336,7/16/2014 13:44:29,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,40,23,,,44,32,DRUG,TOLERANCE,DRUG,40,17-23,local TOLERANCE,The systemic and local tolerance of the drug was satisfactory.,40,23,40,23,44,32,-1,RO-has_causative_agent,903908,The systemic and local tolerance of the drug was satisfactory,drug,tolerance
503461384,7/16/2014 13:53:01,,1324262187,7/16/2014 13:52:37,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,40,23,,,44,32,DRUG,TOLERANCE,tolerance of the DRUG,23-33-36-40,23-33-36-40,TOLERANCE of the drug,The systemic and local tolerance of the drug was satisfactory.,40,23,40,23,44,32,-1,RO-has_causative_agent,903908,The systemic and local tolerance of the drug was satisfactory,drug,tolerance
503461384,7/16/2014 13:54:34,,1324262838,7/16/2014 13:53:52,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,40,23,,,44,32,DRUG,TOLERANCE,DRUG,40,4-13-17-23,systemic and local TOLERANCE,The systemic and local tolerance of the drug was satisfactory.,40,23,40,23,44,32,-1,RO-has_causative_agent,903908,The systemic and local tolerance of the drug was satisfactory,drug,tolerance
503461384,7/16/2014 13:58:48,,1324264664,7/16/2014 13:58:33,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,40,23,,,44,32,DRUG,TOLERANCE,DRUG,40,23,TOLERANCE,The systemic and local tolerance of the drug was satisfactory.,40,23,40,23,44,32,-1,RO-has_causative_agent,903908,The systemic and local tolerance of the drug was satisfactory,drug,tolerance
503461384,7/16/2014 13:59:35,,1324265072,7/16/2014 13:59:10,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,40,23,,,44,32,DRUG,TOLERANCE,tolerance of the DRUG,23-33-36-40,23-33-36-40,TOLERANCE of the drug,The systemic and local tolerance of the drug was satisfactory.,40,23,40,23,44,32,-1,RO-has_causative_agent,903908,The systemic and local tolerance of the drug was satisfactory,drug,tolerance
503461384,7/16/2014 14:04:16,,1324266932,7/16/2014 14:03:57,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,40,23,,,44,32,DRUG,TOLERANCE,systemic local tolerance DRUG,4-23-40-17,4-17-23-40,systemic local TOLERANCE drug,The systemic and local tolerance of the drug was satisfactory.,40,23,40,23,44,32,-1,RO-has_causative_agent,903908,The systemic and local tolerance of the drug was satisfactory,drug,tolerance
503461384,7/16/2014 14:10:01,,1324269462,7/16/2014 14:09:50,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,40,23,,,44,32,DRUG,TOLERANCE,tolerance of the DRUG was satisfactory.,23-33-36-40-45-49,4-13-17-23-33-36-40,systemic and local TOLERANCE of the drug,The systemic and local tolerance of the drug was satisfactory.,40,23,40,23,44,32,-1,RO-has_causative_agent,903908,The systemic and local tolerance of the drug was satisfactory,drug,tolerance
503461384,7/16/2014 14:13:03,,1324270762,7/16/2014 14:12:27,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,40,23,,,44,32,DRUG,TOLERANCE,tolerance of the DRUG,23-33-40-36,4-13-17-23,systemic and local TOLERANCE,The systemic and local tolerance of the drug was satisfactory.,40,23,40,23,44,32,-1,RO-has_causative_agent,903908,The systemic and local tolerance of the drug was satisfactory,drug,tolerance
503461384,7/16/2014 14:13:52,,1324271117,7/16/2014 14:13:42,prodege,1.0,17932518,GBR,"","",81.133.61.60,40,23,,,44,32,DRUG,TOLERANCE,DRUG,40,23,TOLERANCE,The systemic and local tolerance of the drug was satisfactory.,40,23,40,23,44,32,-1,RO-has_causative_agent,903908,The systemic and local tolerance of the drug was satisfactory,drug,tolerance
503461384,7/16/2014 14:25:08,,1324275598,7/16/2014 14:23:58,prodege,1.0,26790109,USA,"","",23.125.64.233,40,23,,,44,32,DRUG,TOLERANCE,tolerance of the DRUG was satisfactory.,23-33-36-40-45-49,4-13-17-23-33-36-40,systemic and local TOLERANCE of the drug,The systemic and local tolerance of the drug was satisfactory.,40,23,40,23,44,32,-1,RO-has_causative_agent,903908,The systemic and local tolerance of the drug was satisfactory,drug,tolerance
503461385,7/16/2014 13:40:55,,1324257965,7/16/2014 13:40:47,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,67,176,,,71,181,SKIN,NEVUS,"SKIN tumors,",67-72,165-171-176,nevus cell NEVUS.,"There was no positive reactivity of anti-D-1 antibodies with other skin tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and nevus cell nevus.",67,176,67,176,71,181,1,RO-has_finding_site,905154,"There was no positive reactivity of anti-D-1 antibodies with other skin tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and nevus cell nevus",skin,nevus
503461385,7/16/2014 13:51:01,,1324261497,7/16/2014 13:50:39,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,67,176,,,71,181,SKIN,NEVUS,"antibodies with other SKIN tumors, including squamous cell carcinoma,",45-56-61-67-72-80-90-99-104,165-171-176,nevus cell NEVUS.,"There was no positive reactivity of anti-D-1 antibodies with other skin tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and nevus cell nevus.",67,176,67,176,71,181,1,RO-has_finding_site,905154,"There was no positive reactivity of anti-D-1 antibodies with other skin tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and nevus cell nevus",skin,nevus
503461385,7/16/2014 13:58:03,,1324264351,7/16/2014 13:57:34,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,67,176,,,71,181,SKIN,NEVUS,"SKIN tumors, nevus.",67-72-176,67-72-176,"skin tumors, NEVUS.","There was no positive reactivity of anti-D-1 antibodies with other skin tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and nevus cell nevus.",67,176,67,176,71,181,1,RO-has_finding_site,905154,"There was no positive reactivity of anti-D-1 antibodies with other skin tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and nevus cell nevus",skin,nevus
503461385,7/16/2014 14:03:34,,1324266625,7/16/2014 14:03:12,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,67,176,,,71,181,SKIN,NEVUS,"SKIN tumors,",67-72,165-171-176,nevus cell NEVUS.,"There was no positive reactivity of anti-D-1 antibodies with other skin tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and nevus cell nevus.",67,176,67,176,71,181,1,RO-has_finding_site,905154,"There was no positive reactivity of anti-D-1 antibodies with other skin tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and nevus cell nevus",skin,nevus
503461385,7/16/2014 14:04:48,,1324267157,7/16/2014 14:03:42,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,67,176,,,71,181,SKIN,NEVUS,SKIN,67,176,NEVUS.,"There was no positive reactivity of anti-D-1 antibodies with other skin tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and nevus cell nevus.",67,176,67,176,71,181,1,RO-has_finding_site,905154,"There was no positive reactivity of anti-D-1 antibodies with other skin tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and nevus cell nevus",skin,nevus
503461385,7/16/2014 14:14:55,,1324271511,7/16/2014 14:14:23,vivatic,1.0,25451531,GBR,"","",83.67.28.193,67,176,,,71,181,SKIN,NEVUS,"SKIN tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and nevus cell nevus.",67-72-80-90-99-104-115-121-126-139-150-161-165-176-171,165-171-176,nevus cell NEVUS.,"There was no positive reactivity of anti-D-1 antibodies with other skin tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and nevus cell nevus.",67,176,67,176,71,181,1,RO-has_finding_site,905154,"There was no positive reactivity of anti-D-1 antibodies with other skin tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and nevus cell nevus",skin,nevus
503461385,7/16/2014 14:54:08,,1324285738,7/16/2014 14:53:32,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.72,67,176,,,71,181,SKIN,NEVUS,"SKIN tumors,",67-72,176,NEVUS.,"There was no positive reactivity of anti-D-1 antibodies with other skin tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and nevus cell nevus.",67,176,67,176,71,181,1,RO-has_finding_site,905154,"There was no positive reactivity of anti-D-1 antibodies with other skin tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and nevus cell nevus",skin,nevus
503461385,7/16/2014 14:55:58,,1324286393,7/16/2014 14:55:44,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,67,176,,,71,181,SKIN,NEVUS,"SKIN tumors,",67-72,176,NEVUS.,"There was no positive reactivity of anti-D-1 antibodies with other skin tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and nevus cell nevus.",67,176,67,176,71,181,1,RO-has_finding_site,905154,"There was no positive reactivity of anti-D-1 antibodies with other skin tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and nevus cell nevus",skin,nevus
503461385,7/16/2014 14:56:13,,1324286470,7/16/2014 14:55:35,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,67,176,,,71,181,SKIN,NEVUS,"SKIN tumors,",67-72,165-176-171,nevus cell NEVUS.,"There was no positive reactivity of anti-D-1 antibodies with other skin tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and nevus cell nevus.",67,176,67,176,71,181,1,RO-has_finding_site,905154,"There was no positive reactivity of anti-D-1 antibodies with other skin tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and nevus cell nevus",skin,nevus
503461385,7/16/2014 14:59:11,,1324287670,7/16/2014 14:58:58,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,67,176,,,71,181,SKIN,NEVUS,SKIN,67,165-171-176,nevus cell NEVUS.,"There was no positive reactivity of anti-D-1 antibodies with other skin tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and nevus cell nevus.",67,176,67,176,71,181,1,RO-has_finding_site,905154,"There was no positive reactivity of anti-D-1 antibodies with other skin tumors, including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and nevus cell nevus",skin,nevus
503461386,7/16/2014 13:45:01,,1324259447,7/16/2014 13:44:35,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,81,45,,,89,53,HEADACHE,MIGRAINE,migraine HEADACHE.,72-81,45,MIGRAINE,Pharmacologic management of acute attacks of migraine and prevention of migraine headache.,81,45,81,45,89,53,-1,RO-has_definitional_manifestation,904694,Pharmacologic management of acute attacks of migraine and prevention of migraine headache,headache,migraine
503461386,7/16/2014 13:46:11,,1324259807,7/16/2014 13:45:58,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,81,45,,,89,53,HEADACHE,MIGRAINE,HEADACHE.,81,45,MIGRAINE,Pharmacologic management of acute attacks of migraine and prevention of migraine headache.,81,45,81,45,89,53,-1,RO-has_definitional_manifestation,904694,Pharmacologic management of acute attacks of migraine and prevention of migraine headache,headache,migraine
503461386,7/16/2014 14:15:53,,1324271860,7/16/2014 14:15:43,instagc,1.0,13763729,USA,"","",75.182.89.225,81,45,,,89,53,HEADACHE,MIGRAINE,migraine HEADACHE.,72-81,45,MIGRAINE,Pharmacologic management of acute attacks of migraine and prevention of migraine headache.,81,45,81,45,89,53,-1,RO-has_definitional_manifestation,904694,Pharmacologic management of acute attacks of migraine and prevention of migraine headache,headache,migraine
503461386,7/16/2014 14:31:32,,1324278310,7/16/2014 14:31:11,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,81,45,,,89,53,HEADACHE,MIGRAINE,migraine HEADACHE.,81-45,45-81,MIGRAINE headache.,Pharmacologic management of acute attacks of migraine and prevention of migraine headache.,81,45,81,45,89,53,-1,RO-has_definitional_manifestation,904694,Pharmacologic management of acute attacks of migraine and prevention of migraine headache,headache,migraine
503461386,7/16/2014 14:42:24,,1324282311,7/16/2014 14:41:44,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,81,45,,,89,53,HEADACHE,MIGRAINE,migraine HEADACHE.,72-81,28-34-42-45,acute attacks of MIGRAINE,Pharmacologic management of acute attacks of migraine and prevention of migraine headache.,81,45,81,45,89,53,-1,RO-has_definitional_manifestation,904694,Pharmacologic management of acute attacks of migraine and prevention of migraine headache,headache,migraine
503461386,7/16/2014 14:55:03,,1324286028,7/16/2014 14:54:15,tremorgames,1.0,25257192,CAN,ON,Toronto,68.68.13.209,81,45,,,89,53,HEADACHE,MIGRAINE,migraine HEADACHE.,81-72,45-81,MIGRAINE headache.,Pharmacologic management of acute attacks of migraine and prevention of migraine headache.,81,45,81,45,89,53,-1,RO-has_definitional_manifestation,904694,Pharmacologic management of acute attacks of migraine and prevention of migraine headache,headache,migraine
503461386,7/16/2014 14:57:39,,1324287099,7/16/2014 14:57:26,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,81,45,,,89,53,HEADACHE,MIGRAINE,migraine HEADACHE.,72-81,45,MIGRAINE,Pharmacologic management of acute attacks of migraine and prevention of migraine headache.,81,45,81,45,89,53,-1,RO-has_definitional_manifestation,904694,Pharmacologic management of acute attacks of migraine and prevention of migraine headache,headache,migraine
503461386,7/16/2014 14:58:12,,1324287299,7/16/2014 14:57:53,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,81,45,,,89,53,HEADACHE,MIGRAINE,migraine HEADACHE.,72-81,45,MIGRAINE,Pharmacologic management of acute attacks of migraine and prevention of migraine headache.,81,45,81,45,89,53,-1,RO-has_definitional_manifestation,904694,Pharmacologic management of acute attacks of migraine and prevention of migraine headache,headache,migraine
503461386,7/16/2014 15:00:28,,1324288107,7/16/2014 15:00:15,irazoo,1.0,7022810,USA,IA,Ankeny,216.161.121.1,81,45,,,89,53,HEADACHE,MIGRAINE,migraine HEADACHE.,72-81,28-34-42-45,acute attacks of MIGRAINE,Pharmacologic management of acute attacks of migraine and prevention of migraine headache.,81,45,81,45,89,53,-1,RO-has_definitional_manifestation,904694,Pharmacologic management of acute attacks of migraine and prevention of migraine headache,headache,migraine
503461386,7/16/2014 15:01:25,,1324288484,7/16/2014 15:00:42,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.72,81,45,,,89,53,HEADACHE,MIGRAINE,migraine HEADACHE.,81-72,45,MIGRAINE,Pharmacologic management of acute attacks of migraine and prevention of migraine headache.,81,45,81,45,89,53,-1,RO-has_definitional_manifestation,904694,Pharmacologic management of acute attacks of migraine and prevention of migraine headache,headache,migraine
503461387,7/16/2014 13:42:14,,1324258536,7/16/2014 13:42:04,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,21,37,,,28,51,BRONCHI,BRONCHIECTASIS,BRONCHI,21,37,BRONCHIECTASIS,"Of the 101 segmental bronchi showing bronchiectasis on bronchography, CT correctly identified bronchiectasis in 98 segments (97%.",21,37,21,37,28,51,1,RO-has_finding_site,905364,"Of the 101 segmental bronchi showing bronchiectasis on bronchography, CT correctly identified bronchiectasis in 98 segments (97%",bronchi,bronchiectasis
503461387,7/16/2014 14:00:36,,1324265376,7/16/2014 13:59:59,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,21,37,,,28,51,BRONCHI,BRONCHIECTASIS,segmental BRONCHI,11-21,37,BRONCHIECTASIS,"Of the 101 segmental bronchi showing bronchiectasis on bronchography, CT correctly identified bronchiectasis in 98 segments (97%.",21,37,21,37,28,51,1,RO-has_finding_site,905364,"Of the 101 segmental bronchi showing bronchiectasis on bronchography, CT correctly identified bronchiectasis in 98 segments (97%",bronchi,bronchiectasis
503461387,7/16/2014 14:10:46,,1324269784,7/16/2014 14:10:30,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,21,37,,,28,51,BRONCHI,BRONCHIECTASIS,segmental BRONCHI,11-21,37,BRONCHIECTASIS,"Of the 101 segmental bronchi showing bronchiectasis on bronchography, CT correctly identified bronchiectasis in 98 segments (97%.",21,37,21,37,28,51,1,RO-has_finding_site,905364,"Of the 101 segmental bronchi showing bronchiectasis on bronchography, CT correctly identified bronchiectasis in 98 segments (97%",bronchi,bronchiectasis
503461387,7/16/2014 14:36:44,,1324280455,7/16/2014 14:36:26,prodege,1.0,6316959,GBR,"","",46.208.145.114,21,37,,,28,51,BRONCHI,BRONCHIECTASIS,segmental BRONCHI,11-21,37,BRONCHIECTASIS,"Of the 101 segmental bronchi showing bronchiectasis on bronchography, CT correctly identified bronchiectasis in 98 segments (97%.",21,37,21,37,28,51,1,RO-has_finding_site,905364,"Of the 101 segmental bronchi showing bronchiectasis on bronchography, CT correctly identified bronchiectasis in 98 segments (97%",bronchi,bronchiectasis
503461387,7/16/2014 14:50:24,,1324284612,7/16/2014 14:50:10,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,21,37,,,28,51,BRONCHI,BRONCHIECTASIS,BRONCHI,21,37,BRONCHIECTASIS,"Of the 101 segmental bronchi showing bronchiectasis on bronchography, CT correctly identified bronchiectasis in 98 segments (97%.",21,37,21,37,28,51,1,RO-has_finding_site,905364,"Of the 101 segmental bronchi showing bronchiectasis on bronchography, CT correctly identified bronchiectasis in 98 segments (97%",bronchi,bronchiectasis
503461387,7/16/2014 14:52:43,,1324285249,7/16/2014 14:52:16,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.72,21,37,,,28,51,BRONCHI,BRONCHIECTASIS,BRONCHI,21,37,BRONCHIECTASIS,"Of the 101 segmental bronchi showing bronchiectasis on bronchography, CT correctly identified bronchiectasis in 98 segments (97%.",21,37,21,37,28,51,1,RO-has_finding_site,905364,"Of the 101 segmental bronchi showing bronchiectasis on bronchography, CT correctly identified bronchiectasis in 98 segments (97%",bronchi,bronchiectasis
503461387,7/16/2014 14:54:13,,1324285754,7/16/2014 14:53:33,tremorgames,1.0,25257192,CAN,ON,Toronto,68.68.13.209,21,37,,,28,51,BRONCHI,BRONCHIECTASIS,BRONCHI,21,37,BRONCHIECTASIS,"Of the 101 segmental bronchi showing bronchiectasis on bronchography, CT correctly identified bronchiectasis in 98 segments (97%.",21,37,21,37,28,51,1,RO-has_finding_site,905364,"Of the 101 segmental bronchi showing bronchiectasis on bronchography, CT correctly identified bronchiectasis in 98 segments (97%",bronchi,bronchiectasis
503461387,7/16/2014 14:54:40,,1324285914,7/16/2014 14:54:09,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,21,37,,,28,51,BRONCHI,BRONCHIECTASIS,101 segmental BRONCHI,7-11-21,37,BRONCHIECTASIS,"Of the 101 segmental bronchi showing bronchiectasis on bronchography, CT correctly identified bronchiectasis in 98 segments (97%.",21,37,21,37,28,51,1,RO-has_finding_site,905364,"Of the 101 segmental bronchi showing bronchiectasis on bronchography, CT correctly identified bronchiectasis in 98 segments (97%",bronchi,bronchiectasis
503461387,7/16/2014 14:59:03,,1324287608,7/16/2014 14:58:35,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,21,37,,,28,51,BRONCHI,BRONCHIECTASIS,BRONCHI,21,37,BRONCHIECTASIS,"Of the 101 segmental bronchi showing bronchiectasis on bronchography, CT correctly identified bronchiectasis in 98 segments (97%.",21,37,21,37,28,51,1,RO-has_finding_site,905364,"Of the 101 segmental bronchi showing bronchiectasis on bronchography, CT correctly identified bronchiectasis in 98 segments (97%",bronchi,bronchiectasis
503461387,7/16/2014 14:59:27,,1324287707,7/16/2014 14:59:12,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,21,37,,,28,51,BRONCHI,BRONCHIECTASIS,segmental BRONCHI,11-21,37,BRONCHIECTASIS,"Of the 101 segmental bronchi showing bronchiectasis on bronchography, CT correctly identified bronchiectasis in 98 segments (97%.",21,37,21,37,28,51,1,RO-has_finding_site,905364,"Of the 101 segmental bronchi showing bronchiectasis on bronchography, CT correctly identified bronchiectasis in 98 segments (97%",bronchi,bronchiectasis
503461388,7/16/2014 14:11:40,,1324270196,7/16/2014 14:11:29,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,220,285,,,235,297,M. TUBERCULOSIS,TUBERCULOSIS,"2001, and the M. TUBERCULOSIS strains H37Rv, M.",206-212-216-220-223-236-244-251,274-278-282-285-298-301-305,BCG and M. TUBERCULOSIS in the specimens,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north-west of Russia, including those in Saint Petersburg, in 1998-2001, and the M. tuberculosis strains H37Rv, M. bovis, and M. bovic BCG and M. tuberculosis in the specimens painted for microscopy.",220 223,285,220,285,235,297,-1,RO-has_causative_agent,903535,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north-west of Russia, including those in Saint Petersburg, in 1998-2001, and the M. tuberculosis strains H37Rv, M. bovis, and M. bovic BCG and M. tuberculosis in the specimens painted for microscopy",M. tuberculosis,tuberculosis
503461388,7/16/2014 14:45:02,,1324282997,7/16/2014 14:44:48,neodev,1.0,28336203,USA,PA,Harrisburg,50.149.53.150,220,285,,,235,297,M. TUBERCULOSIS,TUBERCULOSIS,"M. TUBERCULOSIS strains H37Rv, M. bovis, M. bovic BCG M. tuberculosis",220-223-236-244-251-254-265-268-274-282-285,274-278-282-285,BCG and M. TUBERCULOSIS,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north-west of Russia, including those in Saint Petersburg, in 1998-2001, and the M. tuberculosis strains H37Rv, M. bovis, and M. bovic BCG and M. tuberculosis in the specimens painted for microscopy.",220 223,285,220,285,235,297,-1,RO-has_causative_agent,903535,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north-west of Russia, including those in Saint Petersburg, in 1998-2001, and the M. tuberculosis strains H37Rv, M. bovis, and M. bovic BCG and M. tuberculosis in the specimens painted for microscopy",M. tuberculosis,tuberculosis
503461388,7/16/2014 14:54:07,,1324285730,7/16/2014 14:53:25,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,220,285,,,235,297,M. TUBERCULOSIS,TUBERCULOSIS,"Spoligotyping tuberculosis pulmonary tuberculosis M. TUBERCULOSIS strains H37Rv, tuberculosis",48-102-112-220-223-236-244-285-0,0-48-102-112-236-244-285,"Spoligotyping tuberculosis pulmonary tuberculosis strains H37Rv, TUBERCULOSIS","Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north-west of Russia, including those in Saint Petersburg, in 1998-2001, and the M. tuberculosis strains H37Rv, M. bovis, and M. bovic BCG and M. tuberculosis in the specimens painted for microscopy.",220 223,285,220,285,235,297,-1,RO-has_causative_agent,903535,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north-west of Russia, including those in Saint Petersburg, in 1998-2001, and the M. tuberculosis strains H37Rv, M. bovis, and M. bovic BCG and M. tuberculosis in the specimens painted for microscopy",M. tuberculosis,tuberculosis
503461388,7/16/2014 14:56:44,,1324286723,7/16/2014 14:56:28,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,220,285,,,235,297,M. TUBERCULOSIS,TUBERCULOSIS,M. TUBERCULOSIS strains,220-223-236,282-285,M. TUBERCULOSIS,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north-west of Russia, including those in Saint Petersburg, in 1998-2001, and the M. tuberculosis strains H37Rv, M. bovis, and M. bovic BCG and M. tuberculosis in the specimens painted for microscopy.",220 223,285,220,285,235,297,-1,RO-has_causative_agent,903535,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north-west of Russia, including those in Saint Petersburg, in 1998-2001, and the M. tuberculosis strains H37Rv, M. bovis, and M. bovic BCG and M. tuberculosis in the specimens painted for microscopy",M. tuberculosis,tuberculosis
503461388,7/16/2014 15:00:14,,1324288062,7/16/2014 14:59:48,irazoo,1.0,7022810,USA,IA,Ankeny,216.161.121.1,220,285,,,235,297,M. TUBERCULOSIS,TUBERCULOSIS,M. TUBERCULOSIS strains,220-223-236,282-285,M. TUBERCULOSIS,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north-west of Russia, including those in Saint Petersburg, in 1998-2001, and the M. tuberculosis strains H37Rv, M. bovis, and M. bovic BCG and M. tuberculosis in the specimens painted for microscopy.",220 223,285,220,285,235,297,-1,RO-has_causative_agent,903535,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north-west of Russia, including those in Saint Petersburg, in 1998-2001, and the M. tuberculosis strains H37Rv, M. bovis, and M. bovic BCG and M. tuberculosis in the specimens painted for microscopy",M. tuberculosis,tuberculosis
503461388,7/16/2014 15:00:53,,1324288281,7/16/2014 15:00:34,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,220,285,,,235,297,M. TUBERCULOSIS,TUBERCULOSIS,the M. TUBERCULOSIS,216-220-223,282-285,M. TUBERCULOSIS,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north-west of Russia, including those in Saint Petersburg, in 1998-2001, and the M. tuberculosis strains H37Rv, M. bovis, and M. bovic BCG and M. tuberculosis in the specimens painted for microscopy.",220 223,285,220,285,235,297,-1,RO-has_causative_agent,903535,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north-west of Russia, including those in Saint Petersburg, in 1998-2001, and the M. tuberculosis strains H37Rv, M. bovis, and M. bovic BCG and M. tuberculosis in the specimens painted for microscopy",M. tuberculosis,tuberculosis
503461388,7/16/2014 15:01:32,,1324288550,7/16/2014 15:01:04,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,220,285,,,235,297,M. TUBERCULOSIS,TUBERCULOSIS,M. TUBERCULOSIS,220-223,285-282,M. TUBERCULOSIS,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north-west of Russia, including those in Saint Petersburg, in 1998-2001, and the M. tuberculosis strains H37Rv, M. bovis, and M. bovic BCG and M. tuberculosis in the specimens painted for microscopy.",220 223,285,220,285,235,297,-1,RO-has_causative_agent,903535,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north-west of Russia, including those in Saint Petersburg, in 1998-2001, and the M. tuberculosis strains H37Rv, M. bovis, and M. bovic BCG and M. tuberculosis in the specimens painted for microscopy",M. tuberculosis,tuberculosis
503461388,7/16/2014 15:02:07,,1324288859,7/16/2014 15:01:30,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.72,220,285,,,235,297,M. TUBERCULOSIS,TUBERCULOSIS,M. TUBERCULOSIS,220-223,282-285,M. TUBERCULOSIS,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north-west of Russia, including those in Saint Petersburg, in 1998-2001, and the M. tuberculosis strains H37Rv, M. bovis, and M. bovic BCG and M. tuberculosis in the specimens painted for microscopy.",220 223,285,220,285,235,297,-1,RO-has_causative_agent,903535,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north-west of Russia, including those in Saint Petersburg, in 1998-2001, and the M. tuberculosis strains H37Rv, M. bovis, and M. bovic BCG and M. tuberculosis in the specimens painted for microscopy",M. tuberculosis,tuberculosis
503461388,7/16/2014 15:07:28,,1324291165,7/16/2014 15:07:10,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,220,285,,,235,297,M. TUBERCULOSIS,TUBERCULOSIS,M. TUBERCULOSIS,220-223,285,TUBERCULOSIS,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north-west of Russia, including those in Saint Petersburg, in 1998-2001, and the M. tuberculosis strains H37Rv, M. bovis, and M. bovic BCG and M. tuberculosis in the specimens painted for microscopy.",220 223,285,220,285,235,297,-1,RO-has_causative_agent,903535,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north-west of Russia, including those in Saint Petersburg, in 1998-2001, and the M. tuberculosis strains H37Rv, M. bovis, and M. bovic BCG and M. tuberculosis in the specimens painted for microscopy",M. tuberculosis,tuberculosis
503461388,7/16/2014 15:21:13,,1324295506,7/16/2014 15:20:52,instagc,1,19636746,USA,NY,Andover,192.182.216.225,220,285,,,235,297,M. TUBERCULOSIS,TUBERCULOSIS,"M. TUBERCULOSIS strains H37Rv,",220-223-236-244,282-285,M. TUBERCULOSIS,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north-west of Russia, including those in Saint Petersburg, in 1998-2001, and the M. tuberculosis strains H37Rv, M. bovis, and M. bovic BCG and M. tuberculosis in the specimens painted for microscopy.",220 223,285,220,285,235,297,-1,RO-has_causative_agent,903535,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north-west of Russia, including those in Saint Petersburg, in 1998-2001, and the M. tuberculosis strains H37Rv, M. bovis, and M. bovic BCG and M. tuberculosis in the specimens painted for microscopy",M. tuberculosis,tuberculosis
503461389,7/16/2014 13:45:03,,1324259455,7/16/2014 13:44:49,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,170,141,,,184,149,OSTEOARTHRITIS,NAPROXEN,"OSTEOARTHRITIS of the hip,",170-185-188-192,141,NAPROXEN,"In a double-blind study, the efficacy and tolerability of S-adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and naproxen in the treatment of osteoarthritis of the hip, knee, spine, and hand.",170,141,170,141,184,149,1,RO-may_treat,908100,"In a double-blind study, the efficacy and tolerability of S-adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and naproxen in the treatment of osteoarthritis of the hip, knee, spine, and hand",osteoarthritis,naproxen
503461389,7/16/2014 14:05:50,,1324267599,7/16/2014 14:04:36,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,170,141,,,184,149,OSTEOARTHRITIS,NAPROXEN,"OSTEOARTHRITIS of the hip,",170-185-188-192,141,NAPROXEN,"In a double-blind study, the efficacy and tolerability of S-adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and naproxen in the treatment of osteoarthritis of the hip, knee, spine, and hand.",170,141,170,141,184,149,1,RO-may_treat,908100,"In a double-blind study, the efficacy and tolerability of S-adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and naproxen in the treatment of osteoarthritis of the hip, knee, spine, and hand",osteoarthritis,naproxen
503461389,7/16/2014 14:06:03,,1324267720,7/16/2014 14:05:36,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,170,141,,,184,149,OSTEOARTHRITIS,NAPROXEN,OSTEOARTHRITIS,170,141,NAPROXEN,"In a double-blind study, the efficacy and tolerability of S-adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and naproxen in the treatment of osteoarthritis of the hip, knee, spine, and hand.",170,141,170,141,184,149,1,RO-may_treat,908100,"In a double-blind study, the efficacy and tolerability of S-adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and naproxen in the treatment of osteoarthritis of the hip, knee, spine, and hand",osteoarthritis,naproxen
503461389,7/16/2014 14:11:27,,1324270072,7/16/2014 14:11:19,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,170,141,,,184,149,OSTEOARTHRITIS,NAPROXEN,"the treatment of OSTEOARTHRITIS of the hip,",153-157-167-170-185-188-192,126-129-137-141-150-153-157,of placebo and NAPROXEN in the treatment,"In a double-blind study, the efficacy and tolerability of S-adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and naproxen in the treatment of osteoarthritis of the hip, knee, spine, and hand.",170,141,170,141,184,149,1,RO-may_treat,908100,"In a double-blind study, the efficacy and tolerability of S-adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and naproxen in the treatment of osteoarthritis of the hip, knee, spine, and hand",osteoarthritis,naproxen
503461389,7/16/2014 14:17:33,,1324272539,7/16/2014 14:17:07,vivatic,1.0,25451531,GBR,"","",83.67.28.193,170,141,,,184,149,OSTEOARTHRITIS,NAPROXEN,"OSTEOARTHRITIS of the hip, knee, spine, and hand.",170-185-188-192-197-203-210-214,141,NAPROXEN,"In a double-blind study, the efficacy and tolerability of S-adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and naproxen in the treatment of osteoarthritis of the hip, knee, spine, and hand.",170,141,170,141,184,149,1,RO-may_treat,908100,"In a double-blind study, the efficacy and tolerability of S-adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and naproxen in the treatment of osteoarthritis of the hip, knee, spine, and hand",osteoarthritis,naproxen
503461389,7/16/2014 14:22:32,,1324274591,7/16/2014 14:22:14,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,170,141,,,184,149,OSTEOARTHRITIS,NAPROXEN,OSTEOARTHRITIS,170,141,NAPROXEN,"In a double-blind study, the efficacy and tolerability of S-adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and naproxen in the treatment of osteoarthritis of the hip, knee, spine, and hand.",170,141,170,141,184,149,1,RO-may_treat,908100,"In a double-blind study, the efficacy and tolerability of S-adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and naproxen in the treatment of osteoarthritis of the hip, knee, spine, and hand",osteoarthritis,naproxen
503461389,7/16/2014 14:26:15,,1324276009,7/16/2014 14:25:56,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,170,141,,,184,149,OSTEOARTHRITIS,NAPROXEN,OSTEOARTHRITIS,170,141,NAPROXEN,"In a double-blind study, the efficacy and tolerability of S-adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and naproxen in the treatment of osteoarthritis of the hip, knee, spine, and hand.",170,141,170,141,184,149,1,RO-may_treat,908100,"In a double-blind study, the efficacy and tolerability of S-adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and naproxen in the treatment of osteoarthritis of the hip, knee, spine, and hand",osteoarthritis,naproxen
503461389,7/16/2014 14:28:38,,1324276940,7/16/2014 14:27:50,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,170,141,,,184,149,OSTEOARTHRITIS,NAPROXEN,OSTEOARTHRITIS,170,141,NAPROXEN,"In a double-blind study, the efficacy and tolerability of S-adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and naproxen in the treatment of osteoarthritis of the hip, knee, spine, and hand.",170,141,170,141,184,149,1,RO-may_treat,908100,"In a double-blind study, the efficacy and tolerability of S-adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and naproxen in the treatment of osteoarthritis of the hip, knee, spine, and hand",osteoarthritis,naproxen
503461389,7/16/2014 14:36:28,,1324280345,7/16/2014 14:35:44,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,170,141,,,184,149,OSTEOARTHRITIS,NAPROXEN,naproxen OSTEOARTHRITIS,141-170,141-170,NAPROXEN osteoarthritis,"In a double-blind study, the efficacy and tolerability of S-adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and naproxen in the treatment of osteoarthritis of the hip, knee, spine, and hand.",170,141,170,141,184,149,1,RO-may_treat,908100,"In a double-blind study, the efficacy and tolerability of S-adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and naproxen in the treatment of osteoarthritis of the hip, knee, spine, and hand",osteoarthritis,naproxen
503461389,7/16/2014 14:37:05,,1324280562,7/16/2014 14:36:29,prodege,1.0,26790109,USA,"","",23.125.64.233,170,141,,,184,149,OSTEOARTHRITIS,NAPROXEN,"OSTEOARTHRITIS the hip, knee, spine, and hand.",170-188-192-197-203-210-214,126-129-137-141-150-153-157-167-170-185-188-192-197-203-210-214,"of placebo and NAPROXEN in the treatment of osteoarthritis of the hip, knee, spine, and hand.","In a double-blind study, the efficacy and tolerability of S-adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and naproxen in the treatment of osteoarthritis of the hip, knee, spine, and hand.",170,141,170,141,184,149,1,RO-may_treat,908100,"In a double-blind study, the efficacy and tolerability of S-adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and naproxen in the treatment of osteoarthritis of the hip, knee, spine, and hand",osteoarthritis,naproxen
503461390,7/16/2014 13:50:03,,1324261088,7/16/2014 13:49:45,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,32,68,,,49,74,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,32-39,68-75,ATOPIC families,It also occurs in children with atopic dermatitis and in members of atopic families without concomitant bronchial asthma.,32 39,68,32,68,49,74,-1,RO-cause_of,900373,It also occurs in children with atopic dermatitis and in members of atopic families without concomitant bronchial asthma,atopic dermatitis,atopic
503461390,7/16/2014 14:02:03,,1324265973,7/16/2014 14:01:26,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,32,68,,,49,74,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS atopic bronchial asthma.,32-39-104-114-68,32-39-68-104-114,atopic dermatitis ATOPIC bronchial asthma.,It also occurs in children with atopic dermatitis and in members of atopic families without concomitant bronchial asthma.,32 39,68,32,68,49,74,-1,RO-cause_of,900373,It also occurs in children with atopic dermatitis and in members of atopic families without concomitant bronchial asthma,atopic dermatitis,atopic
503461390,7/16/2014 14:02:14,,1324266013,7/16/2014 14:01:43,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,32,68,,,49,74,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,32-39,68-75,ATOPIC families,It also occurs in children with atopic dermatitis and in members of atopic families without concomitant bronchial asthma.,32 39,68,32,68,49,74,-1,RO-cause_of,900373,It also occurs in children with atopic dermatitis and in members of atopic families without concomitant bronchial asthma,atopic dermatitis,atopic
503461390,7/16/2014 14:06:21,,1324267867,7/16/2014 14:06:04,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,32,68,,,49,74,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,32-39,68-75,ATOPIC families,It also occurs in children with atopic dermatitis and in members of atopic families without concomitant bronchial asthma.,32 39,68,32,68,49,74,-1,RO-cause_of,900373,It also occurs in children with atopic dermatitis and in members of atopic families without concomitant bronchial asthma,atopic dermatitis,atopic
503461390,7/16/2014 14:12:22,,1324270516,7/16/2014 14:12:04,instagc,1.0,13763729,USA,"","",75.182.89.225,32,68,,,49,74,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,32-39,68,ATOPIC,It also occurs in children with atopic dermatitis and in members of atopic families without concomitant bronchial asthma.,32 39,68,32,68,49,74,-1,RO-cause_of,900373,It also occurs in children with atopic dermatitis and in members of atopic families without concomitant bronchial asthma,atopic dermatitis,atopic
503461390,7/16/2014 14:15:55,,1324271868,7/16/2014 14:15:41,prodege,1.0,17932518,GBR,"","",81.133.61.60,32,68,,,49,74,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,32-39,68-92-104-114,ATOPIC concomitant bronchial asthma.,It also occurs in children with atopic dermatitis and in members of atopic families without concomitant bronchial asthma.,32 39,68,32,68,49,74,-1,RO-cause_of,900373,It also occurs in children with atopic dermatitis and in members of atopic families without concomitant bronchial asthma,atopic dermatitis,atopic
503461390,7/16/2014 14:21:52,,1324274324,7/16/2014 14:21:33,vivatic,1.0,25451531,GBR,"","",83.67.28.193,32,68,,,49,74,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,32-39,68-75-84-92-104-114,ATOPIC families without concomitant bronchial asthma.,It also occurs in children with atopic dermatitis and in members of atopic families without concomitant bronchial asthma.,32 39,68,32,68,49,74,-1,RO-cause_of,900373,It also occurs in children with atopic dermatitis and in members of atopic families without concomitant bronchial asthma,atopic dermatitis,atopic
503461390,7/16/2014 14:23:45,,1324275050,7/16/2014 14:23:28,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,32,68,,,49,74,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,32-39,68,ATOPIC,It also occurs in children with atopic dermatitis and in members of atopic families without concomitant bronchial asthma.,32 39,68,32,68,49,74,-1,RO-cause_of,900373,It also occurs in children with atopic dermatitis and in members of atopic families without concomitant bronchial asthma,atopic dermatitis,atopic
503461390,7/16/2014 14:40:18,,1324281732,7/16/2014 14:39:36,prodege,1.0,26790109,USA,"","",23.125.64.233,32,68,,,49,74,ATOPIC DERMATITIS,ATOPIC,in children with ATOPIC DERMATITIS and in members of atopic families without concomitant bronchial asthma.,15-18-27-32-39-50-54-57-65-68-75-84-92-104-114,54-57-65-68-75-84-92-104-114,in members of ATOPIC families without concomitant bronchial asthma.,It also occurs in children with atopic dermatitis and in members of atopic families without concomitant bronchial asthma.,32 39,68,32,68,49,74,-1,RO-cause_of,900373,It also occurs in children with atopic dermatitis and in members of atopic families without concomitant bronchial asthma,atopic dermatitis,atopic
503461390,7/16/2014 14:42:55,,1324282459,7/16/2014 14:42:46,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,32,68,,,49,74,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,32-39,68,ATOPIC,It also occurs in children with atopic dermatitis and in members of atopic families without concomitant bronchial asthma.,32 39,68,32,68,49,74,-1,RO-cause_of,900373,It also occurs in children with atopic dermatitis and in members of atopic families without concomitant bronchial asthma,atopic dermatitis,atopic
503461391,7/16/2014 13:49:29,,1324260905,7/16/2014 13:49:10,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,246,178,,,256,185,PLASMODIUM,MALARIA,PLASMODIUM falciparum infection,246-257-268,178,MALARIA:,"malaria  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta-analysis  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",246,178,246,178,256,185,-1,RO-has_causative_agent,903659,"malaria  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta-analysis  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone",Plasmodium,malaria
503461391,7/16/2014 13:50:04,,1324261109,7/16/2014 13:49:49,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,246,178,,,256,185,PLASMODIUM,MALARIA,PLASMODIUM falciparum infection,246-257-268,178,MALARIA:,"malaria  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta-analysis  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",246,178,246,178,256,185,-1,RO-has_causative_agent,903659,"malaria  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta-analysis  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone",Plasmodium,malaria
503461391,7/16/2014 14:09:05,,1324269017,7/16/2014 14:07:40,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,246,178,,,256,185,PLASMODIUM,MALARIA,PLASMODIUM falciparum infection and disease,246-257-268-278-282,178,MALARIA:,"malaria  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta-analysis  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",246,178,246,178,256,185,-1,RO-has_causative_agent,903659,"malaria  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta-analysis  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone",Plasmodium,malaria
503461391,7/16/2014 14:22:13,,1324274456,7/16/2014 14:21:55,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,246,178,,,256,185,PLASMODIUM,MALARIA,PLASMODIUM falciparum infection,246-257-268,178,MALARIA:,"malaria  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta-analysis  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",246,178,246,178,256,185,-1,RO-has_causative_agent,903659,"malaria  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta-analysis  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone",Plasmodium,malaria
503461391,7/16/2014 14:34:25,,1324279345,7/16/2014 14:33:52,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,246,178,,,256,185,PLASMODIUM,MALARIA,PLASMODIUM falciparum infection,246-257-268,178,MALARIA:,"malaria  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta-analysis  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",246,178,246,178,256,185,-1,RO-has_causative_agent,903659,"malaria  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta-analysis  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone",Plasmodium,malaria
503461391,7/16/2014 14:43:19,,1324282567,7/16/2014 14:42:44,neodev,1.0,28336203,USA,PA,Harrisburg,50.149.53.150,246,178,,,256,185,PLASMODIUM,MALARIA,PLASMODIUM falciparum infection,246-257-268,178,MALARIA:,"malaria  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta-analysis  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",246,178,246,178,256,185,-1,RO-has_causative_agent,903659,"malaria  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta-analysis  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone",Plasmodium,malaria
503461391,7/16/2014 14:52:16,,1324285128,7/16/2014 14:51:49,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,246,178,,,256,185,PLASMODIUM,MALARIA,PLASMODIUM falciparum,246-257,178,MALARIA:,"malaria  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta-analysis  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",246,178,246,178,256,185,-1,RO-has_causative_agent,903659,"malaria  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta-analysis  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone",Plasmodium,malaria
503461391,7/16/2014 14:53:26,,1324285529,7/16/2014 14:52:49,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.72,246,178,,,256,185,PLASMODIUM,MALARIA,PLASMODIUM falciparum infection,246-257-268,178,MALARIA:,"malaria  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta-analysis  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",246,178,246,178,256,185,-1,RO-has_causative_agent,903659,"malaria  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta-analysis  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone",Plasmodium,malaria
503461391,7/16/2014 14:54:02,,1324285714,7/16/2014 14:51:59,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,246,178,,,256,185,PLASMODIUM,MALARIA,PLASMODIUM falciparum infection,246-257-268,178,MALARIA:,"malaria  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta-analysis  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",246,178,246,178,256,185,-1,RO-has_causative_agent,903659,"malaria  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta-analysis  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone",Plasmodium,malaria
503461391,7/16/2014 14:54:53,,1324285980,7/16/2014 14:54:51,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,246,178,,,256,185,PLASMODIUM,MALARIA,AS02A vaccine against PLASMODIUM falciparum infection and,224-230-238-246-257-268-278,161-165-175-178-187-192-202,for treatment of MALARIA: meta analysis Efficacy,"malaria  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta-analysis  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",246,178,246,178,256,185,-1,RO-has_causative_agent,903659,"malaria  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta-analysis  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone",Plasmodium,malaria
503461392,7/16/2014 13:44:00,,1324259122,7/16/2014 13:42:52,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,214,227,,,223,261,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,genital DYSPLASIA or cervical intraepithelial,206-214-227-236-224,206-214-224-227-236-252,genital dysplasia or CERVICAL INTRAEPITHELIAL NEOPLASIA,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible genital dysplasia or cervical intraepithelial neoplasia (CIN) I, and in 1 of 3 patients with past CIN II/III.",214,227 236 252,214,227,223,261,-1,RO-disease_has_finding,901802,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible genital dysplasia or cervical intraepithelial neoplasia (CIN) I, and in 1 of 3 patients with past CIN II/III",dysplasia,cervical intraepithelial neoplasia
503461392,7/16/2014 13:51:52,,1324261764,7/16/2014 13:51:36,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,214,227,,,223,261,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,visible genital DYSPLASIA,198-206-214,227-236-252-262,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN),"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible genital dysplasia or cervical intraepithelial neoplasia (CIN) I, and in 1 of 3 patients with past CIN II/III.",214,227 236 252,214,227,223,261,-1,RO-disease_has_finding,901802,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible genital dysplasia or cervical intraepithelial neoplasia (CIN) I, and in 1 of 3 patients with past CIN II/III",dysplasia,cervical intraepithelial neoplasia
503461392,7/16/2014 13:55:16,,1324263078,7/16/2014 13:54:30,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,214,227,,,223,261,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,"HPV cervical scrapes visible genital dysplasia, visible genital DYSPLASIA cervical intraepithelial neoplasia (CIN) I, CIN II III.",53-89-98-147-155-163-198-206-214-227-236-252-262-304-308-311-268,53-89-98-147-155-163-198-206-214-227-236-252-262-304-308-311-268,"HPV cervical scrapes visible genital dysplasia, visible genital dysplasia CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I, CIN II III.","Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible genital dysplasia or cervical intraepithelial neoplasia (CIN) I, and in 1 of 3 patients with past CIN II/III.",214,227 236 252,214,227,223,261,-1,RO-disease_has_finding,901802,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible genital dysplasia or cervical intraepithelial neoplasia (CIN) I, and in 1 of 3 patients with past CIN II/III",dysplasia,cervical intraepithelial neoplasia
503461392,7/16/2014 14:01:13,,1324265514,7/16/2014 14:00:28,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,214,227,,,223,261,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,DYSPLASIA,214,227-236-252,CERVICAL INTRAEPITHELIAL NEOPLASIA,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible genital dysplasia or cervical intraepithelial neoplasia (CIN) I, and in 1 of 3 patients with past CIN II/III.",214,227 236 252,214,227,223,261,-1,RO-disease_has_finding,901802,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible genital dysplasia or cervical intraepithelial neoplasia (CIN) I, and in 1 of 3 patients with past CIN II/III",dysplasia,cervical intraepithelial neoplasia
503461392,7/16/2014 14:03:20,,1324266518,7/16/2014 14:03:06,instagc,1.0,18960682,GBR,"","",86.29.147.112,214,227,,,223,261,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,visible genital DYSPLASIA,198-206-214,227-236-252-262-268,"CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I,","Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible genital dysplasia or cervical intraepithelial neoplasia (CIN) I, and in 1 of 3 patients with past CIN II/III.",214,227 236 252,214,227,223,261,-1,RO-disease_has_finding,901802,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible genital dysplasia or cervical intraepithelial neoplasia (CIN) I, and in 1 of 3 patients with past CIN II/III",dysplasia,cervical intraepithelial neoplasia
503461392,7/16/2014 14:03:53,,1324266764,7/16/2014 14:02:33,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,214,227,,,223,261,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,genital DYSPLASIA,206-214,227-236-252,CERVICAL INTRAEPITHELIAL NEOPLASIA,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible genital dysplasia or cervical intraepithelial neoplasia (CIN) I, and in 1 of 3 patients with past CIN II/III.",214,227 236 252,214,227,223,261,-1,RO-disease_has_finding,901802,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible genital dysplasia or cervical intraepithelial neoplasia (CIN) I, and in 1 of 3 patients with past CIN II/III",dysplasia,cervical intraepithelial neoplasia
503461392,7/16/2014 14:14:51,,1324271496,7/16/2014 14:14:36,instagc,1.0,13763729,USA,"","",75.182.89.225,214,227,,,223,261,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,genital DYSPLASIA,206-214,227-236-252,CERVICAL INTRAEPITHELIAL NEOPLASIA,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible genital dysplasia or cervical intraepithelial neoplasia (CIN) I, and in 1 of 3 patients with past CIN II/III.",214,227 236 252,214,227,223,261,-1,RO-disease_has_finding,901802,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible genital dysplasia or cervical intraepithelial neoplasia (CIN) I, and in 1 of 3 patients with past CIN II/III",dysplasia,cervical intraepithelial neoplasia
503461392,7/16/2014 14:25:00,,1324275549,7/16/2014 14:24:41,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,214,227,,,223,261,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,DYSPLASIA,214,227-236-252,CERVICAL INTRAEPITHELIAL NEOPLASIA,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible genital dysplasia or cervical intraepithelial neoplasia (CIN) I, and in 1 of 3 patients with past CIN II/III.",214,227 236 252,214,227,223,261,-1,RO-disease_has_finding,901802,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible genital dysplasia or cervical intraepithelial neoplasia (CIN) I, and in 1 of 3 patients with past CIN II/III",dysplasia,cervical intraepithelial neoplasia
503461392,7/16/2014 14:32:22,,1324278557,7/16/2014 14:31:56,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,214,227,,,223,261,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,DYSPLASIA cervical intraepithelial neoplasia,214-227-236-252,214-227-236-252-268,"dysplasia CERVICAL INTRAEPITHELIAL NEOPLASIA I,","Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible genital dysplasia or cervical intraepithelial neoplasia (CIN) I, and in 1 of 3 patients with past CIN II/III.",214,227 236 252,214,227,223,261,-1,RO-disease_has_finding,901802,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible genital dysplasia or cervical intraepithelial neoplasia (CIN) I, and in 1 of 3 patients with past CIN II/III",dysplasia,cervical intraepithelial neoplasia
503461392,7/16/2014 14:44:19,,1324282831,7/16/2014 14:43:54,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,214,227,,,223,261,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,genital DYSPLASIA,206-214,227-236-252-262-268,"CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I,","Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible genital dysplasia or cervical intraepithelial neoplasia (CIN) I, and in 1 of 3 patients with past CIN II/III.",214,227 236 252,214,227,223,261,-1,RO-disease_has_finding,901802,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible genital dysplasia or cervical intraepithelial neoplasia (CIN) I, and in 1 of 3 patients with past CIN II/III",dysplasia,cervical intraepithelial neoplasia
503461393,7/16/2014 13:49:36,,1324260940,7/16/2014 13:49:13,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,112,170,,,116,182,BONE,OSTEOPOROSIS,effects on BONE cells,101-109-112-117,150-154-167-170,the pathogenesis of OSTEOPOROSIS.,"Interleukin-6 (IL-6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on bone cells and has been implicated in the pathogenesis of osteoporosis.",112,170,112,170,116,182,1,RO-disease_has_primary_anatomic_site,902076,"Interleukin-6 (IL-6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on bone cells and has been implicated in the pathogenesis of osteoporosis",bone,osteoporosis
503461393,7/16/2014 13:55:47,,1324263326,7/16/2014 13:55:22,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,112,170,,,116,182,BONE,OSTEOPOROSIS,BONE cells osteoporosis.,112-117-170,112-170-117,bone cells OSTEOPOROSIS.,"Interleukin-6 (IL-6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on bone cells and has been implicated in the pathogenesis of osteoporosis.",112,170,112,170,116,182,1,RO-disease_has_primary_anatomic_site,902076,"Interleukin-6 (IL-6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on bone cells and has been implicated in the pathogenesis of osteoporosis",bone,osteoporosis
503461393,7/16/2014 14:14:48,,1324271482,7/16/2014 14:14:10,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,112,170,,,116,182,BONE,OSTEOPOROSIS,BONE cells,112-117,170,OSTEOPOROSIS.,"Interleukin-6 (IL-6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on bone cells and has been implicated in the pathogenesis of osteoporosis.",112,170,112,170,116,182,1,RO-disease_has_primary_anatomic_site,902076,"Interleukin-6 (IL-6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on bone cells and has been implicated in the pathogenesis of osteoporosis",bone,osteoporosis
503461393,7/16/2014 14:23:33,,1324274982,7/16/2014 14:23:19,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,112,170,,,116,182,BONE,OSTEOPOROSIS,BONE cells,112-117,170,OSTEOPOROSIS.,"Interleukin-6 (IL-6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on bone cells and has been implicated in the pathogenesis of osteoporosis.",112,170,112,170,116,182,1,RO-disease_has_primary_anatomic_site,902076,"Interleukin-6 (IL-6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on bone cells and has been implicated in the pathogenesis of osteoporosis",bone,osteoporosis
503461393,7/16/2014 14:37:57,,1324280934,7/16/2014 14:37:46,prodege,1.0,6316959,GBR,"","",46.208.145.114,112,170,,,116,182,BONE,OSTEOPOROSIS,BONE cells,112-117,170,OSTEOPOROSIS.,"Interleukin-6 (IL-6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on bone cells and has been implicated in the pathogenesis of osteoporosis.",112,170,112,170,116,182,1,RO-disease_has_primary_anatomic_site,902076,"Interleukin-6 (IL-6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on bone cells and has been implicated in the pathogenesis of osteoporosis",bone,osteoporosis
503461393,7/16/2014 14:45:05,,1324283000,7/16/2014 14:44:58,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,112,170,,,116,182,BONE,OSTEOPOROSIS,BONE,112,154-167-170,pathogenesis of OSTEOPOROSIS.,"Interleukin-6 (IL-6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on bone cells and has been implicated in the pathogenesis of osteoporosis.",112,170,112,170,116,182,1,RO-disease_has_primary_anatomic_site,902076,"Interleukin-6 (IL-6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on bone cells and has been implicated in the pathogenesis of osteoporosis",bone,osteoporosis
503461393,7/16/2014 14:46:28,,1324283371,7/16/2014 14:46:14,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,112,170,,,116,182,BONE,OSTEOPOROSIS,BONE cells,112-117,170,OSTEOPOROSIS.,"Interleukin-6 (IL-6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on bone cells and has been implicated in the pathogenesis of osteoporosis.",112,170,112,170,116,182,1,RO-disease_has_primary_anatomic_site,902076,"Interleukin-6 (IL-6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on bone cells and has been implicated in the pathogenesis of osteoporosis",bone,osteoporosis
503461393,7/16/2014 14:53:56,,1324285680,7/16/2014 14:53:46,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,112,170,,,116,182,BONE,OSTEOPOROSIS,BONE cells,112-117,170,OSTEOPOROSIS.,"Interleukin-6 (IL-6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on bone cells and has been implicated in the pathogenesis of osteoporosis.",112,170,112,170,116,182,1,RO-disease_has_primary_anatomic_site,902076,"Interleukin-6 (IL-6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on bone cells and has been implicated in the pathogenesis of osteoporosis",bone,osteoporosis
503461393,7/16/2014 14:54:36,,1324285899,7/16/2014 14:54:08,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,112,170,,,116,182,BONE,OSTEOPOROSIS,Interleukin 6 (IL - 6) osteoporosis BONE pathogenesis osteoporosis.,0-12-14-17-18-57-112-154-170,0-12-14-18-57-112-117-154-167-170,Interleukin 6 (IL 6) osteoporosis bone cells pathogenesis of OSTEOPOROSIS.,"Interleukin-6 (IL-6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on bone cells and has been implicated in the pathogenesis of osteoporosis.",112,170,112,170,116,182,1,RO-disease_has_primary_anatomic_site,902076,"Interleukin-6 (IL-6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on bone cells and has been implicated in the pathogenesis of osteoporosis",bone,osteoporosis
503461393,7/16/2014 14:56:27,,1324286591,7/16/2014 14:56:15,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,112,170,,,116,182,BONE,OSTEOPOROSIS,BONE cells,112-117,170,OSTEOPOROSIS.,"Interleukin-6 (IL-6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on bone cells and has been implicated in the pathogenesis of osteoporosis.",112,170,112,170,116,182,1,RO-disease_has_primary_anatomic_site,902076,"Interleukin-6 (IL-6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on bone cells and has been implicated in the pathogenesis of osteoporosis",bone,osteoporosis
503461394,7/16/2014 13:52:57,,1324262164,7/16/2014 13:52:45,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,100,133,,,131,138,GASTROINTESTINAL STROMAL TUMORS,GISTS,GASTROINTESTINAL STROMAL TUMORS (GISTs.,100-117-125-132,117-125-132-100,gastrointestinal stromal tumors (GISTS.,"Stromal tumors in the gastrointestinal (GI) tract consist of myogenic tumors, neurogenic tumors and gastrointestinal stromal tumors (GISTs.",100 117 125,,100,133,131,138,-1,RO-has_manifestation,906004,"Stromal tumors in the gastrointestinal (GI) tract consist of myogenic tumors, neurogenic tumors and gastrointestinal stromal tumors (GISTs",gastrointestinal stromal tumors,GISTs
503461394,7/16/2014 13:53:17,,1324262312,7/16/2014 13:53:09,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,100,133,,,131,138,GASTROINTESTINAL STROMAL TUMORS,GISTS,neurogenic tumors and GASTROINTESTINAL STROMAL TUMORS,78-89-96-100-117-125,117-125-132-100,gastrointestinal stromal tumors (GISTS.,"Stromal tumors in the gastrointestinal (GI) tract consist of myogenic tumors, neurogenic tumors and gastrointestinal stromal tumors (GISTs.",100 117 125,,100,133,131,138,-1,RO-has_manifestation,906004,"Stromal tumors in the gastrointestinal (GI) tract consist of myogenic tumors, neurogenic tumors and gastrointestinal stromal tumors (GISTs",gastrointestinal stromal tumors,GISTs
503461394,7/16/2014 14:02:04,,1324265972,7/16/2014 14:01:47,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,100,133,,,131,138,GASTROINTESTINAL STROMAL TUMORS,GISTS,GASTROINTESTINAL STROMAL TUMORS (GISTs.,100-117-125-132,117-125-132-100,gastrointestinal stromal tumors (GISTS.,"Stromal tumors in the gastrointestinal (GI) tract consist of myogenic tumors, neurogenic tumors and gastrointestinal stromal tumors (GISTs.",100 117 125,,100,133,131,138,-1,RO-has_manifestation,906004,"Stromal tumors in the gastrointestinal (GI) tract consist of myogenic tumors, neurogenic tumors and gastrointestinal stromal tumors (GISTs",gastrointestinal stromal tumors,GISTs
503461394,7/16/2014 14:25:07,,1324275592,7/16/2014 14:24:55,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,100,133,,,131,138,GASTROINTESTINAL STROMAL TUMORS,GISTS,GASTROINTESTINAL STROMAL TUMORS,100-117-125,117-125-132,stromal tumors (GISTS.,"Stromal tumors in the gastrointestinal (GI) tract consist of myogenic tumors, neurogenic tumors and gastrointestinal stromal tumors (GISTs.",100 117 125,,100,133,131,138,-1,RO-has_manifestation,906004,"Stromal tumors in the gastrointestinal (GI) tract consist of myogenic tumors, neurogenic tumors and gastrointestinal stromal tumors (GISTs",gastrointestinal stromal tumors,GISTs
503461394,7/16/2014 14:33:01,,1324278791,7/16/2014 14:32:40,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,100,133,,,131,138,GASTROINTESTINAL STROMAL TUMORS,GISTS,GASTROINTESTINAL STROMAL TUMORS (GISTs.,100-117-125-132,117-125-132-100,gastrointestinal stromal tumors (GISTS.,"Stromal tumors in the gastrointestinal (GI) tract consist of myogenic tumors, neurogenic tumors and gastrointestinal stromal tumors (GISTs.",100 117 125,,100,133,131,138,-1,RO-has_manifestation,906004,"Stromal tumors in the gastrointestinal (GI) tract consist of myogenic tumors, neurogenic tumors and gastrointestinal stromal tumors (GISTs",gastrointestinal stromal tumors,GISTs
503461394,7/16/2014 14:40:41,,1324281823,7/16/2014 14:40:18,prodege,1.0,26790109,USA,"","",23.125.64.233,100,133,,,131,138,GASTROINTESTINAL STROMAL TUMORS,GISTS,neurogenic tumors and GASTROINTESTINAL STROMAL TUMORS,78-89-96-100-117-125,117-125-132-100,gastrointestinal stromal tumors (GISTS.,"Stromal tumors in the gastrointestinal (GI) tract consist of myogenic tumors, neurogenic tumors and gastrointestinal stromal tumors (GISTs.",100 117 125,,100,133,131,138,-1,RO-has_manifestation,906004,"Stromal tumors in the gastrointestinal (GI) tract consist of myogenic tumors, neurogenic tumors and gastrointestinal stromal tumors (GISTs",gastrointestinal stromal tumors,GISTs
503461394,7/16/2014 14:52:32,,1324285215,7/16/2014 14:52:14,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,100,133,,,131,138,GASTROINTESTINAL STROMAL TUMORS,GISTS,GASTROINTESTINAL STROMAL TUMORS (GISTs.,100-117-125-132,117-125-132-100,gastrointestinal stromal tumors (GISTS.,"Stromal tumors in the gastrointestinal (GI) tract consist of myogenic tumors, neurogenic tumors and gastrointestinal stromal tumors (GISTs.",100 117 125,,100,133,131,138,-1,RO-has_manifestation,906004,"Stromal tumors in the gastrointestinal (GI) tract consist of myogenic tumors, neurogenic tumors and gastrointestinal stromal tumors (GISTs",gastrointestinal stromal tumors,GISTs
503461394,7/16/2014 14:55:10,,1324286100,7/16/2014 14:55:09,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,100,133,,,131,138,GASTROINTESTINAL STROMAL TUMORS,GISTS,neurogenic tumors and GASTROINTESTINAL STROMAL TUMORS,78-89-96-100-117-125,117-125-132,stromal tumors (GISTS.,"Stromal tumors in the gastrointestinal (GI) tract consist of myogenic tumors, neurogenic tumors and gastrointestinal stromal tumors (GISTs.",100 117 125,,100,133,131,138,-1,RO-has_manifestation,906004,"Stromal tumors in the gastrointestinal (GI) tract consist of myogenic tumors, neurogenic tumors and gastrointestinal stromal tumors (GISTs",gastrointestinal stromal tumors,GISTs
503461394,7/16/2014 14:56:59,,1324286832,7/16/2014 14:56:36,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,100,133,,,131,138,GASTROINTESTINAL STROMAL TUMORS,GISTS,GASTROINTESTINAL STROMAL TUMORS (GISTs.,100-117-125-132,117-125-132-100,gastrointestinal stromal tumors (GISTS.,"Stromal tumors in the gastrointestinal (GI) tract consist of myogenic tumors, neurogenic tumors and gastrointestinal stromal tumors (GISTs.",100 117 125,,100,133,131,138,-1,RO-has_manifestation,906004,"Stromal tumors in the gastrointestinal (GI) tract consist of myogenic tumors, neurogenic tumors and gastrointestinal stromal tumors (GISTs",gastrointestinal stromal tumors,GISTs
503461394,7/16/2014 14:58:15,,1324287312,7/16/2014 14:58:00,irazoo,1.0,7022810,USA,IA,Ankeny,216.161.121.1,100,133,,,131,138,GASTROINTESTINAL STROMAL TUMORS,GISTS,GASTROINTESTINAL STROMAL TUMORS (GISTs.,100-117-125-132,117-125-132-100,gastrointestinal stromal tumors (GISTS.,"Stromal tumors in the gastrointestinal (GI) tract consist of myogenic tumors, neurogenic tumors and gastrointestinal stromal tumors (GISTs.",100 117 125,,100,133,131,138,-1,RO-has_manifestation,906004,"Stromal tumors in the gastrointestinal (GI) tract consist of myogenic tumors, neurogenic tumors and gastrointestinal stromal tumors (GISTs",gastrointestinal stromal tumors,GISTs
503461395,7/16/2014 13:52:42,,1324262067,7/16/2014 13:52:29,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,57,76,,,63,110,CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA,"CERVIX,",57,76-85-101,CERVICAL INTRAEPITHELIAL NEOPLASIA,"Altogether, 1924 women were studied: 42.8% with a normal cervix, 16.2% with cervical intraepithelial neoplasia (CIN) I, 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",57,76 85 101,57,76,63,110,1,RO-disease_has_primary_anatomic_site,902157,"Altogether, 1924 women were studied: 42.8% with a normal cervix, 16.2% with cervical intraepithelial neoplasia (CIN) I, 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC",cervix,cervical intraepithelial neoplasia
503461395,7/16/2014 13:59:07,,1324264824,7/16/2014 13:58:50,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,57,76,,,63,110,CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA,"normal CERVIX,",50-57,76-85-101-111-117,"CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I,","Altogether, 1924 women were studied: 42.8% with a normal cervix, 16.2% with cervical intraepithelial neoplasia (CIN) I, 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",57,76 85 101,57,76,63,110,1,RO-disease_has_primary_anatomic_site,902157,"Altogether, 1924 women were studied: 42.8% with a normal cervix, 16.2% with cervical intraepithelial neoplasia (CIN) I, 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC",cervix,cervical intraepithelial neoplasia
503461395,7/16/2014 14:01:42,,1324265807,7/16/2014 14:01:22,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,57,76,,,63,110,CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA,"normal CERVIX,",50-57,76-85-101-111,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN),"Altogether, 1924 women were studied: 42.8% with a normal cervix, 16.2% with cervical intraepithelial neoplasia (CIN) I, 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",57,76 85 101,57,76,63,110,1,RO-disease_has_primary_anatomic_site,902157,"Altogether, 1924 women were studied: 42.8% with a normal cervix, 16.2% with cervical intraepithelial neoplasia (CIN) I, 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC",cervix,cervical intraepithelial neoplasia
503461395,7/16/2014 14:07:51,,1324268473,7/16/2014 14:07:34,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,57,76,,,63,110,CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA,"CERVIX,",57,76-85-101-111-117,"CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I,","Altogether, 1924 women were studied: 42.8% with a normal cervix, 16.2% with cervical intraepithelial neoplasia (CIN) I, 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",57,76 85 101,57,76,63,110,1,RO-disease_has_primary_anatomic_site,902157,"Altogether, 1924 women were studied: 42.8% with a normal cervix, 16.2% with cervical intraepithelial neoplasia (CIN) I, 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC",cervix,cervical intraepithelial neoplasia
503461395,7/16/2014 14:11:26,,1324270071,7/16/2014 14:11:09,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,57,76,,,63,110,CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA,"CERVIX,",57,76-85-101,CERVICAL INTRAEPITHELIAL NEOPLASIA,"Altogether, 1924 women were studied: 42.8% with a normal cervix, 16.2% with cervical intraepithelial neoplasia (CIN) I, 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",57,76 85 101,57,76,63,110,1,RO-disease_has_primary_anatomic_site,902157,"Altogether, 1924 women were studied: 42.8% with a normal cervix, 16.2% with cervical intraepithelial neoplasia (CIN) I, 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC",cervix,cervical intraepithelial neoplasia
503461395,7/16/2014 14:25:55,,1324275932,7/16/2014 14:25:37,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,57,76,,,63,110,CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA,"CERVIX,",57,76-85-101,CERVICAL INTRAEPITHELIAL NEOPLASIA,"Altogether, 1924 women were studied: 42.8% with a normal cervix, 16.2% with cervical intraepithelial neoplasia (CIN) I, 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",57,76 85 101,57,76,63,110,1,RO-disease_has_primary_anatomic_site,902157,"Altogether, 1924 women were studied: 42.8% with a normal cervix, 16.2% with cervical intraepithelial neoplasia (CIN) I, 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC",cervix,cervical intraepithelial neoplasia
503461395,7/16/2014 14:32:40,,1324278681,7/16/2014 14:32:24,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,57,76,,,63,110,CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA,"CERVIX,",57,76-85-101-111,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN),"Altogether, 1924 women were studied: 42.8% with a normal cervix, 16.2% with cervical intraepithelial neoplasia (CIN) I, 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",57,76 85 101,57,76,63,110,1,RO-disease_has_primary_anatomic_site,902157,"Altogether, 1924 women were studied: 42.8% with a normal cervix, 16.2% with cervical intraepithelial neoplasia (CIN) I, 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC",cervix,cervical intraepithelial neoplasia
503461395,7/16/2014 14:33:31,,1324279014,7/16/2014 14:33:05,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,57,76,,,63,110,CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA,"a CERVIX, cervical intraepithelial neoplasia",48-57-76-85-101,57-76-85-101,"cervix, CERVICAL INTRAEPITHELIAL NEOPLASIA","Altogether, 1924 women were studied: 42.8% with a normal cervix, 16.2% with cervical intraepithelial neoplasia (CIN) I, 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",57,76 85 101,57,76,63,110,1,RO-disease_has_primary_anatomic_site,902157,"Altogether, 1924 women were studied: 42.8% with a normal cervix, 16.2% with cervical intraepithelial neoplasia (CIN) I, 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC",cervix,cervical intraepithelial neoplasia
503461395,7/16/2014 14:46:17,,1324283319,7/16/2014 14:46:04,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,57,76,,,63,110,CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA,"CERVIX,",57,76-85-101,CERVICAL INTRAEPITHELIAL NEOPLASIA,"Altogether, 1924 women were studied: 42.8% with a normal cervix, 16.2% with cervical intraepithelial neoplasia (CIN) I, 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",57,76 85 101,57,76,63,110,1,RO-disease_has_primary_anatomic_site,902157,"Altogether, 1924 women were studied: 42.8% with a normal cervix, 16.2% with cervical intraepithelial neoplasia (CIN) I, 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC",cervix,cervical intraepithelial neoplasia
503461395,7/16/2014 14:47:50,,1324283797,7/16/2014 14:47:35,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,57,76,,,63,110,CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA,"CERVIX,",57,76-85-101-111-117,"CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I,","Altogether, 1924 women were studied: 42.8% with a normal cervix, 16.2% with cervical intraepithelial neoplasia (CIN) I, 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",57,76 85 101,57,76,63,110,1,RO-disease_has_primary_anatomic_site,902157,"Altogether, 1924 women were studied: 42.8% with a normal cervix, 16.2% with cervical intraepithelial neoplasia (CIN) I, 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC",cervix,cervical intraepithelial neoplasia
503461396,7/16/2014 13:47:14,,1324260155,7/16/2014 13:47:01,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,61,88,,,71,108,SALMONELLA,SALMONELLA INFECTION,SALMONELLA,61,88-99,"SALMONELLA INFECTION),","Since the Nu locus does not affect the resistance of mice to salmonella (at 4 days post salmonella infection), these results indicate that MHV infection and the nude phenotype interact to increase susceptibility to salmonella.",61,88 99,61,88,71,108,-1,RO-has_causative_agent,903780,"Since the Nu locus does not affect the resistance of mice to salmonella (at 4 days post salmonella infection), these results indicate that MHV infection and the nude phenotype interact to increase susceptibility to salmonella",salmonella,salmonella infection
503461396,7/16/2014 13:59:48,,1324265147,7/16/2014 13:59:36,instagc,1.0,18960682,GBR,"","",86.29.147.112,61,88,,,71,108,SALMONELLA,SALMONELLA INFECTION,SALMONELLA,61,88-99,"SALMONELLA INFECTION),","Since the Nu locus does not affect the resistance of mice to salmonella (at 4 days post salmonella infection), these results indicate that MHV infection and the nude phenotype interact to increase susceptibility to salmonella.",61,88 99,61,88,71,108,-1,RO-has_causative_agent,903780,"Since the Nu locus does not affect the resistance of mice to salmonella (at 4 days post salmonella infection), these results indicate that MHV infection and the nude phenotype interact to increase susceptibility to salmonella",salmonella,salmonella infection
503461396,7/16/2014 13:59:48,,1324265156,7/16/2014 13:59:32,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,61,88,,,71,108,SALMONELLA,SALMONELLA INFECTION,SALMONELLA,61,61-88-99,"salmonella SALMONELLA INFECTION),","Since the Nu locus does not affect the resistance of mice to salmonella (at 4 days post salmonella infection), these results indicate that MHV infection and the nude phenotype interact to increase susceptibility to salmonella.",61,88 99,61,88,71,108,-1,RO-has_causative_agent,903780,"Since the Nu locus does not affect the resistance of mice to salmonella (at 4 days post salmonella infection), these results indicate that MHV infection and the nude phenotype interact to increase susceptibility to salmonella",salmonella,salmonella infection
503461396,7/16/2014 14:10:24,,1324269619,7/16/2014 14:10:05,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,61,88,,,71,108,SALMONELLA,SALMONELLA INFECTION,SALMONELLA,61,88-99,"SALMONELLA INFECTION),","Since the Nu locus does not affect the resistance of mice to salmonella (at 4 days post salmonella infection), these results indicate that MHV infection and the nude phenotype interact to increase susceptibility to salmonella.",61,88 99,61,88,71,108,-1,RO-has_causative_agent,903780,"Since the Nu locus does not affect the resistance of mice to salmonella (at 4 days post salmonella infection), these results indicate that MHV infection and the nude phenotype interact to increase susceptibility to salmonella",salmonella,salmonella infection
503461396,7/16/2014 14:14:41,,1324271474,7/16/2014 14:14:30,prodege,1.0,17932518,GBR,"","",81.133.61.60,61,88,,,71,108,SALMONELLA,SALMONELLA INFECTION,SALMONELLA,61,88-99,"SALMONELLA INFECTION),","Since the Nu locus does not affect the resistance of mice to salmonella (at 4 days post salmonella infection), these results indicate that MHV infection and the nude phenotype interact to increase susceptibility to salmonella.",61,88 99,61,88,71,108,-1,RO-has_causative_agent,903780,"Since the Nu locus does not affect the resistance of mice to salmonella (at 4 days post salmonella infection), these results indicate that MHV infection and the nude phenotype interact to increase susceptibility to salmonella",salmonella,salmonella infection
503461396,7/16/2014 14:24:05,,1324275145,7/16/2014 14:23:36,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,61,88,,,71,108,SALMONELLA,SALMONELLA INFECTION,SALMONELLA,61,88-99,"SALMONELLA INFECTION),","Since the Nu locus does not affect the resistance of mice to salmonella (at 4 days post salmonella infection), these results indicate that MHV infection and the nude phenotype interact to increase susceptibility to salmonella.",61,88 99,61,88,71,108,-1,RO-has_causative_agent,903780,"Since the Nu locus does not affect the resistance of mice to salmonella (at 4 days post salmonella infection), these results indicate that MHV infection and the nude phenotype interact to increase susceptibility to salmonella",salmonella,salmonella infection
503461396,7/16/2014 14:32:23,,1324278583,7/16/2014 14:31:50,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,61,88,,,71,108,SALMONELLA,SALMONELLA INFECTION,SALMONELLA,61,88-99,"SALMONELLA INFECTION),","Since the Nu locus does not affect the resistance of mice to salmonella (at 4 days post salmonella infection), these results indicate that MHV infection and the nude phenotype interact to increase susceptibility to salmonella.",61,88 99,61,88,71,108,-1,RO-has_causative_agent,903780,"Since the Nu locus does not affect the resistance of mice to salmonella (at 4 days post salmonella infection), these results indicate that MHV infection and the nude phenotype interact to increase susceptibility to salmonella",salmonella,salmonella infection
503461396,7/16/2014 14:34:42,,1324279491,7/16/2014 14:33:52,prodege,1.0,26790109,USA,"","",23.125.64.233,61,88,,,71,108,SALMONELLA,SALMONELLA INFECTION,Nu locus does not affect the resistance of mice to SALMONELLA,10-13-19-24-28-39-50-53-58-61-35,76-78-83-88-99-111-117-125-134-139-143-153-157-161-166-176-185-188-197-212-215,"4 days post SALMONELLA INFECTION), these results indicate that MHV infection and the nude phenotype interact to increase susceptibility to salmonella.","Since the Nu locus does not affect the resistance of mice to salmonella (at 4 days post salmonella infection), these results indicate that MHV infection and the nude phenotype interact to increase susceptibility to salmonella.",61,88 99,61,88,71,108,-1,RO-has_causative_agent,903780,"Since the Nu locus does not affect the resistance of mice to salmonella (at 4 days post salmonella infection), these results indicate that MHV infection and the nude phenotype interact to increase susceptibility to salmonella",salmonella,salmonella infection
503461396,7/16/2014 14:45:15,,1324283033,7/16/2014 14:45:05,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,61,88,,,71,108,SALMONELLA,SALMONELLA INFECTION,SALMONELLA,61,88-99,"SALMONELLA INFECTION),","Since the Nu locus does not affect the resistance of mice to salmonella (at 4 days post salmonella infection), these results indicate that MHV infection and the nude phenotype interact to increase susceptibility to salmonella.",61,88 99,61,88,71,108,-1,RO-has_causative_agent,903780,"Since the Nu locus does not affect the resistance of mice to salmonella (at 4 days post salmonella infection), these results indicate that MHV infection and the nude phenotype interact to increase susceptibility to salmonella",salmonella,salmonella infection
503461396,7/16/2014 14:54:50,,1324285958,7/16/2014 14:54:38,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,61,88,,,71,108,SALMONELLA,SALMONELLA INFECTION,"SALMONELLA salmonella infection), MHV infection",61-88-99-139-143,88-99,"SALMONELLA INFECTION),","Since the Nu locus does not affect the resistance of mice to salmonella (at 4 days post salmonella infection), these results indicate that MHV infection and the nude phenotype interact to increase susceptibility to salmonella.",61,88 99,61,88,71,108,-1,RO-has_causative_agent,903780,"Since the Nu locus does not affect the resistance of mice to salmonella (at 4 days post salmonella infection), these results indicate that MHV infection and the nude phenotype interact to increase susceptibility to salmonella",salmonella,salmonella infection
503461397,7/16/2014 13:41:21,,1324258136,7/16/2014 13:41:09,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,178,228,,,195,233,ALLERGIC RHINITIS,ATOPY,"ALLERGIC RHINITIS,",178-187,221-228,family ATOPY,"The prevalences of current asthma, cumulative asthma and asthma-like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20-44 years age group and the prevalences of allergic rhinitis, allergic dermatitis and family atopy were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",178 187,228,178,228,195,233,-1,RO-cause_of,900052,"The prevalences of current asthma, cumulative asthma and asthma-like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20-44 years age group and the prevalences of allergic rhinitis, allergic dermatitis and family atopy were found in 14.5, 10.9, and 15.2%, respectively, in all age group",allergic rhinitis,atopy
503461397,7/16/2014 13:46:21,,1324259859,7/16/2014 13:46:12,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,178,228,,,195,233,ALLERGIC RHINITIS,ATOPY,"ALLERGIC RHINITIS,",178-187,221-228,family ATOPY,"The prevalences of current asthma, cumulative asthma and asthma-like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20-44 years age group and the prevalences of allergic rhinitis, allergic dermatitis and family atopy were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",178 187,228,178,228,195,233,-1,RO-cause_of,900052,"The prevalences of current asthma, cumulative asthma and asthma-like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20-44 years age group and the prevalences of allergic rhinitis, allergic dermatitis and family atopy were found in 14.5, 10.9, and 15.2%, respectively, in all age group",allergic rhinitis,atopy
503461397,7/16/2014 13:46:36,,1324259959,7/16/2014 13:45:12,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,178,228,,,195,233,ALLERGIC RHINITIS,ATOPY,"the prevalences of ALLERGIC RHINITIS, allergic dermatitis and",159-163-175-178-187-197-206-217,206-217-221-228-234-239-245,dermatitis and family ATOPY were found in,"The prevalences of current asthma, cumulative asthma and asthma-like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20-44 years age group and the prevalences of allergic rhinitis, allergic dermatitis and family atopy were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",178 187,228,178,228,195,233,-1,RO-cause_of,900052,"The prevalences of current asthma, cumulative asthma and asthma-like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20-44 years age group and the prevalences of allergic rhinitis, allergic dermatitis and family atopy were found in 14.5, 10.9, and 15.2%, respectively, in all age group",allergic rhinitis,atopy
503461397,7/16/2014 13:49:36,,1324260935,7/16/2014 13:49:12,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,178,228,,,195,233,ALLERGIC RHINITIS,ATOPY,"ALLERGIC RHINITIS,",178-187,221-228,family ATOPY,"The prevalences of current asthma, cumulative asthma and asthma-like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20-44 years age group and the prevalences of allergic rhinitis, allergic dermatitis and family atopy were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",178 187,228,178,228,195,233,-1,RO-cause_of,900052,"The prevalences of current asthma, cumulative asthma and asthma-like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20-44 years age group and the prevalences of allergic rhinitis, allergic dermatitis and family atopy were found in 14.5, 10.9, and 15.2%, respectively, in all age group",allergic rhinitis,atopy
503461397,7/16/2014 13:51:56,,1324261777,7/16/2014 13:51:22,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,178,228,,,195,233,ALLERGIC RHINITIS,ATOPY,"asthma, cumulative asthma asthma like symptoms ALLERGIC RHINITIS, allergic dermatitis family atopy",27-35-46-57-64-69-178-187-197-206-221-228,19-27-35-46-57-64-69-178-187-197-206-221-228,"current asthma, cumulative asthma asthma like symptoms allergic rhinitis, allergic dermatitis family ATOPY","The prevalences of current asthma, cumulative asthma and asthma-like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20-44 years age group and the prevalences of allergic rhinitis, allergic dermatitis and family atopy were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",178 187,228,178,228,195,233,-1,RO-cause_of,900052,"The prevalences of current asthma, cumulative asthma and asthma-like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20-44 years age group and the prevalences of allergic rhinitis, allergic dermatitis and family atopy were found in 14.5, 10.9, and 15.2%, respectively, in all age group",allergic rhinitis,atopy
503461397,7/16/2014 13:55:56,,1324263375,7/16/2014 13:55:45,instagc,1.0,18960682,GBR,"","",86.29.147.112,178,228,,,195,233,ALLERGIC RHINITIS,ATOPY,"the ALLERGIC RHINITIS,",159-178-187,221-228,family ATOPY,"The prevalences of current asthma, cumulative asthma and asthma-like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20-44 years age group and the prevalences of allergic rhinitis, allergic dermatitis and family atopy were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",178 187,228,178,228,195,233,-1,RO-cause_of,900052,"The prevalences of current asthma, cumulative asthma and asthma-like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20-44 years age group and the prevalences of allergic rhinitis, allergic dermatitis and family atopy were found in 14.5, 10.9, and 15.2%, respectively, in all age group",allergic rhinitis,atopy
503461397,7/16/2014 13:56:13,,1324263487,7/16/2014 13:55:52,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,178,228,,,195,233,ALLERGIC RHINITIS,ATOPY,"the ALLERGIC RHINITIS,",159-178-187,221-228,family ATOPY,"The prevalences of current asthma, cumulative asthma and asthma-like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20-44 years age group and the prevalences of allergic rhinitis, allergic dermatitis and family atopy were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",178 187,228,178,228,195,233,-1,RO-cause_of,900052,"The prevalences of current asthma, cumulative asthma and asthma-like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20-44 years age group and the prevalences of allergic rhinitis, allergic dermatitis and family atopy were found in 14.5, 10.9, and 15.2%, respectively, in all age group",allergic rhinitis,atopy
503461397,7/16/2014 13:59:44,,1324265137,7/16/2014 13:59:19,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,178,228,,,195,233,ALLERGIC RHINITIS,ATOPY,"ALLERGIC RHINITIS, atopy",178-187-228,178-228-187,"allergic rhinitis, ATOPY","The prevalences of current asthma, cumulative asthma and asthma-like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20-44 years age group and the prevalences of allergic rhinitis, allergic dermatitis and family atopy were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",178 187,228,178,228,195,233,-1,RO-cause_of,900052,"The prevalences of current asthma, cumulative asthma and asthma-like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20-44 years age group and the prevalences of allergic rhinitis, allergic dermatitis and family atopy were found in 14.5, 10.9, and 15.2%, respectively, in all age group",allergic rhinitis,atopy
503461397,7/16/2014 14:02:30,,1324266132,7/16/2014 14:02:05,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,178,228,,,195,233,ALLERGIC RHINITIS,ATOPY,"ALLERGIC RHINITIS, allergic dermatitis",178-187-197-206,221-228,family ATOPY,"The prevalences of current asthma, cumulative asthma and asthma-like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20-44 years age group and the prevalences of allergic rhinitis, allergic dermatitis and family atopy were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",178 187,228,178,228,195,233,-1,RO-cause_of,900052,"The prevalences of current asthma, cumulative asthma and asthma-like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20-44 years age group and the prevalences of allergic rhinitis, allergic dermatitis and family atopy were found in 14.5, 10.9, and 15.2%, respectively, in all age group",allergic rhinitis,atopy
503461397,7/16/2014 14:09:03,,1324269012,7/16/2014 14:08:50,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,178,228,,,195,233,ALLERGIC RHINITIS,ATOPY,"ALLERGIC RHINITIS,",178-187,228-221,family ATOPY,"The prevalences of current asthma, cumulative asthma and asthma-like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20-44 years age group and the prevalences of allergic rhinitis, allergic dermatitis and family atopy were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",178 187,228,178,228,195,233,-1,RO-cause_of,900052,"The prevalences of current asthma, cumulative asthma and asthma-like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20-44 years age group and the prevalences of allergic rhinitis, allergic dermatitis and family atopy were found in 14.5, 10.9, and 15.2%, respectively, in all age group",allergic rhinitis,atopy
503461398,7/16/2014 13:57:56,,1324264270,7/16/2014 13:57:28,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,172,209,,,189,215,ALLERGIC RHINITIS,ATOPIC,"ALLERGIC RHINITIS, asthma, and other atopic diseases.",172-181-191-199-203-209-216,172-191-199-203-209-216-181,"allergic rhinitis, asthma, and other ATOPIC diseases.","Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as allergic rhinitis, asthma, and other atopic diseases.",172 181,209,172,209,189,215,-1,RO-cause_of,900405,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as allergic rhinitis, asthma, and other atopic diseases",allergic rhinitis,atopic
503461398,7/16/2014 14:10:12,,1324269539,7/16/2014 14:10:04,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,172,209,,,189,215,ALLERGIC RHINITIS,ATOPIC,"diseases such as ALLERGIC RHINITIS, asthma, and other",155-164-169-172-181-191-199-203,191-199-203-209-216,"asthma, and other ATOPIC diseases.","Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as allergic rhinitis, asthma, and other atopic diseases.",172 181,209,172,209,189,215,-1,RO-cause_of,900405,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as allergic rhinitis, asthma, and other atopic diseases",allergic rhinitis,atopic
503461398,7/16/2014 14:11:40,,1324270193,7/16/2014 14:09:50,prodege,1,17932518,GBR,"","",81.133.61.60,172,209,,,189,215,ALLERGIC RHINITIS,ATOPIC,"ALLERGIC RHINITIS,",172-181,209-216,ATOPIC diseases.,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as allergic rhinitis, asthma, and other atopic diseases.",172 181,209,172,209,189,215,-1,RO-cause_of,900405,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as allergic rhinitis, asthma, and other atopic diseases",allergic rhinitis,atopic
503461398,7/16/2014 14:21:24,,1324274135,7/16/2014 14:21:10,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,172,209,,,189,215,ALLERGIC RHINITIS,ATOPIC,"ALLERGIC RHINITIS,",172-181,209,ATOPIC,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as allergic rhinitis, asthma, and other atopic diseases.",172 181,209,172,209,189,215,-1,RO-cause_of,900405,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as allergic rhinitis, asthma, and other atopic diseases",allergic rhinitis,atopic
503461398,7/16/2014 14:43:09,,1324282527,7/16/2014 14:42:56,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,172,209,,,189,215,ALLERGIC RHINITIS,ATOPIC,"ALLERGIC RHINITIS,",172-181,209-216,ATOPIC diseases.,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as allergic rhinitis, asthma, and other atopic diseases.",172 181,209,172,209,189,215,-1,RO-cause_of,900405,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as allergic rhinitis, asthma, and other atopic diseases",allergic rhinitis,atopic
503461398,7/16/2014 14:49:32,,1324284328,7/16/2014 14:48:27,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,172,209,,,189,215,ALLERGIC RHINITIS,ATOPIC,"ALLERGIC RHINITIS,",172-181,209-216,ATOPIC diseases.,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as allergic rhinitis, asthma, and other atopic diseases.",172 181,209,172,209,189,215,-1,RO-cause_of,900405,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as allergic rhinitis, asthma, and other atopic diseases",allergic rhinitis,atopic
503461398,7/16/2014 14:58:30,,1324287397,7/16/2014 14:58:16,irazoo,1.0,7022810,USA,IA,Ankeny,216.161.121.1,172,209,,,189,215,ALLERGIC RHINITIS,ATOPIC,"ALLERGIC RHINITIS,",172-181,209-216,ATOPIC diseases.,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as allergic rhinitis, asthma, and other atopic diseases.",172 181,209,172,209,189,215,-1,RO-cause_of,900405,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as allergic rhinitis, asthma, and other atopic diseases",allergic rhinitis,atopic
503461398,7/16/2014 14:59:11,,1324287669,7/16/2014 14:58:58,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,172,209,,,189,215,ALLERGIC RHINITIS,ATOPIC,"ALLERGIC RHINITIS,",172-181,209-216,ATOPIC diseases.,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as allergic rhinitis, asthma, and other atopic diseases.",172 181,209,172,209,189,215,-1,RO-cause_of,900405,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as allergic rhinitis, asthma, and other atopic diseases",allergic rhinitis,atopic
503461398,7/16/2014 15:01:02,,1324288334,7/16/2014 15:00:40,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,172,209,,,189,215,ALLERGIC RHINITIS,ATOPIC,"ALLERGIC RHINITIS,",172-181,209-216,ATOPIC diseases.,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as allergic rhinitis, asthma, and other atopic diseases.",172 181,209,172,209,189,215,-1,RO-cause_of,900405,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as allergic rhinitis, asthma, and other atopic diseases",allergic rhinitis,atopic
503461398,7/16/2014 15:01:43,,1324288640,7/16/2014 15:01:18,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,172,209,,,189,215,ALLERGIC RHINITIS,ATOPIC,"ALLERGIC RHINITIS,",172-181,209-216,ATOPIC diseases.,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as allergic rhinitis, asthma, and other atopic diseases.",172 181,209,172,209,189,215,-1,RO-cause_of,900405,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as allergic rhinitis, asthma, and other atopic diseases",allergic rhinitis,atopic
503461399,7/16/2014 13:43:32,,1324258951,7/16/2014 13:43:23,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,189,214,,,210,234,MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID,MYOCARDIAL INFARCTION,189-200,214-230,ACETYLSALICYLIC ACID.,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of myocardial infarction by acetylsalicylic acid.",189 200,214 230,189,214,210,234,1,RO-may_prevent,907247,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of myocardial infarction by acetylsalicylic acid",myocardial infarction,acetylsalicylic acid
503461399,7/16/2014 13:53:12,,1324262263,7/16/2014 13:52:32,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,189,214,,,210,234,MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID,MYOCARDIAL INFARCTION,189-200,214-230,ACETYLSALICYLIC ACID.,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of myocardial infarction by acetylsalicylic acid.",189 200,214 230,189,214,210,234,1,RO-may_prevent,907247,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of myocardial infarction by acetylsalicylic acid",myocardial infarction,acetylsalicylic acid
503461399,7/16/2014 14:01:45,,1324265858,7/16/2014 14:01:35,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,189,214,,,210,234,MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID,MYOCARDIAL INFARCTION,189-200,189-200-214-230,myocardial infarction ACETYLSALICYLIC ACID.,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of myocardial infarction by acetylsalicylic acid.",189 200,214 230,189,214,210,234,1,RO-may_prevent,907247,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of myocardial infarction by acetylsalicylic acid",myocardial infarction,acetylsalicylic acid
503461399,7/16/2014 14:06:53,,1324268058,7/16/2014 14:06:40,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,189,214,,,210,234,MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID,MYOCARDIAL INFARCTION,189-200,214-230,ACETYLSALICYLIC ACID.,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of myocardial infarction by acetylsalicylic acid.",189 200,214 230,189,214,210,234,1,RO-may_prevent,907247,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of myocardial infarction by acetylsalicylic acid",myocardial infarction,acetylsalicylic acid
503461399,7/16/2014 14:13:40,,1324271023,7/16/2014 14:13:25,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,189,214,,,210,234,MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID,the prevention of MYOCARDIAL INFARCTION by acetylsalicylic acid.,171-175-186-189-200-211-214-230,189-200-211-214-230,myocardial infarction by ACETYLSALICYLIC ACID.,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of myocardial infarction by acetylsalicylic acid.",189 200,214 230,189,214,210,234,1,RO-may_prevent,907247,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of myocardial infarction by acetylsalicylic acid",myocardial infarction,acetylsalicylic acid
503461399,7/16/2014 14:22:30,,1324274574,7/16/2014 14:22:16,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,189,214,,,210,234,MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID,MYOCARDIAL INFARCTION,189-200,214-230,ACETYLSALICYLIC ACID.,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of myocardial infarction by acetylsalicylic acid.",189 200,214 230,189,214,210,234,1,RO-may_prevent,907247,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of myocardial infarction by acetylsalicylic acid",myocardial infarction,acetylsalicylic acid
503461399,7/16/2014 14:24:39,,1324275399,7/16/2014 14:24:25,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,189,214,,,210,234,MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID,MYOCARDIAL INFARCTION,189-200,214-230,ACETYLSALICYLIC ACID.,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of myocardial infarction by acetylsalicylic acid.",189 200,214 230,189,214,210,234,1,RO-may_prevent,907247,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of myocardial infarction by acetylsalicylic acid",myocardial infarction,acetylsalicylic acid
503461399,7/16/2014 14:25:29,,1324275734,7/16/2014 14:25:04,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,189,214,,,210,234,MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID,MYOCARDIAL INFARCTION,189-200,214-230,ACETYLSALICYLIC ACID.,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of myocardial infarction by acetylsalicylic acid.",189 200,214 230,189,214,210,234,1,RO-may_prevent,907247,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of myocardial infarction by acetylsalicylic acid",myocardial infarction,acetylsalicylic acid
503461399,7/16/2014 14:52:54,,1324285302,7/16/2014 14:52:36,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,189,214,,,210,234,MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID,MYOCARDIAL INFARCTION,189-200,214-230,ACETYLSALICYLIC ACID.,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of myocardial infarction by acetylsalicylic acid.",189 200,214 230,189,214,210,234,1,RO-may_prevent,907247,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of myocardial infarction by acetylsalicylic acid",myocardial infarction,acetylsalicylic acid
503461399,7/16/2014 14:53:30,,1324285534,7/16/2014 14:53:20,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,189,214,,,210,234,MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID,MYOCARDIAL INFARCTION,189-200,214-230,ACETYLSALICYLIC ACID.,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of myocardial infarction by acetylsalicylic acid.",189 200,214 230,189,214,210,234,1,RO-may_prevent,907247,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of myocardial infarction by acetylsalicylic acid",myocardial infarction,acetylsalicylic acid
503461400,7/16/2014 13:47:31,,1324260268,7/16/2014 13:47:18,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,8,106,,,15,135,ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,ANXIETY,8,106-116-127,OBSESSIVE COMPULSIVE NEUROSIS,"Whereas anxiety responds independently to exposure therapy, and hence that the anxiety reduction model of obsessive compulsive neurosis is inadequate.",8,106 116 127,8,106,15,135,-1,RO-has_definitional_manifestation,904918,"Whereas anxiety responds independently to exposure therapy, and hence that the anxiety reduction model of obsessive compulsive neurosis is inadequate",anxiety,obsessive compulsive neurosis
503461400,7/16/2014 13:48:39,,1324260645,7/16/2014 13:48:27,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,8,106,,,15,135,ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,ANXIETY,8,106-116-127,OBSESSIVE COMPULSIVE NEUROSIS,"Whereas anxiety responds independently to exposure therapy, and hence that the anxiety reduction model of obsessive compulsive neurosis is inadequate.",8,106 116 127,8,106,15,135,-1,RO-has_definitional_manifestation,904918,"Whereas anxiety responds independently to exposure therapy, and hence that the anxiety reduction model of obsessive compulsive neurosis is inadequate",anxiety,obsessive compulsive neurosis
503461400,7/16/2014 13:48:42,,1324260670,7/16/2014 13:48:24,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,8,106,,,15,135,ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,ANXIETY,8,87-97-103-106-116-127,reduction model of OBSESSIVE COMPULSIVE NEUROSIS,"Whereas anxiety responds independently to exposure therapy, and hence that the anxiety reduction model of obsessive compulsive neurosis is inadequate.",8,106 116 127,8,106,15,135,-1,RO-has_definitional_manifestation,904918,"Whereas anxiety responds independently to exposure therapy, and hence that the anxiety reduction model of obsessive compulsive neurosis is inadequate",anxiety,obsessive compulsive neurosis
503461400,7/16/2014 13:52:38,,1324262047,7/16/2014 13:52:16,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,8,106,,,15,135,ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,"ANXIETY exposure therapy, anxiety reduction model obsessive compulsive neurosis",8-42-79-87-97-106-116-127-51,8-42-51-79-87-97-106-116-127,"anxiety exposure therapy, anxiety reduction model OBSESSIVE COMPULSIVE NEUROSIS","Whereas anxiety responds independently to exposure therapy, and hence that the anxiety reduction model of obsessive compulsive neurosis is inadequate.",8,106 116 127,8,106,15,135,-1,RO-has_definitional_manifestation,904918,"Whereas anxiety responds independently to exposure therapy, and hence that the anxiety reduction model of obsessive compulsive neurosis is inadequate",anxiety,obsessive compulsive neurosis
503461400,7/16/2014 13:55:44,,1324263297,7/16/2014 13:55:33,instagc,1.0,18960682,GBR,"","",86.29.147.112,8,106,,,15,135,ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,ANXIETY,8,106-116-127,OBSESSIVE COMPULSIVE NEUROSIS,"Whereas anxiety responds independently to exposure therapy, and hence that the anxiety reduction model of obsessive compulsive neurosis is inadequate.",8,106 116 127,8,106,15,135,-1,RO-has_definitional_manifestation,904918,"Whereas anxiety responds independently to exposure therapy, and hence that the anxiety reduction model of obsessive compulsive neurosis is inadequate",anxiety,obsessive compulsive neurosis
503461400,7/16/2014 13:56:45,,1324263727,7/16/2014 13:56:32,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,8,106,,,15,135,ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,ANXIETY,8,106-116-127,OBSESSIVE COMPULSIVE NEUROSIS,"Whereas anxiety responds independently to exposure therapy, and hence that the anxiety reduction model of obsessive compulsive neurosis is inadequate.",8,106 116 127,8,106,15,135,-1,RO-has_definitional_manifestation,904918,"Whereas anxiety responds independently to exposure therapy, and hence that the anxiety reduction model of obsessive compulsive neurosis is inadequate",anxiety,obsessive compulsive neurosis
503461400,7/16/2014 14:10:49,,1324269822,7/16/2014 14:10:34,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,8,106,,,15,135,ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,Whereas ANXIETY responds independently to,0-8-16-25-39,87-97-103-106-116-127-136-139,reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.,"Whereas anxiety responds independently to exposure therapy, and hence that the anxiety reduction model of obsessive compulsive neurosis is inadequate.",8,106 116 127,8,106,15,135,-1,RO-has_definitional_manifestation,904918,"Whereas anxiety responds independently to exposure therapy, and hence that the anxiety reduction model of obsessive compulsive neurosis is inadequate",anxiety,obsessive compulsive neurosis
503461400,7/16/2014 14:19:34,,1324273376,7/16/2014 14:19:20,vivatic,1.0,25451531,GBR,"","",83.67.28.193,8,106,,,15,135,ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,ANXIETY,8,106-116-127,OBSESSIVE COMPULSIVE NEUROSIS,"Whereas anxiety responds independently to exposure therapy, and hence that the anxiety reduction model of obsessive compulsive neurosis is inadequate.",8,106 116 127,8,106,15,135,-1,RO-has_definitional_manifestation,904918,"Whereas anxiety responds independently to exposure therapy, and hence that the anxiety reduction model of obsessive compulsive neurosis is inadequate",anxiety,obsessive compulsive neurosis
503461400,7/16/2014 14:23:18,,1324274857,7/16/2014 14:23:04,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,8,106,,,15,135,ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,ANXIETY,8,106-116-127,OBSESSIVE COMPULSIVE NEUROSIS,"Whereas anxiety responds independently to exposure therapy, and hence that the anxiety reduction model of obsessive compulsive neurosis is inadequate.",8,106 116 127,8,106,15,135,-1,RO-has_definitional_manifestation,904918,"Whereas anxiety responds independently to exposure therapy, and hence that the anxiety reduction model of obsessive compulsive neurosis is inadequate",anxiety,obsessive compulsive neurosis
503461400,7/16/2014 14:26:30,,1324276097,7/16/2014 14:26:10,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,8,106,,,15,135,ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,ANXIETY,8,106-116-127,OBSESSIVE COMPULSIVE NEUROSIS,"Whereas anxiety responds independently to exposure therapy, and hence that the anxiety reduction model of obsessive compulsive neurosis is inadequate.",8,106 116 127,8,106,15,135,-1,RO-has_definitional_manifestation,904918,"Whereas anxiety responds independently to exposure therapy, and hence that the anxiety reduction model of obsessive compulsive neurosis is inadequate",anxiety,obsessive compulsive neurosis
503461401,7/16/2014 13:54:43,,1324262913,7/16/2014 13:54:14,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,316,399,,,325,433,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,metaplasia,301,301,metaplasia,"This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia.",,,316,399,325,433,-1,RO-disease_has_finding,901707,"This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia",dysplasia,cervical intraepithelial neoplasia
503461401,7/16/2014 13:57:05,,1324263859,7/16/2014 13:55:16,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,316,399,,,325,433,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,CFR-1 CFR 1/PAM 1 dysplasia metaplasia of the metaplasia dysplasia epithelial,5-9-15-256-301-326-329-358-373-413--1,5-9-15-256-301-358-373-386-395,CFR 1/PAM 1 dysplasia metaplasia metaplasia dysplasia the and,"This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia.",,,316,399,325,433,-1,RO-disease_has_finding,901707,"This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia",dysplasia,cervical intraepithelial neoplasia
503461401,7/16/2014 13:57:09,,1324263916,7/16/2014 13:55:54,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,316,399,,,325,433,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,CFR-1 of the,383-386--1,-1,CFR-1,"This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia.",,,316,399,325,433,-1,RO-disease_has_finding,901707,"This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia",dysplasia,cervical intraepithelial neoplasia
503461401,7/16/2014 13:58:30,,1324264540,7/16/2014 13:57:53,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,316,399,,,325,433,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,metaplasia,301,-1,CFR-1,"This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia.",,,316,399,325,433,-1,RO-disease_has_finding,901707,"This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia",dysplasia,cervical intraepithelial neoplasia
503461401,7/16/2014 14:14:18,,1324271327,7/16/2014 14:14:06,prodege,1.0,17932518,GBR,"","",81.133.61.60,316,399,,,325,433,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,metaplasia,301,-1,CFR-1,"This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia.",,,316,399,325,433,-1,RO-disease_has_finding,901707,"This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia",dysplasia,cervical intraepithelial neoplasia
503461401,7/16/2014 14:33:08,,1324278835,7/16/2014 14:32:03,prodege,1.0,26790109,USA,"","",23.125.64.233,316,399,,,325,433,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,CFR-1 dysplasia of the of the,256-279-282-326-329--1,386-395,the and,"This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia.",,,316,399,325,433,-1,RO-disease_has_finding,901707,"This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia",dysplasia,cervical intraepithelial neoplasia
503461401,7/16/2014 14:42:33,,1324282362,7/16/2014 14:41:43,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,316,399,,,325,433,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,dysplasia metaplasia,256-301,-1,CFR-1,"This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia.",,,316,399,325,433,-1,RO-disease_has_finding,901707,"This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia",dysplasia,cervical intraepithelial neoplasia
503461401,7/16/2014 14:55:34,,1324286253,7/16/2014 14:55:16,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,316,399,,,325,433,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,dysplasia,256,-1,CFR-1,"This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia.",,,316,399,325,433,-1,RO-disease_has_finding,901707,"This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia",dysplasia,cervical intraepithelial neoplasia
503461401,7/16/2014 14:55:42,,1324286286,7/16/2014 14:55:11,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,316,399,,,325,433,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,metaplasia,301,,,"This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia.",,,316,399,325,433,-1,RO-disease_has_finding,901707,"This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia",dysplasia,cervical intraepithelial neoplasia
503461401,7/16/2014 14:56:39,,1324286705,7/16/2014 14:55:19,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,316,399,,,325,433,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,CFR-1,-1,-1,CFR-1,"This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia.",,,316,399,325,433,-1,RO-disease_has_finding,901707,"This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia",dysplasia,cervical intraepithelial neoplasia
503461402,7/16/2014 13:45:14,,1324259525,7/16/2014 13:45:03,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,4,52,,,11,60,ASCITES,HEPATOMA,ASCITES form,4-12,41-48-52,"guinea pig HEPATOMA,","The ascites form of a chemically induced guinea pig hepatoma, line-10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",4,52,4,52,11,60,-1,RO-disease_may_have_finding,902866,"The ascites form of a chemically induced guinea pig hepatoma, line-10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement",ascites,hepatoma
503461402,7/16/2014 13:49:45,,1324260984,7/16/2014 13:49:30,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,4,52,,,11,60,ASCITES,HEPATOMA,ASCITES,4,52-62-67,"HEPATOMA, line 10,","The ascites form of a chemically induced guinea pig hepatoma, line-10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",4,52,4,52,11,60,-1,RO-disease_may_have_finding,902866,"The ascites form of a chemically induced guinea pig hepatoma, line-10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement",ascites,hepatoma
503461402,7/16/2014 14:04:27,,1324266987,7/16/2014 14:04:09,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,4,52,,,11,60,ASCITES,HEPATOMA,ASCITES,4,33-41-48-52-22,"chemically induced guinea pig HEPATOMA,","The ascites form of a chemically induced guinea pig hepatoma, line-10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",4,52,4,52,11,60,-1,RO-disease_may_have_finding,902866,"The ascites form of a chemically induced guinea pig hepatoma, line-10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement",ascites,hepatoma
503461402,7/16/2014 14:06:32,,1324267935,7/16/2014 14:06:12,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,4,52,,,11,60,ASCITES,HEPATOMA,"ASCITES hepatoma,",4-52,52,"HEPATOMA,","The ascites form of a chemically induced guinea pig hepatoma, line-10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",4,52,4,52,11,60,-1,RO-disease_may_have_finding,902866,"The ascites form of a chemically induced guinea pig hepatoma, line-10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement",ascites,hepatoma
503461402,7/16/2014 14:14:53,,1324271501,7/16/2014 14:14:42,prodege,1.0,17932518,GBR,"","",81.133.61.60,4,52,,,11,60,ASCITES,HEPATOMA,ASCITES,4,52,"HEPATOMA,","The ascites form of a chemically induced guinea pig hepatoma, line-10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",4,52,4,52,11,60,-1,RO-disease_may_have_finding,902866,"The ascites form of a chemically induced guinea pig hepatoma, line-10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement",ascites,hepatoma
503461402,7/16/2014 14:32:59,,1324278782,7/16/2014 14:32:42,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,4,52,,,11,60,ASCITES,HEPATOMA,ASCITES,4,52,"HEPATOMA,","The ascites form of a chemically induced guinea pig hepatoma, line-10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",4,52,4,52,11,60,-1,RO-disease_may_have_finding,902866,"The ascites form of a chemically induced guinea pig hepatoma, line-10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement",ascites,hepatoma
503461402,7/16/2014 14:42:44,,1324282401,7/16/2014 14:42:11,neodev,1,28336203,USA,PA,Harrisburg,50.149.53.150,4,52,,,11,60,ASCITES,HEPATOMA,ASCITES,4,52,"HEPATOMA,","The ascites form of a chemically induced guinea pig hepatoma, line-10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",4,52,4,52,11,60,-1,RO-disease_may_have_finding,902866,"The ascites form of a chemically induced guinea pig hepatoma, line-10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement",ascites,hepatoma
503461402,7/16/2014 14:56:33,,1324286640,7/16/2014 14:56:06,irazoo,1.0,7022810,USA,IA,Ankeny,216.161.121.1,4,52,,,11,60,ASCITES,HEPATOMA,ASCITES form,4-12,22-33-41-48-52,"chemically induced guinea pig HEPATOMA,","The ascites form of a chemically induced guinea pig hepatoma, line-10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",4,52,4,52,11,60,-1,RO-disease_may_have_finding,902866,"The ascites form of a chemically induced guinea pig hepatoma, line-10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement",ascites,hepatoma
503461402,7/16/2014 14:59:01,,1324287602,7/16/2014 14:58:42,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.72,4,52,,,11,60,ASCITES,HEPATOMA,ASCITES,4,52,"HEPATOMA,","The ascites form of a chemically induced guinea pig hepatoma, line-10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",4,52,4,52,11,60,-1,RO-disease_may_have_finding,902866,"The ascites form of a chemically induced guinea pig hepatoma, line-10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement",ascites,hepatoma
503461402,7/16/2014 15:00:32,,1324288130,7/16/2014 15:00:18,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,4,52,,,11,60,ASCITES,HEPATOMA,ASCITES,4,52-62-67,"HEPATOMA, line 10,","The ascites form of a chemically induced guinea pig hepatoma, line-10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",4,52,4,52,11,60,-1,RO-disease_may_have_finding,902866,"The ascites form of a chemically induced guinea pig hepatoma, line-10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement",ascites,hepatoma
503461403,7/16/2014 13:52:04,,1324261799,7/16/2014 13:51:42,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,119,131,,,123,147,PART,HYPERSENSITIVITY,PART of the hypersensitivity,119-124-127-131,131-148-151,HYPERSENSITIVITY to Epo,"Epo-RS462A activation was prolonged and BaF3 cells expressing this receptor are hypersensitive to Epo, suggesting that part of the hypersensitivity to Epo in familial polycythemia could be the result of the lack of beta-Trcp recruitment to the Epo-R.",119,131,119,131,123,147,-1,RO-cause_of,900244,"Epo-RS462A activation was prolonged and BaF3 cells expressing this receptor are hypersensitive to Epo, suggesting that part of the hypersensitivity to Epo in familial polycythemia could be the result of the lack of beta-Trcp recruitment to the Epo-R",part,hypersensitivity
503461403,7/16/2014 14:00:13,,1324265278,7/16/2014 14:00:01,instagc,1.0,18960682,GBR,"","",86.29.147.112,119,131,,,123,147,PART,HYPERSENSITIVITY,PART,119,131,HYPERSENSITIVITY,"Epo-RS462A activation was prolonged and BaF3 cells expressing this receptor are hypersensitive to Epo, suggesting that part of the hypersensitivity to Epo in familial polycythemia could be the result of the lack of beta-Trcp recruitment to the Epo-R.",119,131,119,131,123,147,-1,RO-cause_of,900244,"Epo-RS462A activation was prolonged and BaF3 cells expressing this receptor are hypersensitive to Epo, suggesting that part of the hypersensitivity to Epo in familial polycythemia could be the result of the lack of beta-Trcp recruitment to the Epo-R",part,hypersensitivity
503461403,7/16/2014 14:11:11,,1324269964,7/16/2014 14:10:57,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,119,131,,,123,147,PART,HYPERSENSITIVITY,PART of the hypersensitivity to Epo,119-124-127-131-148-151,119-124-127-131-148-151,part of the HYPERSENSITIVITY to Epo,"Epo-RS462A activation was prolonged and BaF3 cells expressing this receptor are hypersensitive to Epo, suggesting that part of the hypersensitivity to Epo in familial polycythemia could be the result of the lack of beta-Trcp recruitment to the Epo-R.",119,131,119,131,123,147,-1,RO-cause_of,900244,"Epo-RS462A activation was prolonged and BaF3 cells expressing this receptor are hypersensitive to Epo, suggesting that part of the hypersensitivity to Epo in familial polycythemia could be the result of the lack of beta-Trcp recruitment to the Epo-R",part,hypersensitivity
503461403,7/16/2014 14:27:01,,1324276277,7/16/2014 14:26:47,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,119,131,,,123,147,PART,HYPERSENSITIVITY,PART,119,131,HYPERSENSITIVITY,"Epo-RS462A activation was prolonged and BaF3 cells expressing this receptor are hypersensitive to Epo, suggesting that part of the hypersensitivity to Epo in familial polycythemia could be the result of the lack of beta-Trcp recruitment to the Epo-R.",119,131,119,131,123,147,-1,RO-cause_of,900244,"Epo-RS462A activation was prolonged and BaF3 cells expressing this receptor are hypersensitive to Epo, suggesting that part of the hypersensitivity to Epo in familial polycythemia could be the result of the lack of beta-Trcp recruitment to the Epo-R",part,hypersensitivity
503461403,7/16/2014 14:44:01,,1324282733,7/16/2014 14:43:45,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,119,131,,,123,147,PART,HYPERSENSITIVITY,PART of the hypersensitivity,119-124-131-127,119-124-127-131,part of the HYPERSENSITIVITY,"Epo-RS462A activation was prolonged and BaF3 cells expressing this receptor are hypersensitive to Epo, suggesting that part of the hypersensitivity to Epo in familial polycythemia could be the result of the lack of beta-Trcp recruitment to the Epo-R.",119,131,119,131,123,147,-1,RO-cause_of,900244,"Epo-RS462A activation was prolonged and BaF3 cells expressing this receptor are hypersensitive to Epo, suggesting that part of the hypersensitivity to Epo in familial polycythemia could be the result of the lack of beta-Trcp recruitment to the Epo-R",part,hypersensitivity
503461403,7/16/2014 14:51:19,,1324284865,7/16/2014 14:50:52,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,119,131,,,123,147,PART,HYPERSENSITIVITY,PART,119,131,HYPERSENSITIVITY,"Epo-RS462A activation was prolonged and BaF3 cells expressing this receptor are hypersensitive to Epo, suggesting that part of the hypersensitivity to Epo in familial polycythemia could be the result of the lack of beta-Trcp recruitment to the Epo-R.",119,131,119,131,123,147,-1,RO-cause_of,900244,"Epo-RS462A activation was prolonged and BaF3 cells expressing this receptor are hypersensitive to Epo, suggesting that part of the hypersensitivity to Epo in familial polycythemia could be the result of the lack of beta-Trcp recruitment to the Epo-R",part,hypersensitivity
503461403,7/16/2014 14:54:19,,1324285771,7/16/2014 14:54:03,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,119,131,,,123,147,PART,HYPERSENSITIVITY,PART,119,131-151,HYPERSENSITIVITY Epo,"Epo-RS462A activation was prolonged and BaF3 cells expressing this receptor are hypersensitive to Epo, suggesting that part of the hypersensitivity to Epo in familial polycythemia could be the result of the lack of beta-Trcp recruitment to the Epo-R.",119,131,119,131,123,147,-1,RO-cause_of,900244,"Epo-RS462A activation was prolonged and BaF3 cells expressing this receptor are hypersensitive to Epo, suggesting that part of the hypersensitivity to Epo in familial polycythemia could be the result of the lack of beta-Trcp recruitment to the Epo-R",part,hypersensitivity
503461403,7/16/2014 14:54:43,,1324285924,7/16/2014 14:53:55,irazoo,1.0,7022810,USA,IA,Ankeny,216.161.121.1,119,131,,,123,147,PART,HYPERSENSITIVITY,PART of the hypersensitivity,119-124-131-127,131,HYPERSENSITIVITY,"Epo-RS462A activation was prolonged and BaF3 cells expressing this receptor are hypersensitive to Epo, suggesting that part of the hypersensitivity to Epo in familial polycythemia could be the result of the lack of beta-Trcp recruitment to the Epo-R.",119,131,119,131,123,147,-1,RO-cause_of,900244,"Epo-RS462A activation was prolonged and BaF3 cells expressing this receptor are hypersensitive to Epo, suggesting that part of the hypersensitivity to Epo in familial polycythemia could be the result of the lack of beta-Trcp recruitment to the Epo-R",part,hypersensitivity
503461403,7/16/2014 14:58:12,,1324287297,7/16/2014 14:57:43,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,119,131,,,123,147,PART,HYPERSENSITIVITY,PART,119,131,HYPERSENSITIVITY,"Epo-RS462A activation was prolonged and BaF3 cells expressing this receptor are hypersensitive to Epo, suggesting that part of the hypersensitivity to Epo in familial polycythemia could be the result of the lack of beta-Trcp recruitment to the Epo-R.",119,131,119,131,123,147,-1,RO-cause_of,900244,"Epo-RS462A activation was prolonged and BaF3 cells expressing this receptor are hypersensitive to Epo, suggesting that part of the hypersensitivity to Epo in familial polycythemia could be the result of the lack of beta-Trcp recruitment to the Epo-R",part,hypersensitivity
503461403,7/16/2014 14:58:56,,1324287566,7/16/2014 14:58:35,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,119,131,,,123,147,PART,HYPERSENSITIVITY,PART of the hypersensitivity,119-124-127-131,119-124-127-131-155,part of the HYPERSENSITIVITY in,"Epo-RS462A activation was prolonged and BaF3 cells expressing this receptor are hypersensitive to Epo, suggesting that part of the hypersensitivity to Epo in familial polycythemia could be the result of the lack of beta-Trcp recruitment to the Epo-R.",119,131,119,131,123,147,-1,RO-cause_of,900244,"Epo-RS462A activation was prolonged and BaF3 cells expressing this receptor are hypersensitive to Epo, suggesting that part of the hypersensitivity to Epo in familial polycythemia could be the result of the lack of beta-Trcp recruitment to the Epo-R",part,hypersensitivity
503461404,7/16/2014 13:53:35,,1324262410,7/16/2014 13:53:06,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,133,202,,,137,220,SKIN,PEMPHIGUS VULGARIS,antigenic properties of SKIN pemphigus vulgaris,109-119-130-133-202-212,109-119-130-202-212-133,antigenic properties of skin PEMPHIGUS VULGARIS,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the antigenic properties of skin was investigated by mapping the expression of the skin-specific pemphigus vulgaris and bullous pemphigoid antigens in different regions of the body.,133,202 212,133,202,137,220,1,RO-disease_has_primary_anatomic_site,902125,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the antigenic properties of skin was investigated by mapping the expression of the skin-specific pemphigus vulgaris and bullous pemphigoid antigens in different regions of the body,skin,pemphigus vulgaris
503461404,7/16/2014 13:55:54,,1324263360,7/16/2014 13:55:36,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,133,202,,,137,220,SKIN,PEMPHIGUS VULGARIS,antigenic properties of SKIN,109-119-130-133,184-188-193-202-212-221-225-233-244,the skin specific PEMPHIGUS VULGARIS and bullous pemphigoid antigens,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the antigenic properties of skin was investigated by mapping the expression of the skin-specific pemphigus vulgaris and bullous pemphigoid antigens in different regions of the body.,133,202 212,133,202,137,220,1,RO-disease_has_primary_anatomic_site,902125,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the antigenic properties of skin was investigated by mapping the expression of the skin-specific pemphigus vulgaris and bullous pemphigoid antigens in different regions of the body,skin,pemphigus vulgaris
503461404,7/16/2014 14:33:41,,1324279073,7/16/2014 14:33:26,prodege,1.0,6316959,GBR,"","",46.208.145.114,133,202,,,137,220,SKIN,PEMPHIGUS VULGARIS,SKIN,133,188-193-202-212,skin specific PEMPHIGUS VULGARIS,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the antigenic properties of skin was investigated by mapping the expression of the skin-specific pemphigus vulgaris and bullous pemphigoid antigens in different regions of the body.,133,202 212,133,202,137,220,1,RO-disease_has_primary_anatomic_site,902125,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the antigenic properties of skin was investigated by mapping the expression of the skin-specific pemphigus vulgaris and bullous pemphigoid antigens in different regions of the body,skin,pemphigus vulgaris
503461404,7/16/2014 14:55:05,,1324286079,7/16/2014 14:54:40,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,133,202,,,137,220,SKIN,PEMPHIGUS VULGARIS,antigenic properties of SKIN,109-119-133-130,188-193-202-212,skin specific PEMPHIGUS VULGARIS,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the antigenic properties of skin was investigated by mapping the expression of the skin-specific pemphigus vulgaris and bullous pemphigoid antigens in different regions of the body.,133,202 212,133,202,137,220,1,RO-disease_has_primary_anatomic_site,902125,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the antigenic properties of skin was investigated by mapping the expression of the skin-specific pemphigus vulgaris and bullous pemphigoid antigens in different regions of the body,skin,pemphigus vulgaris
503461404,7/16/2014 14:59:08,,1324287634,7/16/2014 14:58:48,irazoo,1.0,7022810,USA,IA,Ankeny,216.161.121.1,133,202,,,137,220,SKIN,PEMPHIGUS VULGARIS,antigenic properties of SKIN,109-119-130-133,184-188-193-202-212,the skin specific PEMPHIGUS VULGARIS,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the antigenic properties of skin was investigated by mapping the expression of the skin-specific pemphigus vulgaris and bullous pemphigoid antigens in different regions of the body.,133,202 212,133,202,137,220,1,RO-disease_has_primary_anatomic_site,902125,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the antigenic properties of skin was investigated by mapping the expression of the skin-specific pemphigus vulgaris and bullous pemphigoid antigens in different regions of the body,skin,pemphigus vulgaris
503461404,7/16/2014 14:59:31,,1324287709,7/16/2014 14:59:04,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,133,202,,,137,220,SKIN,PEMPHIGUS VULGARIS,SKIN,133,202-212,PEMPHIGUS VULGARIS,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the antigenic properties of skin was investigated by mapping the expression of the skin-specific pemphigus vulgaris and bullous pemphigoid antigens in different regions of the body.,133,202 212,133,202,137,220,1,RO-disease_has_primary_anatomic_site,902125,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the antigenic properties of skin was investigated by mapping the expression of the skin-specific pemphigus vulgaris and bullous pemphigoid antigens in different regions of the body,skin,pemphigus vulgaris
503461404,7/16/2014 15:00:10,,1324288006,7/16/2014 14:59:42,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.72,133,202,,,137,220,SKIN,PEMPHIGUS VULGARIS,SKIN,133,202-212,PEMPHIGUS VULGARIS,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the antigenic properties of skin was investigated by mapping the expression of the skin-specific pemphigus vulgaris and bullous pemphigoid antigens in different regions of the body.,133,202 212,133,202,137,220,1,RO-disease_has_primary_anatomic_site,902125,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the antigenic properties of skin was investigated by mapping the expression of the skin-specific pemphigus vulgaris and bullous pemphigoid antigens in different regions of the body,skin,pemphigus vulgaris
503461404,7/16/2014 15:00:33,,1324288131,7/16/2014 15:00:14,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,133,202,,,137,220,SKIN,PEMPHIGUS VULGARIS,SKIN,133,202-212,PEMPHIGUS VULGARIS,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the antigenic properties of skin was investigated by mapping the expression of the skin-specific pemphigus vulgaris and bullous pemphigoid antigens in different regions of the body.,133,202 212,133,202,137,220,1,RO-disease_has_primary_anatomic_site,902125,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the antigenic properties of skin was investigated by mapping the expression of the skin-specific pemphigus vulgaris and bullous pemphigoid antigens in different regions of the body,skin,pemphigus vulgaris
503461404,7/16/2014 15:00:50,,1324288269,7/16/2014 15:00:33,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,133,202,,,137,220,SKIN,PEMPHIGUS VULGARIS,SKIN,133,202-212,PEMPHIGUS VULGARIS,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the antigenic properties of skin was investigated by mapping the expression of the skin-specific pemphigus vulgaris and bullous pemphigoid antigens in different regions of the body.,133,202 212,133,202,137,220,1,RO-disease_has_primary_anatomic_site,902125,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the antigenic properties of skin was investigated by mapping the expression of the skin-specific pemphigus vulgaris and bullous pemphigoid antigens in different regions of the body,skin,pemphigus vulgaris
503461404,7/16/2014 15:13:56,,1324293242,7/16/2014 15:11:16,coinworker,1.0,23778084,USA,PA,Bellefonte,75.102.101.165,133,202,,,137,220,SKIN,PEMPHIGUS VULGARIS,SKIN,133,202-212,PEMPHIGUS VULGARIS,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the antigenic properties of skin was investigated by mapping the expression of the skin-specific pemphigus vulgaris and bullous pemphigoid antigens in different regions of the body.,133,202 212,133,202,137,220,1,RO-disease_has_primary_anatomic_site,902125,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the antigenic properties of skin was investigated by mapping the expression of the skin-specific pemphigus vulgaris and bullous pemphigoid antigens in different regions of the body,skin,pemphigus vulgaris
503461405,7/16/2014 13:43:08,,1324258787,7/16/2014 13:42:32,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,225,266,,,250,278,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,WBB6F(1)-W,-1,-1,WBB6F(1)-W,"We found that genetically mast cell-deficient WBB6F(1)-W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of bronchial hyperreactivity to aerosolized methacholine, lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1)-+/+ normal mice.",,,225,266,250,278,1,RO-may_diagnose,906530,"We found that genetically mast cell-deficient WBB6F(1)-W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of bronchial hyperreactivity to aerosolized methacholine, lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1)-+/+ normal mice",bronchial hyperreactivity,methacholine
503461405,7/16/2014 13:44:43,,1324259352,7/16/2014 13:44:27,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,225,266,,,250,278,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,WBB6F(1)-W,-1,-1,WBB6F(1)-W,"We found that genetically mast cell-deficient WBB6F(1)-W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of bronchial hyperreactivity to aerosolized methacholine, lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1)-+/+ normal mice.",,,225,266,250,278,1,RO-may_diagnose,906530,"We found that genetically mast cell-deficient WBB6F(1)-W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of bronchial hyperreactivity to aerosolized methacholine, lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1)-+/+ normal mice",bronchial hyperreactivity,methacholine
503461405,7/16/2014 13:49:24,,1324260871,7/16/2014 13:49:13,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,225,266,,,250,278,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,WBB6F(1)-W,-1,-1,WBB6F(1)-W,"We found that genetically mast cell-deficient WBB6F(1)-W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of bronchial hyperreactivity to aerosolized methacholine, lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1)-+/+ normal mice.",,,225,266,250,278,1,RO-may_diagnose,906530,"We found that genetically mast cell-deficient WBB6F(1)-W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of bronchial hyperreactivity to aerosolized methacholine, lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1)-+/+ normal mice",bronchial hyperreactivity,methacholine
503461405,7/16/2014 13:54:18,,1324262757,7/16/2014 13:53:56,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,225,266,,,250,278,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,WBB6F(1)-W,-1,-1,WBB6F(1)-W,"We found that genetically mast cell-deficient WBB6F(1)-W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of bronchial hyperreactivity to aerosolized methacholine, lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1)-+/+ normal mice.",,,225,266,250,278,1,RO-may_diagnose,906530,"We found that genetically mast cell-deficient WBB6F(1)-W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of bronchial hyperreactivity to aerosolized methacholine, lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1)-+/+ normal mice",bronchial hyperreactivity,methacholine
503461405,7/16/2014 13:57:37,,1324264173,7/16/2014 13:55:53,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,225,266,,,250,278,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,WBB6F(1)-W,-1,,,"We found that genetically mast cell-deficient WBB6F(1)-W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of bronchial hyperreactivity to aerosolized methacholine, lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1)-+/+ normal mice.",,,225,266,250,278,1,RO-may_diagnose,906530,"We found that genetically mast cell-deficient WBB6F(1)-W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of bronchial hyperreactivity to aerosolized methacholine, lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1)-+/+ normal mice",bronchial hyperreactivity,methacholine
503461405,7/16/2014 14:01:22,,1324265650,7/16/2014 14:00:23,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,225,266,,,250,278,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,WBB6F(1)-W,-1,,,"We found that genetically mast cell-deficient WBB6F(1)-W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of bronchial hyperreactivity to aerosolized methacholine, lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1)-+/+ normal mice.",,,225,266,250,278,1,RO-may_diagnose,906530,"We found that genetically mast cell-deficient WBB6F(1)-W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of bronchial hyperreactivity to aerosolized methacholine, lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1)-+/+ normal mice",bronchial hyperreactivity,methacholine
503461405,7/16/2014 14:03:32,,1324266604,7/16/2014 14:02:44,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,225,266,,,250,278,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,WBB6F(1)-W,-1,-1,WBB6F(1)-W,"We found that genetically mast cell-deficient WBB6F(1)-W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of bronchial hyperreactivity to aerosolized methacholine, lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1)-+/+ normal mice.",,,225,266,250,278,1,RO-may_diagnose,906530,"We found that genetically mast cell-deficient WBB6F(1)-W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of bronchial hyperreactivity to aerosolized methacholine, lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1)-+/+ normal mice",bronchial hyperreactivity,methacholine
503461405,7/16/2014 14:04:34,,1324267027,7/16/2014 14:04:02,instagc,1.0,18960682,GBR,"","",86.29.147.112,225,266,,,250,278,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,WBB6F(1)-W,-1,251--1,WBB6F(1)-W to,"We found that genetically mast cell-deficient WBB6F(1)-W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of bronchial hyperreactivity to aerosolized methacholine, lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1)-+/+ normal mice.",,,225,266,250,278,1,RO-may_diagnose,906530,"We found that genetically mast cell-deficient WBB6F(1)-W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of bronchial hyperreactivity to aerosolized methacholine, lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1)-+/+ normal mice",bronchial hyperreactivity,methacholine
503461405,7/16/2014 14:12:42,,1324270667,7/16/2014 14:12:24,prodege,1.0,17932518,GBR,"","",81.133.61.60,225,266,,,250,278,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,WBB6F(1)-W,-1,-1,WBB6F(1)-W,"We found that genetically mast cell-deficient WBB6F(1)-W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of bronchial hyperreactivity to aerosolized methacholine, lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1)-+/+ normal mice.",,,225,266,250,278,1,RO-may_diagnose,906530,"We found that genetically mast cell-deficient WBB6F(1)-W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of bronchial hyperreactivity to aerosolized methacholine, lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1)-+/+ normal mice",bronchial hyperreactivity,methacholine
503461405,7/16/2014 14:14:03,,1324271218,7/16/2014 14:13:55,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,225,266,,,250,278,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,to,251,251,to,"We found that genetically mast cell-deficient WBB6F(1)-W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of bronchial hyperreactivity to aerosolized methacholine, lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1)-+/+ normal mice.",,,225,266,250,278,1,RO-may_diagnose,906530,"We found that genetically mast cell-deficient WBB6F(1)-W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of bronchial hyperreactivity to aerosolized methacholine, lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1)-+/+ normal mice",bronchial hyperreactivity,methacholine
503461406,7/16/2014 13:40:36,,1324257877,7/16/2014 13:40:28,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,27,65,,,46,73,PARKINSON'S DISEASE,LEVODOPA,PARKINSON'S DISEASE,27-39,65,LEVODOPA.,Eighty-eight patients with Parkinson's disease were treated with levodopa.,27 39,65,27,65,46,73,1,RO-may_treat,908327,Eighty-eight patients with Parkinson's disease were treated with levodopa,Parkinson's disease,levodopa
503461406,7/16/2014 13:47:26,,1324260260,7/16/2014 13:46:37,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,27,65,,,46,73,PARKINSON'S DISEASE,LEVODOPA,PARKINSON'S DISEASE were treated with,27-39-47-52-60,65,LEVODOPA.,Eighty-eight patients with Parkinson's disease were treated with levodopa.,27 39,65,27,65,46,73,1,RO-may_treat,908327,Eighty-eight patients with Parkinson's disease were treated with levodopa,Parkinson's disease,levodopa
503461406,7/16/2014 13:49:05,,1324260798,7/16/2014 13:48:59,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,27,65,,,46,73,PARKINSON'S DISEASE,LEVODOPA,PARKINSON'S DISEASE,27-39,65,LEVODOPA.,Eighty-eight patients with Parkinson's disease were treated with levodopa.,27 39,65,27,65,46,73,1,RO-may_treat,908327,Eighty-eight patients with Parkinson's disease were treated with levodopa,Parkinson's disease,levodopa
503461406,7/16/2014 13:57:29,,1324264076,7/16/2014 13:57:02,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,27,65,,,46,73,PARKINSON'S DISEASE,LEVODOPA,PARKINSON'S DISEASE levodopa.,27-39-65,27-65-39,Parkinson's disease LEVODOPA.,Eighty-eight patients with Parkinson's disease were treated with levodopa.,27 39,65,27,65,46,73,1,RO-may_treat,908327,Eighty-eight patients with Parkinson's disease were treated with levodopa,Parkinson's disease,levodopa
503461406,7/16/2014 13:58:07,,1324264372,7/16/2014 13:57:55,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,27,65,,,46,73,PARKINSON'S DISEASE,LEVODOPA,PARKINSON'S DISEASE,27-39,27-39-65,Parkinson's disease LEVODOPA.,Eighty-eight patients with Parkinson's disease were treated with levodopa.,27 39,65,27,65,46,73,1,RO-may_treat,908327,Eighty-eight patients with Parkinson's disease were treated with levodopa,Parkinson's disease,levodopa
503461406,7/16/2014 14:03:46,,1324266715,7/16/2014 14:02:44,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,27,65,,,46,73,PARKINSON'S DISEASE,LEVODOPA,PARKINSON'S DISEASE,27-39,65,LEVODOPA.,Eighty-eight patients with Parkinson's disease were treated with levodopa.,27 39,65,27,65,46,73,1,RO-may_treat,908327,Eighty-eight patients with Parkinson's disease were treated with levodopa,Parkinson's disease,levodopa
503461406,7/16/2014 14:19:52,,1324273487,7/16/2014 14:19:42,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,27,65,,,46,73,PARKINSON'S DISEASE,LEVODOPA,PARKINSON'S DISEASE,27-39,65,LEVODOPA.,Eighty-eight patients with Parkinson's disease were treated with levodopa.,27 39,65,27,65,46,73,1,RO-may_treat,908327,Eighty-eight patients with Parkinson's disease were treated with levodopa,Parkinson's disease,levodopa
503461406,7/16/2014 14:23:56,,1324275109,7/16/2014 14:23:44,vivatic,1.0,25451531,GBR,"","",83.67.28.193,27,65,,,46,73,PARKINSON'S DISEASE,LEVODOPA,PARKINSON'S DISEASE,27-39,65,LEVODOPA.,Eighty-eight patients with Parkinson's disease were treated with levodopa.,27 39,65,27,65,46,73,1,RO-may_treat,908327,Eighty-eight patients with Parkinson's disease were treated with levodopa,Parkinson's disease,levodopa
503461406,7/16/2014 14:41:10,,1324281970,7/16/2014 14:40:58,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,27,65,,,46,73,PARKINSON'S DISEASE,LEVODOPA,PARKINSON'S DISEASE,27-39,65,LEVODOPA.,Eighty-eight patients with Parkinson's disease were treated with levodopa.,27 39,65,27,65,46,73,1,RO-may_treat,908327,Eighty-eight patients with Parkinson's disease were treated with levodopa,Parkinson's disease,levodopa
503461406,7/16/2014 14:53:09,,1324285423,7/16/2014 14:53:01,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,27,65,,,46,73,PARKINSON'S DISEASE,LEVODOPA,PARKINSON'S DISEASE,27-39,65,LEVODOPA.,Eighty-eight patients with Parkinson's disease were treated with levodopa.,27 39,65,27,65,46,73,1,RO-may_treat,908327,Eighty-eight patients with Parkinson's disease were treated with levodopa,Parkinson's disease,levodopa
503461407,7/16/2014 13:48:00,,1324260433,7/16/2014 13:47:46,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,62,26,,,85,40,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B,CRYPTOCOCCAL MENINGITIS,62-75,26-39,AMPHOTERICIN B,Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial.,62 75,26 39,62,26,85,40,1,RO-may_treat,907508,Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial,cryptococcal meningitis,amphotericin B
503461407,7/16/2014 13:51:14,,1324261560,7/16/2014 13:51:01,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,62,26,,,85,40,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B,CRYPTOCOCCAL MENINGITIS,62-75,26-39,AMPHOTERICIN B,Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial.,62 75,26 39,62,26,85,40,1,RO-may_treat,907508,Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial,cryptococcal meningitis,amphotericin B
503461407,7/16/2014 13:52:27,,1324261972,7/16/2014 13:52:12,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,62,26,,,85,40,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B,CRYPTOCOCCAL MENINGITIS,62-75,26-39,AMPHOTERICIN B,Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial.,62 75,26 39,62,26,85,40,1,RO-may_treat,907508,Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial,cryptococcal meningitis,amphotericin B
503461407,7/16/2014 13:58:03,,1324264355,7/16/2014 13:57:45,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,62,26,,,85,40,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B,CRYPTOCOCCAL MENINGITIS,62-75,26-39,AMPHOTERICIN B,Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial.,62 75,26 39,62,26,85,40,1,RO-may_treat,907508,Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial,cryptococcal meningitis,amphotericin B
503461407,7/16/2014 14:09:09,,1324269059,7/16/2014 14:08:33,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,62,26,,,85,40,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B,CRYPTOCOCCAL MENINGITIS in AIDS:,62-75-86-89,0-12-26-39-41-46-21,Fluconazole compared with AMPHOTERICIN B plus flucytosine,Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial.,62 75,26 39,62,26,85,40,1,RO-may_treat,907508,Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial,cryptococcal meningitis,amphotericin B
503461407,7/16/2014 14:17:27,,1324272501,7/16/2014 14:17:12,prodege,1.0,17932518,GBR,"","",81.133.61.60,62,26,,,85,40,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B,CRYPTOCOCCAL MENINGITIS,62-75,26-39,AMPHOTERICIN B,Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial.,62 75,26 39,62,26,85,40,1,RO-may_treat,907508,Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial,cryptococcal meningitis,amphotericin B
503461407,7/16/2014 14:22:51,,1324274711,7/16/2014 14:22:33,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,62,26,,,85,40,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B,CRYPTOCOCCAL MENINGITIS,62-75,26-39,AMPHOTERICIN B,Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial.,62 75,26 39,62,26,85,40,1,RO-may_treat,907508,Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial,cryptococcal meningitis,amphotericin B
503461407,7/16/2014 14:23:27,,1324274960,7/16/2014 14:23:08,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,62,26,,,85,40,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B,CRYPTOCOCCAL MENINGITIS,62-75,26-39,AMPHOTERICIN B,Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial.,62 75,26 39,62,26,85,40,1,RO-may_treat,907508,Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial,cryptococcal meningitis,amphotericin B
503461407,7/16/2014 14:23:48,,1324275052,7/16/2014 14:23:34,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,62,26,,,85,40,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B,CRYPTOCOCCAL MENINGITIS,62-75,26-39,AMPHOTERICIN B,Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial.,62 75,26 39,62,26,85,40,1,RO-may_treat,907508,Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial,cryptococcal meningitis,amphotericin B
503461407,7/16/2014 14:34:58,,1324279621,7/16/2014 14:34:36,prodege,1.0,6316959,GBR,"","",46.208.145.114,62,26,,,85,40,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B,CRYPTOCOCCAL MENINGITIS,62-75,26-39,AMPHOTERICIN B,Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial.,62 75,26 39,62,26,85,40,1,RO-may_treat,907508,Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial,cryptococcal meningitis,amphotericin B
503461408,7/16/2014 13:43:22,,1324258875,7/16/2014 13:43:09,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,84,127,,,92,143,DIARRHEA,CHRONIC DIARRHEA,DIARRHEA,84,127-135,CHRONIC DIARRHEA,"HIV infection was common in children with chronic diarrhea, and parasitic agents of diarrhea may be important in children with chronic diarrhea both with and without HIV infection in this setting.",84,127 135,84,127,92,143,-1,RO-has_definitional_manifestation,904968,"HIV infection was common in children with chronic diarrhea, and parasitic agents of diarrhea may be important in children with chronic diarrhea both with and without HIV infection in this setting",diarrhea,chronic diarrhea
503461408,7/16/2014 13:50:13,,1324261169,7/16/2014 13:49:53,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,84,127,,,92,143,DIARRHEA,CHRONIC DIARRHEA,DIARRHEA,84,127-135,CHRONIC DIARRHEA,"HIV infection was common in children with chronic diarrhea, and parasitic agents of diarrhea may be important in children with chronic diarrhea both with and without HIV infection in this setting.",84,127 135,84,127,92,143,-1,RO-has_definitional_manifestation,904968,"HIV infection was common in children with chronic diarrhea, and parasitic agents of diarrhea may be important in children with chronic diarrhea both with and without HIV infection in this setting",diarrhea,chronic diarrhea
503461408,7/16/2014 13:51:46,,1324261720,7/16/2014 13:51:31,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,84,127,,,92,143,DIARRHEA,CHRONIC DIARRHEA,DIARRHEA,84,127-135,CHRONIC DIARRHEA,"HIV infection was common in children with chronic diarrhea, and parasitic agents of diarrhea may be important in children with chronic diarrhea both with and without HIV infection in this setting.",84,127 135,84,127,92,143,-1,RO-has_definitional_manifestation,904968,"HIV infection was common in children with chronic diarrhea, and parasitic agents of diarrhea may be important in children with chronic diarrhea both with and without HIV infection in this setting",diarrhea,chronic diarrhea
503461408,7/16/2014 14:01:13,,1324265508,7/16/2014 14:00:37,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,84,127,,,92,143,DIARRHEA,CHRONIC DIARRHEA,DIARRHEA,84,127-135,CHRONIC DIARRHEA,"HIV infection was common in children with chronic diarrhea, and parasitic agents of diarrhea may be important in children with chronic diarrhea both with and without HIV infection in this setting.",84,127 135,84,127,92,143,-1,RO-has_definitional_manifestation,904968,"HIV infection was common in children with chronic diarrhea, and parasitic agents of diarrhea may be important in children with chronic diarrhea both with and without HIV infection in this setting",diarrhea,chronic diarrhea
503461408,7/16/2014 14:02:40,,1324266211,7/16/2014 14:02:08,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,84,127,,,92,143,DIARRHEA,CHRONIC DIARRHEA,DIARRHEA chronic diarrhea,84-127-135,84-127-135,diarrhea CHRONIC DIARRHEA,"HIV infection was common in children with chronic diarrhea, and parasitic agents of diarrhea may be important in children with chronic diarrhea both with and without HIV infection in this setting.",84,127 135,84,127,92,143,-1,RO-has_definitional_manifestation,904968,"HIV infection was common in children with chronic diarrhea, and parasitic agents of diarrhea may be important in children with chronic diarrhea both with and without HIV infection in this setting",diarrhea,chronic diarrhea
503461408,7/16/2014 14:12:03,,1324270362,7/16/2014 14:11:47,instagc,1.0,13763729,USA,"","",75.182.89.225,84,127,,,92,143,DIARRHEA,CHRONIC DIARRHEA,DIARRHEA,84,127-135,CHRONIC DIARRHEA,"HIV infection was common in children with chronic diarrhea, and parasitic agents of diarrhea may be important in children with chronic diarrhea both with and without HIV infection in this setting.",84,127 135,84,127,92,143,-1,RO-has_definitional_manifestation,904968,"HIV infection was common in children with chronic diarrhea, and parasitic agents of diarrhea may be important in children with chronic diarrhea both with and without HIV infection in this setting",diarrhea,chronic diarrhea
503461408,7/16/2014 14:20:24,,1324273683,7/16/2014 14:19:58,vivatic,1.0,25451531,GBR,"","",83.67.28.193,84,127,,,92,143,DIARRHEA,CHRONIC DIARRHEA,parasitic agents of DIARRHEA,64-74-81-84,127-135-144-149-154-158-166-170,CHRONIC DIARRHEA both with and without HIV infection,"HIV infection was common in children with chronic diarrhea, and parasitic agents of diarrhea may be important in children with chronic diarrhea both with and without HIV infection in this setting.",84,127 135,84,127,92,143,-1,RO-has_definitional_manifestation,904968,"HIV infection was common in children with chronic diarrhea, and parasitic agents of diarrhea may be important in children with chronic diarrhea both with and without HIV infection in this setting",diarrhea,chronic diarrhea
503461408,7/16/2014 14:28:11,,1324276756,7/16/2014 14:27:56,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,84,127,,,92,143,DIARRHEA,CHRONIC DIARRHEA,DIARRHEA,84,127-135,CHRONIC DIARRHEA,"HIV infection was common in children with chronic diarrhea, and parasitic agents of diarrhea may be important in children with chronic diarrhea both with and without HIV infection in this setting.",84,127 135,84,127,92,143,-1,RO-has_definitional_manifestation,904968,"HIV infection was common in children with chronic diarrhea, and parasitic agents of diarrhea may be important in children with chronic diarrhea both with and without HIV infection in this setting",diarrhea,chronic diarrhea
503461408,7/16/2014 14:34:21,,1324279329,7/16/2014 14:33:03,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,84,127,,,92,143,DIARRHEA,CHRONIC DIARRHEA,parasitic agents of DIARRHEA,64-74-81-84,127-135,CHRONIC DIARRHEA,"HIV infection was common in children with chronic diarrhea, and parasitic agents of diarrhea may be important in children with chronic diarrhea both with and without HIV infection in this setting.",84,127 135,84,127,92,143,-1,RO-has_definitional_manifestation,904968,"HIV infection was common in children with chronic diarrhea, and parasitic agents of diarrhea may be important in children with chronic diarrhea both with and without HIV infection in this setting",diarrhea,chronic diarrhea
503461408,7/16/2014 14:54:54,,1324285988,7/16/2014 14:54:39,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,84,127,,,92,143,DIARRHEA,CHRONIC DIARRHEA,DIARRHEA,84,127-135,CHRONIC DIARRHEA,"HIV infection was common in children with chronic diarrhea, and parasitic agents of diarrhea may be important in children with chronic diarrhea both with and without HIV infection in this setting.",84,127 135,84,127,92,143,-1,RO-has_definitional_manifestation,904968,"HIV infection was common in children with chronic diarrhea, and parasitic agents of diarrhea may be important in children with chronic diarrhea both with and without HIV infection in this setting",diarrhea,chronic diarrhea
503461409,7/16/2014 13:44:27,,1324259292,7/16/2014 13:44:16,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,336,392,,,350,398,MILD DYSPLASIA,CIN] I,"MILD DYSPLASIA,",336-341,365-381-391-397,intraepithelial neoplasia [CIN] I),"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low-grade SIL (human papillomavirus [HPV]-associated cellular changes, mild dysplasia, and cervical intraepithelial neoplasia [CIN] I) and high-grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",336 341,397,336,392,350,398,-1,RO-disease_has_finding,901595,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low-grade SIL (human papillomavirus [HPV]-associated cellular changes, mild dysplasia, and cervical intraepithelial neoplasia [CIN] I) and high-grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma",mild dysplasia,CIN] I
503461409,7/16/2014 13:50:21,,1324261234,7/16/2014 13:50:06,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,336,392,,,350,398,MILD DYSPLASIA,CIN] I,"MILD DYSPLASIA,",336-341,397,I),"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low-grade SIL (human papillomavirus [HPV]-associated cellular changes, mild dysplasia, and cervical intraepithelial neoplasia [CIN] I) and high-grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",336 341,397,336,392,350,398,-1,RO-disease_has_finding,901595,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low-grade SIL (human papillomavirus [HPV]-associated cellular changes, mild dysplasia, and cervical intraepithelial neoplasia [CIN] I) and high-grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma",mild dysplasia,CIN] I
503461409,7/16/2014 13:50:37,,1324261336,7/16/2014 13:50:08,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,336,392,,,350,398,MILD DYSPLASIA,CIN] I,"MILD DYSPLASIA, intraepithelial neoplasia [CIN]",336-341-365-381-391,341-365-381-391-397-336,"mild dysplasia, intraepithelial neoplasia [CIN] I)","The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low-grade SIL (human papillomavirus [HPV]-associated cellular changes, mild dysplasia, and cervical intraepithelial neoplasia [CIN] I) and high-grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",336 341,397,336,392,350,398,-1,RO-disease_has_finding,901595,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low-grade SIL (human papillomavirus [HPV]-associated cellular changes, mild dysplasia, and cervical intraepithelial neoplasia [CIN] I) and high-grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma",mild dysplasia,CIN] I
503461409,7/16/2014 13:57:10,,1324263926,7/16/2014 13:56:37,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,336,392,,,350,398,MILD DYSPLASIA,CIN] I,"MILD DYSPLASIA, and cervical intraepithelial neoplasia [CIN] I)",336-341-352-356-365-381-391-397,356-365-381-391-397-400-404-409-415,cervical intraepithelial neoplasia [CIN] I) and high grade SIL,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low-grade SIL (human papillomavirus [HPV]-associated cellular changes, mild dysplasia, and cervical intraepithelial neoplasia [CIN] I) and high-grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",336 341,397,336,392,350,398,-1,RO-disease_has_finding,901595,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low-grade SIL (human papillomavirus [HPV]-associated cellular changes, mild dysplasia, and cervical intraepithelial neoplasia [CIN] I) and high-grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma",mild dysplasia,CIN] I
503461409,7/16/2014 14:00:31,,1324265360,7/16/2014 14:00:15,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,336,392,,,350,398,MILD DYSPLASIA,CIN] I,"MILD DYSPLASIA,",336-341,336-341-397,"mild dysplasia, I)","The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low-grade SIL (human papillomavirus [HPV]-associated cellular changes, mild dysplasia, and cervical intraepithelial neoplasia [CIN] I) and high-grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",336 341,397,336,392,350,398,-1,RO-disease_has_finding,901595,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low-grade SIL (human papillomavirus [HPV]-associated cellular changes, mild dysplasia, and cervical intraepithelial neoplasia [CIN] I) and high-grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma",mild dysplasia,CIN] I
503461409,7/16/2014 14:10:24,,1324269620,7/16/2014 14:09:07,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,336,392,,,350,398,MILD DYSPLASIA,CIN] I,"MILD DYSPLASIA,",336-341,356-365-381-391-397,cervical intraepithelial neoplasia [CIN] I),"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low-grade SIL (human papillomavirus [HPV]-associated cellular changes, mild dysplasia, and cervical intraepithelial neoplasia [CIN] I) and high-grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",336 341,397,336,392,350,398,-1,RO-disease_has_finding,901595,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low-grade SIL (human papillomavirus [HPV]-associated cellular changes, mild dysplasia, and cervical intraepithelial neoplasia [CIN] I) and high-grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma",mild dysplasia,CIN] I
503461409,7/16/2014 14:15:51,,1324271836,7/16/2014 14:15:16,vivatic,1.0,25451531,GBR,"","",83.67.28.193,336,392,,,350,398,MILD DYSPLASIA,CIN] I,"MILD DYSPLASIA,",336-341,356-365-381-391-397,cervical intraepithelial neoplasia [CIN] I),"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low-grade SIL (human papillomavirus [HPV]-associated cellular changes, mild dysplasia, and cervical intraepithelial neoplasia [CIN] I) and high-grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",336 341,397,336,392,350,398,-1,RO-disease_has_finding,901595,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low-grade SIL (human papillomavirus [HPV]-associated cellular changes, mild dysplasia, and cervical intraepithelial neoplasia [CIN] I) and high-grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma",mild dysplasia,CIN] I
503461409,7/16/2014 14:23:07,,1324274811,7/16/2014 14:22:11,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,336,392,,,350,398,MILD DYSPLASIA,CIN] I,"MILD DYSPLASIA,",336-341,391-397,[CIN] I),"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low-grade SIL (human papillomavirus [HPV]-associated cellular changes, mild dysplasia, and cervical intraepithelial neoplasia [CIN] I) and high-grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",336 341,397,336,392,350,398,-1,RO-disease_has_finding,901595,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low-grade SIL (human papillomavirus [HPV]-associated cellular changes, mild dysplasia, and cervical intraepithelial neoplasia [CIN] I) and high-grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma",mild dysplasia,CIN] I
503461409,7/16/2014 14:30:26,,1324277822,7/16/2014 14:29:32,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,336,392,,,350,398,MILD DYSPLASIA,CIN] I,"MILD DYSPLASIA,",336-341,356-365-381-391-397,cervical intraepithelial neoplasia [CIN] I),"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low-grade SIL (human papillomavirus [HPV]-associated cellular changes, mild dysplasia, and cervical intraepithelial neoplasia [CIN] I) and high-grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",336 341,397,336,392,350,398,-1,RO-disease_has_finding,901595,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low-grade SIL (human papillomavirus [HPV]-associated cellular changes, mild dysplasia, and cervical intraepithelial neoplasia [CIN] I) and high-grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma",mild dysplasia,CIN] I
503461409,7/16/2014 14:42:55,,1324282465,7/16/2014 14:42:25,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,336,392,,,350,398,MILD DYSPLASIA,CIN] I,"MILD DYSPLASIA,",336-341,356-365-381-391-397,cervical intraepithelial neoplasia [CIN] I),"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low-grade SIL (human papillomavirus [HPV]-associated cellular changes, mild dysplasia, and cervical intraepithelial neoplasia [CIN] I) and high-grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",336 341,397,336,392,350,398,-1,RO-disease_has_finding,901595,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low-grade SIL (human papillomavirus [HPV]-associated cellular changes, mild dysplasia, and cervical intraepithelial neoplasia [CIN] I) and high-grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma",mild dysplasia,CIN] I
503461410,7/16/2014 13:49:13,,1324260820,7/16/2014 13:48:36,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,8,29,,,13,48,EIGHT,MALIGNANT MELANOMAS,EIGHT malignant melanomas multiparameter flow cytometry aneuploid,8-29-39-61-76-81-96,29-39-61-76-81-96,MALIGNANT MELANOMAS multiparameter flow cytometry aneuploid,Four of eight of these small malignant melanomas analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,8,29 39,8,29,13,48,-1,RO-has_manifestation,906238,Four of eight of these small malignant melanomas analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1,eight,malignant melanomas
503461410,7/16/2014 13:54:30,,1324262828,7/16/2014 13:54:13,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,8,29,,,13,48,EIGHT,MALIGNANT MELANOMAS,EIGHT,8,29-39,MALIGNANT MELANOMAS,Four of eight of these small malignant melanomas analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,8,29 39,8,29,13,48,-1,RO-has_manifestation,906238,Four of eight of these small malignant melanomas analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1,eight,malignant melanomas
503461410,7/16/2014 14:08:01,,1324268562,7/16/2014 14:07:52,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,8,29,,,13,48,EIGHT,MALIGNANT MELANOMAS,Four of EIGHT of these small,0-5-8-14-17-23,14-17-23-29-39-49-58-61,of these small MALIGNANT MELANOMAS analyzed by multiparameter,Four of eight of these small malignant melanomas analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,8,29 39,8,29,13,48,-1,RO-has_manifestation,906238,Four of eight of these small malignant melanomas analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1,eight,malignant melanomas
503461410,7/16/2014 14:09:35,,1324269246,7/16/2014 14:09:16,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,8,29,,,13,48,EIGHT,MALIGNANT MELANOMAS,Four of EIGHT of these small malignant melanomas,0-5-8-14-17-23-29-39,29-39,MALIGNANT MELANOMAS,Four of eight of these small malignant melanomas analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,8,29 39,8,29,13,48,-1,RO-has_manifestation,906238,Four of eight of these small malignant melanomas analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1,eight,malignant melanomas
503461410,7/16/2014 14:14:35,,1324271432,7/16/2014 14:14:12,instagc,1.0,13763729,USA,"","",75.182.89.225,8,29,,,13,48,EIGHT,MALIGNANT MELANOMAS,EIGHT,8,29-39,MALIGNANT MELANOMAS,Four of eight of these small malignant melanomas analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,8,29 39,8,29,13,48,-1,RO-has_manifestation,906238,Four of eight of these small malignant melanomas analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1,eight,malignant melanomas
503461410,7/16/2014 14:15:17,,1324271607,7/16/2014 14:15:03,prodege,1.0,17932518,GBR,"","",81.133.61.60,8,29,,,13,48,EIGHT,MALIGNANT MELANOMAS,EIGHT malignant melanomas,8-29-39,29-39,MALIGNANT MELANOMAS,Four of eight of these small malignant melanomas analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,8,29 39,8,29,13,48,-1,RO-has_manifestation,906238,Four of eight of these small malignant melanomas analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1,eight,malignant melanomas
503461410,7/16/2014 14:33:47,,1324279129,7/16/2014 14:33:18,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,8,29,,,13,48,EIGHT,MALIGNANT MELANOMAS,EIGHT,8,29-39,MALIGNANT MELANOMAS,Four of eight of these small malignant melanomas analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,8,29 39,8,29,13,48,-1,RO-has_manifestation,906238,Four of eight of these small malignant melanomas analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1,eight,malignant melanomas
503461410,7/16/2014 14:39:06,,1324281327,7/16/2014 14:38:45,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,8,29,,,13,48,EIGHT,MALIGNANT MELANOMAS,EIGHT,8,29-39,MALIGNANT MELANOMAS,Four of eight of these small malignant melanomas analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,8,29 39,8,29,13,48,-1,RO-has_manifestation,906238,Four of eight of these small malignant melanomas analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1,eight,malignant melanomas
503461410,7/16/2014 14:45:42,,1324283152,7/16/2014 14:45:17,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,8,29,,,13,48,EIGHT,MALIGNANT MELANOMAS,Four of EIGHT of these small malignant melanomas,0-8-14-17-23-29-39-5,29-39,MALIGNANT MELANOMAS,Four of eight of these small malignant melanomas analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,8,29 39,8,29,13,48,-1,RO-has_manifestation,906238,Four of eight of these small malignant melanomas analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1,eight,malignant melanomas
503461410,7/16/2014 14:52:27,,1324285174,7/16/2014 14:52:11,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,8,29,,,13,48,EIGHT,MALIGNANT MELANOMAS,EIGHT,8,29-39,MALIGNANT MELANOMAS,Four of eight of these small malignant melanomas analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,8,29 39,8,29,13,48,-1,RO-has_manifestation,906238,Four of eight of these small malignant melanomas analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1,eight,malignant melanomas
503461411,7/16/2014 13:46:53,,1324260076,7/16/2014 13:46:26,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,143,108,,,148,128,HEART,MYOCARDIAL ISCHAEMIA,HEART:,143,108-119,MYOCARDIAL ISCHAEMIA,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of myocardial ischaemia in guinea pig heart: (1) 45 min complete ischaemia, (2) 60 min low-flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",143,108 119,143,108,148,128,1,RO-has_finding_site,905220,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of myocardial ischaemia in guinea pig heart: (1) 45 min complete ischaemia, (2) 60 min low-flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added",heart,myocardial ischaemia
503461411,7/16/2014 13:47:43,,1324260344,7/16/2014 13:47:34,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,143,108,,,148,128,HEART,MYOCARDIAL ISCHAEMIA,guinea pig HEART:,132-139-143,108-119,MYOCARDIAL ISCHAEMIA,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of myocardial ischaemia in guinea pig heart: (1) 45 min complete ischaemia, (2) 60 min low-flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",143,108 119,143,108,148,128,1,RO-has_finding_site,905220,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of myocardial ischaemia in guinea pig heart: (1) 45 min complete ischaemia, (2) 60 min low-flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added",heart,myocardial ischaemia
503461411,7/16/2014 13:52:33,,1324261991,7/16/2014 13:52:09,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,143,108,,,148,128,HEART,MYOCARDIAL ISCHAEMIA,HEART:,143,108-119,MYOCARDIAL ISCHAEMIA,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of myocardial ischaemia in guinea pig heart: (1) 45 min complete ischaemia, (2) 60 min low-flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",143,108 119,143,108,148,128,1,RO-has_finding_site,905220,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of myocardial ischaemia in guinea pig heart: (1) 45 min complete ischaemia, (2) 60 min low-flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added",heart,myocardial ischaemia
503461411,7/16/2014 13:57:58,,1324264286,7/16/2014 13:57:38,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,143,108,,,148,128,HEART,MYOCARDIAL ISCHAEMIA,guinea pig HEART:,132-139-143,108-119,MYOCARDIAL ISCHAEMIA,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of myocardial ischaemia in guinea pig heart: (1) 45 min complete ischaemia, (2) 60 min low-flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",143,108 119,143,108,148,128,1,RO-has_finding_site,905220,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of myocardial ischaemia in guinea pig heart: (1) 45 min complete ischaemia, (2) 60 min low-flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added",heart,myocardial ischaemia
503461411,7/16/2014 14:16:19,,1324272014,7/16/2014 14:16:08,prodege,1.0,17932518,GBR,"","",81.133.61.60,143,108,,,148,128,HEART,MYOCARDIAL ISCHAEMIA,HEART:,143,108-119,MYOCARDIAL ISCHAEMIA,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of myocardial ischaemia in guinea pig heart: (1) 45 min complete ischaemia, (2) 60 min low-flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",143,108 119,143,108,148,128,1,RO-has_finding_site,905220,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of myocardial ischaemia in guinea pig heart: (1) 45 min complete ischaemia, (2) 60 min low-flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added",heart,myocardial ischaemia
503461411,7/16/2014 14:17:58,,1324272708,7/16/2014 14:17:16,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,143,108,,,148,128,HEART,MYOCARDIAL ISCHAEMIA,HEART:,143,108-119,MYOCARDIAL ISCHAEMIA,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of myocardial ischaemia in guinea pig heart: (1) 45 min complete ischaemia, (2) 60 min low-flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",143,108 119,143,108,148,128,1,RO-has_finding_site,905220,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of myocardial ischaemia in guinea pig heart: (1) 45 min complete ischaemia, (2) 60 min low-flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added",heart,myocardial ischaemia
503461411,7/16/2014 14:24:41,,1324275433,7/16/2014 14:24:27,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,143,108,,,148,128,HEART,MYOCARDIAL ISCHAEMIA,HEART:,143,108-119,MYOCARDIAL ISCHAEMIA,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of myocardial ischaemia in guinea pig heart: (1) 45 min complete ischaemia, (2) 60 min low-flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",143,108 119,143,108,148,128,1,RO-has_finding_site,905220,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of myocardial ischaemia in guinea pig heart: (1) 45 min complete ischaemia, (2) 60 min low-flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added",heart,myocardial ischaemia
503461411,7/16/2014 14:28:19,,1324276818,7/16/2014 14:27:53,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,143,108,,,148,128,HEART,MYOCARDIAL ISCHAEMIA,myocardial ischaemia HEART:,108-143-119,108-119-143,MYOCARDIAL ISCHAEMIA heart:,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of myocardial ischaemia in guinea pig heart: (1) 45 min complete ischaemia, (2) 60 min low-flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",143,108 119,143,108,148,128,1,RO-has_finding_site,905220,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of myocardial ischaemia in guinea pig heart: (1) 45 min complete ischaemia, (2) 60 min low-flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added",heart,myocardial ischaemia
503461411,7/16/2014 14:31:11,,1324278167,7/16/2014 14:29:39,prodege,1.0,26790109,USA,"","",23.125.64.233,143,108,,,148,128,HEART,MYOCARDIAL ISCHAEMIA,"four conditions of myocardial ischaemia in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",89-94-105-108-119-129-132-139-143-150-154-157-161-170-181-185-188-192-196-201-208-218-223-226-228-232-239-243-251-256-258-267-274-284-288-291-295-300-304-307-316-321-327-330-334-345-349-353-356-360-365-369-372-378-383,89-94-105-108-119-129-132-139,four conditions of MYOCARDIAL ISCHAEMIA in guinea pig,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of myocardial ischaemia in guinea pig heart: (1) 45 min complete ischaemia, (2) 60 min low-flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",143,108 119,143,108,148,128,1,RO-has_finding_site,905220,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of myocardial ischaemia in guinea pig heart: (1) 45 min complete ischaemia, (2) 60 min low-flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added",heart,myocardial ischaemia
503461411,7/16/2014 14:32:21,,1324278553,7/16/2014 14:32:01,prodege,1.0,6316959,GBR,"","",46.208.145.114,143,108,,,148,128,HEART,MYOCARDIAL ISCHAEMIA,guinea pig HEART:,132-139-143,108-119,MYOCARDIAL ISCHAEMIA,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of myocardial ischaemia in guinea pig heart: (1) 45 min complete ischaemia, (2) 60 min low-flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",143,108 119,143,108,148,128,1,RO-has_finding_site,905220,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of myocardial ischaemia in guinea pig heart: (1) 45 min complete ischaemia, (2) 60 min low-flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added",heart,myocardial ischaemia
503461412,7/16/2014 13:49:58,,1324261075,7/16/2014 13:49:37,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,79,18,,,89,32,ARRHYTHMIA,ANTIARRHYTHMIC,"ARRHYTHMIA,",79,18-33,ANTIARRHYTHMIC treatment,"The choice of the antiarrhythmic treatment must always be based on the type of arrhythmia, the presence of a structural cardiopathy and the potential side effects of the antiarrhythmic drug.",79,18,79,18,89,32,1,RO-may_prevent,907386,"The choice of the antiarrhythmic treatment must always be based on the type of arrhythmia, the presence of a structural cardiopathy and the potential side effects of the antiarrhythmic drug",arrhythmia,antiarrhythmic
503461412,7/16/2014 14:03:05,,1324266413,7/16/2014 14:02:50,instagc,1.0,18960682,GBR,"","",86.29.147.112,79,18,,,89,32,ARRHYTHMIA,ANTIARRHYTHMIC,"ARRHYTHMIA,",79,18,ANTIARRHYTHMIC,"The choice of the antiarrhythmic treatment must always be based on the type of arrhythmia, the presence of a structural cardiopathy and the potential side effects of the antiarrhythmic drug.",79,18,79,18,89,32,1,RO-may_prevent,907386,"The choice of the antiarrhythmic treatment must always be based on the type of arrhythmia, the presence of a structural cardiopathy and the potential side effects of the antiarrhythmic drug",arrhythmia,antiarrhythmic
503461412,7/16/2014 14:11:28,,1324270076,7/16/2014 14:11:12,instagc,1.0,13763729,USA,"","",75.182.89.225,79,18,,,89,32,ARRHYTHMIA,ANTIARRHYTHMIC,"ARRHYTHMIA,",79,18-33,ANTIARRHYTHMIC treatment,"The choice of the antiarrhythmic treatment must always be based on the type of arrhythmia, the presence of a structural cardiopathy and the potential side effects of the antiarrhythmic drug.",79,18,79,18,89,32,1,RO-may_prevent,907386,"The choice of the antiarrhythmic treatment must always be based on the type of arrhythmia, the presence of a structural cardiopathy and the potential side effects of the antiarrhythmic drug",arrhythmia,antiarrhythmic
503461412,7/16/2014 14:13:32,,1324270952,7/16/2014 14:13:05,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,79,18,,,89,32,ARRHYTHMIA,ANTIARRHYTHMIC,"ARRHYTHMIA,",79,18-33,ANTIARRHYTHMIC treatment,"The choice of the antiarrhythmic treatment must always be based on the type of arrhythmia, the presence of a structural cardiopathy and the potential side effects of the antiarrhythmic drug.",79,18,79,18,89,32,1,RO-may_prevent,907386,"The choice of the antiarrhythmic treatment must always be based on the type of arrhythmia, the presence of a structural cardiopathy and the potential side effects of the antiarrhythmic drug",arrhythmia,antiarrhythmic
503461412,7/16/2014 14:21:15,,1324274072,7/16/2014 14:20:55,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,79,18,,,89,32,ARRHYTHMIA,ANTIARRHYTHMIC,"ARRHYTHMIA,",79,18-33,ANTIARRHYTHMIC treatment,"The choice of the antiarrhythmic treatment must always be based on the type of arrhythmia, the presence of a structural cardiopathy and the potential side effects of the antiarrhythmic drug.",79,18,79,18,89,32,1,RO-may_prevent,907386,"The choice of the antiarrhythmic treatment must always be based on the type of arrhythmia, the presence of a structural cardiopathy and the potential side effects of the antiarrhythmic drug",arrhythmia,antiarrhythmic
503461412,7/16/2014 14:37:46,,1324280895,7/16/2014 14:37:27,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,79,18,,,89,32,ARRHYTHMIA,ANTIARRHYTHMIC,"antiarrhythmic ARRHYTHMIA,",79-18,18-79,"ANTIARRHYTHMIC arrhythmia,","The choice of the antiarrhythmic treatment must always be based on the type of arrhythmia, the presence of a structural cardiopathy and the potential side effects of the antiarrhythmic drug.",79,18,79,18,89,32,1,RO-may_prevent,907386,"The choice of the antiarrhythmic treatment must always be based on the type of arrhythmia, the presence of a structural cardiopathy and the potential side effects of the antiarrhythmic drug",arrhythmia,antiarrhythmic
503461412,7/16/2014 14:47:09,,1324283588,7/16/2014 14:46:59,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,79,18,,,89,32,ARRHYTHMIA,ANTIARRHYTHMIC,"ARRHYTHMIA,",79,18,ANTIARRHYTHMIC,"The choice of the antiarrhythmic treatment must always be based on the type of arrhythmia, the presence of a structural cardiopathy and the potential side effects of the antiarrhythmic drug.",79,18,79,18,89,32,1,RO-may_prevent,907386,"The choice of the antiarrhythmic treatment must always be based on the type of arrhythmia, the presence of a structural cardiopathy and the potential side effects of the antiarrhythmic drug",arrhythmia,antiarrhythmic
503461412,7/16/2014 14:50:54,,1324284739,7/16/2014 14:50:09,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,79,18,,,89,32,ARRHYTHMIA,ANTIARRHYTHMIC,"ARRHYTHMIA,",79,18,ANTIARRHYTHMIC,"The choice of the antiarrhythmic treatment must always be based on the type of arrhythmia, the presence of a structural cardiopathy and the potential side effects of the antiarrhythmic drug.",79,18,79,18,89,32,1,RO-may_prevent,907386,"The choice of the antiarrhythmic treatment must always be based on the type of arrhythmia, the presence of a structural cardiopathy and the potential side effects of the antiarrhythmic drug",arrhythmia,antiarrhythmic
503461412,7/16/2014 14:58:56,,1324287565,7/16/2014 14:58:36,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,79,18,,,89,32,ARRHYTHMIA,ANTIARRHYTHMIC,"ARRHYTHMIA,",79,18,ANTIARRHYTHMIC,"The choice of the antiarrhythmic treatment must always be based on the type of arrhythmia, the presence of a structural cardiopathy and the potential side effects of the antiarrhythmic drug.",79,18,79,18,89,32,1,RO-may_prevent,907386,"The choice of the antiarrhythmic treatment must always be based on the type of arrhythmia, the presence of a structural cardiopathy and the potential side effects of the antiarrhythmic drug",arrhythmia,antiarrhythmic
503461412,7/16/2014 14:59:36,,1324287759,7/16/2014 14:59:07,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.72,79,18,,,89,32,ARRHYTHMIA,ANTIARRHYTHMIC,"ARRHYTHMIA,",79,18,ANTIARRHYTHMIC,"The choice of the antiarrhythmic treatment must always be based on the type of arrhythmia, the presence of a structural cardiopathy and the potential side effects of the antiarrhythmic drug.",79,18,79,18,89,32,1,RO-may_prevent,907386,"The choice of the antiarrhythmic treatment must always be based on the type of arrhythmia, the presence of a structural cardiopathy and the potential side effects of the antiarrhythmic drug",arrhythmia,antiarrhythmic
503461413,7/16/2014 13:54:49,,1324262931,7/16/2014 13:54:31,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,82,15,,,102,25,ERECTILE DYSFUNCTION,PAPAVERINE,ERECTILE DYSFUNCTION,82-91,15,PAPAVERINE,Intracorporeal papaverine has been used as an out-patient procedure to assess the erectile dysfunction of 129 men.,82 91,15,82,15,102,25,1,RO-may_diagnose,906591,Intracorporeal papaverine has been used as an out-patient procedure to assess the erectile dysfunction of 129 men,erectile dysfunction,papaverine
503461413,7/16/2014 14:03:00,,1324266362,7/16/2014 14:02:43,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,82,15,,,102,25,ERECTILE DYSFUNCTION,PAPAVERINE,Intracorporeal papaverine ERECTILE DYSFUNCTION,0-15-82-91,0-15-82-91,Intracorporeal PAPAVERINE erectile dysfunction,Intracorporeal papaverine has been used as an out-patient procedure to assess the erectile dysfunction of 129 men.,82 91,15,82,15,102,25,1,RO-may_diagnose,906591,Intracorporeal papaverine has been used as an out-patient procedure to assess the erectile dysfunction of 129 men,erectile dysfunction,papaverine
503461413,7/16/2014 14:16:41,,1324272149,7/16/2014 14:16:28,vivatic,1.0,25451531,GBR,"","",83.67.28.193,82,15,,,102,25,ERECTILE DYSFUNCTION,PAPAVERINE,ERECTILE DYSFUNCTION,82-91,0-15,Intracorporeal PAPAVERINE,Intracorporeal papaverine has been used as an out-patient procedure to assess the erectile dysfunction of 129 men.,82 91,15,82,15,102,25,1,RO-may_diagnose,906591,Intracorporeal papaverine has been used as an out-patient procedure to assess the erectile dysfunction of 129 men,erectile dysfunction,papaverine
503461413,7/16/2014 14:27:34,,1324276515,7/16/2014 14:27:12,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,82,15,,,102,25,ERECTILE DYSFUNCTION,PAPAVERINE,papaverine ERECTILE DYSFUNCTION,82-91-15,15-82-91,PAPAVERINE erectile dysfunction,Intracorporeal papaverine has been used as an out-patient procedure to assess the erectile dysfunction of 129 men.,82 91,15,82,15,102,25,1,RO-may_diagnose,906591,Intracorporeal papaverine has been used as an out-patient procedure to assess the erectile dysfunction of 129 men,erectile dysfunction,papaverine
503461413,7/16/2014 14:30:59,,1324278083,7/16/2014 14:30:44,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,82,15,,,102,25,ERECTILE DYSFUNCTION,PAPAVERINE,ERECTILE DYSFUNCTION,82-91,15,PAPAVERINE,Intracorporeal papaverine has been used as an out-patient procedure to assess the erectile dysfunction of 129 men.,82 91,15,82,15,102,25,1,RO-may_diagnose,906591,Intracorporeal papaverine has been used as an out-patient procedure to assess the erectile dysfunction of 129 men,erectile dysfunction,papaverine
503461413,7/16/2014 14:32:41,,1324278698,7/16/2014 14:32:25,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,82,15,,,102,25,ERECTILE DYSFUNCTION,PAPAVERINE,ERECTILE DYSFUNCTION,82-91,0-15,Intracorporeal PAPAVERINE,Intracorporeal papaverine has been used as an out-patient procedure to assess the erectile dysfunction of 129 men.,82 91,15,82,15,102,25,1,RO-may_diagnose,906591,Intracorporeal papaverine has been used as an out-patient procedure to assess the erectile dysfunction of 129 men,erectile dysfunction,papaverine
503461413,7/16/2014 14:36:28,,1324280347,7/16/2014 14:36:01,prodege,1.0,26790109,USA,"","",23.125.64.233,82,15,,,102,25,ERECTILE DYSFUNCTION,PAPAVERINE,Intracorporeal papaverine out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,0-15-46-50-68-71-78-82-91-103-106-110-58,0-15-26-30-35-40-43-46-50-58-68-71-78-82-91-106-110-103,Intracorporeal PAPAVERINE has been used as an out patient procedure to assess the erectile dysfunction of 129 men.,Intracorporeal papaverine has been used as an out-patient procedure to assess the erectile dysfunction of 129 men.,82 91,15,82,15,102,25,1,RO-may_diagnose,906591,Intracorporeal papaverine has been used as an out-patient procedure to assess the erectile dysfunction of 129 men,erectile dysfunction,papaverine
503461413,7/16/2014 14:41:27,,1324282058,7/16/2014 14:41:11,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,82,15,,,102,25,ERECTILE DYSFUNCTION,PAPAVERINE,ERECTILE DYSFUNCTION,82-91,0-15,Intracorporeal PAPAVERINE,Intracorporeal papaverine has been used as an out-patient procedure to assess the erectile dysfunction of 129 men.,82 91,15,82,15,102,25,1,RO-may_diagnose,906591,Intracorporeal papaverine has been used as an out-patient procedure to assess the erectile dysfunction of 129 men,erectile dysfunction,papaverine
503461413,7/16/2014 14:47:12,,1324283595,7/16/2014 14:46:56,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,82,15,,,102,25,ERECTILE DYSFUNCTION,PAPAVERINE,ERECTILE DYSFUNCTION,82-91,0-15,Intracorporeal PAPAVERINE,Intracorporeal papaverine has been used as an out-patient procedure to assess the erectile dysfunction of 129 men.,82 91,15,82,15,102,25,1,RO-may_diagnose,906591,Intracorporeal papaverine has been used as an out-patient procedure to assess the erectile dysfunction of 129 men,erectile dysfunction,papaverine
503461413,7/16/2014 14:55:18,,1324286129,7/16/2014 14:55:17,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,82,15,,,102,25,ERECTILE DYSFUNCTION,PAPAVERINE,to assess the ERECTILE DYSFUNCTION of 129 men.,68-71-78-82-91-103-106-110,0-15-26-30-35,Intracorporeal PAPAVERINE has been used,Intracorporeal papaverine has been used as an out-patient procedure to assess the erectile dysfunction of 129 men.,82 91,15,82,15,102,25,1,RO-may_diagnose,906591,Intracorporeal papaverine has been used as an out-patient procedure to assess the erectile dysfunction of 129 men,erectile dysfunction,papaverine
503461414,7/16/2014 13:45:03,,1324259451,7/16/2014 13:44:52,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,166,120,,,174,139,VOMITING,NAUSEA AND VOMITING,VOMITING,166,120-127-131,NAUSEA AND VOMITING,"1 ,   33  Class:  5-HT3 Receptor Antagonists 56:22.20; GA700 (VA)  Synonyms:  Zofran  Uses  Cancer Chemotherapy-induced Nausea and Vomiting  Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; may use orally with highly emetogenic chemotherapy (i.e., cisplatin ?50 mg/m 2 ) or initial and repeat courses of moderately emetogenic chemotherapy, or IV with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin.",166,120 127 131,166,120,174,139,-1,RO-has_definitional_manifestation,904776,"1 ,   33  Class:  5-HT3 Receptor Antagonists 56:22.20; GA700 (VA)  Synonyms:  Zofran  Uses  Cancer Chemotherapy-induced Nausea and Vomiting  Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; may use orally with highly emetogenic chemotherapy (i.e., cisplatin ?50 mg/m 2 ) or initial and repeat courses of moderately emetogenic chemotherapy, or IV with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin",vomiting,Nausea and Vomiting
503461414,7/16/2014 13:45:22,,1324259592,7/16/2014 13:45:04,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,166,120,,,174,139,VOMITING,NAUSEA AND VOMITING,VOMITING,166,92-99-112-120-127-131,Cancer Chemotherapy induced NAUSEA AND VOMITING,"1 ,   33  Class:  5-HT3 Receptor Antagonists 56:22.20; GA700 (VA)  Synonyms:  Zofran  Uses  Cancer Chemotherapy-induced Nausea and Vomiting  Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; may use orally with highly emetogenic chemotherapy (i.e., cisplatin ?50 mg/m 2 ) or initial and repeat courses of moderately emetogenic chemotherapy, or IV with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin.",166,120 127 131,166,120,174,139,-1,RO-has_definitional_manifestation,904776,"1 ,   33  Class:  5-HT3 Receptor Antagonists 56:22.20; GA700 (VA)  Synonyms:  Zofran  Uses  Cancer Chemotherapy-induced Nausea and Vomiting  Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; may use orally with highly emetogenic chemotherapy (i.e., cisplatin ?50 mg/m 2 ) or initial and repeat courses of moderately emetogenic chemotherapy, or IV with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin",vomiting,Nausea and Vomiting
503461414,7/16/2014 13:49:12,,1324260817,7/16/2014 13:48:58,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,166,120,,,174,139,VOMITING,NAUSEA AND VOMITING,VOMITING,166,120-127-131,NAUSEA AND VOMITING,"1 ,   33  Class:  5-HT3 Receptor Antagonists 56:22.20; GA700 (VA)  Synonyms:  Zofran  Uses  Cancer Chemotherapy-induced Nausea and Vomiting  Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; may use orally with highly emetogenic chemotherapy (i.e., cisplatin ?50 mg/m 2 ) or initial and repeat courses of moderately emetogenic chemotherapy, or IV with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin.",166,120 127 131,166,120,174,139,-1,RO-has_definitional_manifestation,904776,"1 ,   33  Class:  5-HT3 Receptor Antagonists 56:22.20; GA700 (VA)  Synonyms:  Zofran  Uses  Cancer Chemotherapy-induced Nausea and Vomiting  Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; may use orally with highly emetogenic chemotherapy (i.e., cisplatin ?50 mg/m 2 ) or initial and repeat courses of moderately emetogenic chemotherapy, or IV with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin",vomiting,Nausea and Vomiting
503461414,7/16/2014 13:53:41,,1324262472,7/16/2014 13:53:14,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,166,120,,,174,139,VOMITING,NAUSEA AND VOMITING,nausea and VOMITING associated with emetogenic,155-162-166-175-186-191,92-99-112-120-127-131,Cancer Chemotherapy induced NAUSEA AND VOMITING,"1 ,   33  Class:  5-HT3 Receptor Antagonists 56:22.20; GA700 (VA)  Synonyms:  Zofran  Uses  Cancer Chemotherapy-induced Nausea and Vomiting  Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; may use orally with highly emetogenic chemotherapy (i.e., cisplatin ?50 mg/m 2 ) or initial and repeat courses of moderately emetogenic chemotherapy, or IV with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin.",166,120 127 131,166,120,174,139,-1,RO-has_definitional_manifestation,904776,"1 ,   33  Class:  5-HT3 Receptor Antagonists 56:22.20; GA700 (VA)  Synonyms:  Zofran  Uses  Cancer Chemotherapy-induced Nausea and Vomiting  Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; may use orally with highly emetogenic chemotherapy (i.e., cisplatin ?50 mg/m 2 ) or initial and repeat courses of moderately emetogenic chemotherapy, or IV with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin",vomiting,Nausea and Vomiting
503461414,7/16/2014 14:00:27,,1324265338,7/16/2014 14:00:05,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,166,120,,,174,139,VOMITING,NAUSEA AND VOMITING,VOMITING,166,120-127-131,NAUSEA AND VOMITING,"1 ,   33  Class:  5-HT3 Receptor Antagonists 56:22.20; GA700 (VA)  Synonyms:  Zofran  Uses  Cancer Chemotherapy-induced Nausea and Vomiting  Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; may use orally with highly emetogenic chemotherapy (i.e., cisplatin ?50 mg/m 2 ) or initial and repeat courses of moderately emetogenic chemotherapy, or IV with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin.",166,120 127 131,166,120,174,139,-1,RO-has_definitional_manifestation,904776,"1 ,   33  Class:  5-HT3 Receptor Antagonists 56:22.20; GA700 (VA)  Synonyms:  Zofran  Uses  Cancer Chemotherapy-induced Nausea and Vomiting  Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; may use orally with highly emetogenic chemotherapy (i.e., cisplatin ?50 mg/m 2 ) or initial and repeat courses of moderately emetogenic chemotherapy, or IV with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin",vomiting,Nausea and Vomiting
503461414,7/16/2014 14:21:09,,1324274054,7/16/2014 14:20:51,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,166,120,,,174,139,VOMITING,NAUSEA AND VOMITING,of nausea and VOMITING,152-155-162-166,99-112-120-127-131,Chemotherapy induced NAUSEA AND VOMITING,"1 ,   33  Class:  5-HT3 Receptor Antagonists 56:22.20; GA700 (VA)  Synonyms:  Zofran  Uses  Cancer Chemotherapy-induced Nausea and Vomiting  Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; may use orally with highly emetogenic chemotherapy (i.e., cisplatin ?50 mg/m 2 ) or initial and repeat courses of moderately emetogenic chemotherapy, or IV with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin.",166,120 127 131,166,120,174,139,-1,RO-has_definitional_manifestation,904776,"1 ,   33  Class:  5-HT3 Receptor Antagonists 56:22.20; GA700 (VA)  Synonyms:  Zofran  Uses  Cancer Chemotherapy-induced Nausea and Vomiting  Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; may use orally with highly emetogenic chemotherapy (i.e., cisplatin ?50 mg/m 2 ) or initial and repeat courses of moderately emetogenic chemotherapy, or IV with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin",vomiting,Nausea and Vomiting
503461414,7/16/2014 14:32:21,,1324278554,7/16/2014 14:31:44,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,166,120,,,174,139,VOMITING,NAUSEA AND VOMITING,VOMITING,166,120-127-131,NAUSEA AND VOMITING,"1 ,   33  Class:  5-HT3 Receptor Antagonists 56:22.20; GA700 (VA)  Synonyms:  Zofran  Uses  Cancer Chemotherapy-induced Nausea and Vomiting  Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; may use orally with highly emetogenic chemotherapy (i.e., cisplatin ?50 mg/m 2 ) or initial and repeat courses of moderately emetogenic chemotherapy, or IV with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin.",166,120 127 131,166,120,174,139,-1,RO-has_definitional_manifestation,904776,"1 ,   33  Class:  5-HT3 Receptor Antagonists 56:22.20; GA700 (VA)  Synonyms:  Zofran  Uses  Cancer Chemotherapy-induced Nausea and Vomiting  Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; may use orally with highly emetogenic chemotherapy (i.e., cisplatin ?50 mg/m 2 ) or initial and repeat courses of moderately emetogenic chemotherapy, or IV with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin",vomiting,Nausea and Vomiting
503461414,7/16/2014 14:44:25,,1324282849,7/16/2014 14:43:20,neodev,1.0,28336203,USA,PA,Harrisburg,50.149.53.150,166,120,,,174,139,VOMITING,NAUSEA AND VOMITING,nausea and VOMITING,155-166-162,120-127-131,NAUSEA AND VOMITING,"1 ,   33  Class:  5-HT3 Receptor Antagonists 56:22.20; GA700 (VA)  Synonyms:  Zofran  Uses  Cancer Chemotherapy-induced Nausea and Vomiting  Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; may use orally with highly emetogenic chemotherapy (i.e., cisplatin ?50 mg/m 2 ) or initial and repeat courses of moderately emetogenic chemotherapy, or IV with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin.",166,120 127 131,166,120,174,139,-1,RO-has_definitional_manifestation,904776,"1 ,   33  Class:  5-HT3 Receptor Antagonists 56:22.20; GA700 (VA)  Synonyms:  Zofran  Uses  Cancer Chemotherapy-induced Nausea and Vomiting  Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; may use orally with highly emetogenic chemotherapy (i.e., cisplatin ?50 mg/m 2 ) or initial and repeat courses of moderately emetogenic chemotherapy, or IV with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin",vomiting,Nausea and Vomiting
503461414,7/16/2014 14:46:58,,1324283538,7/16/2014 14:46:49,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,166,120,,,174,139,VOMITING,NAUSEA AND VOMITING,nausea and VOMITING,155-162-166,120-127-131,NAUSEA AND VOMITING,"1 ,   33  Class:  5-HT3 Receptor Antagonists 56:22.20; GA700 (VA)  Synonyms:  Zofran  Uses  Cancer Chemotherapy-induced Nausea and Vomiting  Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; may use orally with highly emetogenic chemotherapy (i.e., cisplatin ?50 mg/m 2 ) or initial and repeat courses of moderately emetogenic chemotherapy, or IV with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin.",166,120 127 131,166,120,174,139,-1,RO-has_definitional_manifestation,904776,"1 ,   33  Class:  5-HT3 Receptor Antagonists 56:22.20; GA700 (VA)  Synonyms:  Zofran  Uses  Cancer Chemotherapy-induced Nausea and Vomiting  Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; may use orally with highly emetogenic chemotherapy (i.e., cisplatin ?50 mg/m 2 ) or initial and repeat courses of moderately emetogenic chemotherapy, or IV with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin",vomiting,Nausea and Vomiting
503461414,7/16/2014 14:51:16,,1324284857,7/16/2014 14:50:51,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,166,120,,,174,139,VOMITING,NAUSEA AND VOMITING,VOMITING,166,120-127-131-155,NAUSEA AND VOMITING nausea,"1 ,   33  Class:  5-HT3 Receptor Antagonists 56:22.20; GA700 (VA)  Synonyms:  Zofran  Uses  Cancer Chemotherapy-induced Nausea and Vomiting  Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; may use orally with highly emetogenic chemotherapy (i.e., cisplatin ?50 mg/m 2 ) or initial and repeat courses of moderately emetogenic chemotherapy, or IV with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin.",166,120 127 131,166,120,174,139,-1,RO-has_definitional_manifestation,904776,"1 ,   33  Class:  5-HT3 Receptor Antagonists 56:22.20; GA700 (VA)  Synonyms:  Zofran  Uses  Cancer Chemotherapy-induced Nausea and Vomiting  Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; may use orally with highly emetogenic chemotherapy (i.e., cisplatin ?50 mg/m 2 ) or initial and repeat courses of moderately emetogenic chemotherapy, or IV with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin",vomiting,Nausea and Vomiting
503461415,7/16/2014 13:46:33,,1324259937,7/16/2014 13:46:20,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,92,68,,,123,77,MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE,"MALIGNANT HYPERTHERMIA SYNDROME,",92-102-115,68,HALOTHANE,"At the end of the growth period, when the pigs were challenged with halothane to detect the malignant hyperthermia syndrome, 3 pigs were found to be susceptible.",92 102 115,68,92,68,123,77,1,RO-may_diagnose,906757,"At the end of the growth period, when the pigs were challenged with halothane to detect the malignant hyperthermia syndrome, 3 pigs were found to be susceptible",malignant hyperthermia syndrome,halothane
503461415,7/16/2014 13:49:19,,1324260855,7/16/2014 13:49:04,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,92,68,,,123,77,MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE,"MALIGNANT HYPERTHERMIA SYNDROME,",92-102-115,68,HALOTHANE,"At the end of the growth period, when the pigs were challenged with halothane to detect the malignant hyperthermia syndrome, 3 pigs were found to be susceptible.",92 102 115,68,92,68,123,77,1,RO-may_diagnose,906757,"At the end of the growth period, when the pigs were challenged with halothane to detect the malignant hyperthermia syndrome, 3 pigs were found to be susceptible",malignant hyperthermia syndrome,halothane
503461415,7/16/2014 14:00:17,,1324265293,7/16/2014 13:59:49,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,92,68,,,123,77,MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE,"halothane MALIGNANT HYPERTHERMIA SYNDROME,",92-102-115-68,68-92-102-115,"HALOTHANE malignant hyperthermia syndrome,","At the end of the growth period, when the pigs were challenged with halothane to detect the malignant hyperthermia syndrome, 3 pigs were found to be susceptible.",92 102 115,68,92,68,123,77,1,RO-may_diagnose,906757,"At the end of the growth period, when the pigs were challenged with halothane to detect the malignant hyperthermia syndrome, 3 pigs were found to be susceptible",malignant hyperthermia syndrome,halothane
503461415,7/16/2014 14:06:48,,1324268024,7/16/2014 14:06:30,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,92,68,,,123,77,MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE,"halothane MALIGNANT HYPERTHERMIA SYNDROME, susceptible.",68-92-102-115-149,68-78-92-102-115-149,"HALOTHANE to malignant hyperthermia syndrome, susceptible.","At the end of the growth period, when the pigs were challenged with halothane to detect the malignant hyperthermia syndrome, 3 pigs were found to be susceptible.",92 102 115,68,92,68,123,77,1,RO-may_diagnose,906757,"At the end of the growth period, when the pigs were challenged with halothane to detect the malignant hyperthermia syndrome, 3 pigs were found to be susceptible",malignant hyperthermia syndrome,halothane
503461415,7/16/2014 14:11:47,,1324270262,7/16/2014 14:11:29,instagc,1.0,13763729,USA,"","",75.182.89.225,92,68,,,123,77,MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE,"MALIGNANT HYPERTHERMIA SYNDROME,",92-102-115,68,HALOTHANE,"At the end of the growth period, when the pigs were challenged with halothane to detect the malignant hyperthermia syndrome, 3 pigs were found to be susceptible.",92 102 115,68,92,68,123,77,1,RO-may_diagnose,906757,"At the end of the growth period, when the pigs were challenged with halothane to detect the malignant hyperthermia syndrome, 3 pigs were found to be susceptible",malignant hyperthermia syndrome,halothane
503461415,7/16/2014 14:19:04,,1324273155,7/16/2014 14:17:56,prodege,1.0,17932518,GBR,"","",81.133.61.60,92,68,,,123,77,MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE,"MALIGNANT HYPERTHERMIA SYNDROME,",92-102-115,68,HALOTHANE,"At the end of the growth period, when the pigs were challenged with halothane to detect the malignant hyperthermia syndrome, 3 pigs were found to be susceptible.",92 102 115,68,92,68,123,77,1,RO-may_diagnose,906757,"At the end of the growth period, when the pigs were challenged with halothane to detect the malignant hyperthermia syndrome, 3 pigs were found to be susceptible",malignant hyperthermia syndrome,halothane
503461415,7/16/2014 14:22:37,,1324274622,7/16/2014 14:21:57,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,92,68,,,123,77,MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE,"MALIGNANT HYPERTHERMIA SYNDROME,",92-102-115,68,HALOTHANE,"At the end of the growth period, when the pigs were challenged with halothane to detect the malignant hyperthermia syndrome, 3 pigs were found to be susceptible.",92 102 115,68,92,68,123,77,1,RO-may_diagnose,906757,"At the end of the growth period, when the pigs were challenged with halothane to detect the malignant hyperthermia syndrome, 3 pigs were found to be susceptible",malignant hyperthermia syndrome,halothane
503461415,7/16/2014 14:30:28,,1324277841,7/16/2014 14:30:12,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,92,68,,,123,77,MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE,"MALIGNANT HYPERTHERMIA SYNDROME,",92-102-115,68,HALOTHANE,"At the end of the growth period, when the pigs were challenged with halothane to detect the malignant hyperthermia syndrome, 3 pigs were found to be susceptible.",92 102 115,68,92,68,123,77,1,RO-may_diagnose,906757,"At the end of the growth period, when the pigs were challenged with halothane to detect the malignant hyperthermia syndrome, 3 pigs were found to be susceptible",malignant hyperthermia syndrome,halothane
503461415,7/16/2014 14:35:10,,1324279698,7/16/2014 14:34:43,prodege,1.0,26790109,USA,"","",23.125.64.233,92,68,,,123,77,MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE,"to detect the MALIGNANT HYPERTHERMIA SYNDROME, 3 pigs were found to be susceptible.",78-81-88-92-102-115-125-127-132-137-143-146-149,47-52-63-68-78-81-88-92-102-115,"were challenged with HALOTHANE to detect the malignant hyperthermia syndrome,","At the end of the growth period, when the pigs were challenged with halothane to detect the malignant hyperthermia syndrome, 3 pigs were found to be susceptible.",92 102 115,68,92,68,123,77,1,RO-may_diagnose,906757,"At the end of the growth period, when the pigs were challenged with halothane to detect the malignant hyperthermia syndrome, 3 pigs were found to be susceptible",malignant hyperthermia syndrome,halothane
503461415,7/16/2014 14:54:09,,1324285739,7/16/2014 14:53:50,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,92,68,,,123,77,MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE,"MALIGNANT HYPERTHERMIA SYNDROME,",92-102-115,68,HALOTHANE,"At the end of the growth period, when the pigs were challenged with halothane to detect the malignant hyperthermia syndrome, 3 pigs were found to be susceptible.",92 102 115,68,92,68,123,77,1,RO-may_diagnose,906757,"At the end of the growth period, when the pigs were challenged with halothane to detect the malignant hyperthermia syndrome, 3 pigs were found to be susceptible",malignant hyperthermia syndrome,halothane
503461416,7/16/2014 13:50:22,,1324261240,7/16/2014 13:50:08,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,73,119,,,79,134,ASTHMA,CYSTIC FIBROSIS,"ASTHMA,",73,119-126,"CYSTIC FIBROSIS,","Differential diagnosis must exclude an endobronchial obstructive lesion, asthma, nocturnal aspiration, bronchiectasis, cystic fibrosis, and immotile cilia syndrome.",73,119 126,73,119,79,134,-1,RO-has_manifestation,906342,"Differential diagnosis must exclude an endobronchial obstructive lesion, asthma, nocturnal aspiration, bronchiectasis, cystic fibrosis, and immotile cilia syndrome",asthma,cystic fibrosis
503461416,7/16/2014 13:50:49,,1324261439,7/16/2014 13:50:33,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,73,119,,,79,134,ASTHMA,CYSTIC FIBROSIS,"ASTHMA,",73,119-126,"CYSTIC FIBROSIS,","Differential diagnosis must exclude an endobronchial obstructive lesion, asthma, nocturnal aspiration, bronchiectasis, cystic fibrosis, and immotile cilia syndrome.",73,119 126,73,119,79,134,-1,RO-has_manifestation,906342,"Differential diagnosis must exclude an endobronchial obstructive lesion, asthma, nocturnal aspiration, bronchiectasis, cystic fibrosis, and immotile cilia syndrome",asthma,cystic fibrosis
503461416,7/16/2014 13:51:19,,1324261585,7/16/2014 13:50:58,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,73,119,,,79,134,ASTHMA,CYSTIC FIBROSIS,"ASTHMA,",73,119-126,"CYSTIC FIBROSIS,","Differential diagnosis must exclude an endobronchial obstructive lesion, asthma, nocturnal aspiration, bronchiectasis, cystic fibrosis, and immotile cilia syndrome.",73,119 126,73,119,79,134,-1,RO-has_manifestation,906342,"Differential diagnosis must exclude an endobronchial obstructive lesion, asthma, nocturnal aspiration, bronchiectasis, cystic fibrosis, and immotile cilia syndrome",asthma,cystic fibrosis
503461416,7/16/2014 14:02:48,,1324266255,7/16/2014 14:02:36,instagc,1.0,18960682,GBR,"","",86.29.147.112,73,119,,,79,134,ASTHMA,CYSTIC FIBROSIS,"ASTHMA,",73,119-126,"CYSTIC FIBROSIS,","Differential diagnosis must exclude an endobronchial obstructive lesion, asthma, nocturnal aspiration, bronchiectasis, cystic fibrosis, and immotile cilia syndrome.",73,119 126,73,119,79,134,-1,RO-has_manifestation,906342,"Differential diagnosis must exclude an endobronchial obstructive lesion, asthma, nocturnal aspiration, bronchiectasis, cystic fibrosis, and immotile cilia syndrome",asthma,cystic fibrosis
503461416,7/16/2014 14:14:05,,1324271226,7/16/2014 14:13:53,prodege,1.0,17932518,GBR,"","",81.133.61.60,73,119,,,79,134,ASTHMA,CYSTIC FIBROSIS,"ASTHMA,",73,119-126,"CYSTIC FIBROSIS,","Differential diagnosis must exclude an endobronchial obstructive lesion, asthma, nocturnal aspiration, bronchiectasis, cystic fibrosis, and immotile cilia syndrome.",73,119 126,73,119,79,134,-1,RO-has_manifestation,906342,"Differential diagnosis must exclude an endobronchial obstructive lesion, asthma, nocturnal aspiration, bronchiectasis, cystic fibrosis, and immotile cilia syndrome",asthma,cystic fibrosis
503461416,7/16/2014 14:22:28,,1324274566,7/16/2014 14:22:14,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,73,119,,,79,134,ASTHMA,CYSTIC FIBROSIS,"ASTHMA,",73,119-126,"CYSTIC FIBROSIS,","Differential diagnosis must exclude an endobronchial obstructive lesion, asthma, nocturnal aspiration, bronchiectasis, cystic fibrosis, and immotile cilia syndrome.",73,119 126,73,119,79,134,-1,RO-has_manifestation,906342,"Differential diagnosis must exclude an endobronchial obstructive lesion, asthma, nocturnal aspiration, bronchiectasis, cystic fibrosis, and immotile cilia syndrome",asthma,cystic fibrosis
503461416,7/16/2014 14:27:48,,1324276640,7/16/2014 14:27:33,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,73,119,,,79,134,ASTHMA,CYSTIC FIBROSIS,"ASTHMA,",73,119-126,"CYSTIC FIBROSIS,","Differential diagnosis must exclude an endobronchial obstructive lesion, asthma, nocturnal aspiration, bronchiectasis, cystic fibrosis, and immotile cilia syndrome.",73,119 126,73,119,79,134,-1,RO-has_manifestation,906342,"Differential diagnosis must exclude an endobronchial obstructive lesion, asthma, nocturnal aspiration, bronchiectasis, cystic fibrosis, and immotile cilia syndrome",asthma,cystic fibrosis
503461416,7/16/2014 14:51:32,,1324284919,7/16/2014 14:51:13,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,73,119,,,79,134,ASTHMA,CYSTIC FIBROSIS,"ASTHMA,",73,119-126,"CYSTIC FIBROSIS,","Differential diagnosis must exclude an endobronchial obstructive lesion, asthma, nocturnal aspiration, bronchiectasis, cystic fibrosis, and immotile cilia syndrome.",73,119 126,73,119,79,134,-1,RO-has_manifestation,906342,"Differential diagnosis must exclude an endobronchial obstructive lesion, asthma, nocturnal aspiration, bronchiectasis, cystic fibrosis, and immotile cilia syndrome",asthma,cystic fibrosis
503461416,7/16/2014 14:52:07,,1324285072,7/16/2014 14:51:58,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,73,119,,,79,134,ASTHMA,CYSTIC FIBROSIS,"ASTHMA,",73,119-126,"CYSTIC FIBROSIS,","Differential diagnosis must exclude an endobronchial obstructive lesion, asthma, nocturnal aspiration, bronchiectasis, cystic fibrosis, and immotile cilia syndrome.",73,119 126,73,119,79,134,-1,RO-has_manifestation,906342,"Differential diagnosis must exclude an endobronchial obstructive lesion, asthma, nocturnal aspiration, bronchiectasis, cystic fibrosis, and immotile cilia syndrome",asthma,cystic fibrosis
503461416,7/16/2014 14:59:58,,1324287900,7/16/2014 14:59:45,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,73,119,,,79,134,ASTHMA,CYSTIC FIBROSIS,"ASTHMA,",73,119-126,"CYSTIC FIBROSIS,","Differential diagnosis must exclude an endobronchial obstructive lesion, asthma, nocturnal aspiration, bronchiectasis, cystic fibrosis, and immotile cilia syndrome.",73,119 126,73,119,79,134,-1,RO-has_manifestation,906342,"Differential diagnosis must exclude an endobronchial obstructive lesion, asthma, nocturnal aspiration, bronchiectasis, cystic fibrosis, and immotile cilia syndrome",asthma,cystic fibrosis
503461417,7/16/2014 13:40:34,,1324257871,7/16/2014 13:40:25,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,90,0,,,102,31,OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA,progressive OSSIFICATION,78-90,0-9-20,MYOSITIS OSSIFICANS PROGRESSIVA,"Myositis ossificans progressiva is an autosomal dominant disease resulting in progressive ossification and skeletal deformities, mainly in the connective tissue of muscle.",90,0 9 20,90,0,102,31,1,RO-disease_has_finding,901735,"Myositis ossificans progressiva is an autosomal dominant disease resulting in progressive ossification and skeletal deformities, mainly in the connective tissue of muscle",ossification,Myositis ossificans progressiva
503461417,7/16/2014 13:44:17,,1324259230,7/16/2014 13:44:01,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,90,0,,,102,31,OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA,"progressive OSSIFICATION and skeletal deformities,",78-90-103-107-116,0-9-20,MYOSITIS OSSIFICANS PROGRESSIVA,"Myositis ossificans progressiva is an autosomal dominant disease resulting in progressive ossification and skeletal deformities, mainly in the connective tissue of muscle.",90,0 9 20,90,0,102,31,1,RO-disease_has_finding,901735,"Myositis ossificans progressiva is an autosomal dominant disease resulting in progressive ossification and skeletal deformities, mainly in the connective tissue of muscle",ossification,Myositis ossificans progressiva
503461417,7/16/2014 13:58:43,,1324264624,7/16/2014 13:58:09,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,90,0,,,102,31,OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA,Myositis ossificans progressiva OSSIFICATION,0-9-90-20,0-9-20-90,MYOSITIS OSSIFICANS PROGRESSIVA ossification,"Myositis ossificans progressiva is an autosomal dominant disease resulting in progressive ossification and skeletal deformities, mainly in the connective tissue of muscle.",90,0 9 20,90,0,102,31,1,RO-disease_has_finding,901735,"Myositis ossificans progressiva is an autosomal dominant disease resulting in progressive ossification and skeletal deformities, mainly in the connective tissue of muscle",ossification,Myositis ossificans progressiva
503461417,7/16/2014 13:59:19,,1324264899,7/16/2014 13:59:08,instagc,1.0,18960682,GBR,"","",86.29.147.112,90,0,,,102,31,OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA,progressive OSSIFICATION,78-90,0-9-20,MYOSITIS OSSIFICANS PROGRESSIVA,"Myositis ossificans progressiva is an autosomal dominant disease resulting in progressive ossification and skeletal deformities, mainly in the connective tissue of muscle.",90,0 9 20,90,0,102,31,1,RO-disease_has_finding,901735,"Myositis ossificans progressiva is an autosomal dominant disease resulting in progressive ossification and skeletal deformities, mainly in the connective tissue of muscle",ossification,Myositis ossificans progressiva
503461417,7/16/2014 14:02:47,,1324266247,7/16/2014 14:02:31,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,90,0,,,102,31,OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA,progressive OSSIFICATION,78-90,0-9-20,MYOSITIS OSSIFICANS PROGRESSIVA,"Myositis ossificans progressiva is an autosomal dominant disease resulting in progressive ossification and skeletal deformities, mainly in the connective tissue of muscle.",90,0 9 20,90,0,102,31,1,RO-disease_has_finding,901735,"Myositis ossificans progressiva is an autosomal dominant disease resulting in progressive ossification and skeletal deformities, mainly in the connective tissue of muscle",ossification,Myositis ossificans progressiva
503461417,7/16/2014 14:07:26,,1324268307,7/16/2014 14:07:16,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,90,0,,,102,31,OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA,"resulting in progressive OSSIFICATION and skeletal deformities,",65-75-78-90-103-107-116,0-9-20-32-35-38,MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal,"Myositis ossificans progressiva is an autosomal dominant disease resulting in progressive ossification and skeletal deformities, mainly in the connective tissue of muscle.",90,0 9 20,90,0,102,31,1,RO-disease_has_finding,901735,"Myositis ossificans progressiva is an autosomal dominant disease resulting in progressive ossification and skeletal deformities, mainly in the connective tissue of muscle",ossification,Myositis ossificans progressiva
503461417,7/16/2014 14:10:44,,1324269768,7/16/2014 14:10:32,instagc,1.0,13763729,USA,"","",75.182.89.225,90,0,,,102,31,OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA,OSSIFICATION,90,0-9-20,MYOSITIS OSSIFICANS PROGRESSIVA,"Myositis ossificans progressiva is an autosomal dominant disease resulting in progressive ossification and skeletal deformities, mainly in the connective tissue of muscle.",90,0 9 20,90,0,102,31,1,RO-disease_has_finding,901735,"Myositis ossificans progressiva is an autosomal dominant disease resulting in progressive ossification and skeletal deformities, mainly in the connective tissue of muscle",ossification,Myositis ossificans progressiva
503461417,7/16/2014 14:24:49,,1324275478,7/16/2014 14:24:29,vivatic,1.0,25451531,GBR,"","",83.67.28.193,90,0,,,102,31,OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA,progressive OSSIFICATION,78-90,0-9-20,MYOSITIS OSSIFICANS PROGRESSIVA,"Myositis ossificans progressiva is an autosomal dominant disease resulting in progressive ossification and skeletal deformities, mainly in the connective tissue of muscle.",90,0 9 20,90,0,102,31,1,RO-disease_has_finding,901735,"Myositis ossificans progressiva is an autosomal dominant disease resulting in progressive ossification and skeletal deformities, mainly in the connective tissue of muscle",ossification,Myositis ossificans progressiva
503461417,7/16/2014 14:44:20,,1324282835,7/16/2014 14:44:13,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,90,0,,,102,31,OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA,progressive OSSIFICATION,78-90,0-9-20,MYOSITIS OSSIFICANS PROGRESSIVA,"Myositis ossificans progressiva is an autosomal dominant disease resulting in progressive ossification and skeletal deformities, mainly in the connective tissue of muscle.",90,0 9 20,90,0,102,31,1,RO-disease_has_finding,901735,"Myositis ossificans progressiva is an autosomal dominant disease resulting in progressive ossification and skeletal deformities, mainly in the connective tissue of muscle",ossification,Myositis ossificans progressiva
503461417,7/16/2014 14:49:22,,1324284280,7/16/2014 14:48:31,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,90,0,,,102,31,OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA,"Myositis ossificans progressiva progressive OSSIFICATION and skeletal deformities,",0-9-20-78-90-103-107-116,0-9-20-78-90-103-107-116,"MYOSITIS OSSIFICANS PROGRESSIVA progressive ossification and skeletal deformities,","Myositis ossificans progressiva is an autosomal dominant disease resulting in progressive ossification and skeletal deformities, mainly in the connective tissue of muscle.",90,0 9 20,90,0,102,31,1,RO-disease_has_finding,901735,"Myositis ossificans progressiva is an autosomal dominant disease resulting in progressive ossification and skeletal deformities, mainly in the connective tissue of muscle",ossification,Myositis ossificans progressiva
503461418,7/16/2014 13:39:42,,1324257479,7/16/2014 13:39:30,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,70,44,,,89,49,HYPERPARATHYROIDISM,MEN2A,primary HYPERPARATHYROIDISM,62-70,44,MEN2A,? Data from cohort studies of patients with MEN2a reveal that primary hyperparathyroidism is present in approximately 30% of patients with MEN2a.,70,44,70,44,89,49,1,RO-has_manifestation,906333,? Data from cohort studies of patients with MEN2a reveal that primary hyperparathyroidism is present in approximately 30% of patients with MEN2a,hyperparathyroidism,MEN2a
503461418,7/16/2014 13:41:09,,1324258059,7/16/2014 13:40:58,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,70,44,,,89,49,HYPERPARATHYROIDISM,MEN2A,HYPERPARATHYROIDISM,70,44,MEN2A,? Data from cohort studies of patients with MEN2a reveal that primary hyperparathyroidism is present in approximately 30% of patients with MEN2a.,70,44,70,44,89,49,1,RO-has_manifestation,906333,? Data from cohort studies of patients with MEN2a reveal that primary hyperparathyroidism is present in approximately 30% of patients with MEN2a,hyperparathyroidism,MEN2a
503461418,7/16/2014 13:47:04,,1324260116,7/16/2014 13:46:33,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,70,44,,,89,49,HYPERPARATHYROIDISM,MEN2A,MEN2a HYPERPARATHYROIDISM in,70-101-44,44-70,MEN2A hyperparathyroidism,? Data from cohort studies of patients with MEN2a reveal that primary hyperparathyroidism is present in approximately 30% of patients with MEN2a.,70,44,70,44,89,49,1,RO-has_manifestation,906333,? Data from cohort studies of patients with MEN2a reveal that primary hyperparathyroidism is present in approximately 30% of patients with MEN2a,hyperparathyroidism,MEN2a
503461418,7/16/2014 13:53:54,,1324262570,7/16/2014 13:53:39,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,70,44,,,89,49,HYPERPARATHYROIDISM,MEN2A,primary HYPERPARATHYROIDISM,62-70,44,MEN2A,? Data from cohort studies of patients with MEN2a reveal that primary hyperparathyroidism is present in approximately 30% of patients with MEN2a.,70,44,70,44,89,49,1,RO-has_manifestation,906333,? Data from cohort studies of patients with MEN2a reveal that primary hyperparathyroidism is present in approximately 30% of patients with MEN2a,hyperparathyroidism,MEN2a
503461418,7/16/2014 13:59:04,,1324264799,7/16/2014 13:58:49,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,70,44,,,89,49,HYPERPARATHYROIDISM,MEN2A,HYPERPARATHYROIDISM,70,44-70,MEN2A hyperparathyroidism,? Data from cohort studies of patients with MEN2a reveal that primary hyperparathyroidism is present in approximately 30% of patients with MEN2a.,70,44,70,44,89,49,1,RO-has_manifestation,906333,? Data from cohort studies of patients with MEN2a reveal that primary hyperparathyroidism is present in approximately 30% of patients with MEN2a,hyperparathyroidism,MEN2a
503461418,7/16/2014 14:17:40,,1324272584,7/16/2014 14:17:27,prodege,1.0,17932518,GBR,"","",81.133.61.60,70,44,,,89,49,HYPERPARATHYROIDISM,MEN2A,primary HYPERPARATHYROIDISM,62-70,44,MEN2A,? Data from cohort studies of patients with MEN2a reveal that primary hyperparathyroidism is present in approximately 30% of patients with MEN2a.,70,44,70,44,89,49,1,RO-has_manifestation,906333,? Data from cohort studies of patients with MEN2a reveal that primary hyperparathyroidism is present in approximately 30% of patients with MEN2a,hyperparathyroidism,MEN2a
503461418,7/16/2014 14:40:16,,1324281731,7/16/2014 14:39:55,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,70,44,,,89,49,HYPERPARATHYROIDISM,MEN2A,primary HYPERPARATHYROIDISM,62-70,44,MEN2A,? Data from cohort studies of patients with MEN2a reveal that primary hyperparathyroidism is present in approximately 30% of patients with MEN2a.,70,44,70,44,89,49,1,RO-has_manifestation,906333,? Data from cohort studies of patients with MEN2a reveal that primary hyperparathyroidism is present in approximately 30% of patients with MEN2a,hyperparathyroidism,MEN2a
503461418,7/16/2014 14:50:08,,1324284541,7/16/2014 14:49:45,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,70,44,,,89,49,HYPERPARATHYROIDISM,MEN2A,MEN2a HYPERPARATHYROIDISM,70-44,44-70,MEN2A hyperparathyroidism,? Data from cohort studies of patients with MEN2a reveal that primary hyperparathyroidism is present in approximately 30% of patients with MEN2a.,70,44,70,44,89,49,1,RO-has_manifestation,906333,? Data from cohort studies of patients with MEN2a reveal that primary hyperparathyroidism is present in approximately 30% of patients with MEN2a,hyperparathyroidism,MEN2a
503461418,7/16/2014 14:55:56,,1324286372,7/16/2014 14:55:45,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,70,44,,,89,49,HYPERPARATHYROIDISM,MEN2A,HYPERPARATHYROIDISM,70,44,MEN2A,? Data from cohort studies of patients with MEN2a reveal that primary hyperparathyroidism is present in approximately 30% of patients with MEN2a.,70,44,70,44,89,49,1,RO-has_manifestation,906333,? Data from cohort studies of patients with MEN2a reveal that primary hyperparathyroidism is present in approximately 30% of patients with MEN2a,hyperparathyroidism,MEN2a
503461418,7/16/2014 14:57:11,,1324286926,7/16/2014 14:56:56,irazoo,1.0,7022810,USA,IA,Ankeny,216.161.121.1,70,44,,,89,49,HYPERPARATHYROIDISM,MEN2A,primary HYPERPARATHYROIDISM,62-70,44,MEN2A,? Data from cohort studies of patients with MEN2a reveal that primary hyperparathyroidism is present in approximately 30% of patients with MEN2a.,70,44,70,44,89,49,1,RO-has_manifestation,906333,? Data from cohort studies of patients with MEN2a reveal that primary hyperparathyroidism is present in approximately 30% of patients with MEN2a,hyperparathyroidism,MEN2a
503461419,7/16/2014 13:41:55,,1324258352,7/16/2014 13:41:44,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,89,42,,,96,46,ASCITES,OHSS,"ASCITES,",89,42,OHSS,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",89,42,89,42,96,46,1,RO-has_manifestation,906261,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis",ascites,OHSS
503461419,7/16/2014 13:54:49,,1324262930,7/16/2014 13:54:21,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,89,42,,,96,46,ASCITES,OHSS,"weight gain, ovarian enlargement, ASCITES, pleural effusion, hemoconcentration,",62-68-76-89-98-106-116-55,19-30-39-42-47-55-62,"laboratory findings of OHSS include weight gain,","Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",89,42,89,42,96,46,1,RO-has_manifestation,906261,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis",ascites,OHSS
503461419,7/16/2014 13:56:10,,1324263472,7/16/2014 13:55:57,instagc,1.0,18960682,GBR,"","",86.29.147.112,89,42,,,96,46,ASCITES,OHSS,"ASCITES,",89,42,OHSS,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",89,42,89,42,96,46,1,RO-has_manifestation,906261,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis",ascites,OHSS
503461419,7/16/2014 13:56:34,,1324263649,7/16/2014 13:56:20,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,89,42,,,96,46,ASCITES,OHSS,"ASCITES,",89,42,OHSS,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",89,42,89,42,96,46,1,RO-has_manifestation,906261,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis",ascites,OHSS
503461419,7/16/2014 13:58:20,,1324264448,7/16/2014 13:57:59,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,89,42,,,96,46,ASCITES,OHSS,"OHSS weight gain, ovarian enlargement, ASCITES, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, thrombosis.",42-55-62-68-76-89-98-106-116-135-147-159-165-182,42-55-62-68-76-89-98-106-116-135-147-159-165-182,"OHSS weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, thrombosis.","Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",89,42,89,42,96,46,1,RO-has_manifestation,906261,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis",ascites,OHSS
503461419,7/16/2014 14:15:27,,1324271658,7/16/2014 14:15:14,instagc,1.0,13763729,USA,"","",75.182.89.225,89,42,,,96,46,ASCITES,OHSS,"ASCITES,",89,42,OHSS,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",89,42,89,42,96,46,1,RO-has_manifestation,906261,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis",ascites,OHSS
503461419,7/16/2014 14:21:52,,1324274325,7/16/2014 14:21:38,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,89,42,,,96,46,ASCITES,OHSS,"ASCITES,",89,42,OHSS,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",89,42,89,42,96,46,1,RO-has_manifestation,906261,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis",ascites,OHSS
503461419,7/16/2014 14:33:56,,1324279183,7/16/2014 14:33:33,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,89,42,,,96,46,ASCITES,OHSS,"OHSS ASCITES,",42-89,42-89,"OHSS ascites,","Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",89,42,89,42,96,46,1,RO-has_manifestation,906261,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis",ascites,OHSS
503461419,7/16/2014 14:51:12,,1324284836,7/16/2014 14:50:49,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,89,42,,,96,46,ASCITES,OHSS,"gain, ovarian enlargement, ASCITES, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, thrombosis.",62-68-76-89-98-106-116-135-147-159-165-182,42-55-62-68-76-89-98-106-116-135-147-159-165-182,"OHSS weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, thrombosis.","Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",89,42,89,42,96,46,1,RO-has_manifestation,906261,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis",ascites,OHSS
503461419,7/16/2014 14:51:58,,1324285047,7/16/2014 14:51:31,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,89,42,,,96,46,ASCITES,OHSS,"ASCITES,",89,42,OHSS,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",89,42,89,42,96,46,1,RO-has_manifestation,906261,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis",ascites,OHSS
503461420,7/16/2014 13:46:42,,1324259992,7/16/2014 13:46:34,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,0,70,,,20,87,MECONIUM PERITONITIS,BOWEL PERFORATION,MECONIUM PERITONITIS,0-9,70-76,BOWEL PERFORATION,Meconium peritonitis is a chemical peritonitis which occurs following bowel perforation during fetal life.,0 9,70 76,0,70,20,87,1,RO-cause_of,900224,Meconium peritonitis is a chemical peritonitis which occurs following bowel perforation during fetal life,Meconium peritonitis,bowel perforation
503461420,7/16/2014 13:47:58,,1324260435,7/16/2014 13:47:52,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,0,70,,,20,87,MECONIUM PERITONITIS,BOWEL PERFORATION,MECONIUM PERITONITIS,0-9,70-76,BOWEL PERFORATION,Meconium peritonitis is a chemical peritonitis which occurs following bowel perforation during fetal life.,0 9,70 76,0,70,20,87,1,RO-cause_of,900224,Meconium peritonitis is a chemical peritonitis which occurs following bowel perforation during fetal life,Meconium peritonitis,bowel perforation
503461420,7/16/2014 13:51:45,,1324261712,7/16/2014 13:51:33,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,0,70,,,20,87,MECONIUM PERITONITIS,BOWEL PERFORATION,MECONIUM PERITONITIS,0-9,70-76,BOWEL PERFORATION,Meconium peritonitis is a chemical peritonitis which occurs following bowel perforation during fetal life.,0 9,70 76,0,70,20,87,1,RO-cause_of,900224,Meconium peritonitis is a chemical peritonitis which occurs following bowel perforation during fetal life,Meconium peritonitis,bowel perforation
503461420,7/16/2014 13:59:31,,1324265058,7/16/2014 13:59:18,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,0,70,,,20,87,MECONIUM PERITONITIS,BOWEL PERFORATION,MECONIUM PERITONITIS,0-9,0-70-76-9,Meconium peritonitis BOWEL PERFORATION,Meconium peritonitis is a chemical peritonitis which occurs following bowel perforation during fetal life.,0 9,70 76,0,70,20,87,1,RO-cause_of,900224,Meconium peritonitis is a chemical peritonitis which occurs following bowel perforation during fetal life,Meconium peritonitis,bowel perforation
503461420,7/16/2014 14:08:28,,1324268774,7/16/2014 14:08:17,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,0,70,,,20,87,MECONIUM PERITONITIS,BOWEL PERFORATION,MECONIUM PERITONITIS,0-9,70-76,BOWEL PERFORATION,Meconium peritonitis is a chemical peritonitis which occurs following bowel perforation during fetal life.,0 9,70 76,0,70,20,87,1,RO-cause_of,900224,Meconium peritonitis is a chemical peritonitis which occurs following bowel perforation during fetal life,Meconium peritonitis,bowel perforation
503461420,7/16/2014 14:08:35,,1324268809,7/16/2014 14:08:28,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,0,70,,,20,87,MECONIUM PERITONITIS,BOWEL PERFORATION,MECONIUM PERITONITIS is a chemical,0-9-21-24-26,47-53-60-70-76-88-95-101,which occurs following BOWEL PERFORATION during fetal life.,Meconium peritonitis is a chemical peritonitis which occurs following bowel perforation during fetal life.,0 9,70 76,0,70,20,87,1,RO-cause_of,900224,Meconium peritonitis is a chemical peritonitis which occurs following bowel perforation during fetal life,Meconium peritonitis,bowel perforation
503461420,7/16/2014 14:22:09,,1324274446,7/16/2014 14:21:52,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,0,70,,,20,87,MECONIUM PERITONITIS,BOWEL PERFORATION,MECONIUM PERITONITIS,0-9,70-76,BOWEL PERFORATION,Meconium peritonitis is a chemical peritonitis which occurs following bowel perforation during fetal life.,0 9,70 76,0,70,20,87,1,RO-cause_of,900224,Meconium peritonitis is a chemical peritonitis which occurs following bowel perforation during fetal life,Meconium peritonitis,bowel perforation
503461420,7/16/2014 14:25:48,,1324275853,7/16/2014 14:25:37,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,0,70,,,20,87,MECONIUM PERITONITIS,BOWEL PERFORATION,MECONIUM PERITONITIS,0-9,70-76,BOWEL PERFORATION,Meconium peritonitis is a chemical peritonitis which occurs following bowel perforation during fetal life.,0 9,70 76,0,70,20,87,1,RO-cause_of,900224,Meconium peritonitis is a chemical peritonitis which occurs following bowel perforation during fetal life,Meconium peritonitis,bowel perforation
503461420,7/16/2014 14:29:56,,1324277594,7/16/2014 14:29:37,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,0,70,,,20,87,MECONIUM PERITONITIS,BOWEL PERFORATION,MECONIUM PERITONITIS bowel perforation,0-9-70-76,0-9-70-76,Meconium peritonitis BOWEL PERFORATION,Meconium peritonitis is a chemical peritonitis which occurs following bowel perforation during fetal life.,0 9,70 76,0,70,20,87,1,RO-cause_of,900224,Meconium peritonitis is a chemical peritonitis which occurs following bowel perforation during fetal life,Meconium peritonitis,bowel perforation
503461420,7/16/2014 14:48:07,,1324283873,7/16/2014 14:47:45,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,0,70,,,20,87,MECONIUM PERITONITIS,BOWEL PERFORATION,MECONIUM PERITONITIS,0-9,0-9-70-76,Meconium peritonitis BOWEL PERFORATION,Meconium peritonitis is a chemical peritonitis which occurs following bowel perforation during fetal life.,0 9,70 76,0,70,20,87,1,RO-cause_of,900224,Meconium peritonitis is a chemical peritonitis which occurs following bowel perforation during fetal life,Meconium peritonitis,bowel perforation
503461421,7/16/2014 13:40:57,,1324257972,7/16/2014 13:40:47,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,68,0,,,88,7,MYCOBACTERIUM LEPRAE,LEPROSY,"LEPRAE),",82,0,LEPROSY,"Leprosy is unique in terms of the nature of the causative organism (Mycobacterium leprae), the chronicity of the disease, its prolonged treatment and the definitions of ""cure"" and ""relapse.",82,0,68,0,88,7,1,RO-has_causative_agent,903748,"Leprosy is unique in terms of the nature of the causative organism (Mycobacterium leprae), the chronicity of the disease, its prolonged treatment and the definitions of &quot;cure&quot; and &quot;relapse",Mycobacterium leprae,Leprosy
503461421,7/16/2014 13:49:49,,1324261004,7/16/2014 13:49:38,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,68,0,,,88,7,MYCOBACTERIUM LEPRAE,LEPROSY,"(MYCOBACTERIUM LEPRAE),",67-82,0,LEPROSY,"Leprosy is unique in terms of the nature of the causative organism (Mycobacterium leprae), the chronicity of the disease, its prolonged treatment and the definitions of ""cure"" and ""relapse.",82,0,68,0,88,7,1,RO-has_causative_agent,903748,"Leprosy is unique in terms of the nature of the causative organism (Mycobacterium leprae), the chronicity of the disease, its prolonged treatment and the definitions of &quot;cure&quot; and &quot;relapse",Mycobacterium leprae,Leprosy
503461421,7/16/2014 13:50:43,,1324261417,7/16/2014 13:50:30,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,68,0,,,88,7,MYCOBACTERIUM LEPRAE,LEPROSY,"(MYCOBACTERIUM LEPRAE),",67-82,0,LEPROSY,"Leprosy is unique in terms of the nature of the causative organism (Mycobacterium leprae), the chronicity of the disease, its prolonged treatment and the definitions of ""cure"" and ""relapse.",82,0,68,0,88,7,1,RO-has_causative_agent,903748,"Leprosy is unique in terms of the nature of the causative organism (Mycobacterium leprae), the chronicity of the disease, its prolonged treatment and the definitions of &quot;cure&quot; and &quot;relapse",Mycobacterium leprae,Leprosy
503461421,7/16/2014 13:53:40,,1324262470,7/16/2014 13:53:12,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,68,0,,,88,7,MYCOBACTERIUM LEPRAE,LEPROSY,"Leprosy causative organism (MYCOBACTERIUM LEPRAE), disease, ""cure"" ""relapse.",0-48-58-67-82-113-180-169,0-48-58-67-82-113-169-180,"LEPROSY causative organism (Mycobacterium leprae), disease, ""cure"" ""relapse.","Leprosy is unique in terms of the nature of the causative organism (Mycobacterium leprae), the chronicity of the disease, its prolonged treatment and the definitions of ""cure"" and ""relapse.",82,0,68,0,88,7,1,RO-has_causative_agent,903748,"Leprosy is unique in terms of the nature of the causative organism (Mycobacterium leprae), the chronicity of the disease, its prolonged treatment and the definitions of &quot;cure&quot; and &quot;relapse",Mycobacterium leprae,Leprosy
503461421,7/16/2014 13:54:01,,1324262632,7/16/2014 13:53:42,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,68,0,,,88,7,MYCOBACTERIUM LEPRAE,LEPROSY,"causative organism (MYCOBACTERIUM LEPRAE),",48-58-67-82,0,LEPROSY,"Leprosy is unique in terms of the nature of the causative organism (Mycobacterium leprae), the chronicity of the disease, its prolonged treatment and the definitions of ""cure"" and ""relapse.",82,0,68,0,88,7,1,RO-has_causative_agent,903748,"Leprosy is unique in terms of the nature of the causative organism (Mycobacterium leprae), the chronicity of the disease, its prolonged treatment and the definitions of &quot;cure&quot; and &quot;relapse",Mycobacterium leprae,Leprosy
503461421,7/16/2014 13:54:39,,1324262872,7/16/2014 13:54:22,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,68,0,,,88,7,MYCOBACTERIUM LEPRAE,LEPROSY,"(MYCOBACTERIUM LEPRAE),",67-82,0,LEPROSY,"Leprosy is unique in terms of the nature of the causative organism (Mycobacterium leprae), the chronicity of the disease, its prolonged treatment and the definitions of ""cure"" and ""relapse.",82,0,68,0,88,7,1,RO-has_causative_agent,903748,"Leprosy is unique in terms of the nature of the causative organism (Mycobacterium leprae), the chronicity of the disease, its prolonged treatment and the definitions of &quot;cure&quot; and &quot;relapse",Mycobacterium leprae,Leprosy
503461421,7/16/2014 13:55:51,,1324263333,7/16/2014 13:55:35,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,68,0,,,88,7,MYCOBACTERIUM LEPRAE,LEPROSY,"LEPRAE),",82,0,LEPROSY,"Leprosy is unique in terms of the nature of the causative organism (Mycobacterium leprae), the chronicity of the disease, its prolonged treatment and the definitions of ""cure"" and ""relapse.",82,0,68,0,88,7,1,RO-has_causative_agent,903748,"Leprosy is unique in terms of the nature of the causative organism (Mycobacterium leprae), the chronicity of the disease, its prolonged treatment and the definitions of &quot;cure&quot; and &quot;relapse",Mycobacterium leprae,Leprosy
503461421,7/16/2014 13:57:15,,1324263959,7/16/2014 13:55:42,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,68,0,,,88,7,MYCOBACTERIUM LEPRAE,LEPROSY,"(MYCOBACTERIUM LEPRAE),",67-82,0,LEPROSY,"Leprosy is unique in terms of the nature of the causative organism (Mycobacterium leprae), the chronicity of the disease, its prolonged treatment and the definitions of ""cure"" and ""relapse.",82,0,68,0,88,7,1,RO-has_causative_agent,903748,"Leprosy is unique in terms of the nature of the causative organism (Mycobacterium leprae), the chronicity of the disease, its prolonged treatment and the definitions of &quot;cure&quot; and &quot;relapse",Mycobacterium leprae,Leprosy
503461421,7/16/2014 13:57:59,,1324264329,7/16/2014 13:57:47,instagc,1.0,18960682,GBR,"","",86.29.147.112,68,0,,,88,7,MYCOBACTERIUM LEPRAE,LEPROSY,"(MYCOBACTERIUM LEPRAE),",67-82,0,LEPROSY,"Leprosy is unique in terms of the nature of the causative organism (Mycobacterium leprae), the chronicity of the disease, its prolonged treatment and the definitions of ""cure"" and ""relapse.",82,0,68,0,88,7,1,RO-has_causative_agent,903748,"Leprosy is unique in terms of the nature of the causative organism (Mycobacterium leprae), the chronicity of the disease, its prolonged treatment and the definitions of &quot;cure&quot; and &quot;relapse",Mycobacterium leprae,Leprosy
503461421,7/16/2014 14:04:05,,1324266865,7/16/2014 14:03:52,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,68,0,,,88,7,MYCOBACTERIUM LEPRAE,LEPROSY,"Leprosy LEPRAE),",0-82,0,LEPROSY,"Leprosy is unique in terms of the nature of the causative organism (Mycobacterium leprae), the chronicity of the disease, its prolonged treatment and the definitions of ""cure"" and ""relapse.",82,0,68,0,88,7,1,RO-has_causative_agent,903748,"Leprosy is unique in terms of the nature of the causative organism (Mycobacterium leprae), the chronicity of the disease, its prolonged treatment and the definitions of &quot;cure&quot; and &quot;relapse",Mycobacterium leprae,Leprosy
503461422,7/16/2014 13:46:08,,1324259797,7/16/2014 13:45:57,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,15,62,,,35,74,BORRELIA BURGDORFERI,LYME DISEASE,spirochete BORRELIA BURGDORFERI,4-15-24,62-67,"LYME DISEASE,","The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the leading vector-borne illness in the United States.",15 24,62 67,15,62,35,74,1,RO-has_causative_agent,903501,"The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the leading vector-borne illness in the United States",Borrelia burgdorferi,Lyme disease
503461422,7/16/2014 13:48:36,,1324260623,7/16/2014 13:48:27,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,15,62,,,35,74,BORRELIA BURGDORFERI,LYME DISEASE,spirochete BORRELIA BURGDORFERI,4-15-24,62-67,"LYME DISEASE,","The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the leading vector-borne illness in the United States.",15 24,62 67,15,62,35,74,1,RO-has_causative_agent,903501,"The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the leading vector-borne illness in the United States",Borrelia burgdorferi,Lyme disease
503461422,7/16/2014 13:54:13,,1324262713,7/16/2014 13:54:01,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,15,62,,,35,74,BORRELIA BURGDORFERI,LYME DISEASE,spirochete BORRELIA BURGDORFERI,4-15-24,62-67,"LYME DISEASE,","The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the leading vector-borne illness in the United States.",15 24,62 67,15,62,35,74,1,RO-has_causative_agent,903501,"The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the leading vector-borne illness in the United States",Borrelia burgdorferi,Lyme disease
503461422,7/16/2014 13:57:43,,1324264197,7/16/2014 13:57:27,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,15,62,,,35,74,BORRELIA BURGDORFERI,LYME DISEASE,BORRELIA BURGDORFERI,15-24,62-67,"LYME DISEASE,","The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the leading vector-borne illness in the United States.",15 24,62 67,15,62,35,74,1,RO-has_causative_agent,903501,"The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the leading vector-borne illness in the United States",Borrelia burgdorferi,Lyme disease
503461422,7/16/2014 13:58:46,,1324264656,7/16/2014 13:58:21,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,15,62,,,35,74,BORRELIA BURGDORFERI,LYME DISEASE,"spirochete BORRELIA BURGDORFERI causative agent Lyme disease, vector borne illness",4-15-24-43-53-62-67-88-95-101,4-15-24-43-53-62-67-88-95-101,"spirochete Borrelia burgdorferi causative agent LYME DISEASE, vector borne illness","The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the leading vector-borne illness in the United States.",15 24,62 67,15,62,35,74,1,RO-has_causative_agent,903501,"The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the leading vector-borne illness in the United States",Borrelia burgdorferi,Lyme disease
503461422,7/16/2014 14:02:27,,1324266108,7/16/2014 14:02:12,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,15,62,,,35,74,BORRELIA BURGDORFERI,LYME DISEASE,"BORRELIA BURGDORFERI Lyme disease,",15-24-62-67,62-67,"LYME DISEASE,","The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the leading vector-borne illness in the United States.",15 24,62 67,15,62,35,74,1,RO-has_causative_agent,903501,"The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the leading vector-borne illness in the United States",Borrelia burgdorferi,Lyme disease
503461422,7/16/2014 14:03:32,,1324266607,7/16/2014 14:03:21,instagc,1.0,18960682,GBR,"","",86.29.147.112,15,62,,,35,74,BORRELIA BURGDORFERI,LYME DISEASE,The spirochete BORRELIA BURGDORFERI,0-4-15-24,62-67,"LYME DISEASE,","The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the leading vector-borne illness in the United States.",15 24,62 67,15,62,35,74,1,RO-has_causative_agent,903501,"The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the leading vector-borne illness in the United States",Borrelia burgdorferi,Lyme disease
503461422,7/16/2014 14:09:50,,1324269364,7/16/2014 14:09:37,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,15,62,,,35,74,BORRELIA BURGDORFERI,LYME DISEASE,spirochete BORRELIA BURGDORFERI,4-15-24,62-67,"LYME DISEASE,","The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the leading vector-borne illness in the United States.",15 24,62 67,15,62,35,74,1,RO-has_causative_agent,903501,"The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the leading vector-borne illness in the United States",Borrelia burgdorferi,Lyme disease
503461422,7/16/2014 14:11:43,,1324270220,7/16/2014 14:11:05,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,15,62,,,35,74,BORRELIA BURGDORFERI,LYME DISEASE,BORRELIA BURGDORFERI,15-24,62-67,"LYME DISEASE,","The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the leading vector-borne illness in the United States.",15 24,62 67,15,62,35,74,1,RO-has_causative_agent,903501,"The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the leading vector-borne illness in the United States",Borrelia burgdorferi,Lyme disease
503461422,7/16/2014 14:24:05,,1324275144,7/16/2014 14:23:44,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,15,62,,,35,74,BORRELIA BURGDORFERI,LYME DISEASE,BORRELIA BURGDORFERI,15-24,62-67,"LYME DISEASE,","The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the leading vector-borne illness in the United States.",15 24,62 67,15,62,35,74,1,RO-has_causative_agent,903501,"The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the leading vector-borne illness in the United States",Borrelia burgdorferi,Lyme disease
503461423,7/16/2014 13:59:29,,1324265014,7/16/2014 13:59:01,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,23,148,,,56,161,HUMAN IMMUNODEFICIENCY VIRUS (HIV,HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),23-29-46-52,148-152,HIV INFECTION.,The Tat protein of the human immunodeficiency virus (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV infection.,23 29 46 52,148 152,23,148,56,161,1,RO-has_causative_agent,903769,The Tat protein of the human immunodeficiency virus (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV infection,human immunodeficiency virus (HIV,HIV infection
503461423,7/16/2014 14:04:51,,1324267181,7/16/2014 14:04:20,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,23,148,,,56,161,HUMAN IMMUNODEFICIENCY VIRUS (HIV,HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV) HIV infection.,23-29-46-52-148-152,23-29-46-148-152-52,human immunodeficiency virus (HIV) HIV INFECTION.,The Tat protein of the human immunodeficiency virus (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV infection.,23 29 46 52,148 152,23,148,56,161,1,RO-has_causative_agent,903769,The Tat protein of the human immunodeficiency virus (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV infection,human immunodeficiency virus (HIV,HIV infection
503461423,7/16/2014 14:07:33,,1324268359,7/16/2014 14:07:24,elite,1,28503042,USA,NJ,Woodbridge,54.191.150.115,23,148,,,56,161,HUMAN IMMUNODEFICIENCY VIRUS (HIV,HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),23-29-46-52,148-152,HIV INFECTION.,The Tat protein of the human immunodeficiency virus (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV infection.,23 29 46 52,148 152,23,148,56,161,1,RO-has_causative_agent,903769,The Tat protein of the human immunodeficiency virus (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV infection,human immunodeficiency virus (HIV,HIV infection
503461423,7/16/2014 14:24:54,,1324275520,7/16/2014 14:24:43,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,23,148,,,56,161,HUMAN IMMUNODEFICIENCY VIRUS (HIV,HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),23-29-46-52,148-152,HIV INFECTION.,The Tat protein of the human immunodeficiency virus (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV infection.,23 29 46 52,148 152,23,148,56,161,1,RO-has_causative_agent,903769,The Tat protein of the human immunodeficiency virus (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV infection,human immunodeficiency virus (HIV,HIV infection
503461423,7/16/2014 14:25:53,,1324275906,7/16/2014 14:25:27,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,23,148,,,56,161,HUMAN IMMUNODEFICIENCY VIRUS (HIV,HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV) HIV infection.,23-29-46-52-148-152,23-29-46-52-148-152,human immunodeficiency virus (HIV) HIV INFECTION.,The Tat protein of the human immunodeficiency virus (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV infection.,23 29 46 52,148 152,23,148,56,161,1,RO-has_causative_agent,903769,The Tat protein of the human immunodeficiency virus (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV infection,human immunodeficiency virus (HIV,HIV infection
503461423,7/16/2014 14:41:43,,1324282108,7/16/2014 14:41:28,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,23,148,,,56,161,HUMAN IMMUNODEFICIENCY VIRUS (HIV,HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),23-29-46-52,148-152,HIV INFECTION.,The Tat protein of the human immunodeficiency virus (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV infection.,23 29 46 52,148 152,23,148,56,161,1,RO-has_causative_agent,903769,The Tat protein of the human immunodeficiency virus (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV infection,human immunodeficiency virus (HIV,HIV infection
503461423,7/16/2014 14:43:35,,1324282637,7/16/2014 14:43:24,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,23,148,,,56,161,HUMAN IMMUNODEFICIENCY VIRUS (HIV,HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),23-29-46-52,148-152,HIV INFECTION.,The Tat protein of the human immunodeficiency virus (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV infection.,23 29 46 52,148 152,23,148,56,161,1,RO-has_causative_agent,903769,The Tat protein of the human immunodeficiency virus (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV infection,human immunodeficiency virus (HIV,HIV infection
503461423,7/16/2014 14:51:12,,1324284837,7/16/2014 14:51:02,tremorgames,1,26860817,NLD,06,Boxmeer,84.29.157.221,23,148,,,56,161,HUMAN IMMUNODEFICIENCY VIRUS (HIV,HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),23-29-46-52,148-152,HIV INFECTION.,The Tat protein of the human immunodeficiency virus (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV infection.,23 29 46 52,148 152,23,148,56,161,1,RO-has_causative_agent,903769,The Tat protein of the human immunodeficiency virus (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV infection,human immunodeficiency virus (HIV,HIV infection
503461423,7/16/2014 14:53:19,,1324285474,7/16/2014 14:53:10,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,23,148,,,56,161,HUMAN IMMUNODEFICIENCY VIRUS (HIV,HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),23-29-46-52,148-152,HIV INFECTION.,The Tat protein of the human immunodeficiency virus (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV infection.,23 29 46 52,148 152,23,148,56,161,1,RO-has_causative_agent,903769,The Tat protein of the human immunodeficiency virus (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV infection,human immunodeficiency virus (HIV,HIV infection
503461423,7/16/2014 14:55:03,,1324286034,7/16/2014 14:54:45,irazoo,1.0,7022810,USA,IA,Ankeny,216.161.121.1,23,148,,,56,161,HUMAN IMMUNODEFICIENCY VIRUS (HIV,HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),23-29-46-52,148-152,HIV INFECTION.,The Tat protein of the human immunodeficiency virus (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV infection.,23 29 46 52,148 152,23,148,56,161,1,RO-has_causative_agent,903769,The Tat protein of the human immunodeficiency virus (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV infection,human immunodeficiency virus (HIV,HIV infection
503461424,7/16/2014 14:01:46,,1324265861,7/16/2014 14:01:19,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,196,233,,,209,272,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,involvement of PRION PROTEIN,181-193-196-202,217-230-233-247-258,pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY.,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of prion protein in the pathogenesis of transmissible spongiform encephalopathy.,196 202,233 247 258,196,233,209,272,1,RO-has_causative_agent,903808,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of prion protein in the pathogenesis of transmissible spongiform encephalopathy,prion protein,transmissible spongiform encephalopathy
503461424,7/16/2014 14:02:34,,1324266165,7/16/2014 14:02:24,instagc,1.0,18960682,GBR,"","",86.29.147.112,196,233,,,209,272,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,196-202,233-247-258,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY.,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of prion protein in the pathogenesis of transmissible spongiform encephalopathy.,196 202,233 247 258,196,233,209,272,1,RO-has_causative_agent,903808,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of prion protein in the pathogenesis of transmissible spongiform encephalopathy,prion protein,transmissible spongiform encephalopathy
503461424,7/16/2014 14:08:03,,1324268569,7/16/2014 14:07:53,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,196,233,,,209,272,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,196-202,233-247-258,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY.,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of prion protein in the pathogenesis of transmissible spongiform encephalopathy.,196 202,233 247 258,196,233,209,272,1,RO-has_causative_agent,903808,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of prion protein in the pathogenesis of transmissible spongiform encephalopathy,prion protein,transmissible spongiform encephalopathy
503461424,7/16/2014 14:13:41,,1324271046,7/16/2014 14:13:32,prodege,1.0,17932518,GBR,"","",81.133.61.60,196,233,,,209,272,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,196-202,233-247-258,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY.,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of prion protein in the pathogenesis of transmissible spongiform encephalopathy.,196 202,233 247 258,196,233,209,272,1,RO-has_causative_agent,903808,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of prion protein in the pathogenesis of transmissible spongiform encephalopathy,prion protein,transmissible spongiform encephalopathy
503461424,7/16/2014 14:20:12,,1324273640,7/16/2014 14:19:56,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,196,233,,,209,272,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,196-202,233-247-258,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY.,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of prion protein in the pathogenesis of transmissible spongiform encephalopathy.,196 202,233 247 258,196,233,209,272,1,RO-has_causative_agent,903808,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of prion protein in the pathogenesis of transmissible spongiform encephalopathy,prion protein,transmissible spongiform encephalopathy
503461424,7/16/2014 14:27:54,,1324276680,7/16/2014 14:27:40,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,196,233,,,209,272,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,196-202,233-247-258,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY.,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of prion protein in the pathogenesis of transmissible spongiform encephalopathy.,196 202,233 247 258,196,233,209,272,1,RO-has_causative_agent,903808,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of prion protein in the pathogenesis of transmissible spongiform encephalopathy,prion protein,transmissible spongiform encephalopathy
503461424,7/16/2014 14:33:05,,1324278825,7/16/2014 14:32:46,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,196,233,,,209,272,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,196-202,233-247-258,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY.,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of prion protein in the pathogenesis of transmissible spongiform encephalopathy.,196 202,233 247 258,196,233,209,272,1,RO-has_causative_agent,903808,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of prion protein in the pathogenesis of transmissible spongiform encephalopathy,prion protein,transmissible spongiform encephalopathy
503461424,7/16/2014 14:55:16,,1324286112,7/16/2014 14:55:14,clixsense,1.0,21478140,CAN,ON,Toronto,69.165.146.96,196,233,,,209,272,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,the involvement of PRION PROTEIN in the pathogenesis,177-181-193-196-202-210-213-217,213-217-230-233-247-258,the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY.,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of prion protein in the pathogenesis of transmissible spongiform encephalopathy.,196 202,233 247 258,196,233,209,272,1,RO-has_causative_agent,903808,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of prion protein in the pathogenesis of transmissible spongiform encephalopathy,prion protein,transmissible spongiform encephalopathy
503461424,7/16/2014 14:57:05,,1324286869,7/16/2014 14:56:53,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,196,233,,,209,272,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,196-202,233-247-258,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY.,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of prion protein in the pathogenesis of transmissible spongiform encephalopathy.,196 202,233 247 258,196,233,209,272,1,RO-has_causative_agent,903808,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of prion protein in the pathogenesis of transmissible spongiform encephalopathy,prion protein,transmissible spongiform encephalopathy
503461424,7/16/2014 14:57:06,,1324286888,7/16/2014 14:56:40,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,196,233,,,209,272,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,196-202,233-247-258,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY.,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of prion protein in the pathogenesis of transmissible spongiform encephalopathy.,196 202,233 247 258,196,233,209,272,1,RO-has_causative_agent,903808,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of prion protein in the pathogenesis of transmissible spongiform encephalopathy,prion protein,transmissible spongiform encephalopathy
503461425,7/16/2014 14:05:34,,1324267510,7/16/2014 14:05:12,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,126,56,,,141,60,LYMPHADENOPATHY,AILD,"diffuse LYMPHADENOPATHY,",118-126,0-19-40-55-35,Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD),"Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a rare lymphoproliferative disorder characterized by diffuse lymphadenopathy, fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",126,,126,56,141,60,1,RO-disease_may_have_finding,902569,"Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a rare lymphoproliferative disorder characterized by diffuse lymphadenopathy, fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia",lymphadenopathy,AILD
503461425,7/16/2014 14:09:22,,1324269159,7/16/2014 14:09:13,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,126,56,,,141,60,LYMPHADENOPATHY,AILD,"characterized by diffuse LYMPHADENOPATHY, fever, hepatosplenomegaly, hemolytic",101-115-118-126-143-150-170,35-40-55-62-65-67,with dysproteinemia (AILD) is a rare,"Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a rare lymphoproliferative disorder characterized by diffuse lymphadenopathy, fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",126,,126,56,141,60,1,RO-disease_may_have_finding,902569,"Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a rare lymphoproliferative disorder characterized by diffuse lymphadenopathy, fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia",lymphadenopathy,AILD
503461425,7/16/2014 14:55:04,,1324286056,7/16/2014 14:54:39,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,126,56,,,141,60,LYMPHADENOPATHY,AILD,"diffuse LYMPHADENOPATHY,",118-126,0-19-40-55-35,Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD),"Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a rare lymphoproliferative disorder characterized by diffuse lymphadenopathy, fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",126,,126,56,141,60,1,RO-disease_may_have_finding,902569,"Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a rare lymphoproliferative disorder characterized by diffuse lymphadenopathy, fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia",lymphadenopathy,AILD
503461425,7/16/2014 14:58:34,,1324287408,7/16/2014 14:57:57,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.72,126,56,,,141,60,LYMPHADENOPATHY,AILD,"diffuse LYMPHADENOPATHY,",126-118,40-55,dysproteinemia (AILD),"Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a rare lymphoproliferative disorder characterized by diffuse lymphadenopathy, fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",126,,126,56,141,60,1,RO-disease_may_have_finding,902569,"Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a rare lymphoproliferative disorder characterized by diffuse lymphadenopathy, fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia",lymphadenopathy,AILD
503461425,7/16/2014 14:59:26,,1324287706,7/16/2014 14:59:08,irazoo,1.0,7022810,USA,IA,Ankeny,216.161.121.1,126,56,,,141,60,LYMPHADENOPATHY,AILD,"diffuse LYMPHADENOPATHY,",118-126,40-55,dysproteinemia (AILD),"Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a rare lymphoproliferative disorder characterized by diffuse lymphadenopathy, fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",126,,126,56,141,60,1,RO-disease_may_have_finding,902569,"Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a rare lymphoproliferative disorder characterized by diffuse lymphadenopathy, fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia",lymphadenopathy,AILD
503461425,7/16/2014 15:00:16,,1324288080,7/16/2014 14:59:59,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,126,56,,,141,60,LYMPHADENOPATHY,AILD,"LYMPHADENOPATHY,",126,40-55,dysproteinemia (AILD),"Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a rare lymphoproliferative disorder characterized by diffuse lymphadenopathy, fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",126,,126,56,141,60,1,RO-disease_may_have_finding,902569,"Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a rare lymphoproliferative disorder characterized by diffuse lymphadenopathy, fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia",lymphadenopathy,AILD
503461425,7/16/2014 15:00:39,,1324288180,7/16/2014 15:00:09,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,126,56,,,141,60,LYMPHADENOPATHY,AILD,"LYMPHADENOPATHY,",126,0-19-35-40-55,Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD),"Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a rare lymphoproliferative disorder characterized by diffuse lymphadenopathy, fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",126,,126,56,141,60,1,RO-disease_may_have_finding,902569,"Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a rare lymphoproliferative disorder characterized by diffuse lymphadenopathy, fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia",lymphadenopathy,AILD
503461425,7/16/2014 15:01:17,,1324288441,7/16/2014 15:00:54,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,126,56,,,141,60,LYMPHADENOPATHY,AILD,"LYMPHADENOPATHY,",126,40-55,dysproteinemia (AILD),"Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a rare lymphoproliferative disorder characterized by diffuse lymphadenopathy, fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",126,,126,56,141,60,1,RO-disease_may_have_finding,902569,"Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a rare lymphoproliferative disorder characterized by diffuse lymphadenopathy, fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia",lymphadenopathy,AILD
503461425,7/16/2014 15:06:46,,1324290892,7/16/2014 15:06:22,elite,1.0,28276268,USA,MI,Fenton,68.188.185.225,126,56,,,141,60,LYMPHADENOPATHY,AILD,"LYMPHADENOPATHY,",126,55,(AILD),"Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a rare lymphoproliferative disorder characterized by diffuse lymphadenopathy, fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",126,,126,56,141,60,1,RO-disease_may_have_finding,902569,"Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a rare lymphoproliferative disorder characterized by diffuse lymphadenopathy, fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia",lymphadenopathy,AILD
503461425,7/16/2014 15:14:26,,1324293439,7/16/2014 15:13:57,coinworker,1,23778084,USA,PA,Bellefonte,75.102.101.165,126,56,,,141,60,LYMPHADENOPATHY,AILD,"LYMPHADENOPATHY,",126,0-19-35-40-55,Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD),"Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a rare lymphoproliferative disorder characterized by diffuse lymphadenopathy, fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",126,,126,56,141,60,1,RO-disease_may_have_finding,902569,"Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a rare lymphoproliferative disorder characterized by diffuse lymphadenopathy, fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia",lymphadenopathy,AILD
503461426,7/16/2014 13:40:11,,1324257723,7/16/2014 13:39:52,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,132,60,,,147,89,LYMPHADENOPATHY,CHRONIC LYMPHOCYTIC LEUKAEMIA,LYMPHADENOPATHY,132,60-68-80,"CHRONIC LYMPHOCYTIC LEUKAEMIA,","We report a case of a 68 years old male patient treated for chronic lymphocytic leukaemia, presenting a right inguino-crural tender lymphadenopathy with periadenitis.",132,60 68 80,132,60,147,89,1,RO-disease_may_have_finding,902791,"We report a case of a 68 years old male patient treated for chronic lymphocytic leukaemia, presenting a right inguino-crural tender lymphadenopathy with periadenitis",lymphadenopathy,chronic lymphocytic leukaemia
503461426,7/16/2014 13:47:49,,1324260366,7/16/2014 13:47:27,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,132,60,,,147,89,LYMPHADENOPATHY,CHRONIC LYMPHOCYTIC LEUKAEMIA,inguino crural tender LYMPHADENOPATHY with periadenitis.,110-118-125-132-148-153,40-48-56-60-68-80-91-102-104,"patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA, presenting a right","We report a case of a 68 years old male patient treated for chronic lymphocytic leukaemia, presenting a right inguino-crural tender lymphadenopathy with periadenitis.",132,60 68 80,132,60,147,89,1,RO-disease_may_have_finding,902791,"We report a case of a 68 years old male patient treated for chronic lymphocytic leukaemia, presenting a right inguino-crural tender lymphadenopathy with periadenitis",lymphadenopathy,chronic lymphocytic leukaemia
503461426,7/16/2014 14:06:38,,1324267980,7/16/2014 14:06:21,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,132,60,,,147,89,LYMPHADENOPATHY,CHRONIC LYMPHOCYTIC LEUKAEMIA,right inguino crural tender LYMPHADENOPATHY,110-118-125-132-104,60-68-80,"CHRONIC LYMPHOCYTIC LEUKAEMIA,","We report a case of a 68 years old male patient treated for chronic lymphocytic leukaemia, presenting a right inguino-crural tender lymphadenopathy with periadenitis.",132,60 68 80,132,60,147,89,1,RO-disease_may_have_finding,902791,"We report a case of a 68 years old male patient treated for chronic lymphocytic leukaemia, presenting a right inguino-crural tender lymphadenopathy with periadenitis",lymphadenopathy,chronic lymphocytic leukaemia
503461426,7/16/2014 14:19:19,,1324273303,7/16/2014 14:18:42,vivatic,1.0,25451531,GBR,"","",83.67.28.193,132,60,,,147,89,LYMPHADENOPATHY,CHRONIC LYMPHOCYTIC LEUKAEMIA,"lymphocytic leukaemia, presenting a right inguino crural tender LYMPHADENOPATHY with periadenitis.",80-91-102-104-110-118-125-132-148-153-68,60-68-80-91-102-104-110-118-125-132-153-148,"CHRONIC LYMPHOCYTIC LEUKAEMIA, presenting a right inguino crural tender lymphadenopathy with periadenitis.","We report a case of a 68 years old male patient treated for chronic lymphocytic leukaemia, presenting a right inguino-crural tender lymphadenopathy with periadenitis.",132,60 68 80,132,60,147,89,1,RO-disease_may_have_finding,902791,"We report a case of a 68 years old male patient treated for chronic lymphocytic leukaemia, presenting a right inguino-crural tender lymphadenopathy with periadenitis",lymphadenopathy,chronic lymphocytic leukaemia
503461426,7/16/2014 14:28:55,,1324277126,7/16/2014 14:28:35,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,132,60,,,147,89,LYMPHADENOPATHY,CHRONIC LYMPHOCYTIC LEUKAEMIA,LYMPHADENOPATHY,132,60-68-80,"CHRONIC LYMPHOCYTIC LEUKAEMIA,","We report a case of a 68 years old male patient treated for chronic lymphocytic leukaemia, presenting a right inguino-crural tender lymphadenopathy with periadenitis.",132,60 68 80,132,60,147,89,1,RO-disease_may_have_finding,902791,"We report a case of a 68 years old male patient treated for chronic lymphocytic leukaemia, presenting a right inguino-crural tender lymphadenopathy with periadenitis",lymphadenopathy,chronic lymphocytic leukaemia
503461426,7/16/2014 14:42:50,,1324282440,7/16/2014 14:42:17,tremorgames,1,25257192,CAN,ON,Toronto,68.68.13.209,132,60,,,147,89,LYMPHADENOPATHY,CHRONIC LYMPHOCYTIC LEUKAEMIA,inguino crural tender LYMPHADENOPATHY periadenitis.,110-118-125-132-153,60-68-80-110-118-125-132,"CHRONIC LYMPHOCYTIC LEUKAEMIA, inguino crural tender lymphadenopathy","We report a case of a 68 years old male patient treated for chronic lymphocytic leukaemia, presenting a right inguino-crural tender lymphadenopathy with periadenitis.",132,60 68 80,132,60,147,89,1,RO-disease_may_have_finding,902791,"We report a case of a 68 years old male patient treated for chronic lymphocytic leukaemia, presenting a right inguino-crural tender lymphadenopathy with periadenitis",lymphadenopathy,chronic lymphocytic leukaemia
503461426,7/16/2014 14:49:26,,1324284322,7/16/2014 14:49:10,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,132,60,,,147,89,LYMPHADENOPATHY,CHRONIC LYMPHOCYTIC LEUKAEMIA,right inguino crural tender LYMPHADENOPATHY with periadenitis.,110-118-125-132-148-153-104,60-68-80,"CHRONIC LYMPHOCYTIC LEUKAEMIA,","We report a case of a 68 years old male patient treated for chronic lymphocytic leukaemia, presenting a right inguino-crural tender lymphadenopathy with periadenitis.",132,60 68 80,132,60,147,89,1,RO-disease_may_have_finding,902791,"We report a case of a 68 years old male patient treated for chronic lymphocytic leukaemia, presenting a right inguino-crural tender lymphadenopathy with periadenitis",lymphadenopathy,chronic lymphocytic leukaemia
503461426,7/16/2014 14:49:58,,1324284465,7/16/2014 14:49:20,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,132,60,,,147,89,LYMPHADENOPATHY,CHRONIC LYMPHOCYTIC LEUKAEMIA,LYMPHADENOPATHY,132,60-68-80,"CHRONIC LYMPHOCYTIC LEUKAEMIA,","We report a case of a 68 years old male patient treated for chronic lymphocytic leukaemia, presenting a right inguino-crural tender lymphadenopathy with periadenitis.",132,60 68 80,132,60,147,89,1,RO-disease_may_have_finding,902791,"We report a case of a 68 years old male patient treated for chronic lymphocytic leukaemia, presenting a right inguino-crural tender lymphadenopathy with periadenitis",lymphadenopathy,chronic lymphocytic leukaemia
503461426,7/16/2014 14:52:31,,1324285204,7/16/2014 14:52:19,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,132,60,,,147,89,LYMPHADENOPATHY,CHRONIC LYMPHOCYTIC LEUKAEMIA,LYMPHADENOPATHY,132,60-68-80,"CHRONIC LYMPHOCYTIC LEUKAEMIA,","We report a case of a 68 years old male patient treated for chronic lymphocytic leukaemia, presenting a right inguino-crural tender lymphadenopathy with periadenitis.",132,60 68 80,132,60,147,89,1,RO-disease_may_have_finding,902791,"We report a case of a 68 years old male patient treated for chronic lymphocytic leukaemia, presenting a right inguino-crural tender lymphadenopathy with periadenitis",lymphadenopathy,chronic lymphocytic leukaemia
503461426,7/16/2014 14:58:34,,1324287407,7/16/2014 14:58:13,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,132,60,,,147,89,LYMPHADENOPATHY,CHRONIC LYMPHOCYTIC LEUKAEMIA,LYMPHADENOPATHY,132,60-68-80,"CHRONIC LYMPHOCYTIC LEUKAEMIA,","We report a case of a 68 years old male patient treated for chronic lymphocytic leukaemia, presenting a right inguino-crural tender lymphadenopathy with periadenitis.",132,60 68 80,132,60,147,89,1,RO-disease_may_have_finding,902791,"We report a case of a 68 years old male patient treated for chronic lymphocytic leukaemia, presenting a right inguino-crural tender lymphadenopathy with periadenitis",lymphadenopathy,chronic lymphocytic leukaemia
503461427,7/16/2014 13:52:01,,1324261791,7/16/2014 13:51:47,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,157,183,,,171,208,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,"THROMBOCYTOSIS,",157,183-193,ESSENTIAL THROMBOCYTHEMIA,"Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) clonal thrombocytosis, including essential thrombocythemia and related myeloproliferative disorders.",157,183 193,157,183,171,208,1,RO-disease_has_finding,901539,"Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) clonal thrombocytosis, including essential thrombocythemia and related myeloproliferative disorders",thrombocytosis,essential thrombocythemia
503461427,7/16/2014 13:55:52,,1324263334,7/16/2014 13:55:33,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,157,183,,,171,208,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,"clonal THROMBOCYTOSIS,",150-157,183-193,ESSENTIAL THROMBOCYTHEMIA,"Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) clonal thrombocytosis, including essential thrombocythemia and related myeloproliferative disorders.",157,183 193,157,183,171,208,1,RO-disease_has_finding,901539,"Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) clonal thrombocytosis, including essential thrombocythemia and related myeloproliferative disorders",thrombocytosis,essential thrombocythemia
503461427,7/16/2014 13:59:35,,1324265079,7/16/2014 13:59:20,instagc,1.0,18960682,GBR,"","",86.29.147.112,157,183,,,171,208,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,"clonal THROMBOCYTOSIS,",150-157,183-193,ESSENTIAL THROMBOCYTHEMIA,"Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) clonal thrombocytosis, including essential thrombocythemia and related myeloproliferative disorders.",157,183 193,157,183,171,208,1,RO-disease_has_finding,901539,"Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) clonal thrombocytosis, including essential thrombocythemia and related myeloproliferative disorders",thrombocytosis,essential thrombocythemia
503461427,7/16/2014 14:02:31,,1324266148,7/16/2014 14:00:41,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,157,183,,,171,208,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,"clonal THROMBOCYTOSIS,",150-157,183-193-209-213-221,ESSENTIAL THROMBOCYTHEMIA and related myeloproliferative,"Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) clonal thrombocytosis, including essential thrombocythemia and related myeloproliferative disorders.",157,183 193,157,183,171,208,1,RO-disease_has_finding,901539,"Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) clonal thrombocytosis, including essential thrombocythemia and related myeloproliferative disorders",thrombocytosis,essential thrombocythemia
503461427,7/16/2014 14:05:57,,1324267683,7/16/2014 14:05:32,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,157,183,,,171,208,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,"clonal THROMBOCYTOSIS,",150-157,150-157-173-183-193,"clonal thrombocytosis, including ESSENTIAL THROMBOCYTHEMIA","Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) clonal thrombocytosis, including essential thrombocythemia and related myeloproliferative disorders.",157,183 193,157,183,171,208,1,RO-disease_has_finding,901539,"Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) clonal thrombocytosis, including essential thrombocythemia and related myeloproliferative disorders",thrombocytosis,essential thrombocythemia
503461427,7/16/2014 14:13:31,,1324270950,7/16/2014 14:12:55,prodege,1.0,17932518,GBR,"","",81.133.61.60,157,183,,,171,208,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,"THROMBOCYTOSIS,",157,150-183-193,clonal ESSENTIAL THROMBOCYTHEMIA,"Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) clonal thrombocytosis, including essential thrombocythemia and related myeloproliferative disorders.",157,183 193,157,183,171,208,1,RO-disease_has_finding,901539,"Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) clonal thrombocytosis, including essential thrombocythemia and related myeloproliferative disorders",thrombocytosis,essential thrombocythemia
503461427,7/16/2014 14:27:32,,1324276504,7/16/2014 14:27:01,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,157,183,,,171,208,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,"clonal THROMBOCYTOSIS,",150-157,183-193,ESSENTIAL THROMBOCYTHEMIA,"Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) clonal thrombocytosis, including essential thrombocythemia and related myeloproliferative disorders.",157,183 193,157,183,171,208,1,RO-disease_has_finding,901539,"Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) clonal thrombocytosis, including essential thrombocythemia and related myeloproliferative disorders",thrombocytosis,essential thrombocythemia
503461427,7/16/2014 14:32:45,,1324278718,7/16/2014 14:32:22,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,157,183,,,171,208,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,"THROMBOCYTOSIS,",157,183-193,ESSENTIAL THROMBOCYTHEMIA,"Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) clonal thrombocytosis, including essential thrombocythemia and related myeloproliferative disorders.",157,183 193,157,183,171,208,1,RO-disease_has_finding,901539,"Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) clonal thrombocytosis, including essential thrombocythemia and related myeloproliferative disorders",thrombocytosis,essential thrombocythemia
503461427,7/16/2014 14:35:34,,1324279908,7/16/2014 14:35:12,prodege,1.0,26790109,USA,"","",23.125.64.233,157,183,,,171,208,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,"clonal THROMBOCYTOSIS, including essential thrombocythemia and related myeloproliferative disorders.",150-157-173-183-193-209-213-221-240,150-157-173-183-193-209-213-221-240,"clonal thrombocytosis, including ESSENTIAL THROMBOCYTHEMIA and related myeloproliferative disorders.","Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) clonal thrombocytosis, including essential thrombocythemia and related myeloproliferative disorders.",157,183 193,157,183,171,208,1,RO-disease_has_finding,901539,"Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) clonal thrombocytosis, including essential thrombocythemia and related myeloproliferative disorders",thrombocytosis,essential thrombocythemia
503461427,7/16/2014 14:51:11,,1324284830,7/16/2014 14:50:56,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,157,183,,,171,208,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,"clonal THROMBOCYTOSIS,",150-157,183-193,ESSENTIAL THROMBOCYTHEMIA,"Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) clonal thrombocytosis, including essential thrombocythemia and related myeloproliferative disorders.",157,183 193,157,183,171,208,1,RO-disease_has_finding,901539,"Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) clonal thrombocytosis, including essential thrombocythemia and related myeloproliferative disorders",thrombocytosis,essential thrombocythemia
503461428,7/16/2014 13:47:28,,1324260251,7/16/2014 13:47:15,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,66,139,,,74,154,HEADACHE,MEDULLOBLASTOMA,"HEADACHE,",66,139,MEDULLOBLASTOMA,"The authors report a case of a 13-year-old boy who presented with headache, unsteadiness, diplopia and papilloedema due to posterior fossa medulloblastoma causing obstructive hydrocephalus.",66,139,66,139,74,154,1,RO-disease_may_have_finding,902730,"The authors report a case of a 13-year-old boy who presented with headache, unsteadiness, diplopia and papilloedema due to posterior fossa medulloblastoma causing obstructive hydrocephalus",headache,medulloblastoma
503461428,7/16/2014 13:53:08,,1324262242,7/16/2014 13:52:48,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,66,139,,,74,154,HEADACHE,MEDULLOBLASTOMA,"HEADACHE, unsteadiness, diplopia and papilloedema",66-76-90-99-103,123-133-139-155-163-175,posterior fossa MEDULLOBLASTOMA causing obstructive hydrocephalus.,"The authors report a case of a 13-year-old boy who presented with headache, unsteadiness, diplopia and papilloedema due to posterior fossa medulloblastoma causing obstructive hydrocephalus.",66,139,66,139,74,154,1,RO-disease_may_have_finding,902730,"The authors report a case of a 13-year-old boy who presented with headache, unsteadiness, diplopia and papilloedema due to posterior fossa medulloblastoma causing obstructive hydrocephalus",headache,medulloblastoma
503461428,7/16/2014 14:02:07,,1324265981,7/16/2014 14:01:46,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,66,139,,,74,154,HEADACHE,MEDULLOBLASTOMA,"HEADACHE, unsteadiness, diplopia and papilloedema posterior fossa medulloblastoma obstructive hydrocephalus.",66-76-90-99-103-123-133-139-163-175,66-76-90-103-123-133-139-163-175,"headache, unsteadiness, diplopia papilloedema posterior fossa MEDULLOBLASTOMA obstructive hydrocephalus.","The authors report a case of a 13-year-old boy who presented with headache, unsteadiness, diplopia and papilloedema due to posterior fossa medulloblastoma causing obstructive hydrocephalus.",66,139,66,139,74,154,1,RO-disease_may_have_finding,902730,"The authors report a case of a 13-year-old boy who presented with headache, unsteadiness, diplopia and papilloedema due to posterior fossa medulloblastoma causing obstructive hydrocephalus",headache,medulloblastoma
503461428,7/16/2014 14:02:22,,1324266055,7/16/2014 14:02:10,instagc,1.0,18960682,GBR,"","",86.29.147.112,66,139,,,74,154,HEADACHE,MEDULLOBLASTOMA,"HEADACHE,",66,123-133-139-155-163-175,posterior fossa MEDULLOBLASTOMA causing obstructive hydrocephalus.,"The authors report a case of a 13-year-old boy who presented with headache, unsteadiness, diplopia and papilloedema due to posterior fossa medulloblastoma causing obstructive hydrocephalus.",66,139,66,139,74,154,1,RO-disease_may_have_finding,902730,"The authors report a case of a 13-year-old boy who presented with headache, unsteadiness, diplopia and papilloedema due to posterior fossa medulloblastoma causing obstructive hydrocephalus",headache,medulloblastoma
503461428,7/16/2014 14:06:42,,1324267996,7/16/2014 14:05:57,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,66,139,,,74,154,HEADACHE,MEDULLOBLASTOMA,"presented with HEADACHE,",51-66-61,123-133-139,posterior fossa MEDULLOBLASTOMA,"The authors report a case of a 13-year-old boy who presented with headache, unsteadiness, diplopia and papilloedema due to posterior fossa medulloblastoma causing obstructive hydrocephalus.",66,139,66,139,74,154,1,RO-disease_may_have_finding,902730,"The authors report a case of a 13-year-old boy who presented with headache, unsteadiness, diplopia and papilloedema due to posterior fossa medulloblastoma causing obstructive hydrocephalus",headache,medulloblastoma
503461428,7/16/2014 14:11:04,,1324269941,7/16/2014 14:10:52,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,66,139,,,74,154,HEADACHE,MEDULLOBLASTOMA,"who presented with HEADACHE, unsteadiness, diplopia and",47-51-61-66-76-90-99,120-123-133-139-155-163-175,to posterior fossa MEDULLOBLASTOMA causing obstructive hydrocephalus.,"The authors report a case of a 13-year-old boy who presented with headache, unsteadiness, diplopia and papilloedema due to posterior fossa medulloblastoma causing obstructive hydrocephalus.",66,139,66,139,74,154,1,RO-disease_may_have_finding,902730,"The authors report a case of a 13-year-old boy who presented with headache, unsteadiness, diplopia and papilloedema due to posterior fossa medulloblastoma causing obstructive hydrocephalus",headache,medulloblastoma
503461428,7/16/2014 14:16:36,,1324272086,7/16/2014 14:16:19,prodege,1.0,17932518,GBR,"","",81.133.61.60,66,139,,,74,154,HEADACHE,MEDULLOBLASTOMA,"HEADACHE, diplopia papilloedema",66-90-103,123-139-133,posterior fossa MEDULLOBLASTOMA,"The authors report a case of a 13-year-old boy who presented with headache, unsteadiness, diplopia and papilloedema due to posterior fossa medulloblastoma causing obstructive hydrocephalus.",66,139,66,139,74,154,1,RO-disease_may_have_finding,902730,"The authors report a case of a 13-year-old boy who presented with headache, unsteadiness, diplopia and papilloedema due to posterior fossa medulloblastoma causing obstructive hydrocephalus",headache,medulloblastoma
503461428,7/16/2014 14:27:47,,1324276612,7/16/2014 14:26:57,prodege,1.0,26790109,USA,"","",23.125.64.233,66,139,,,74,154,HEADACHE,MEDULLOBLASTOMA,"who presented with HEADACHE, due to posterior fossa medulloblastoma causing obstructive hydrocephalus.",47-51-61-66-116-120-123-133-139-155-163-175,66-76-90-99-103-120-123-133-139-155-163-175-116,"headache, unsteadiness, diplopia and papilloedema due to posterior fossa MEDULLOBLASTOMA causing obstructive hydrocephalus.","The authors report a case of a 13-year-old boy who presented with headache, unsteadiness, diplopia and papilloedema due to posterior fossa medulloblastoma causing obstructive hydrocephalus.",66,139,66,139,74,154,1,RO-disease_may_have_finding,902730,"The authors report a case of a 13-year-old boy who presented with headache, unsteadiness, diplopia and papilloedema due to posterior fossa medulloblastoma causing obstructive hydrocephalus",headache,medulloblastoma
503461428,7/16/2014 14:49:09,,1324284221,7/16/2014 14:48:35,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,66,139,,,74,154,HEADACHE,MEDULLOBLASTOMA,"HEADACHE,",66,123-133-139-155-163-175,posterior fossa MEDULLOBLASTOMA causing obstructive hydrocephalus.,"The authors report a case of a 13-year-old boy who presented with headache, unsteadiness, diplopia and papilloedema due to posterior fossa medulloblastoma causing obstructive hydrocephalus.",66,139,66,139,74,154,1,RO-disease_may_have_finding,902730,"The authors report a case of a 13-year-old boy who presented with headache, unsteadiness, diplopia and papilloedema due to posterior fossa medulloblastoma causing obstructive hydrocephalus",headache,medulloblastoma
503461428,7/16/2014 14:54:06,,1324285717,7/16/2014 14:53:39,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,66,139,,,74,154,HEADACHE,MEDULLOBLASTOMA,"HEADACHE,",66,139,MEDULLOBLASTOMA,"The authors report a case of a 13-year-old boy who presented with headache, unsteadiness, diplopia and papilloedema due to posterior fossa medulloblastoma causing obstructive hydrocephalus.",66,139,66,139,74,154,1,RO-disease_may_have_finding,902730,"The authors report a case of a 13-year-old boy who presented with headache, unsteadiness, diplopia and papilloedema due to posterior fossa medulloblastoma causing obstructive hydrocephalus",headache,medulloblastoma
503461429,7/16/2014 13:41:43,,1324258264,7/16/2014 13:41:32,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,39,111,,,49,124,POLIOVIRUS,POLIOMYELITIS,POLIOVIRUS,39,111,POLIOMYELITIS.,The proposed unifying model of natural poliovirus evolution has important implications for the epidemiology of poliomyelitis.,39,111,39,111,49,124,1,RO-has_causative_agent,903918,The proposed unifying model of natural poliovirus evolution has important implications for the epidemiology of poliomyelitis,poliovirus,poliomyelitis
503461429,7/16/2014 13:45:32,,1324259635,7/16/2014 13:45:20,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,39,111,,,49,124,POLIOVIRUS,POLIOMYELITIS,POLIOVIRUS,39,111,POLIOMYELITIS.,The proposed unifying model of natural poliovirus evolution has important implications for the epidemiology of poliomyelitis.,39,111,39,111,49,124,1,RO-has_causative_agent,903918,The proposed unifying model of natural poliovirus evolution has important implications for the epidemiology of poliomyelitis,poliovirus,poliomyelitis
503461429,7/16/2014 13:47:07,,1324260127,7/16/2014 13:46:54,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,39,111,,,49,124,POLIOVIRUS,POLIOMYELITIS,POLIOVIRUS,39,91-111,the POLIOMYELITIS.,The proposed unifying model of natural poliovirus evolution has important implications for the epidemiology of poliomyelitis.,39,111,39,111,49,124,1,RO-has_causative_agent,903918,The proposed unifying model of natural poliovirus evolution has important implications for the epidemiology of poliomyelitis,poliovirus,poliomyelitis
503461429,7/16/2014 13:55:23,,1324263129,7/16/2014 13:55:11,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,39,111,,,49,124,POLIOVIRUS,POLIOMYELITIS,POLIOVIRUS,39,111,POLIOMYELITIS.,The proposed unifying model of natural poliovirus evolution has important implications for the epidemiology of poliomyelitis.,39,111,39,111,49,124,1,RO-has_causative_agent,903918,The proposed unifying model of natural poliovirus evolution has important implications for the epidemiology of poliomyelitis,poliovirus,poliomyelitis
503461429,7/16/2014 14:08:15,,1324268657,7/16/2014 14:07:51,prodege,1.0,9525153,CAN,ON,Toronto,65.95.94.44,39,111,,,49,124,POLIOVIRUS,POLIOMYELITIS,natural POLIOVIRUS evolution epidemiology poliomyelitis.,31-39-50-95-111,31-39-50-95-111,natural poliovirus evolution epidemiology POLIOMYELITIS.,The proposed unifying model of natural poliovirus evolution has important implications for the epidemiology of poliomyelitis.,39,111,39,111,49,124,1,RO-has_causative_agent,903918,The proposed unifying model of natural poliovirus evolution has important implications for the epidemiology of poliomyelitis,poliovirus,poliomyelitis
503461429,7/16/2014 14:09:35,,1324269250,7/16/2014 14:09:25,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,39,111,,,49,124,POLIOVIRUS,POLIOMYELITIS,model of natural POLIOVIRUS evolution has important,22-28-31-39-50-60-64,91-95-108-111,the epidemiology of POLIOMYELITIS.,The proposed unifying model of natural poliovirus evolution has important implications for the epidemiology of poliomyelitis.,39,111,39,111,49,124,1,RO-has_causative_agent,903918,The proposed unifying model of natural poliovirus evolution has important implications for the epidemiology of poliomyelitis,poliovirus,poliomyelitis
503461429,7/16/2014 14:13:57,,1324271161,7/16/2014 14:13:41,instagc,1.0,13763729,USA,"","",75.182.89.225,39,111,,,49,124,POLIOVIRUS,POLIOMYELITIS,POLIOVIRUS,39,111,POLIOMYELITIS.,The proposed unifying model of natural poliovirus evolution has important implications for the epidemiology of poliomyelitis.,39,111,39,111,49,124,1,RO-has_causative_agent,903918,The proposed unifying model of natural poliovirus evolution has important implications for the epidemiology of poliomyelitis,poliovirus,poliomyelitis
503461429,7/16/2014 14:23:29,,1324274978,7/16/2014 14:22:40,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,39,111,,,49,124,POLIOVIRUS,POLIOMYELITIS,natural POLIOVIRUS evolution,31-39-50,111,POLIOMYELITIS.,The proposed unifying model of natural poliovirus evolution has important implications for the epidemiology of poliomyelitis.,39,111,39,111,49,124,1,RO-has_causative_agent,903918,The proposed unifying model of natural poliovirus evolution has important implications for the epidemiology of poliomyelitis,poliovirus,poliomyelitis
503461429,7/16/2014 14:38:09,,1324280992,7/16/2014 14:37:57,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,39,111,,,49,124,POLIOVIRUS,POLIOMYELITIS,natural POLIOVIRUS evolution,31-39-50,111,POLIOMYELITIS.,The proposed unifying model of natural poliovirus evolution has important implications for the epidemiology of poliomyelitis.,39,111,39,111,49,124,1,RO-has_causative_agent,903918,The proposed unifying model of natural poliovirus evolution has important implications for the epidemiology of poliomyelitis,poliovirus,poliomyelitis
503461429,7/16/2014 14:46:56,,1324283529,7/16/2014 14:46:29,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,39,111,,,49,124,POLIOVIRUS,POLIOMYELITIS,POLIOVIRUS,39,111,POLIOMYELITIS.,The proposed unifying model of natural poliovirus evolution has important implications for the epidemiology of poliomyelitis.,39,111,39,111,49,124,1,RO-has_causative_agent,903918,The proposed unifying model of natural poliovirus evolution has important implications for the epidemiology of poliomyelitis,poliovirus,poliomyelitis
503461430,7/16/2014 13:44:26,,1324259281,7/16/2014 13:44:09,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,101,13,,,114,29,OPTIC ATROPHY,WOLFRAM SYNDROME,OPTIC ATROPHY,101-107,13-21,WOLFRAM SYNDROME,"Although the Wolfram syndrome is rare, it should be considered in diabetic patients with unexplained optic atrophy and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",101 107,13 21,101,13,114,29,1,RO-has_manifestation,906228,"Although the Wolfram syndrome is rare, it should be considered in diabetic patients with unexplained optic atrophy and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control",optic atrophy,Wolfram syndrome
503461430,7/16/2014 13:45:46,,1324259701,7/16/2014 13:45:33,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,101,13,,,114,29,OPTIC ATROPHY,WOLFRAM SYNDROME,OPTIC ATROPHY,101-107,13-21,WOLFRAM SYNDROME,"Although the Wolfram syndrome is rare, it should be considered in diabetic patients with unexplained optic atrophy and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",101 107,13 21,101,13,114,29,1,RO-has_manifestation,906228,"Although the Wolfram syndrome is rare, it should be considered in diabetic patients with unexplained optic atrophy and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control",optic atrophy,Wolfram syndrome
503461430,7/16/2014 13:47:45,,1324260342,7/16/2014 13:47:32,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,101,13,,,114,29,OPTIC ATROPHY,WOLFRAM SYNDROME,OPTIC ATROPHY,101-107,13-21,WOLFRAM SYNDROME,"Although the Wolfram syndrome is rare, it should be considered in diabetic patients with unexplained optic atrophy and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",101 107,13 21,101,13,114,29,1,RO-has_manifestation,906228,"Although the Wolfram syndrome is rare, it should be considered in diabetic patients with unexplained optic atrophy and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control",optic atrophy,Wolfram syndrome
503461430,7/16/2014 13:48:47,,1324260714,7/16/2014 13:48:36,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,101,13,,,114,29,OPTIC ATROPHY,WOLFRAM SYNDROME,unexplained OPTIC ATROPHY,89-101-107,13-21,WOLFRAM SYNDROME,"Although the Wolfram syndrome is rare, it should be considered in diabetic patients with unexplained optic atrophy and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",101 107,13 21,101,13,114,29,1,RO-has_manifestation,906228,"Although the Wolfram syndrome is rare, it should be considered in diabetic patients with unexplained optic atrophy and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control",optic atrophy,Wolfram syndrome
503461430,7/16/2014 13:51:00,,1324261495,7/16/2014 13:50:45,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,101,13,,,114,29,OPTIC ATROPHY,WOLFRAM SYNDROME,OPTIC ATROPHY,101-107,13-21,WOLFRAM SYNDROME,"Although the Wolfram syndrome is rare, it should be considered in diabetic patients with unexplained optic atrophy and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",101 107,13 21,101,13,114,29,1,RO-has_manifestation,906228,"Although the Wolfram syndrome is rare, it should be considered in diabetic patients with unexplained optic atrophy and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control",optic atrophy,Wolfram syndrome
503461430,7/16/2014 14:00:27,,1324265345,7/16/2014 14:00:15,instagc,1.0,18960682,GBR,"","",86.29.147.112,101,13,,,114,29,OPTIC ATROPHY,WOLFRAM SYNDROME,unexplained OPTIC ATROPHY,89-101-107,13-21-9,the WOLFRAM SYNDROME,"Although the Wolfram syndrome is rare, it should be considered in diabetic patients with unexplained optic atrophy and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",101 107,13 21,101,13,114,29,1,RO-has_manifestation,906228,"Although the Wolfram syndrome is rare, it should be considered in diabetic patients with unexplained optic atrophy and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control",optic atrophy,Wolfram syndrome
503461430,7/16/2014 14:05:31,,1324267488,7/16/2014 14:05:09,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,101,13,,,114,29,OPTIC ATROPHY,WOLFRAM SYNDROME,unexplained OPTIC ATROPHY,89-101-107,13-21,WOLFRAM SYNDROME,"Although the Wolfram syndrome is rare, it should be considered in diabetic patients with unexplained optic atrophy and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",101 107,13 21,101,13,114,29,1,RO-has_manifestation,906228,"Although the Wolfram syndrome is rare, it should be considered in diabetic patients with unexplained optic atrophy and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control",optic atrophy,Wolfram syndrome
503461430,7/16/2014 14:25:36,,1324275790,7/16/2014 14:25:21,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,101,13,,,114,29,OPTIC ATROPHY,WOLFRAM SYNDROME,unexplained OPTIC ATROPHY,89-101-107,13-21,WOLFRAM SYNDROME,"Although the Wolfram syndrome is rare, it should be considered in diabetic patients with unexplained optic atrophy and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",101 107,13 21,101,13,114,29,1,RO-has_manifestation,906228,"Although the Wolfram syndrome is rare, it should be considered in diabetic patients with unexplained optic atrophy and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control",optic atrophy,Wolfram syndrome
503461430,7/16/2014 14:35:46,,1324279991,7/16/2014 14:35:17,prodege,1.0,6316959,GBR,"","",46.208.145.114,101,13,,,114,29,OPTIC ATROPHY,WOLFRAM SYNDROME,unexplained OPTIC ATROPHY,89-101-107,13-21,WOLFRAM SYNDROME,"Although the Wolfram syndrome is rare, it should be considered in diabetic patients with unexplained optic atrophy and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",101 107,13 21,101,13,114,29,1,RO-has_manifestation,906228,"Although the Wolfram syndrome is rare, it should be considered in diabetic patients with unexplained optic atrophy and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control",optic atrophy,Wolfram syndrome
503461430,7/16/2014 14:43:03,,1324282515,7/16/2014 14:42:01,prodege,1.0,26790109,USA,"","",23.125.64.233,101,13,,,114,29,OPTIC ATROPHY,WOLFRAM SYNDROME,diabetic patients with unexplained OPTIC ATROPHY and hearing loss,66-75-84-89-101-107-115-119-127,13-21-30-33-39-42-49-52-63-66-75-84-89-101-107-115-119-127-132-135-140-149-153-164-167-171-180-183-192-198-204,"WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with unexplained optic atrophy and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.","Although the Wolfram syndrome is rare, it should be considered in diabetic patients with unexplained optic atrophy and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",101 107,13 21,101,13,114,29,1,RO-has_manifestation,906228,"Although the Wolfram syndrome is rare, it should be considered in diabetic patients with unexplained optic atrophy and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control",optic atrophy,Wolfram syndrome
503461431,7/16/2014 13:46:27,,1324259902,7/16/2014 13:45:55,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,82,132,,,97,135,LYMPHADENOPATHY,CLL,"LYMPHADENOPATHY, hepatosplenomegaly, CLL",82-103-132,103-132-82,"lymphadenopathy, hepatosplenomegaly, CLL","? In patients with rapidly advancing disease characterized by B symptoms, massive lymphadenopathy, and hepatosplenomegaly, consider CLL transformation (see  disease-specific drug treatment in patients with transformed CLL.",82,132,82,132,97,135,1,RO-disease_may_have_finding,902686,"? In patients with rapidly advancing disease characterized by B symptoms, massive lymphadenopathy, and hepatosplenomegaly, consider CLL transformation (see  disease-specific drug treatment in patients with transformed CLL",lymphadenopathy,CLL
503461431,7/16/2014 13:54:00,,1324262631,7/16/2014 13:53:35,prodege,1.0,13300986,CAN,AB,Edmonton,68.150.33.230,82,132,,,97,135,LYMPHADENOPATHY,CLL,"massive LYMPHADENOPATHY,",74-82,132,CLL,"? In patients with rapidly advancing disease characterized by B symptoms, massive lymphadenopathy, and hepatosplenomegaly, consider CLL transformation (see  disease-specific drug treatment in patients with transformed CLL.",82,132,82,132,97,135,1,RO-disease_may_have_finding,902686,"? In patients with rapidly advancing disease characterized by B symptoms, massive lymphadenopathy, and hepatosplenomegaly, consider CLL transformation (see  disease-specific drug treatment in patients with transformed CLL",lymphadenopathy,CLL
503461431,7/16/2014 13:57:17,,1324263973,7/16/2014 13:57:01,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,82,132,,,97,135,LYMPHADENOPATHY,CLL,"LYMPHADENOPATHY,",82,132-136,CLL transformation,"? In patients with rapidly advancing disease characterized by B symptoms, massive lymphadenopathy, and hepatosplenomegaly, consider CLL transformation (see  disease-specific drug treatment in patients with transformed CLL.",82,132,82,132,97,135,1,RO-disease_may_have_finding,902686,"? In patients with rapidly advancing disease characterized by B symptoms, massive lymphadenopathy, and hepatosplenomegaly, consider CLL transformation (see  disease-specific drug treatment in patients with transformed CLL",lymphadenopathy,CLL
503461431,7/16/2014 13:57:57,,1324264285,7/16/2014 13:57:31,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,82,132,,,97,135,LYMPHADENOPATHY,CLL,"massive LYMPHADENOPATHY, and hepatosplenomegaly,",74-82-99-103,123-132-136,consider CLL transformation,"? In patients with rapidly advancing disease characterized by B symptoms, massive lymphadenopathy, and hepatosplenomegaly, consider CLL transformation (see  disease-specific drug treatment in patients with transformed CLL.",82,132,82,132,97,135,1,RO-disease_may_have_finding,902686,"? In patients with rapidly advancing disease characterized by B symptoms, massive lymphadenopathy, and hepatosplenomegaly, consider CLL transformation (see  disease-specific drug treatment in patients with transformed CLL",lymphadenopathy,CLL
503461431,7/16/2014 13:58:54,,1324264716,7/16/2014 13:58:41,instagc,1.0,18960682,GBR,"","",86.29.147.112,82,132,,,97,135,LYMPHADENOPATHY,CLL,"LYMPHADENOPATHY,",82,132-136,CLL transformation,"? In patients with rapidly advancing disease characterized by B symptoms, massive lymphadenopathy, and hepatosplenomegaly, consider CLL transformation (see  disease-specific drug treatment in patients with transformed CLL.",82,132,82,132,97,135,1,RO-disease_may_have_finding,902686,"? In patients with rapidly advancing disease characterized by B symptoms, massive lymphadenopathy, and hepatosplenomegaly, consider CLL transformation (see  disease-specific drug treatment in patients with transformed CLL",lymphadenopathy,CLL
503461431,7/16/2014 14:05:54,,1324267651,7/16/2014 14:05:36,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,82,132,,,97,135,LYMPHADENOPATHY,CLL,"LYMPHADENOPATHY,",82,82-132,"lymphadenopathy, CLL","? In patients with rapidly advancing disease characterized by B symptoms, massive lymphadenopathy, and hepatosplenomegaly, consider CLL transformation (see  disease-specific drug treatment in patients with transformed CLL.",82,132,82,132,97,135,1,RO-disease_may_have_finding,902686,"? In patients with rapidly advancing disease characterized by B symptoms, massive lymphadenopathy, and hepatosplenomegaly, consider CLL transformation (see  disease-specific drug treatment in patients with transformed CLL",lymphadenopathy,CLL
503461431,7/16/2014 14:07:39,,1324268383,7/16/2014 14:06:11,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,82,132,,,97,135,LYMPHADENOPATHY,CLL,"massive LYMPHADENOPATHY,",74-82,132-136,CLL transformation,"? In patients with rapidly advancing disease characterized by B symptoms, massive lymphadenopathy, and hepatosplenomegaly, consider CLL transformation (see  disease-specific drug treatment in patients with transformed CLL.",82,132,82,132,97,135,1,RO-disease_may_have_finding,902686,"? In patients with rapidly advancing disease characterized by B symptoms, massive lymphadenopathy, and hepatosplenomegaly, consider CLL transformation (see  disease-specific drug treatment in patients with transformed CLL",lymphadenopathy,CLL
503461431,7/16/2014 14:08:38,,1324268810,7/16/2014 14:08:16,instagc,1.0,13763729,USA,"","",75.182.89.225,82,132,,,97,135,LYMPHADENOPATHY,CLL,"LYMPHADENOPATHY,",82,132,CLL,"? In patients with rapidly advancing disease characterized by B symptoms, massive lymphadenopathy, and hepatosplenomegaly, consider CLL transformation (see  disease-specific drug treatment in patients with transformed CLL.",82,132,82,132,97,135,1,RO-disease_may_have_finding,902686,"? In patients with rapidly advancing disease characterized by B symptoms, massive lymphadenopathy, and hepatosplenomegaly, consider CLL transformation (see  disease-specific drug treatment in patients with transformed CLL",lymphadenopathy,CLL
503461431,7/16/2014 14:11:55,,1324270309,7/16/2014 14:11:30,clixsense,1.0,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,82,132,,,97,135,LYMPHADENOPATHY,CLL,"LYMPHADENOPATHY,",82,132,CLL,"? In patients with rapidly advancing disease characterized by B symptoms, massive lymphadenopathy, and hepatosplenomegaly, consider CLL transformation (see  disease-specific drug treatment in patients with transformed CLL.",82,132,82,132,97,135,1,RO-disease_may_have_finding,902686,"? In patients with rapidly advancing disease characterized by B symptoms, massive lymphadenopathy, and hepatosplenomegaly, consider CLL transformation (see  disease-specific drug treatment in patients with transformed CLL",lymphadenopathy,CLL
503461431,7/16/2014 14:19:08,,1324273195,7/16/2014 14:18:50,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,82,132,,,97,135,LYMPHADENOPATHY,CLL,"LYMPHADENOPATHY,",82,132,CLL,"? In patients with rapidly advancing disease characterized by B symptoms, massive lymphadenopathy, and hepatosplenomegaly, consider CLL transformation (see  disease-specific drug treatment in patients with transformed CLL.",82,132,82,132,97,135,1,RO-disease_may_have_finding,902686,"? In patients with rapidly advancing disease characterized by B symptoms, massive lymphadenopathy, and hepatosplenomegaly, consider CLL transformation (see  disease-specific drug treatment in patients with transformed CLL",lymphadenopathy,CLL
503461432,7/16/2014 13:50:23,,1324261244,7/16/2014 13:50:08,clixsense,1.0,20709884,CAN,NS,Berwick,24.142.36.5,72,0,,,84,16,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION.,72,0-17-20-22,PHEOCHROMOCYTOMA is a catecholamine,Pheochromocytoma is a catecholamine-producing tumor and a rare cause of hypertension.,72,0,72,0,84,16,1,RO-disease_may_have_finding,902691,Pheochromocytoma is a catecholamine-producing tumor and a rare cause of hypertension,hypertension,Pheochromocytoma
503461432,7/16/2014 13:51:35,,1324261670,7/16/2014 13:51:27,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,72,0,,,84,16,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION.,72,0,PHEOCHROMOCYTOMA,Pheochromocytoma is a catecholamine-producing tumor and a rare cause of hypertension.,72,0,72,0,84,16,1,RO-disease_may_have_finding,902691,Pheochromocytoma is a catecholamine-producing tumor and a rare cause of hypertension,hypertension,Pheochromocytoma
503461432,7/16/2014 13:53:44,,1324262507,7/16/2014 13:53:10,prodege,1,28012033,USA,NY,Mount Vernon,74.101.43.9,72,0,,,84,16,HYPERTENSION,PHEOCHROMOCYTOMA,rare cause of HYPERTENSION.,58-63-69-72,0-17-20-22,PHEOCHROMOCYTOMA is a catecholamine,Pheochromocytoma is a catecholamine-producing tumor and a rare cause of hypertension.,72,0,72,0,84,16,1,RO-disease_may_have_finding,902691,Pheochromocytoma is a catecholamine-producing tumor and a rare cause of hypertension,hypertension,Pheochromocytoma
503461432,7/16/2014 14:00:02,,1324265245,7/16/2014 13:59:49,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,72,0,,,84,16,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION.,72,0-72,PHEOCHROMOCYTOMA hypertension.,Pheochromocytoma is a catecholamine-producing tumor and a rare cause of hypertension.,72,0,72,0,84,16,1,RO-disease_may_have_finding,902691,Pheochromocytoma is a catecholamine-producing tumor and a rare cause of hypertension,hypertension,Pheochromocytoma
503461432,7/16/2014 14:06:33,,1324267940,7/16/2014 14:05:51,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,72,0,,,84,16,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION.,72,0,PHEOCHROMOCYTOMA,Pheochromocytoma is a catecholamine-producing tumor and a rare cause of hypertension.,72,0,72,0,84,16,1,RO-disease_may_have_finding,902691,Pheochromocytoma is a catecholamine-producing tumor and a rare cause of hypertension,hypertension,Pheochromocytoma
503461432,7/16/2014 14:06:58,,1324268105,7/16/2014 14:06:43,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,72,0,,,84,16,HYPERTENSION,PHEOCHROMOCYTOMA,cause of HYPERTENSION.,63-69-72,0,PHEOCHROMOCYTOMA,Pheochromocytoma is a catecholamine-producing tumor and a rare cause of hypertension.,72,0,72,0,84,16,1,RO-disease_may_have_finding,902691,Pheochromocytoma is a catecholamine-producing tumor and a rare cause of hypertension,hypertension,Pheochromocytoma
503461432,7/16/2014 14:09:50,,1324269358,7/16/2014 14:09:31,instagc,1.0,13763729,USA,"","",75.182.89.225,72,0,,,84,16,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION.,72,0,PHEOCHROMOCYTOMA,Pheochromocytoma is a catecholamine-producing tumor and a rare cause of hypertension.,72,0,72,0,84,16,1,RO-disease_may_have_finding,902691,Pheochromocytoma is a catecholamine-producing tumor and a rare cause of hypertension,hypertension,Pheochromocytoma
503461432,7/16/2014 14:16:57,,1324272243,7/16/2014 14:16:49,prodege,1.0,17932518,GBR,"","",81.133.61.60,72,0,,,84,16,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION.,72,0,PHEOCHROMOCYTOMA,Pheochromocytoma is a catecholamine-producing tumor and a rare cause of hypertension.,72,0,72,0,84,16,1,RO-disease_may_have_finding,902691,Pheochromocytoma is a catecholamine-producing tumor and a rare cause of hypertension,hypertension,Pheochromocytoma
503461432,7/16/2014 14:19:30,,1324273364,7/16/2014 14:18:56,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,72,0,,,84,16,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION.,72,0,PHEOCHROMOCYTOMA,Pheochromocytoma is a catecholamine-producing tumor and a rare cause of hypertension.,72,0,72,0,84,16,1,RO-disease_may_have_finding,902691,Pheochromocytoma is a catecholamine-producing tumor and a rare cause of hypertension,hypertension,Pheochromocytoma
503461432,7/16/2014 14:26:22,,1324276071,7/16/2014 14:25:30,prodege,1.0,26790109,USA,"","",23.125.64.233,72,0,,,84,16,HYPERTENSION,PHEOCHROMOCYTOMA,catecholamine producing tumor and a rare cause of HYPERTENSION.,22-36-46-52-58-63-69-72-56,0-17-20-22-35-36-46-52-58-63-69-72,PHEOCHROMOCYTOMA is a catecholamine - producing tumor and rare cause of hypertension.,Pheochromocytoma is a catecholamine-producing tumor and a rare cause of hypertension.,72,0,72,0,84,16,1,RO-disease_may_have_finding,902691,Pheochromocytoma is a catecholamine-producing tumor and a rare cause of hypertension,hypertension,Pheochromocytoma
503461433,7/16/2014 13:44:02,,1324259140,7/16/2014 13:43:51,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,153,88,,,172,96,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY.,153-162,75-88,experimental DIABETES,A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy.,153 162,88,153,88,172,96,1,RO-cause_of,900234,A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy,diabetic neuropathy,diabetes
503461433,7/16/2014 13:54:09,,1324262691,7/16/2014 13:53:41,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,153,88,,,172,96,DIABETIC NEUROPATHY,DIABETES,diabetes DIABETIC NEUROPATHY.,88-153-162,88-153-162,DIABETES diabetic neuropathy.,A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy.,153 162,88,153,88,172,96,1,RO-cause_of,900234,A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy,diabetic neuropathy,diabetes
503461433,7/16/2014 14:05:21,,1324267421,7/16/2014 14:05:00,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.208.109,153,88,,,172,96,DIABETIC NEUROPATHY,DIABETES,diabetes DIABETIC NEUROPATHY.,153-162-88,88,DIABETES,A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy.,153 162,88,153,88,172,96,1,RO-cause_of,900234,A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy,diabetic neuropathy,diabetes
503461433,7/16/2014 14:19:57,,1324273516,7/16/2014 14:19:35,vivatic,1.0,25451531,GBR,"","",83.67.28.193,153,88,,,172,96,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY.,153-162,75-88,experimental DIABETES,A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy.,153 162,88,153,88,172,96,1,RO-cause_of,900234,A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy,diabetic neuropathy,diabetes
503461433,7/16/2014 14:30:36,,1324277905,7/16/2014 14:30:20,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,153,88,,,172,96,DIABETIC NEUROPATHY,DIABETES,diabetes DIABETIC NEUROPATHY.,153-162-88,88-153-162,DIABETES diabetic neuropathy.,A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy.,153 162,88,153,88,172,96,1,RO-cause_of,900234,A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy,diabetic neuropathy,diabetes
503461433,7/16/2014 14:42:10,,1324282258,7/16/2014 14:41:59,neodev,1.0,28336203,USA,PA,Harrisburg,50.149.53.150,153,88,,,172,96,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY.,153-162,88,DIABETES,A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy.,153 162,88,153,88,172,96,1,RO-cause_of,900234,A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy,diabetic neuropathy,diabetes
503461433,7/16/2014 14:45:46,,1324283165,7/16/2014 14:45:22,prodege,1.0,1889141,USA,NC,Goldsboro,198.86.16.151,153,88,,,172,96,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY.,153-162,88-75,experimental DIABETES,A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy.,153 162,88,153,88,172,96,1,RO-cause_of,900234,A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy,diabetic neuropathy,diabetes
503461433,7/16/2014 14:52:13,,1324285095,7/16/2014 14:51:58,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.74,153,88,,,172,96,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY.,153-162,75-88,experimental DIABETES,A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy.,153 162,88,153,88,172,96,1,RO-cause_of,900234,A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy,diabetic neuropathy,diabetes
503461433,7/16/2014 14:54:38,,1324285911,7/16/2014 14:54:29,clixsense,1.0,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,153,88,,,172,96,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY.,153-162,88,DIABETES,A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy.,153 162,88,153,88,172,96,1,RO-cause_of,900234,A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy,diabetic neuropathy,diabetes
503461433,7/16/2014 14:55:44,,1324286319,7/16/2014 14:55:35,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,153,88,,,172,96,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY.,153-162,88,DIABETES,A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy.,153 162,88,153,88,172,96,1,RO-cause_of,900234,A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy,diabetic neuropathy,diabetes
503461434,7/16/2014 13:42:31,,1324258642,7/16/2014 13:42:15,prodege,1.0,17780691,CAN,ON,Toronto,24.114.226.82,74,12,,,95,34,CUTANEOUS INVOLVEMENT,CICATRICIAL PEMPHIGOID,CUTANEOUS INVOLVEMENT,74-84,12-24,CICATRICIAL PEMPHIGOID,DPA-induced cicatricial pemphigoid is a severe disease of both mucous and cutaneous involvement with a prognosis similar to the spontaneous disease.,74 84,12 24,74,12,95,34,1,RO-disease_has_finding,901974,DPA-induced cicatricial pemphigoid is a severe disease of both mucous and cutaneous involvement with a prognosis similar to the spontaneous disease,cutaneous involvement,cicatricial pemphigoid
503461434,7/16/2014 13:53:51,,1324262529,7/16/2014 13:53:13,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,74,12,,,95,34,CUTANEOUS INVOLVEMENT,CICATRICIAL PEMPHIGOID,mucous and CUTANEOUS INVOLVEMENT,63-70-74-84,0-4-12-24,DPA induced CICATRICIAL PEMPHIGOID,DPA-induced cicatricial pemphigoid is a severe disease of both mucous and cutaneous involvement with a prognosis similar to the spontaneous disease.,74 84,12 24,74,12,95,34,1,RO-disease_has_finding,901974,DPA-induced cicatricial pemphigoid is a severe disease of both mucous and cutaneous involvement with a prognosis similar to the spontaneous disease,cutaneous involvement,cicatricial pemphigoid
503461434,7/16/2014 13:53:55,,1324262580,7/16/2014 13:53:31,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,74,12,,,95,34,CUTANEOUS INVOLVEMENT,CICATRICIAL PEMPHIGOID,CUTANEOUS INVOLVEMENT,74-84,12-24,CICATRICIAL PEMPHIGOID,DPA-induced cicatricial pemphigoid is a severe disease of both mucous and cutaneous involvement with a prognosis similar to the spontaneous disease.,74 84,12 24,74,12,95,34,1,RO-disease_has_finding,901974,DPA-induced cicatricial pemphigoid is a severe disease of both mucous and cutaneous involvement with a prognosis similar to the spontaneous disease,cutaneous involvement,cicatricial pemphigoid
503461434,7/16/2014 13:54:08,,1324262683,7/16/2014 13:53:55,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,74,12,,,95,34,CUTANEOUS INVOLVEMENT,CICATRICIAL PEMPHIGOID,CUTANEOUS INVOLVEMENT,74-84,0-4-12-24,DPA induced CICATRICIAL PEMPHIGOID,DPA-induced cicatricial pemphigoid is a severe disease of both mucous and cutaneous involvement with a prognosis similar to the spontaneous disease.,74 84,12 24,74,12,95,34,1,RO-disease_has_finding,901974,DPA-induced cicatricial pemphigoid is a severe disease of both mucous and cutaneous involvement with a prognosis similar to the spontaneous disease,cutaneous involvement,cicatricial pemphigoid
503461434,7/16/2014 14:00:47,,1324265448,7/16/2014 14:00:20,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,74,12,,,95,34,CUTANEOUS INVOLVEMENT,CICATRICIAL PEMPHIGOID,mucous and CUTANEOUS INVOLVEMENT,63-70-74-84,0-4-12-24,DPA induced CICATRICIAL PEMPHIGOID,DPA-induced cicatricial pemphigoid is a severe disease of both mucous and cutaneous involvement with a prognosis similar to the spontaneous disease.,74 84,12 24,74,12,95,34,1,RO-disease_has_finding,901974,DPA-induced cicatricial pemphigoid is a severe disease of both mucous and cutaneous involvement with a prognosis similar to the spontaneous disease,cutaneous involvement,cicatricial pemphigoid
503461434,7/16/2014 14:14:08,,1324271257,7/16/2014 14:13:33,cotter,1.0,7461147,USA,VA,Saluda,71.253.203.209,74,12,,,95,34,CUTANEOUS INVOLVEMENT,CICATRICIAL PEMPHIGOID,mucous and CUTANEOUS INVOLVEMENT,63-70-74-84,0-4-12-24,DPA induced CICATRICIAL PEMPHIGOID,DPA-induced cicatricial pemphigoid is a severe disease of both mucous and cutaneous involvement with a prognosis similar to the spontaneous disease.,74 84,12 24,74,12,95,34,1,RO-disease_has_finding,901974,DPA-induced cicatricial pemphigoid is a severe disease of both mucous and cutaneous involvement with a prognosis similar to the spontaneous disease,cutaneous involvement,cicatricial pemphigoid
503461434,7/16/2014 14:27:00,,1324276267,7/16/2014 14:26:34,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,74,12,,,95,34,CUTANEOUS INVOLVEMENT,CICATRICIAL PEMPHIGOID,CUTANEOUS INVOLVEMENT,74-84,0-4-12-24,DPA induced CICATRICIAL PEMPHIGOID,DPA-induced cicatricial pemphigoid is a severe disease of both mucous and cutaneous involvement with a prognosis similar to the spontaneous disease.,74 84,12 24,74,12,95,34,1,RO-disease_has_finding,901974,DPA-induced cicatricial pemphigoid is a severe disease of both mucous and cutaneous involvement with a prognosis similar to the spontaneous disease,cutaneous involvement,cicatricial pemphigoid
503461434,7/16/2014 14:29:37,,1324277453,7/16/2014 14:29:18,gifthulk,1.0,22552178,AUS,05,Adelaide,14.2.42.59,74,12,,,95,34,CUTANEOUS INVOLVEMENT,CICATRICIAL PEMPHIGOID,CUTANEOUS INVOLVEMENT,74-84,12-24,CICATRICIAL PEMPHIGOID,DPA-induced cicatricial pemphigoid is a severe disease of both mucous and cutaneous involvement with a prognosis similar to the spontaneous disease.,74 84,12 24,74,12,95,34,1,RO-disease_has_finding,901974,DPA-induced cicatricial pemphigoid is a severe disease of both mucous and cutaneous involvement with a prognosis similar to the spontaneous disease,cutaneous involvement,cicatricial pemphigoid
503461434,7/16/2014 14:36:07,,1324280185,7/16/2014 14:35:40,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,74,12,,,95,34,CUTANEOUS INVOLVEMENT,CICATRICIAL PEMPHIGOID,mucous and CUTANEOUS INVOLVEMENT,63-70-74-84,0-4-12-24,DPA induced CICATRICIAL PEMPHIGOID,DPA-induced cicatricial pemphigoid is a severe disease of both mucous and cutaneous involvement with a prognosis similar to the spontaneous disease.,74 84,12 24,74,12,95,34,1,RO-disease_has_finding,901974,DPA-induced cicatricial pemphigoid is a severe disease of both mucous and cutaneous involvement with a prognosis similar to the spontaneous disease,cutaneous involvement,cicatricial pemphigoid
503461434,7/16/2014 14:42:00,,1324282179,7/16/2014 14:41:17,prodege,1.0,26790109,USA,"","",23.125.64.233,74,12,,,95,34,CUTANEOUS INVOLVEMENT,CICATRICIAL PEMPHIGOID,DPA induced cicatricial pemphigoid is a severe disease CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,0-4-12-24-35-38-40-47-74-84-96-101-103-113-121-124-128-140,0-4-12-24-35-38-40-47-55-58-63-70-74-84-96-101-103-113-121-124-128-140,DPA induced CICATRICIAL PEMPHIGOID is a severe disease of both mucous and cutaneous involvement with a prognosis similar to the spontaneous disease.,DPA-induced cicatricial pemphigoid is a severe disease of both mucous and cutaneous involvement with a prognosis similar to the spontaneous disease.,74 84,12 24,74,12,95,34,1,RO-disease_has_finding,901974,DPA-induced cicatricial pemphigoid is a severe disease of both mucous and cutaneous involvement with a prognosis similar to the spontaneous disease,cutaneous involvement,cicatricial pemphigoid
